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REAMBLE (UPDATED)
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced in the detection,
anagement, or prevention of disease states. Rigorous and
xpert analysis of the available data documenting the abso-
ute and relative benefits and risks of those procedures and
herapies can produce helpful guidelines that improve the
ffectiveness of care, optimize patient outcomes, and favor-
bly affect the overall cost of care by focusing resources on
he most effective strategies.
The American College of Cardiology (ACC) and the
merican Heart Association (AHA) have jointly engaged
n the production of such guidelines in the area of cardio-
ascular disease since 1980. This effort is directed by the
CC/AHA Task Force on Practice Guidelines, whose
harge is to develop, update, or revise practice guidelines for
mportant cardiovascular diseases and procedures. Writing
ommittees are charged with the task of performing an
ssessment of the evidence and acting as an independent
roup of authors to develop and update written recommen-
ations for clinical practice.
Experts in the subject under consideration are selected from
oth organizations to examine subject-specific data and write
uidelines. The process includes additional representatives
rom other medical practitioner and specialty groups where
ppropriate. Writing committees are specifically charged to
erform a formal literature review, weigh the strength of
vidence for or against a particular treatment or procedure, and
nclude estimates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of patient
reference that may influence the choice of particular tests or
herapies are considered, as well as frequency of follow-up.
hen available, information from studies on cost will be
onsidered; however, review of data on efficacy and clinical
utcomes will be the primary basis for preparing recommen-
ation in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflicts of interest that may arise as a result of an
utside relationship or personal interest of a member of the
riting committee. Specifically, all members of the writing
ommittee and peer reviewers of the document are asked to
rovide disclosure statements of all such relationships that ray be perceived as real or potential conflicts of interest.
riting committee members are also strongly encouraged
o declare a previous relationship with industry that may be
erceived as relevant to guideline development. If a writing
ommittee member develops a new relationship with indus-
ry during his or her tenure, he or she is required to notify
uideline staff in writing. The continued participation of the
riting committee member will be reviewed. These state-
ents are reviewed by the parent task force, reported orally
o all members of the writing panel at each meeting, and
pdated and reviewed by the writing committee as changes
ccur. Please refer to the methodology manual for the ACC/
HA guideline writing committees for further description and
he relationships with industry policy (1067). See Appendix 1
or a list of writing committee member relationships with
ndustry and Appendix 2 for a listing of peer reviewer relation-
hips with industry that are pertinent to this guideline.
These practice guidelines are intended to assist healthcare
roviders in clinical decision making by describing a range
f generally acceptable approaches for the diagnosis, man-
gement, and prevention of specific diseases or conditions.
ee Appendix 3 for a list of abbreviated terms used in this
uideline. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances.
hese guideline recommendations reflect a consensus of expert
pinion after a thorough review of the available, current
cientific evidence and are intended to improve patient care. If
hese guidelines are used as the basis for regulatory/payer
ecisions, the ultimate goal is quality of care and serving the
atient’s best interests. The ultimate judgment regarding care
f a particular patient must be made by the healthcare provider
nd patient in light of all of the circumstances presented by that
atient. There are circumstances in which deviations from
hese guidelines are appropriate.
The current document is a republication of the “ACC/
HA 2006 Guidelines for the Management of Patients
ith Valvular Heart Disease” (1068), revised to incorporate
ndividual recommendations from a 2008 focused update
1069), which spotlights the 2007 AHA Guidelines for
nfective Endocarditis Prophylaxis. For easy reference, this
nline-only version denotes sections that have been up-
ated. All members of the 2006 Valvular Heart Disease
riting Committee were invited to participate in the
riting group; those who agreed were required to disclose
ll relationships with industry relevant to the data under
onsideration (1067), as were all peer reviewers of the
ocument. (See Appendixes 4 and 5 for a listing of
elationships with industry for the 2008 Focused Update
riting Group and peer reviewers, respectively.) Each
ecommendation required a confidential vote by the writing
roup members before and after external review of the
ocument. Any writing group member with a significant
greater than $10 000) relationship with industry relevant to
he recommendation was recused from voting on that
ecommendation.
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. INTRODUCTION
.1. Evidence Review (UPDATED)
he ACC and the AHA have long been involved in the
oint development of practice guidelines designed to assist
ealthcare providers in the management of selected cardio-
ascular disorders or the selection of certain cardiovascular
rocedures. The determination of the disorders or proce-
ures to develop guidelines is based on several factors,
ncluding importance to healthcare providers and whether
here are sufficient data from which to derive accepted
uidelines. One important category of cardiac disorders that
ffect a large number of patients who require diagnostic
rocedures and decisions regarding long-term management
s valvular heart disease.
During the past 2 decades, major advances have occurred
n diagnostic techniques, the understanding of natural
istory, and interventional cardiology and surgical proce-
ures for patients with valvular heart disease. These ad-
ances have resulted in enhanced diagnosis, more scientific
election of patients for surgery or catheter-based interven-
ion versus medical management, and increased survival of
atients with these disorders. The information base from
hich to make clinical management decisions has greatly
xpanded in recent years, yet in many situations, management
ssues remain controversial or uncertain. Unlike many other
orms of cardiovascular disease, there is a scarcity of large-scale
ulticenter trials addressing the diagnosis and treatment of
atients with valvular disease from which to derive definitive
onclusions, and the information available in the literature
epresents primarily the experiences reported by single institu-
ions in relatively small numbers of patients.
The 1998 Committee on Management of Patients With
alvular Heart Disease reviewed and compiled this informa-
ion base and made recommendations for diagnostic testing,
reatment, and physical activity. For topics for which there was
n absence of multiple randomized, controlled trials, the
referred basis for medical decision making in clinical practice
evidence-based medicine), the committee’s recommendations
ere based on data derived from single randomized trials or
onrandomized studies or were based on a consensus opinion
f experts. The 2006 writing committee was charged with
evising the guidelines published in 1998. The committee
eviewed pertinent publications, including abstracts, through a
omputerized search of the English literature since 1998 and
erformed a manual search of final articles. Special attention
as devoted to identification of randomized trials publishedince the original document. A complete listing of all publica- sions covering the treatment of valvular heart disease is beyond
he scope of this document; the document includes those
eports that the committee believes represent the most com-
rehensive or convincing data that are necessary to support its
onclusions. However, evidence tables were updated to reflect
ajor advances over this time period. Inaccuracies or incon-
istencies present in the original publication were identified
nd corrected when possible. Recommendations provided in
his document are based primarily on published data. Because
andomized trials are unavailable in many facets of valvular
eart disease treatment, observational studies, and in some
reas, expert opinions form the basis for recommendations that
re offered.
All of the recommendations in this guideline revision
ere converted from the tabular format used in the 1998
uideline to a listing of recommendations that has been
ritten in full sentences to express a complete thought, such
hat a recommendation, even if separated and presented
part from the rest of the document, would still convey the
ull intent of the recommendation. It is hoped that this will
ncrease the readers’ comprehension of the guidelines. Also,
he level of evidence, either A, B, or C, for each recom-
endation is now provided.
Classification of recommendations and level of evidence
re expressed in the ACC/AHA format as follows:
CLASS I: Conditions for which there is evidence for and/or
general agreement that the procedure or treatment is
beneficial, useful, and effective.
CLASS II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
CLASS IIA: Weight of evidence/opinion is in favor of
usefulness/efficacy.
CLASS IIB: Usefulness/efficacy is less well established by
evidence/opinion.
CLASS III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective and in some cases may be harmful.
In addition, the weight of evidence in support of the
ecommendation is listed as follows:
Level of Evidence A: Data derived from multiple ran-
domized clinical trials.
Level of Evidence B: Data derived from a single ran-
domized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
The schema for classification of recommendations and
evel of evidence is summarized in Figure 1, which also
llustrates how the grading system provides an estimate of
he size of the treatment effect and an estimate of the
ertainty of the treatment effect.
Writing committee membership consisted of cardiovas-
ular disease specialists and representatives of the cardiac
urgery and cardiac anesthesiology fields; both the academic
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatednd private practice sectors were represented. The Society of
ardiovascular Anesthesiologists assigned an official repre-
entative to the writing committee.
.2. Scope of the Document (UPDATED)
he guidelines attempt to deal with general issues of
reatment of patients with heart valve disorders, such as
valuation of patients with heart murmurs, prevention and
reatment of endocarditis, management of valve disease in
regnancy, and treatment of patients with concomitant
oronary artery disease (CAD), as well as more specialized
ssues that pertain to specific valve lesions. The guidelines
ocus primarily on valvular heart disease in the adult, with a
eparate section dealing with specific recommendations for
alve disorders in adolescents and young adults. The diag-
osis and management of infants and young children with
ongenital valvular abnormalities are significantly different
rom those of the adolescent or adult and are beyond the
cope of these guidelines.
This task force report overlaps with several previously
igure 1. Applying Classification of Recommendations and Level o
Data available from clinical trials or registries about the usefulness/efficacy in diffe
nfarction, history of heart failure, and prior aspirin use. A recommendation with Leve
linical questions addressed in the guidelines do not lend themselves to clinical tria
onsensus that a particular test or therapy is useful or effective. †In 2003 the ACC/
se when writing recommendations. All recommendations in this guideline have bee
ion, even if separated and presented apart from the rest of the document (including
mmendation. It is hoped that this will increase readers’ comprehension of the guidublished ACC/AHA guidelines about cardiac imaging and liagnostic testing, including the guidelines for the clinical
se of cardiac radionuclide imaging (1), the clinical appli-
ation of echocardiography (2), exercise testing (3), and
ercutaneous coronary intervention (4). Although these
uidelines are not intended to include detailed information
overed in previous guidelines on the use of imaging and
iagnostic testing, an essential component of this report is
he discussion of indications for these tests in the evaluation
nd treatment of patients with valvular heart disease.
The committee emphasizes the fact that many factors
ltimately determine the most appropriate treatment of
ndividual patients with valvular heart disease within a given
ommunity. These include the availability of diagnostic
quipment and expert diagnosticians, the expertise of inter-
entional cardiologists and surgeons, and notably, the
ishes of well-informed patients. Therefore, deviation from
hese guidelines may be appropriate in some circumstances.
hese guidelines are written with the assumption that a
iagnostic test can be performed and interpreted with skill
ence
ubpopulations, such as gender, age, history of diabetes, history of prior myocardial
vidence B or C does not imply that the recommendation is weak. Many important
n though randomized trials are not available, there may be a very clear clinical
ask Force on Practice Guidelines recently provided a list of suggested phrases to
en in full sentences that express a complete thought, such that a recommenda-
ings above sets of recommendations), would still convey the full intent of the rec-
and will allow queries at the individual recommendation level.f Evid
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nterventional cardiological and surgical procedures can be
erformed by highly trained practitioners within acceptable
afety standards, and that the resources necessary to perform
hese diagnostic procedures and provide this care are readily
vailable. This is not true in all geographic areas, which
urther underscores the committee’s position that its recom-
endations are guidelines and not rigid requirements.
.3. Review and Approval (NEW)
he 2006 document (1068) was reviewed by 2 official reviewers
ominated by the ACC; 2 official reviewers nominated by the
HA; 1 official reviewer from the ACC/AHA Task Force on
ractice Guidelines; reviewers nominated by the Society of
ardiovascular Anesthesiologists, the Society for Cardiovascu-
ar Angiography and Interventions, and the Society of Tho-
acic Surgeons (STS); and individual content reviewers, includ-
ng members of the ACCF Cardiac Catheterization and
ntervention Committee, ACCF Cardiovascular Imaging
ommittee, ACCF Cardiovascular Surgery Committee,
HA Endocarditis Committee, AHA Cardiac Clinical Im-
ging Committee, AHA Cardiovascular Intervention and
maging Committee, and AHA Cerebrovascular Imaging and
ntervention Committee.
As mentioned previously, this document also incorporates
 2008 focused update of the “ACC/AHA 2006 Guidelines
or the Management of Patients With Valvular Heart
isease” (1069), which spotlights the 2007 AHA Guide-
ines for Infective Endocarditis Prophylaxis (1070). Only
ecommendations related to infective endocarditis have
een revised. This document was reviewed by 2 external
eviewers nominated by the ACC and 2 external reviewers
ominated by the AHA, as well as 3 reviewers from the
CCF Congenital Heart Disease and Pediatric Commit-
ee, 2 reviewers from the ACCF Cardiovascular Surgery
ommittee, 5 reviewers from the AHA Heart Failure and
ransplant Committee, and 3 reviewers from the Rheu-
atic Fever, Endocarditis, and Kawasaki Disease Commit-
ee. All information about reviewers’ relationships with
ndustry was collected and distributed to the writing com-
ittee and is published in this document (see Appendix 5
or details). This document was approved for publication by
he governing bodies of the ACCF and the AHA in May
008 and endorsed by the Society of Cardiovascular Anes-
hesiologists, the Society for Cardiovascular Angiography
nd Interventions, and the Society of Thoracic Surgeons.
. GENERAL PRINCIPLES
.1. Evaluation of the Patient With
Cardiac Murmur
.1.1. Introduction (UPDATED)
ardiac auscultation remains the most widely used method
f screening for valvular heart disease (VHD). The produc-
ion of murmurs is due to 3 main factors: ehigh blood flow rate through normal or abnormal orifices
forward flow through a narrowed or irregular orifice into
a dilated vessel or chamber
backward or regurgitant flow through an incompetent
valve
ften, more than 1 of these factors is operative (5–7).
A heart murmur may have no pathological significance or
ay be an important clue to the presence of valvular,
ongenital, or other structural abnormalities of the heart (8).
ost systolic heart murmurs do not signify cardiac disease,
nd many are related to physiological increases in blood flow
elocity (9). In other instances, a heart murmur may be an
mportant clue to the diagnosis of undetected cardiac disease
e.g., valvular aortic stenosis [AS]) that may be important
ven when asymptomatic or that may define the reason for
ardiac symptoms. In these situations, various noninvasive
r invasive cardiac tests may be necessary to establish a firm
iagnosis and form the basis for rational treatment of an
nderlying disorder. Echocardiography is particularly useful
n this regard, as discussed in the “ACC/AHA/ASE 2003
uidelines for the Clinical Application of Echocardiogra-
hy” (2). Diastolic murmurs virtually always represent
athological conditions and require further cardiac evalua-
ion, as do most continuous murmurs. Continuous “inno-
ent” murmurs include venous hums and mammary souffles.
The traditional auscultation method of assessing cardiac
urmurs has been based on their timing in the cardiac cycle,
onfiguration, location and radiation, pitch, intensity
grades 1 through 6), and duration (5–9). The configuration
f a murmur may be crescendo, decrescendo, crescendo-
ecrescendo (diamond-shaped), or plateau. The precise
imes of onset and cessation of a murmur associated with
ardiac pathology depend on the period of time in the
ardiac cycle in which a physiologically important pressure
ifference between 2 chambers occurs (5–9). A classification
f cardiac murmurs is listed in Table 1.
.1.2. Classification of Murmurs
olosystolic (pansystolic) murmurs are generated when
here is flow between chambers that have widely different
ressures throughout systole, such as the left ventricle and
able 1. Classification of Cardiac Murmurs
. Systolic murmurs
a. Holosystolic (pansystolic) murmurs
b. Midsystolic (systolic ejection) murmurs
c. Early systolic murmurs
d. Mid to late systolic murmurs
. Diastolic murmurs
a. Early high-pitched diastolic murmurs
b. Middiastolic murmurs
c. Presystolic murmurs
. Continuous murmursither the left atrium or right ventricle. With an abnormal
r
b
c
d
a
s
s
c
i
m
o
t
b
t
i
a
p
v
a
p
M
f
t
n
b
t
m
p
a
n
d
i
h
s
o
l
a
w
d
S
c
w
b
m
t
s
o
p
l
s
p
r
a
a
a
s
u
m
a
s
p
a
w
p
i
o
u
i
s
m
m
s
b
S
c
p
2
A
c
t
(
v
2
T
n
o
2
a
p
p
l
i
s
p
m
p
r
a
e
e
l
e9JACC Vol. 52, No. 13, 2008 Bonow et al.
September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedegurgitant orifice, the pressure gradient and regurgitant jet
egin early in contraction and last until relaxation is almost
omplete.
Midsystolic (systolic ejection) murmurs, often crescendo-
ecrescendo in configuration, occur when blood is ejected
cross the aortic or pulmonic outflow tracts. The murmurs
tart shortly after S1, when the ventricular pressure rises
ufficiently to open the semilunar valve. As ejection in-
reases, the murmur is augmented, and as ejection declines,
t diminishes.
In the presence of normal semilunar valves, this murmur
ay be caused by an increased flow rate such as that which
ccurs with elevated cardiac output (e.g., pregnancy, thyro-
oxicosis, anemia, and arteriovenous fistula), ejection of
lood into a dilated vessel beyond the valve, or increased
ransmission of sound through a thin chest wall. Most
nnocent murmurs that occur in children and young adults
re midsystolic and originate either from the aortic or
ulmonic outflow tracts. Valvular, supravalvular, or subval-
ular obstruction (stenosis) of either ventricle may also cause
midsystolic murmur, the intensity of which depends in
art on the velocity of blood flow across the narrowed area.
idsystolic murmurs also occur in certain patients with
unctional mitral regurgitation (MR) or, less frequently,
ricuspid regurgitation (TR). Echocardiography is often
ecessary to separate a prominent and exaggerated (grade 3)
enign midsystolic murmur from one due to valvular AS.
Early systolic murmurs are less common; they begin with
he first sound and end in midsystole. An early systolic
urmur is often due to TR that occurs in the absence of
ulmonary hypertension, but it also occurs in patients with
cute MR. In large ventricular septal defects with pulmo-
ary hypertension and small muscular ventricular septal
efects, the shunting at the end of systole may be insignif-
cant, with the murmur limited to early and midsystole.
Late systolic murmurs are soft or moderately loud,
igh-pitched murmurs at the left ventricular (LV) apex that
tart well after ejection and end before or at S2. They are
ften due to apical tethering and malcoaptation of the mitral
eaflets due to anatomic and functional changes of the
nnulus and ventricle. Late systolic murmurs in patients
ith midsystolic clicks result from late systolic regurgitation
ue to prolapse of the mitral leaflet(s) into the left atrium.
uch late systolic murmurs can also occur in the absence of
licks.
Early diastolic murmurs begin with or shortly after S2,
hen the associated ventricular pressure drops sufficiently
elow that in the aorta or pulmonary artery. High-pitched
urmurs of aortic regurgitation (AR) or pulmonic regurgi-
ation due to pulmonary hypertension are generally decre-
cendo, consistent with the rapid decline in volume or rate
f regurgitation during diastole. The diastolic murmur of
ulmonic regurgitation without pulmonary hypertension is
ow to medium pitched, and the onset of this murmur is
lightly delayed because regurgitant flow is minimal at
ulmonic valve closure, when the reverse pressure gradient mesponsible for the regurgitation is minimal. Such murmurs
re common late after repair of tetralogy of Fallot.
Middiastolic murmurs usually originate from the mitral
nd tricuspid valves, occur early during ventricular filling,
nd are due to a relative disproportion between valve orifice
ize and diastolic blood flow volume. Although they are
sually due to mitral or tricuspid stenosis, middiastolic
urmurs may also be due to increased diastolic blood flow
cross the mitral or tricuspid valve when such valves are
everely regurgitant, across the normal mitral valve (MV) in
atients with ventricular septal defect or patent ductus
rteriosus, and across the normal tricuspid valve in patients
ith atrial septal defect. In severe, chronic AR, a low-
itched, rumbling diastolic murmur (Austin-Flint murmur)
s often present at the LV apex; it may be either middiastolic
r presystolic. An opening snap is absent in isolated AR.
Presystolic murmurs begin during the period of ventric-
lar filling that follows atrial contraction and therefore occur
n sinus rhythm. They are usually due to mitral or tricuspid
tenosis. A right or left atrial myxoma may cause either
iddiastolic or presystolic murmurs similar to tricuspid or
itral stenosis (MS).
Continuous murmurs arise from high- to low-pressure
hunts that persist through the end of systole and the
eginning of diastole. Thus, they begin in systole, peak near
2, and continue into all or part of diastole. There are many
auses of continuous murmurs, but they are uncommon in
atients with valvular heart disease (5–9).
.1.2.1. DYNAMIC CARDIAC AUSCULTATION
ttentive cardiac auscultation during dynamic changes in
ardiac hemodynamics often enables the observer to deduce
he correct origin and significance of a cardiac murmur
10–13). Changes in the intensity of heart murmurs during
arious maneuvers are indicated in Table 2.
.1.2.2. OTHER PHYSICAL FINDINGS
he presence of other physical findings, either cardiac or
oncardiac, may provide important clues to the significance
f a cardiac murmur and the need for further testing (Fig.
). For example, a right heart murmur in early to midsystole
t the lower left sternal border likely represents TR without
ulmonary hypertension in an injection drug user who
resents with fever, petechiae, Osler’s nodes, and Janeway
esions.
Associated cardiac findings frequently provide important
nformation about cardiac murmurs. Fixed splitting of the
econd heart sound during inspiration and expiration in a
atient with a grade 2/6 midsystolic murmur in the pul-
onic area and left sternal border should suggest the
ossibility of an atrial septal defect. A soft or absent A2 or
eversed splitting of S2 may denote severe AS. An early
ortic systolic ejection sound heard during inspiration and
xpiration suggests a bicuspid aortic valve, whereas an
jection sound heard only in the pulmonic area and at the
eft sternal border during expiration usually denotes pul-onic valve stenosis. LV dilatation on precordial palpation
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hronic MR in a patient with a grade 2/6 holosystolic
urmur at the cardiac apex. A slow-rising, diminished
rterial pulse suggests severe AS in a patient with a grade
/6 midsystolic murmur at the second right intercostal
pace. The typical parvus et tardus pulse may be absent in
he elderly, even in those with severe AS, secondary to the
ffects of aging on the vasculature. Pulsus parvus may also
ccur with severely reduced cardiac output from any cause.
actors that aid in the differential diagnosis of LV outflow
ract obstruction are listed in Table 3 (14). Examination of
he jugular venous wave forms may provide additional or
able 2. Interventions Used to Alter the Intensity of Cardiac M
espiration
Right-sided murmurs generally increase with inspiration. Left-sided murmurs u
alsalva maneuver
Most murmurs decrease in length and intensity. Two exceptions are the systo
becomes longer and often louder. After release of the Valsalva, right-sided
xercise
Murmurs caused by blood flow across normal or obstructed valves (e.g., PS an
of MR, VSD, and AR also increase with handgrip exercise.
ositional changes
With standing, most murmurs diminish, 2 exceptions being the murmur of HC
With brisk squatting, most murmurs become louder, but those of HCM and
same results as brisk squatting.
ostventricular premature beat or atrial fibrillation
Murmurs originating at normal or stenotic semilunar valves increase in intens
By contrast, systolic murmurs due to atrioventricular valve regurgitation do
harmacological interventions
During the initial relative hypotension after amyl nitrite inhalation, murmurs o
stroke volume. During the later tachycardia phase, murmurs of MS and righ
the Austin-Flint phenomenon from that of MS. The response in MVP often is
ransient arterial occlusion
Transient external compression of both arms by bilateral cuff inflation to 20 m
AR but not murmurs due to other causes.
F indicates atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; HCM, hypertrophic ca
tenosis; VPB, ventricular premature beat; and VSD, ventricular septal defect.
igure 2. Strategy for Evaluating Heart MurmursIf an electrocardiogram or chest X-ray has been obtained and is abnormal, echocardiograorroborative information. For example, regurgitant cv
aves are indicative of TR and are often present without an
udible murmur.
.1.2.3. ASSOCIATED SYMPTOMS
n important consideration in the patient with a cardiac
urmur is the presence or absence of symptoms (15) (Fig.
). For example, symptoms of syncope, angina pectoris, or
eart failure in a patient with a midsystolic murmur will
sually result in a more aggressive diagnostic approach than
n a patient with a similar midsystolic murmur who has
one of these symptoms. An echocardiogram to rule in or
rs
are louder during expiration.
rmur of HCM, which usually becomes much louder, and that of MVP, which
urs tend to return to baseline intensity earlier than left-sided murmurs.
) become louder with both isotonic and isometric (handgrip) exercise. Murmurs
ich becomes louder, and that of MVP, which lengthens and often is intensified.
sually soften and may disappear. Passive leg raising usually produces the
ing the cardiac cycle after a VPB or in the beat after a long cycle length in AF.
ange, diminish (papillary muscle dysfunction), or become shorter (MVP).
VSD, and AR decrease, whereas murmurs of AS increase because of increased
d lesions also increase. This intervention may thus distinguish the murmur of
sic (softer then louder than control).
greater than peak systolic pressure augments the murmurs of MR, VSD, and
pathy; MR, mitral regurgitation; MS, mitral stenosis; MVP, mitral valve prolapse; PS, pulmonicurmu
sually
lic mu
murm
d MS
M, wh
MVP u
ity dur
not ch
f MR,
t-side
bipha
m Hgphy is indicated.
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history of thromboembolism will also usually result in a
ore extensive workup. In patients with cardiac murmurs
nd clinical findings suggestive of endocarditis, echocardi-
graphy is indicated (2).
Conversely, many asymptomatic children and young
dults with grade 2/6 midsystolic murmurs and no other
ardiac physical findings need no further workup after the
nitial history and physical examination (Fig. 2). A partic-
larly important group is the large number of asymptomatic
lder patients, many with systemic hypertension, who have
idsystolic murmurs, usually of grade 1 or 2 intensity,
elated to sclerotic aortic valve leaflets; flow into tortuous,
oncompliant great vessels; or a combination of these
ndings. Such murmurs must be distinguished from those
aused by more significant degrees of aortic valve thicken-
ng, calcification, and reduced excursion that result in milder
r greater degrees of valvular AS. The absence of LV
ypertrophy on the electrocardiogram (ECG) may be reas-
uring, but echocardiography is frequently necessary. Aortic
clerosis can be defined by focal areas of increased echoge-
icity and thickening of the leaflets without restriction of
otion and a peak velocity of less than 2.0 m per second.
he recognition of aortic valve sclerosis may prompt the
nitiation of more aggressive programs of coronary heart
isease prevention. In patients with AS, it is difficult to
ssess the rate and severity of disease progression on the
asis of auscultatory findings alone.
.1.3. Electrocardiography and Chest Roentgenography
lthough echocardiography usually provides more specific
nd often quantitative information about the significance of
heart murmur and may be the only test needed, the ECG
nd chest X-ray are readily available and may have been
btained previously. The absence of ventricular hypertro-
hy, atrial enlargement, arrhythmias, conduction abnormal-
ties, prior myocardial infarction, and evidence of active
schemia on the ECG provides useful negative information
able 3. Factors That Differentiate the Various Causes of Left
Factor Valvular
alve calcification Common after age 40 y
ilated ascending aorta Common after age 40 y
P after VPB Increased
alsalva effect on SM Decreased
urmur of AR Common after age 40 y
ourth heart sound (S4) If severe
aradoxical splitting Sometimes*
jection click Most (unless valve calcified)
aximal thrill and murmur 2nd RIS
arotid pulse Normal to anacrotic* (parvus et tardus)
Depends on severity. Modified with permission from Marriott HJL. Bedside cardiac diagnosis.
AR indicates aortic regurgitation; HCM, hypertrophic cardiomyopathy; LIS, left intercostal space
eat.t a relatively low cost. Abnormal ECG findings in a patientith a heart murmur, such as ventricular hypertrophy or a
rior infarction, should lead to a more extensive evaluation
hat includes echocardiography (Fig. 2).
Posteroanterior and lateral chest roentgenograms often
ield qualitative information on cardiac chamber size, pul-
onary blood flow, pulmonary and systemic venous pres-
ure, and cardiac calcification in patients with cardiac
urmurs. When abnormal findings are present on chest
-ray, echocardiography should be performed (Fig. 2). A
ormal chest X-ray and ECG are likely in asymptomatic
atients with isolated midsystolic murmurs, particularly in
ounger age groups, when the murmur is grade 2 or less in
ntensity and heard along the left sternal border (16–18).
outine ECG and chest radiography are not recommended
n this setting.
.1.4. Echocardiography
LASS I
. Echocardiography is recommended for asymptomatic patients with
diastolic murmurs, continuousmurmurs, holosystolic murmurs, late
systolic murmurs, murmurs associated with ejection clicks, or mur-
murs that radiate to the neck or back. (Level of Evidence: C)
. Echocardiography is recommended for patients with heart murmurs
and symptoms or signs of heart failure, myocardial ischemia/
infarction, syncope, thromboembolism, infective endocarditis, or
other clinical evidence of structural heart disease. (Level of Evi-
dence: C)
. Echocardiography is recommended for asymptomatic patients who
have grade 3 or louder midpeaking systolic murmurs. (Level of
Evidence: C)
LASS IIa
. Echocardiography can be useful for the evaluation of asymptomatic
patients with murmurs associated with other abnormal cardiac
physical findings or murmurs associated with an abnormal ECG or
chest X-ray. (Level of Evidence: C)
. Echocardiography can be useful for patients whose symptoms
and/or signs are likely noncardiac in origin but in whom a cardiac
ricular Outflow Tract Obstruction
upravalvular
Discrete
Subvalvular
Obstructive
HCM
o No No
are Rare Rare
creased Increased Decreased
ecreased Decreased Increased
are Sometimes No
ncommon Uncommon Common
o No Rather common*
o No Uncommon or none
st RIS 2nd RIS 4th LIS
nequal Normal to anacrotic Brisk, jerky, systolic rebound
lphia, Pa: Lippincott; 1993:116.
lse pressure; RIS, right intercostal space; SM, systolic murmur; and VPB, ventricular prematureVent
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Philadebasis cannot be excluded by standard evaluation. (Level of Evidence: C)
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chocardiography is not recommended for patients who have a grade
or softer midsystolic murmur identified as innocent or functional by
n experienced observer. (Level of Evidence: C)
Echocardiography with color flow and spectral Doppler
valuation is an important noninvasive method for assessing
he significance of cardiac murmurs. Information regarding
alve morphology and function, chamber size, wall thick-
ess, ventricular function, pulmonary and hepatic vein flow,
nd estimates of pulmonary artery pressures can be readily
ntegrated.
Although echocardiography can provide important infor-
ation, such testing is not necessary for all patients with
ardiac murmurs and usually adds little but expense in the
valuation of asymptomatic younger patients with short
rade 1 to 2 midsystolic murmurs and otherwise normal
hysical findings. At the other end of the spectrum are
atients with heart murmurs for whom transthoracic echo-
ardiography proves inadequate. Depending on the specific
linical circumstances, transesophageal echocardiography,
ardiac magnetic resonance, or cardiac catheterization may
e indicated for better characterization of the valvular
esion.
It is important to note that Doppler ultrasound devices
re very sensitive and may detect trace or mild valvular
egurgitation through structurally normal tricuspid and
ulmonic valves in a large percentage of young, healthy
ubjects and through normal left-sided valves (particularly
he MV) in a variable but lower percentage of patients
16,19–22).
General recommendations for performing echocardiog-
aphy in patients with heart murmurs are provided. Of
ourse, individual exceptions to these indications may exist.
.1.5. Cardiac Catheterization
ardiac catheterization can provide important information
bout the presence and severity of valvular obstruction,
alvular regurgitation, and intracardiac shunting. It is not
ecessary in most patients with cardiac murmurs and
ormal or diagnostic echocardiograms, but it provides
dditional information for some patients in whom there is a
iscrepancy between the echocardiographic and clinical
ndings. Indications for cardiac catheterization for hemo-
ynamic assessment of specific valve lesions are given in
ection 3, “Specific Valve Lesions,” in these guidelines.
pecific indications for coronary angiography to screen for
he presence of CAD are given in Section 10.2.
.1.6. Exercise Testing
xercise testing can provide valuable information in patients
ith valvular heart disease, especially in those whose symp-
oms are difficult to assess. It can be combined with
chocardiography, radionuclide angiography, and cardiac
atheterization. It has a proven track record of safety, even
mong asymptomatic patients with severe AS. Exercise iesting has generally been underutilized in this patient
opulation and should constitute an important component
f the evaluation process.
.1.7. Approach to the Patient
he evaluation of the patient with a heart murmur may vary
reatly depending on many of the considerations discussed
bove (23,24). These include the timing of the murmur in
he cardiac cycle, its location and radiation, and its response
o various physiological maneuvers (Table 2). Also of impor-
ance is the presence or absence of cardiac and noncardiac
ymptoms and other findings on physical examination that
uggest the murmur is clinically significant (Fig. 2).
Patients with diastolic or continuous heart murmurs not
ue to a cervical venous hum or a mammary souffle during
regnancy are candidates for echocardiography. If the re-
ults of echocardiography indicate significant heart disease,
urther evaluation may be indicated. An echocardiographic
xamination is also recommended for patients with apical or
eft sternal edge holosystolic or late systolic murmurs, for
atients with midsystolic murmurs of grade 3 or greater
ntensity, and for patients with softer systolic murmurs in
hom dynamic cardiac auscultation suggests a definite
iagnosis (e.g., hypertrophic cardiomyopathy).
Echocardiography is also recommended for patients in
hom the intensity of a systolic murmur increases during
he Valsalva maneuver, becomes louder when the patient
ssumes the upright position, and decreases in intensity
hen the patient squats. These responses suggest the
iagnosis of either hypertrophic obstructive cardiomyopathy
r MV prolapse (MVP). Additionally, further assessment is
ndicated when a systolic murmur increases in intensity
uring transient arterial occlusion, becomes louder during
ustained handgrip exercise, or does not increase in intensity
ither in the cardiac cycle that follows a premature ventric-
lar contraction or after a long R-R interval in patients with
trial fibrillation. The diagnosis of MR or ventricular septal
efect in these circumstances is likely.
In many patients with grade 1 or 2 midsystolic murmurs,
n extensive workup is not necessary. This is particularly
rue for children and young adults who are asymptomatic,
ave an otherwise normal cardiac examination, and have no
ther physical findings associated with cardiac disease.
However, echocardiography is indicated in certain pa-
ients with grade 1 or 2 midsystolic murmurs, including
atients with symptoms or signs consistent with infective
ndocarditis, thromboembolism, heart failure, myocardial
schemia/infarction, or syncope. Echocardiography also
sually provides an accurate diagnosis in patients with other
bnormal physical findings, including widely split second
eart sounds, systolic ejection sounds, and specific changes
n intensity of the systolic murmur during certain physio-
ogical maneuvers (Table 2).
Although echocardiography is an important test for
atients with a moderate to high likelihood of a clinically
mportant cardiac murmur, it must be re-emphasized that
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specially affecting the mitral, tricuspid, or pulmonic valves,
s detected by color flow imaging techniques in many
therwise normal patients, including many patients who
ave no heart murmur at all (16,19–22). This observation
ust be considered when the results of echocardiography
re used to guide decisions in asymptomatic patients in
hom echocardiography was used to assess the significance
f an isolated murmur.
Very few data address the cost-effectiveness of various
pproaches to the patient undergoing medical evaluation of
cardiac murmur. Optimal auscultation by well-trained
xaminers who can recognize an insignificant midsystolic
urmur with confidence (by dynamic cardiac auscultation
s indicated) results in less frequent use of expensive
dditional testing to define murmurs that do not indicate
ardiac pathology.
Characteristics of innocent murmurs in asymptomatic adults
hat have no functional significance include the following:
grade 1 to 2 intensity at the left sternal border
a systolic ejection pattern
normal intensity and splitting of the second heart sound
no other abnormal sounds or murmurs
no evidence of ventricular hypertrophy or dilatation and
the absence of increased murmur intensity with the
Valsalva maneuver or with standing from a squatting
position (12).
Such murmurs are especially common in high-output
tates such as anemia and pregnancy (25,26). When the
haracteristic features of individual murmurs are considered
ogether with information obtained from the history and
hysical examination, the correct diagnosis can usually be
stablished (24). In patients with ambiguous clinical find-
ngs, the echocardiogram can often provide a definite
iagnosis, rendering a chest X-ray and/or ECG unnecessary.
In the evaluation of heart murmurs, the purposes of
chocardiography are to
define the primary lesion in terms of cause and severity
define hemodynamics
define coexisting abnormalities
detect secondary lesions
evaluate cardiac chamber size and function
establish a reference point for future comparisons
re-evaluate the patient after an intervention.
Throughout these guidelines, treatment recommenda-
ions will often derive from specific echocardiographic
easurements of LV size and systolic function. Accuracy
nd reproducibility are critical, particularly when applied to
urgical recommendations for asymptomatic patients with
R or AR. Serial measurements over time, or reassessment
ith a different imaging technology (radionuclide ventricu-
ography or cardiac magnetic resonance), are often helpful
or counseling individual patients. Lastly, although hand-
eld echocardiography can be used for screening purposes, its important to note that its accuracy is highly dependent on
he experience of the user. The precise role of handheld
chocardiography for the assessment of patients with valvu-
ar heart disease has not been elucidated.
As valuable as echocardiography may be, the basic car-
iovascular physical examination is still the most appropri-
te method of screening for cardiac disease and will establish
any clinical diagnoses. Echocardiography should not re-
lace the cardiovascular examination but can be useful in
etermining the cause and severity of valvular lesions,
articularly in older and/or symptomatic patients.
.2. Valve Disease Severity Table
lassification of the severity of valve disease in adults is
isted in Table 4 (27). The classification for regurgitant
esions is adapted from the recommendations of the Amer-
can Society of Echocardiography (27). For full recommen-
ations of the American Society of Echocardiography,
lease refer to the original document. Subsequent sections
f the current guidelines refer to the criteria in Table 4 (27)
o define severe valvular stenosis or regurgitation.
.3. Endocarditis and Rheumatic Fever Prophylaxis
UPDATED)
his updated section deals exclusively with the changes in
ecommendations for antibiotic prophylaxis against infec-
ive endocarditis in patients with valvular heart disease.
reatment considerations in patients with congenital heart
isease (CHD) or implanted cardiac devices are reviewed in
etail in other publications (1071), and the upcoming
CC/AHA guideline for the management of adult patients
ith CHD (1072). For an in-depth review of the rationale
or the recommended changes in the approach to patients
ith valvular heart disease, the reader is referred to the
HA guidelines on prevention of infective endocarditis,
ublished online April 2007 (1070).
.3.1. Endocarditis Prophylaxis (UPDATED)
LASS IIa
. Prophylaxis against infective endocarditis is reasonable for the
following patients at highest risk for adverse outcomes from infec-
tive endocarditis who undergo dental procedures that involve ma-
nipulation of either gingival tissue or the periapical region of teeth or
perforation of the oral mucosa (1070):
● Patients with prosthetic cardiac valve or prosthetic material used
for cardiac valve repair. (Level of Evidence: B)
● Patients with previous infective endocarditis. (Level of Evidence: B)
● Patients with CHD. (Level of Evidence: B)
● Unrepaired cyanotic CHD, including palliative shunts and con-
duits. (Level of Evidence: B)
● Completely repaired congenital heart defect repaired with
prosthetic material or device, whether placed by surgery or by
catheter intervention, during the first 6 months after the
procedure. (Level of Evidence: B)
● Repaired CHD with residual defects at the site or adjacent to
the site of a prosthetic patch or prosthetic device (both of
which inhibit endothelialization). (Level of Evidence: B)
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structurally abnormal valve. (Level of Evidence: C)
LASS III
. Prophylaxis against infective endocarditis is not recommended for non-
able 4. Classification of the Severity of Valve Disease in Adul
. Left-sided valve disease
Indicator Mild
et velocity (m per s) Less than 3.0
ean gradient (mm Hg)* Less than 25
alve area (cm2) Greater than 1.5
alve area index (cm2 per m2)
Mild
ean gradient (mm Hg)* Less than 5
ulmonary artery systolic pressure (mm Hg) Less than 30
alve area (cm2) Greater than 1.5
Mild
ualitative
ngiographic grade 1
olor Doppler jet width Central jet, width less than
25% of LVOT
oppler vena contracta width (cm) Less than 0.3
uantitative (cath or echo)
egurgitant volume (ml per beat) Less than 30
egurgitant fraction (%) Less than 30
egurgitant orifice area (cm2) Less than 0.10
dditional essential criteria
eft ventricular size
Mild
ualitative
ngiographic grade 1
olor Doppler jet area Small, central jet (less
than 4 cm2 or less than
20% LA area)
oppler vena contracta width (cm) Less than 0.3
uantitative (cath or echo)
egurgitant volume (ml per beat) Less than 30
egurgitant fraction (%) Less than 30
egurgitant orifice area (cm2) Less than 0.20
dditional essential criteria
eft atrial size
eft ventricular size
. Right-sided valve disease
evere tricuspid stenosis: Valve area less than 1.0 cm2
evere tricuspid regurgitation: Vena contracta width greater t
evere pulmonic stenosis: Jet velocity greater than 4 m p
evere pulmonic regurgitation: Color jet fills outflow tract; den
Valve gradients are flow dependent and when used as estimates of severity of valve stenosis
he Journal of the American Society of Echocardiography, 16, Zoghbi WA, Recommendation
chocardiography, 777–802, Copyright 2003, with permission from American Society of Echoca
AR indicates aortic regurgitation; cath, catheterization; echo, echocardiography; LA, left atrialdental procedures (such as transesophageal echocardiogram, esophago- [gastroduodenoscopy, or colonoscopy) in the absence of active infection.
(Level of Evidence: B) (1070)
Table 5 of the 2006 Valvular Heart Disease Guideline
Aortic Stenosis
Moderate Severe
4.0 Greater than 4.0
0 Greater than 40
1.5 Less than 1.0
Less than 0.6
Mitral Stenosis
Moderate Severe
Greater than 10
0 Greater than 50
1.5 Less than 1.0
Aortic Regurgitation
Moderate Severe
3–4
ter than mild but no
gns of severe AR
Central jet, width greater than 65% LVOT
0.6 Greater than 0.6
9 Greater than or equal to 60
9 Greater than or equal to 50
–0.29 Greater than or equal to 0.30
Increased
Mitral Regurgitation
Moderate Severe
3–4
s of MR greater than
ild present but no
iteria for severe MR
Vena contracta width greater than 0.7 cm with large
central MR jet (area greater than 40% of LA area) or
with a wall-impinging jet of any size, swirling in LA
0.69 Greater than or equal to 0.70
9 Greater than or equal to 60
9 Greater than or equal to 50
–0.39 Greater than or equal to 0.40
Enlarged
Enlarged
Characteristic
.7 cm and systolic flow reversal in hepatic veins
r maximum gradient greater than 60 mmHg
tinuous wave Doppler signal with a steep deceleration slope
be assessed with knowledge of cardiac output or forward flow across the valve. Modified from
valuation of the severity of native valvular regurgitation with two-dimensional and Doppler
phy (27).
; LVOT, left ventricular outflow tract; and MR, mitral regurgitation.ts
3.0–
25–4
1.0–
5–10
30–5
1.0–
2
Grea
si
0.3–
30–5
30–4
0.10
2
Sign
m
cr
0.3–
30–5
30–4
0.20
han 0
er s o
se con
should
s for e1068] is now obsolete.)
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedInfective endocarditis is a serious illness associated with
ignificant morbidity and mortality. Its prevention by the
ppropriate administration of antibiotics before a procedure
xpected to produce bacteremia merits serious consider-
tion. Experimental studies have suggested that endothelial
amage leads to platelet and fibrin deposition and the
ormation of nonbacterial thrombotic endocardial lesions.
n the presence of bacteremia, organisms may adhere to
hese lesions and multiply within the platelet-fibrin com-
lex, leading to an infective vegetation. Valvular and
ongenital abnormalities, especially those associated with
igh velocity jets, can result in endothelial damage,
latelet fibrin deposition, and a predisposition to bacte-
ial colonization. Since 1955, the AHA has made recom-
endations for prevention of infective endocarditis with
ntimicrobial prophylaxis before specific dental, gastro-
ntestinal (GI), and genitourinary (GU) procedures in
atients at risk for its development. However, many
uthorities and societies, as well as the conclusions of
able 6. Endocarditis Prophylaxis for Dental Procedures
UPDATED)*
Reasonable Not Recommended
ndocarditis prophylaxis is
reasonable for patients
with the highest risk of
adverse outcomes who
undergo dental
procedures that involve
manipulation of either
gingival tissue or the
periapical region of
teeth or perforation of
the oral mucosa.
Endocarditis prophylaxis is not
recommended for:
• Routine anesthetic injections through
noninfected tissue
• Dental radiographs
• Placement or removal of
prosthodontic or orthodontic
appliances
• Adjustment of orthodontic appliances
• Placement of orthodontic brackets
• Shedding of deciduous teeth
• Bleeding from trauma to the lips or
oral mucosa
This table corresponds to Table 3 in the ACC/AHA 2008 Guideline Update on Valvular Heart
isease: Focused Update on Infective Endocarditis (1069).
Adapted with permission (28).
able 7. Regimens for a Dental Procedure (UPDATED)*
Situation
ral A
nable to take oral medication A
O
C
llergic to penicillins or ampicillin—oral C
O
C
O
A
llergic to penicillins or ampicillin and unable to take oral medication C
O
C
This table corresponds to Table 4 in the ACC/AHA 2008 Guideline Update on Valvular Heart Di
ephalosporin in equivalent adult or pediatric dosage. ‡Cephalosporins should not be used in an indiv
IM indicates intramuscular; and IV, intravenous.ublished studies, have questioned the efficacy of antimi-
robial prophylaxis in most situations.
On the basis of these concerns, a writing group was
ppointed by the AHA for their expertise in prevention and
reatment of infective endocarditis, with liaison members
epresenting the American Dental Association, the Infec-
ious Disease Society of America, and the American Acad-
my of Pediatrics. The writing group reviewed the relevant
iterature regarding procedure-related bacteremia and infec-
ive endocarditis, in vitro susceptibility data of the most
ommon organisms that cause infective endocarditis, results
f prophylactic studies of animal models of infective endo-
arditis, and both retrospective and prospective studies of
revention of infective endocarditis. As a result, major
hanges were made in the recommendations for prophylaxis
gainst infective endocarditis.
The major changes in the updated recommendations
ncluded the following:
The committee concluded that only an extremely small
number of cases of infective endocarditis might be
prevented by antibiotic prophylaxis for dental procedures
even if such prophylactic therapy were 100 percent effective.
Infective endocarditis prophylaxis for dental procedures
is reasonable only for patients with underlying cardiac
conditions associated with the highest risk of adverse
outcome from infective endocarditis.
For patients with these underlying cardiac conditions,
prophylaxis is reasonable for all dental procedures that
involve manipulation of either gingival tissue or the
periapical region of teeth or perforation of oral mucosa.
Prophylaxis is not recommended based solely on an in-
creased lifetime risk of acquisition of infective endocarditis.
Administration of antibiotics solely to prevent endocar-
ditis is not recommended for patients who undergo GU
or GI tract procedure.
Regimen: Single Dose 30 to 60 min
Before Procedure
Agent Adults Children
cillin 2 g 50 mg/kg
illin 2 g IM or IV 50 mg/kg IM or IV
lin or ceftriaxone 1 g IM or IV 50 mg/kg IM or IV
lexin†‡ 2 g 50 mg/kg
mycin 600 mg 20 mg/kg
mycin or clarithromycin 500 mg 15 mg/kg
lin or ceftriaxone‡ 1 g IM or IV 50 mg/kg IM or IV
mycin 600 mg IM or IV 20 mg/kg IM or IV
Focused Update on Infective Endocarditis (1069). †Or use other first- or second-generation oralmoxi
mpic
R
efazo
epha
R
linda
R
zithro
efazo
R
linda
sease: 
idual with a history of anaphylaxis, angioedema, or urticaria with penicillins or ampicillin.
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142The rationale for these revisions is based on the following:
Infective endocarditis is more likely to result from fre-
quent exposure to random bacteremias associated with
daily activities than from bacteremia caused by a dental,
GI tract, or GU procedure;
Prophylaxis may prevent an exceedingly small number of
cases of infective endocarditis (if any) in individuals who
undergo a dental, GI tract, or GU procedure;
The risk of antibiotic associated adverse effects exceeds
the benefit (if any) from prophylactic antibiotic therapy;
Maintenance of optimal oral health and hygiene may
reduce the incidence of bacteremia from daily activities
and is more important than prophylactic antibiotics for a
dental procedure to reduce the risk of infective
endocarditis.
Table 8 of the 2006 Valvular Heart Disease Guidelines
1068] is now obsolete.)
The AHA Prevention of Infective Endocarditis Commit-
ee recommended that prophylaxis should be given only to
he high-risk group of patients prior to dental procedures
hat involve manipulation of gingival tissue or the periapical
egion of the teeth or perforation of oral mucosa. High-risk
atients were defined as those patients with underlying
ardiac conditions associated with the highest risk of adverse
utcome from infective endocarditis, not necessarily those
ith an increased lifetime risk of acquisition of infective
ndocarditis. Prophylaxis is no longer recommended for
revention of endocarditis for procedures involving the
espiratory tract unless the procedure is performed in a
igh-risk patient and involves incision of the respiratory
ract mucosa, such as tonsillectomy and adenoidectomy.
rophylaxis is no longer recommended for prevention of
nfective endocarditis for GI or GU procedures, including
iagnostic esophagogastroduodenoscopy or colonoscopy.
owever, in high risk-patients with infections of the GI or
U tract, it is reasonable to administer antibiotic therapy to
revent wound infection or sepsis. For high-risk patients
ndergoing elective cystoscopy or other urinary tract ma-
ipulation who have enterococcal urinary tract infection or
olonization, antibiotic therapy to eradicate enterococci
rom the urine before the procedure is reasonable.
These changes are a significant departure from the past
HA (723) and European Society of Cardiology (1073)
ecommendations for prevention of infective endocarditis,
nd may violate longstanding expectations in practice pat-
erns of patients and healthcare providers. However, the
riting committee for these updated guidelines consisted of
xperts in the field of infective endocarditis; input was also
btained from experts not affiliated with the writing group.
ll data to date were thoroughly reviewed, and the current
ecommendations reflect analysis of all relevant literature.
his multidisciplinary team of experts emphasized that
revious published guidelines for the prevention of endo-
arditis contained ambiguities and inconsistencies and relied
ore on opinion than on data. The writing committee pelineated the reasons for which evolutionary refinement in
he approach to infective endocarditis prophylaxis can be
ustified. In determining which patients receive prophylaxis,
here is a clear focus on the risk of adverse outcomes after
nfective endocarditis rather than the lifetime risk of acqui-
ition of infective endocarditis. The current recommenda-
ions result in greater clarity for patients, health care
roviders, and consulting professionals.
Other international societies have published recommen-
ations and guidelines for the prevention of infective endo-
arditis. New recommendations from the British Society for
ntimicrobial Chemotherapy are similar to the current
HA recommendations for prophylaxis before dental pro-
edures. The British Society for Antimicrobial Chemother-
py did differ in continuing to recommend prophylaxis for
igh-risk patients prior to GI or GU procedures associated
ith bacteremia or endocarditis (1074).
Therefore, Class IIa indications for prophylaxis against
nfective endocarditis are reasonable for valvular heart disease
atients at highest risk for adverse outcomes from infective
ndocarditis before dental procedures that involve manipula-
ion of either gingival tissue. This high-risk group includes: 1)
atients with a prosthetic heart valve or prosthetic material
sed for valve repair, 2) patients with a past history of infective
ndocarditis, and 3) patients with cardiac valvulopathy follow-
ng cardiac transplantation, as well as 4) specific patients with
HD. Patients with innocent murmurs and those patients
ho have abnormal echocardiographic findings without an
udible murmur should definitely not be given prophylaxis for
nfective endocarditis. Infective endocarditis prophylaxis is not
ecessary for nondental procedures which do not penetrate the
ucosa, such as transesophageal echocardiography, diagnostic
ronchoscopy, esophagogastroscopy, or colonoscopy, in the
bsence of active infection.
The committee recognizes that decades of previous
ecommendations for patients with most forms of valvu-
ar heart disease and other conditions have been abruptly
hanged by the new AHA guidelines (1069). Because this
ay cause consternation among patients, clinicians
hould be available to discuss the rationale for these new
hanges with their patients, including the lack of scien-
ific evidence to demonstrate a proven benefit for infec-
ive endocarditis prophylaxis. In select circumstances,
he committee also understands that some clinicians and
ome patients may still feel more comfortable continuing
ith prophylaxis for infective endocarditis, particularly
or those with bicuspid aortic valve or coarctation of the
orta, severe mitral valve prolapse, or hypertrophic ob-
tructive cardiomyopathy. In those settings, the clinician
hould determine that the risks associated with antibiot-
cs are low before continuing a prophylaxis regimen.
ver time, and with continuing education, the commit-
ee anticipates increasing acceptance of the new guide-
ines among both provider and patient communities.
A multicenter randomized controlled trial has never been
erformed to evaluate the efficacy of infective endocarditis
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedrophylaxis in patients who undergo dental, GI, or GU
rocedures. On the basis of these new recommendations,
ewer patients will receive infective endocarditis prophylaxis.
t is hoped that the revised recommendations will stimulate
roperly designed prospective studies on the prevention of
nfective endocarditis.
.3.2. Rheumatic Fever Prophylaxis
.3.2.1. GENERAL CONSIDERATIONS
heumatic fever is an important cause of valvular heart disease.
n the United States (and Western Europe), cases of acute
heumatic fever have been uncommon since the 1970s. How-
ver, starting in 1987, an increase in cases has been observed
43,44). With the enhanced understanding of the causative
rganism, group A beta hemolytic streptococcus, its rheumato-
enicity is attributed to the prevalence of M-protein serotypes
f the offending organism. This finding has resulted in the
evelopment of kits that allow rapid detection of group A
treptococci with specificity greater than 95% and more rapid
dentification of their presence in upper respiratory infection.
ecause the test has a low sensitivity, a negative test requires
hroat culture confirmation (44). Prompt recognition and
reatment comprise primary rheumatic fever prevention. For
atients who have had a previous episode of rheumatic fever,
ontinuous antistreptococcal prophylaxis is indicated for sec-
ndary prevention.
.3.2.2. PRIMARY PREVENTION
heumatic fever prevention and treatment guidelines have
een established previously by the AHA (Table 9) (45).
.3.2.3. SECONDARY PREVENTION
LASS I
. Patients who have had rheumatic fever with or without carditis (including
patientswithMS) should receive prophylaxis for recurrent rheumatic fever.
able 9. Primary Prevention of Rheumatic Fever
Agent D
enzathine/Penicillin G Patients 27 kg (60 lb) o
Patients greater than 27
r
enicillin V (phenoxymethyl penicillin) Children: 250 mg 2–3 ti
Adolescents and adults:
or individuals allergic to penicillin
Erythromycin
Estolate 20–40 mg per kg per da
2–4 times daily (maxim
or
Ethylsuccinate 40 mg per kg per day
2–4 times daily (maxim
or
Azithromycin 500 mg on first day
250 mg per day for the
eprinted with permission from Dajani A, Taubert K, Ferrieri P, et al. Treatment of acute strepto
n Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Dise(Level of Evidence: B)
7Patients who have had an episode of rheumatic fever are
t high risk of developing recurrent episodes of acute
heumatic fever. Patients who develop carditis are especially
rone to similar episodes with subsequent attacks. Second-
ry prevention of rheumatic fever recurrence is thus of great
mportance. Continuous antimicrobial prophylaxis has been
hown to be effective. Anyone who has had rheumatic fever
ith or without carditis (including patients with MS)
hould receive prophylaxis for recurrent rheumatic fever.
he 1995 AHA guidelines for secondary prevention are
hown in Table 10, and the 1995 AHA guidelines for
uration of secondary prevention are shown in Table 11 (45).
Mode Duration
600 000 U Intramuscular Once
0 lb): 1 200 000 U
aily Oral 10 d
g 2–3 times daily
Oral 10 d
g per day)
Oral 10 d
g per day)
Oral 5 d
days
haryngitis and prevention of rheumatic fever: a statement for health professionals. Committee
the Young, the American Heart Association. Pediatrics 1995;96:758–64 (45).
able 10. Secondary Prevention of Rheumatic Fever
Agent Dose Mode
enicillin G benzathine 1 200 000 U every 4 wk
(every 3 wk for high-risk*
pts such as those with
residual carditis)
Intramuscular
r
enicillin V 250 mg twice daily Oral
r
ulfadiazine 0.5 g once daily for pts 27 g
(60 lb) or less; 1.0 g once
daily for pts greater than
27 kg (60 lb)
Oral
or individuals allergic to
penicillin and
sulfadiazine
Erythromycin 250 mg twice daily Oral
High-risk patients include patients with residual rheumatic carditis and patients from econom-
cally disadvantaged populations. Dajani A, Taubert K, Ferrieri P, et al. Treatment of acute
treptococcal pharyngitis and prevention of rheumatic fever: a statement for health profession-
ls. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on
ardiovascular Disease in the Young, the American Heart Association. Pediatrics 1995;96:ose
r less:
kg (6
mes d
500 m
y
um 1
um 1
next 458–64 (45).
Pts indicates patients.
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.1. Aortic Stenosis
.1.1. Introduction
he most common cause of AS in adults is calcification of
normal trileaflet or congenital bicuspid valve (46–49).
his calcific disease progresses from the base of the cusps to
he leaflets, eventually causing a reduction in leaflet motion
nd effective valve area without commissural fusion. Calcific
S is an active disease process characterized by lipid
ccumulation, inflammation, and calcification, with many
imilarities to atherosclerosis (50–60). Rheumatic AS due
o fusion of the commissures with scarring and eventual
alcification of the cusps is less common and is invariably
ccompanied by MV disease. A congenital malformation of
he valve may also result in stenosis and is the more common
ause in young adults. The management of congenital AS in
dolescents and young adults is discussed in Section 6.1.
.1.1.1. GRADING THE DEGREE OF STENOSIS
lthough AS is best described as a disease continuum, and
here is no single value that defines severity, for these
uidelines, we graded AS severity on the basis of a variety of
emodynamic and natural history data (Table 4) (27,61),
sing definitions of aortic jet velocity, mean pressure gradi-
nt, and valve area as follows:
Mild (area 1.5 cm2, mean gradient less than 25 mm Hg,
or jet velocity less than 3.0 m per second)
Moderate (area 1.0 to 1.5 cm2, mean gradient 25 to 40
mm Hg, or jet velocity 3.0 to 4.0 m per second)
Severe (area less than 1.0 cm2, mean gradient greater
than 40 mm Hg, or jet velocity greater than 4.0 m per
second).
When stenosis is severe and cardiac output is normal, the
ean transvalvular pressure gradient is generally greater
han 40 mm Hg. However, when cardiac output is low,
evere stenosis may be present with a lower transvalvular
radient and velocity, as discussed below. Some patients
able 11. Duration of Secondary Rheumatic Fever Prophylaxis
Category Duration
heumatic fever with carditis and
residual heart disease
(persistent valvular disease)
10 y or greater since last episode and at
least until age 40 y; sometimes
lifelong prophylaxis*
heumatic fever with carditis but
no residual heart disease (no
valvular disease)
10 y or well into adulthood, whichever is
longer
heumatic fever without carditis 5 y or until age 21 y, whichever is longer
The committee’s interpretation of “lifelong” prophylaxis refers to patients who are at high risk
nd likely to come in contact with populations with a high prevalence of streptococcal infection,
hat is, teachers and day-care workers. Reprinted with permission from Dajani A, Taubert K,
errieri P, et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever:
statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and
awasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart
ssociation. Pediatrics 1995;96:758–64 (45).ith severe AS remain asymptomatic, whereas others with pnly moderate stenosis develop symptoms. Therapeutic
ecisions, particularly those related to corrective surgery, are
ased largely on the presence or absence of symptoms.
hus, the absolute valve area (or transvalvular pressure
radient) is not the primary determinant of the need for
ortic valve replacement (AVR).
.1.2. Pathophysiology
n adults with AS, the obstruction develops gradually—
sually over decades. During this time, the left ventricle
dapts to the systolic pressure overload through a hypertro-
hic process that results in increased LV wall thickness,
hile a normal chamber volume is maintained (62–64). The
esulting increase in relative wall thickness is usually enough
o counter the high intracavitary systolic pressure, and as a
esult, LV systolic wall stress (afterload) remains within the
ange of normal. The inverse relation between systolic wall
tress and ejection fraction is maintained; as long as wall
tress is normal, the ejection fraction is preserved (65).
owever, if the hypertrophic process is inadequate and
elative wall thickness does not increase in proportion to
ressure, wall stress increases and the high afterload causes
decrease in ejection fraction (65–67). Depressed contrac-
ile state of the myocardium may also be responsible for a
ow ejection fraction, and it is often difficult clinically to
etermine whether a low ejection fraction is due to de-
ressed contractility or to excessive afterload (68). When
ow ejection fraction is caused by depressed contractility,
orrective surgery will be less beneficial than in patients with
low ejection fraction caused by high afterload (69).
As a result of increased wall thickness, low volume/mass
atio, and diminished compliance of the chamber, LV
nd-diastolic pressure increases without chamber dilatation
70–72). Thus, increased end-diastolic pressure usually
eflects diastolic dysfunction rather than systolic dysfunction
r failure (73). A forceful atrial contraction that contributes
o an elevated end-diastolic pressure plays an important role
n ventricular filling without increasing mean left atrial or
ulmonary venous pressure (74). Loss of atrial contraction
uch as that which occurs with atrial fibrillation is often
ollowed by serious clinical deterioration.
The development of concentric hypertrophy appears to be
n appropriate and beneficial adaptation to compensate for
igh intracavitary pressures. Unfortunately, this adaptation
ften carries adverse consequences. The hypertrophied heart
ay have reduced coronary blood flow per gram of muscle
nd also exhibit a limited coronary vasodilator reserve, even
n the absence of epicardial CAD (75–77). The hemody-
amic stress of exercise or tachycardia can produce a
aldistribution of coronary blood flow and subendocardial
schemia, which can contribute to systolic or diastolic
ysfunction of the left ventricle. Hypertrophied hearts also
xhibit an increased sensitivity to ischemic injury, with
arger infarcts and higher mortality rates than are seen in the
bsence of hypertrophy (78–80). Another problem that is
articularly common in elderly patients, especially women,
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hickness is greater than necessary to counterbalance the
igh intracavitary pressures (81–84). As a result, systolic
all stress is low and ejection fraction is high; such inap-
ropriate LV hypertrophy has been associated with high
erioperative morbidity and mortality (81,83).
.1.3. Natural History
he natural history of AS in the adult consists of a
rolonged latent period during which morbidity and mor-
ality are very low. The rate of progression of the stenotic
esion has been estimated in a variety of invasive and
oninvasive studies (85). Once even moderate stenosis is
resent (jet velocity greater than 3.0 m per second) (Table 4)
27), the average rate of progression is an increase in jet
elocity of 0.3 m per second per year, an increase in mean
ressure gradient of 7 mm Hg per year, and a decrease in
alve area of 0.1 cm2 per year (86–96). However, there is
arked individual variability in the rate of hemodynamic
rogression. Although it appears that the progression of AS
an be more rapid in patients with degenerative calcific
isease than in those with congenital or rheumatic disease
96–98), it is not possible to predict the rate of progression
n an individual patient. For this reason, regular clinical
ollow-up is mandatory in all patients with asymptomatic
ild to moderate AS. In addition, progression to AS may
ccur in patients with aortic sclerosis, defined as valve
hickening without obstruction to ventricular outflow (99).
Aortic sclerosis, defined as irregular valve thickening
ithout obstruction to LV outflow, is present in about 25%
f adults over 65 years of age and is associated with clinical
actors such as age, sex, hypertension, smoking, serum
ow-density lipoprotein and lipoprotein(a) levels, and dia-
etes mellitus (100). In the Cardiovascular Health Study,
he presence of aortic sclerosis on echocardiography in
ubjects without known coronary disease was also associated
ith adverse clinical outcome, with an approximately 50%
ncreased risk of myocardial infarction and cardiovascular
eath compared with subjects with a normal aortic valve (101).
his has been confirmed in 2 additional studies (102,103). The
ssociation between aortic sclerosis and adverse cardiovascular
utcomes persisted even when age, sex, known cardiovascular
isease, and cardiovascular risk factors were taken into account.
owever, the mechanism of this association is unclear and is
nlikely to be related to valve hemodynamics. Studies are in
rogress to evaluate potential mechanisms of this association,
ncluding subclinical atherosclerosis, endothelial dysfunction,
nd systemic inflammation.
In most patients with severe AS, impaired platelet func-
ion and decreased levels of von Willebrand factor can be
emonstrated. The severity of the coagulation abnormality
orrelates with the severity of AS and resolves after valve
eplacement, except when the prosthetic valve area is small
or patient size (less than 0.8 cm2 per m2). This acquired
on Willebrand syndrome is associated with clinical bleed-ng, most often epistaxis or ecchymoses, in approximately
0% of patients (104).
Eventually, symptoms of angina, syncope, or heart failure
evelop after a long latent period, and the outlook changes
ramatically. After the onset of symptoms, average survival
s 2 to 3 years (105–111), with a high risk of sudden death.
hus, the development of symptoms identifies a critical
oint in the natural history of AS. Management decisions
re based largely on these data; most clinicians treat asymp-
omatic patients conservatively, whereas corrective surgery is
enerally recommended in patients with symptoms thought
o be due to AS. It is important to emphasize that
ymptoms may be subtle and often are not elicited by the
hysician in taking a routine clinical history.
Sudden death is known to occur in patients with severe
S and, in older retrospective studies, has been reported to
ccur without prior symptoms (105,108,112,113). How-
ver, in prospective echocardiographic studies, sudden death
n previously asymptomatic patients is rare (61,96,109,114–
16). Therefore, although sudden death may occur in the
bsence of preceding symptoms in patients with AS
105,108,112,113,116), it is an uncommon event, estimated
t less than 1% per year when patients with known AS are
ollowed up prospectively.
.1.4. Management of the Asymptomatic Patient
symptomatic patients with AS have outcomes similar to
ge-matched normal adults. However, disease progression
ith symptom onset is common, as detailed in Table 12
61,96,109,114–118). In a prospective study of 123 asymp-
omatic adults with an initial jet velocity of at least 2.6 m per
econd, the rate of symptom development was 38% at 3
ears for the total group. However, clinical outcome was
trongly dependent on AS severity, with an event-free
urvival of 84% at 2 years in those with a jet velocity less
han 3 m per second compared with only 21% in those with
jet velocity more than 4 m per second (61,98). In another
tudy of 128 asymptomatic adults with an initial aortic jet
elocity of at least 4 m per second, event-free survival was
7% at 1 year and 33% at 4 years, with predictors of
utcome that included age and the degree of valve calcifi-
ation (96). A third study of patients with aortic jet
elocities greater than 4 m per second provided similar
esults, with 33% remaining asymptomatic without surgery
t 5 years (116). Therefore, patients with asymptomatic AS
equire frequent monitoring for development of symptoms
nd progressive disease.
.1.4.1. ECHOCARDIOGRAPHY (IMAGING, SPECTRAL, AND COLOR DOPPLER)
N AORTIC STENOSIS
LASS I
. Echocardiography is recommended for the diagnosis and assess-
ment of AS severity. (Level of Evidence: B)
. Echocardiography is recommended in patients with AS for the
assessment of LV wall thickness, size, and function. (Level of
Evidence: B)
34
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142. Echocardiography is recommended for re-evaluation of patients with
known AS and changing symptoms or signs. (Level of Evidence: B)
. Echocardiography is recommended for the assessment of changes
in hemodynamic severity and LV function in patients with known AS
during pregnancy. (Level of Evidence: B)
. Transthoracic echocardiography is recommended for re-evaluation
of asymptomatic patients: every year for severe AS; every 1 to 2
years for moderate AS; and every 3 to 5 years for mild AS. (Level of
Evidence: B)
ortic stenosis typically is first suspected on the basis of the
nding of a systolic ejection murmur on cardiac ausculta-
ion; however, physical examination findings are specific but
ot sensitive for the diagnosis of AS severity (119). The
lassic findings of a loud (grade 4/6), late-peaking systolic
urmur that radiates to the carotids, a single or paradoxi-
ally split second heart sound (S2), and a delayed and
iminished carotid upstroke confirm the presence of severe
S. However, in the elderly, the carotid upstroke may be
ormal because of the effects of aging on the vasculature,
able 12. Clinical Outcomes in Prospective Studies of Asympto
Study, Year
No. of
Patients
Severity of Aortic
Stenosis Age, y
elly et al., 1988 (109) 51 Vmax greater than
3.6 m per second
63 8
ellikka et al., 1990 (114) 113 Vmax 4.0 m per second
or greater
40–94
ennedy et al., 1991 (115) 66 AVA 0.7–1.2 cm2 67 1
tto et al., 1997 (61) 123 Vmax greater than
2.6 m per second
63 1
osenhek et al., 2000 (96) 128 Vmax greater than
4.0 m per second
60 1
mato et al., 2001 (117) 66 AVA 1.0 cm2 or
greater
18–80
(50 1
as et al., 2005 (118) 125 AVA less than 1.4 cm2 56–74
(mean 6
ellikka et al., 2005 (116) 622 Vmax 4.0 m per second
or greater
72 1
Positive exercise test indicates symptoms, abnormal ST-segment response, or abnormal blood
AVA indicates aortic valve area; Ca2, aortic valve calcification; and Vmax, peak instantaneound the murmur may be soft or may radiate to the apex. The vnly physical examination finding that is reliable in exclud-
ng the possibility of severe AS is a normally split second
eart sound (119).
Echocardiography is indicated when there is a systolic
urmur that is grade 3/6 or greater, a single S2, or
ymptoms that might be due to AS. The 2-dimensional
2D) echocardiogram is valuable for evaluation of valve
natomy and function and determining the LV response to
ressure overload. In nearly all patients, the severity of the
tenotic lesion can be defined with Doppler echocardio-
raphic measurements of maximum jet velocity, mean
ransvalvular pressure gradient, and continuity equation
alve area, as discussed in the “ACC/AHA/ASE 2003
uidelines for the Clinical Application of Echocardiogra-
hy” (2). Doppler evaluation of AS severity requires atten-
ion to technical details, with the most common error being
nderestimation of disease severity due to a nonparallel
ntercept angle between the ultrasound beam and high-
ic Aortic Stenosis in Adults
Mean
Follow-Up Group
Event-Free Survival
Without Symptoms
5–25 mo Overall 59% at 15 mo
20 mo Overall
Overall
86% at 1 y
62% at 2 y
35 mo Overall 59% at 4 y
2.5 1.4 y Overall 93 5% at 1 y
62 8% at 3 y
26 10% at 5 y
Subgroups:
Vmax less than 3–4 m per second 84 16% at 2 y
Vmax 3–4 m per second 66 13% at 2 y
Vmax greater than 3 m per second 21 18% at 2 y
22 18 mo Overall 67 5% at 1 y
56 55% at 2 y
33 5% at 4 y
Subgroups:
No or mild Ca2 75 9% at 4 y
Moderate-severe Ca2 20 5% at 4 y
15 12 mo Overall 57% at 1 y
38% at 2 y
Subgroups:
AVA 0.7 cm2 or greater 72% at 2 y
AVA less than 0.7 cm2 21% at 2 y
Negative exercise test 85% at 2 y
Positive exercise test* 19% at 2 y
12 mo Subgroups:
AVA 1.2 cm2 or greater
AVA 0.8 cm2 or less
100% at 1 y
46% at 1 y
No symptoms on exercise test 89% at 1 y
Symptoms on exercise test 49% at 1 y
5.4 4.0 y Overall 82% at 1 y
67% at 2 y
33% at 5 y
ure response (less than 20-mm Hg increase) with exercise.
ity.mat
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utflow tract velocity to aortic jet velocity can be substi-
uted for valve area, because this ratio is, in effect,
ndexed for body size. A ratio of 0.9 to 1.0 is normal, with
ratio less than 0.25 indicating severe stenosis. Echocar-
iography is also used to assess LV size and function,
egree of hypertrophy, and presence of other associated
alvular disease.
In some patients, it may be necessary to proceed with
ardiac catheterization and coronary angiography at the
ime of initial evaluation. For example, this is appropriate if
here is a discrepancy between clinical and echocardio-
raphic examinations or if symptoms might be due to CAD.
.1.4.2. EXERCISE TESTING
LASS IIb
. Exercise testing in asymptomatic patients with AS may be consid-
ered to elicit exercise-induced symptoms and abnormal blood pres-
sure responses. (Level of Evidence: B)
LASS III
. Exercise testing should not be performed in symptomatic patients
with AS. (Level of Evidence: B)
Exercise testing in adults with AS has poor diagnostic
ccuracy for evaluation of concurrent CAD. Presumably,
his is due to the presence of an abnormal baseline ECG,
V hypertrophy, and limited coronary flow reserve. Elec-
rocardiographic ST depression during exercise occurs in
0% of adults with asymptomatic AS and has no known
rognostic significance.
Exercise testing should not be performed in symptomatic
atients owing to a high risk of complications. However, in
symptomatic patients, exercise testing is relatively safe and
ay provide information that is not uncovered during the
nitial clinical evaluation (61,117,118,120–124). When the
edical history is unclear, exercise testing can identify a
imited exercise capacity, abnormal blood pressure re-
ponses, or even exercise-induced symptoms (117,118,124).
n one series (117), patients manifesting symptoms, abnor-
al blood pressure (less than 20-mm Hg increase), or
T-segment abnormalities with exercise had a symptom-
ree survival at 2 years of only 19% compared with 85%
ymptom-free survival in those with none of these findings
ith exercise. Four patients died during the course of this
tudy (1.2% annual mortality rate); all had an aortic valve
rea less than 0.7 cm2 and an abnormal exercise test. In
nother series (118), exercise testing brought out symptoms
n 29% of patients who where considered asymptomatic
efore testing; in these patients, spontaneous symptoms
eveloped in 51% over the next year compared with only
1% of patients who had no symptoms on exercise testing.
n abnormal hemodynamic response (e.g., hypotension or
ailure to increase blood pressure with exercise) in a patient
ith severe AS is considered a poor prognostic finding
117,125). Finally, in selected patients, the observations made
uring exercise may provide a basis for advice about physical bctivity. Exercise testing in asymptomatic patients should be
erformed only under the supervision of an experienced phy-
ician with close monitoring of blood pressure and the ECG.
.1.4.3. SERIAL EVALUATIONS
he frequency of follow-up visits to the physician depends
n the severity of the valvular stenosis and on the presence
f comorbid conditions. Recognizing that an optimal sched-
le for repeated medical examinations has not been defined,
any physicians perform an annual history and physical
xamination on patients with asymptomatic AS of any
egree. An essential component of each visit is patient
ducation about the expected disease course and symptoms
f AS. Periodic echocardiography may be appropriate as
iscussed below. Patients should be advised to promptly
eport the development of any change in exercise tolerance,
xertional chest discomfort, dyspnea, lightheadedness, or
yncope.
Serial echocardiography is an important part of an inte-
rated approach that includes a detailed history, physical
xamination, and, in some patients, a carefully monitored
xercise test. Because the rate of progression varies consid-
rably, clinicians often perform an annual echocardiogram
n patients known to have moderate to severe AS. Serial
chocardiograms are helpful for assessing changes in steno-
is severity, LV hypertrophy, and LV function. Therefore,
n patients with severe AS, an echocardiogram every year
ay be appropriate. In patients with moderate AS, serial
tudies performed every 1 to 2 years are satisfactory, and in
atients with mild AS, serial studies can be performed every
to 5 years. Echocardiograms should be performed more
requently if there is a change in signs or symptoms.
.1.4.4. MEDICAL THERAPY (UPDATED)
ntibiotic prophylaxis against recurrent rheumatic fever is
ndicated for patients with rheumatic AS. Patients with
ssociated systemic arterial hypertension should be treated
autiously with appropriate antihypertensive agents. With
hese exceptions, there is no specific medical therapy for
atients who have not yet developed symptoms. Patients
ho develop symptoms require surgery, not medical
herapy.
There are no medical treatments proven to prevent or
elay the disease process in the aortic valve leaflets. How-
ver, the association of AS with clinical factors similar to
hose associated with atherosclerosis and the mechanisms of
isease at the tissue level (50–60,99–103,126–129) have
ed to the hypothesis that intervention may be possible to
low or prevent disease progression in the valve leaflet
127,130). Specifically, the effect of lipid-lowering therapy
n progression of calcific AS has been examined in several
mall retrospective studies using echocardiography or car-
iac computed tomography to measure disease severity
131–136), suggesting a benefit of statins. However, a
rospective, randomized, placebo-controlled trial in patients
ith calcific aortic valve disease failed to demonstrate a
enefit of atorvastatin in reducing the progression of aortic
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142alve stenosis over a 3-year period (137). It is noteworthy
hat the patients in this study had high levels of aortic valve
alcification by computed tomography and evidence of
oderate to severe AS at baseline, based on peak aortic
alve gradient (48 to 50 mm Hg), aortic valve area (1.02 to
.03 cm2), and peak jet velocity (3.39 to 3.45 m per second).
t is possible that the calcific process was too advanced in
hese patients to be reversed by short-term statin therapy.
hus, further trials in patients with less severe aortic valve
alcification, with longer follow-up periods, are needed. In
he meanwhile, evaluation and modification of cardiac risk
actors is important in patients with aortic valve disease to
revent concurrent CAD.
.1.4.5. PHYSICAL ACTIVITY AND EXERCISE
ecommendations for physical activity are based on the
linical examination, with special emphasis on the hemody-
amic severity of the stenotic lesion. The severity can
sually be judged by Doppler echocardiography, but in
orderline cases, diagnostic cardiac catheterization may be
ecessary to accurately define the degree of stenosis.
Recommendations on participation in competitive sports
ave been published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
138). Physical activity is not restricted in asymptomatic
atients with mild AS; these patients can participate in
ompetitive sports. Patients with moderate to severe AS
hould avoid competitive sports that involve high dynamic
nd static muscular demands. Other forms of exercise can be
erformed safely, but it is advisable to evaluate such patients
ith an exercise test before they begin an exercise or athletic
rogram.
.1.5. Indications for Cardiac Catheterization
LASS I
. Coronary angiography is recommended before AVR in patients with
AS at risk for CAD (see Section 10.2). (Level of Evidence: B)
. Cardiac catheterization for hemodynamic measurements is recom-
mended for assessment of severity of AS in symptomatic patients
when noninvasive tests are inconclusive or when there is a discrep-
ancy between noninvasive tests and clinical findings regarding
severity of AS. (Level of Evidence: C)
. Coronary angiography is recommended before AVR in patients with
AS for whom a pulmonary autograft (Ross procedure) is contem-
plated and if the origin of the coronary arteries was not identified by
noninvasive technique. (Level of Evidence: C)
LASS III
. Cardiac catheterization for hemodynamic measurements is not
recommended for the assessment of severity of AS before AVR
when noninvasive tests are adequate and concordant with clinical
findings. (Level of Evidence: C)
. Cardiac catheterization for hemodynamic measurements is not
recommended for the assessment of LV function and severity of AS
in asymptomatic patients. (Level of Evidence: C)
n patients with AS, the indications for cardiac catheteriza-
ion and angiography are essentially the same as in other
onditions, namely, to assess the coronary circulation and vonfirm or clarify the clinical diagnosis. In preparation for
VR, coronary angiography is indicated in patients sus-
ected of having CAD, as discussed in Section 10.2. If the
linical and echocardiographic data are typical of severe
solated AS, coronary angiography may be all that is needed
efore AVR. A complete left- and right-heart catheteriza-
ion may be necessary to assess the hemodynamic severity of
he AS if there is a discrepancy between clinical and
chocardiographic data.
The pressure gradient across a stenotic valve is related to
he valve orifice area and the transvalvular flow (139). Thus,
n the presence of depressed cardiac output, relatively low
ressure gradients may be obtained in patients with severe
S. On the other hand, during exercise or other high-flow
tates, significant pressure gradients can be measured in
inimally stenotic valves. For these reasons, complete
ssessment of AS requires
measurement of transvalvular flow
determination of the mean transvalvular pressure gradient
calculation of the effective valve area.
Attention to detail with accurate measurements of pres-
ure and flow is important, especially in patients with low
ardiac output or a low transvalvular pressure gradient.
.1.6. Low-Flow/Low-Gradient Aortic Stenosis
LASS IIa
. Dobutamine stress echocardiography is reasonable to evaluate
patients with low-flow/low-gradient AS and LV dysfunction. (Level of
Evidence: B)
. Cardiac catheterization for hemodynamic measurements with infu-
sion of dobutamine can be useful for evaluation of patients with
low-flow/low-gradient AS and LV dysfunction. (Level of Evidence: C)
atients with severe AS and low cardiac output often
resent with a relatively low transvalvular pressure gradient
i.e., mean gradient less than 30 mm Hg). Such patients can
e difficult to distinguish from those with low cardiac output
nd only mild to moderate AS. In the former (true anatom-
cally severe AS), the stenotic lesion contributes to an
levated afterload, decreased ejection fraction, and low
troke volume. In the latter, primary contractile dysfunction
s responsible for the decreased ejection fraction and low
troke volume; the problem is further complicated by
educed valve opening forces that contribute to limited valve
obility and apparent stenosis. In both situations, the
ow-flow state and low-pressure gradient contribute to a
alculated effective valve area that can meet criteria for
evere AS. Alternate measures of AS severity have been
roposed as being less flow dependent than gradients or
alve area. These include valve resistance and stroke work
oss. However, all of these measures are flow dependent,
ave not been shown to predict clinical outcome, and have
ot gained widespread clinical use (140).
In selected patients with low-flow/low-gradient AS and
V dysfunction, it may be useful to determine the transval-
ular pressure gradient and to calculate valve area during a
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acological (i.e., dobutamine infusion) stress, with the goal
f determining whether stenosis is severe or only moderate
n severity (123,141–147). Such studies can be performed in
he echocardiography laboratory or in the cardiac catheter-
zation laboratory. This approach is based on the notion that
atients who do not have true anatomically severe stenosis
ill exhibit an increase in the valve area and little change in
radient during an increase in stroke volume (141,142).
hus, if a dobutamine infusion produces an increment in
troke volume and an increase in valve area greater than 0.2
m2 and little change in gradient, it is likely that baseline
valuation overestimated the severity of stenosis. In con-
rast, patients with severe AS will have a fixed valve area
ith an increase in stroke volume and an increase in
radient. These patients are likely to respond favorably to
urgery. Patients who fail to show an increase in stroke
olume with dobutamine (less than 20%), referred to as
lack of contractile reserve,” appear to have a very poor
rognosis with either medical or surgical therapy (2,148).
obutamine stress testing in patients with AS should be
erformed only in centers with experience in pharmacolog-
cal stress testing and with a cardiologist in attendance.
The clinical approach to the patient with low-output AS
elies on integration of multiple sources of data. In addition
o measurement of Doppler velocity, gradient, and valve
rea, the extent of valve calcification should be assessed.
evere calcification suggests that AVR may be beneficial.
hen transthoracic images are suboptimal, transesophageal
maging or fluoroscopy may be used to assess the degree of
alve calcification and orifice area. The risk of surgery and
atient comorbidities also are taken into account. Although
atients with low-output severe AS have a poor prognosis,
n those with contractile reserve, outcome is still better with
VR than with medical therapy (148). Some patients
ithout contractile reserve may also benefit from AVR, but
ecisions in these high-risk patients must be individualized
ecause there are no data indicating who will have a better
utcome with surgery.
.1.7. Indications for Aortic Valve Replacement
LASS I
. AVR is indicated for symptomatic patients with severe AS.* (Level of
Evidence: B)
. AVR is indicated for patients with severe AS* undergoing coronary
artery bypass graft surgery (CABG). (Level of Evidence: C)
. AVR is indicated for patients with severe AS* undergoing surgery on
the aorta or other heart valves. (Level of Evidence: C)
. AVR is recommended for patients with severe AS* and LV systolic
dysfunction (ejection fraction less than 0.50). (Level of Evidence: C)
LASS IIa
. AVR is reasonable for patients with moderate AS* undergoing CABG
or surgery on the aorta or other heart valves (see Section 3.7 on
combined multiple valve disease and Section 10.4 on AVR in
patients undergoing CABG). (Level of Evidence: B)fSee Table 4 (27).LASS IIb
. AVR may be considered for asymptomatic patients with severe AS*
and abnormal response to exercise (e.g., development of symptoms
or asymptomatic hypotension). (Level of Evidence: C)
. AVR may be considered for adults with severe asymptomatic AS* if
there is a high likelihood of rapid progression (age, calcification, and
CAD) or if surgery might be delayed at the time of symptom onset.
(Level of Evidence: C)
. AVRmay be considered in patients undergoing CABG who havemild
AS* when there is evidence, such as moderate to severe valve
calcification, that progression may be rapid. (Level of Evidence: C)
. AVR may be considered for asymptomatic patients with extremely
severe AS (aortic valve area less than 0.6 cm2, mean gradient
greater than 60 mm Hg, and jet velocity greater than 5.0 m per
second) when the patient’s expected operative mortality is 1.0% or
less. (Level of Evidence: C)
LASS III
. AVR is not useful for the prevention of sudden death in asymptom-
atic patients with AS who have none of the findings listed under the
CLASS IIa/IIb recommendations. (Level of Evidence: B)
In adults with severe, symptomatic, calcific AS, AVR is
he only effective treatment. Younger patients with congen-
tal or rheumatic AS may be candidates for valvotomy (see
ection 6.1 under management of adolescents and young
dults). Although there is some lack of agreement about the
ptimal timing of surgery in asymptomatic patients, it is
ossible to develop rational guidelines for most patients. A
roposed management strategy for patients with severe AS
s shown in Figure 3 (149). Particular consideration should
e given to the natural history of asymptomatic patients and
o operative risks and outcomes after surgery. See also
ection 7.2.
.1.7.1. SYMPTOMATIC PATIENTS
n symptomatic patients with AS, AVR improves symptoms
nd improves survival (106,150–155). These salutary results
f surgery are partly dependent on LV function. The
utcome is similar in patients with normal LV function and
n those with moderate depression of contractile function.
he depressed ejection fraction in many patients in this
atter group is caused by excessive afterload (afterload
ismatch) (66), and LV function improves after AVR in
uch patients. If LV dysfunction is not caused by afterload
ismatch, survival is still improved, but improvement in LV
unction and resolution of symptoms might not be complete
fter AVR (150,154,156–158). Therefore, in the absence of
erious comorbid conditions, AVR is indicated in virtually
ll symptomatic patients with severe AS. Because of the risk
f sudden death, AVR should be performed promptly after
he onset of symptoms. Age is not a contraindication to
urgery, with several series showing outcomes similar to
ge-matched normal subjects in the very elderly. The
perative risks can be estimated with readily available and
ell-validated online risk calculators from the Society of
horacic Surgeons (www.sts.org) and the European Systemor Cardiac Operative Risk Evaluation (www.euroscore.org)
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ally for valvular heart surgery by Ambler et al. (162).
.1.7.2. ASYMPTOMATIC PATIENTS
any clinicians are reluctant to proceed with AVR in an
symptomatic patient (163), whereas others are concerned
bout caring for a patient with severe AS without surgery.
lthough AVR is associated with low perioperative mor-
idity and mortality in many centers, the average perioper-
tive mortality in the STS database is 3.0% to 4.0% for
solated AVR and 5.5% to 6.8% for AVR plus CABG
164,165). These rates are 33% higher in centers with low
olume than in centers with the highest surgical volume
166). A review of Medicare data (167), involving 684 US
ospitals and more than 142 000 patients, indicates that the
verage in-hospital mortality for AVR in patients over the
ge of 65 years is 8.8% (13.0% in low-volume centers and
.0% in high-volume centers). In addition, despite im-
roved longevity of current-generation bioprosthetic valves
168,169), AVR in young patients subjects them to the risks
f structural valve deterioration of bioprostheses (168,170–
74) and the appreciable morbidity and mortality of me-
hanical valves (172,174–178). Thus, the combined risk of
urgery in older patients and the late complications of a
rosthesis in younger patients needs to be balanced against
he possibility of preventing sudden death, which, as noted
igure 3. Management Strategy for Patients With Severe Aortic S
reoperative coronary angiography should be performed routinely as determined by a
lso be helpful when there is discordance between clinical findings and echocardiog
ntervention. J Am Coll Cardiol 2006;47:2141–51 (149). AVA indicates aortic valve a
aphy; LV, left ventricular; and Vmax, maximal velocity across aortic valve by Dopplerbove, occurs at a rate of less than 1.0% per year. oDespite these considerations, some difference of opinion
ersists among clinicians regarding the indications for AVR
n asymptomatic patients with severe AS, because the
robability of remaining free of cardiac symptoms without
urgery is less than 50% at 5 years (61,96,116). Some argue
hat irreversible myocardial depression or fibrosis might
evelop during a prolonged asymptomatic stage and that
his might preclude an optimal outcome. Such irreversibility
as not been proved, but this concept has been used to
upport early surgery (152,179). Still others attempt to
dentify patients who are at especially high risk of sudden
eath without surgery, although data supporting this ap-
roach are limited. Currently, there is general agreement
hat the risk of AVR exceeds any potential benefit in
atients with severe AS who are truly asymptomatic with
ormal LV systolic function. However, as improved valve
ubstitutes are developed and methods of valve replacement
ecome safer, the risk-benefit balance may change to favor
arlier intervention in AS.
Studies suggest that patients at risk of rapid disease
rogression and impending symptom onset can be identified
n the basis of clinical and echocardiographic parameters.
he rate of hemodynamic progression is faster in patients
ith asymptomatic severe (96) or mild to moderate (98) AS
hen patient age is over 50 years and severe valve calcifi-
ation or concurrent CAD is present. Adverse clinical
is
mptoms, and coronary risk factors. Cardiac catheterization and angiography may
Modified from CM Otto. Valvular aortic stenosis: disease severity and timing of
P, blood pressure; CABG, coronary artery bypass graft surgery; echo, echocardiog-
ardiography.tenos
ge, sy
raphy.
rea; Butcomes are more likely in patients with a more rapid rate
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedf hemodynamic progression, defined as an annual increase
n aortic jet velocity greater than 0.3 m per second per year
r a decrease in valve area greater than 0.1 cm2 per year
61,96). The presence of left ventricular hypertrophy by
CG and smaller aortic valve area by Doppler echocardi-
graphy predict the development of symptoms (61,116). In
ddition, serum levels of B-type natriuretic peptide may
rovide important prognostic information (180). In situa-
ions in which there is delay between symptom onset and
urgical intervention, patients are at high risk of adverse
utcomes during the waiting period. These higher-risk
atients might warrant more frequent echocardiography or
arlier consideration of valve replacement.
In the 1998 ACC/AHA Guidelines for the Management
f Patients with Valvular Heart Disease, consideration was
iven to performing AVR in patients with AS and severe
V hypertrophy and those with ventricular tachycardia
Class IIb). The current committee determined that there
as insufficient evidence to support those recommenda-
ions, which are not carried forward in the current
ocument.
.1.7.3. PATIENTS UNDERGOING CORONARY ARTERY BYPASS OR
THER CARDIAC SURGERY
atients with severe AS, with or without symptoms, who
re undergoing CABG should undergo AVR at the time of
he revascularization procedure. Similarly, patients with
evere AS undergoing surgery on other valves (such as MV
epair) or the aortic root should also undergo AVR as part
f the surgical procedure. In patients with moderate AS, it
s generally accepted practice to perform AVR at the time of
ABG (181–185). Many clinicians also recommend AVR
or moderate AS at the time of MV or aortic root surgery
for further detail, see Section 3.7, “Multiple Valve Dis-
ase”). However, there are no data to support a policy of
VR for mild AS at the time of CABG, with the exception
f those patients with moderate to severe valvular calcifica-
ion (98,181,182,185–187). Recommendations for AVR at
he time of CABG are discussed in Section 10.4.
.1.8. Aortic Balloon Valvotomy
LASS IIb
. Aortic balloon valvotomymight be reasonable as a bridge to surgery
in hemodynamically unstable adult patients with AS who are at high
risk for AVR. (Level of Evidence: C)
. Aortic balloon valvotomy might be reasonable for palliation in adult
patients with AS in whom AVR cannot be performed because of
serious comorbid conditions. (Level of Evidence: C)
LASS III
. Aortic balloon valvotomy is not recommended as an alternative to
AVR in adult patients with AS; certain younger adults without valve
calcification may be an exception (see Section 6.1.3). (Level of
Evidence: B)
Percutaneous balloon aortic valvotomy is a procedure in
hich 1 or more balloons are placed across a stenotic valvend inflated to decrease the severity of AS (188–190). This mrocedure has an important role in treating adolescents and
oung adults with AS (see Section 6.1.) but a very limited
ole in older adults. The mechanism underlying relief of the
tenotic lesion in older adults is fracture of calcific deposits
ithin the valve leaflets and, to a minor degree, stretching of
he annulus and separation of the calcified or fused com-
issures (191–193). Immediate hemodynamic results in-
lude a moderate reduction in the transvalvular pressure
radient, but the postvalvotomy valve area rarely exceeds 1.0
m2. Despite the modest change in valve area, an early
ymptomatic improvement is usually seen. However, serious
cute complications occur with a frequency greater than
0% (194–200), and restenosis and clinical deterioration
ccur within 6 to 12 months in most patients (195,200–
04). Therefore, in adults with AS, balloon valvotomy is not
substitute for AVR (204–207).
Some clinicians contend that despite the procedural
orbidity and mortality and limited long-term results,
alloon valvotomy can have a temporary role in the man-
gement of some symptomatic patients who are not initially
andidates for AVR (207). For example, patients with
evere AS and refractory pulmonary edema or cardiogenic
hock might benefit from aortic valvuloplasty as a “bridge”
o surgery; an improved hemodynamic state may reduce the
isks of surgery. However, most clinicians recommend
roceeding directly to AVR in these cases. The indications
or palliative valvotomy in patients in whom AVR cannot be
ecommended because of serious comorbid conditions are
ven less well established, with no data to suggest improved
ongevity, although some patients do report a decrease in
ymptoms. Most asymptomatic patients with severe AS
ho require urgent noncardiac surgery can undergo surgery
t a reasonably low risk with monitoring of anesthesia and
ttention to fluid balance (208–212). Balloon aortic valvot-
my is not recommended for these patients. If preoperative
orrection of AS is needed, they should be considered for
VR.
.1.9. Medical Therapy for the Inoperable Patient
omorbid conditions (e.g., malignancy) or, on occasion,
atient preferences might preclude AVR for severe AS.
nder such circumstances, there is no therapy that prolongs
ife, and only limited medical therapies are available to
lleviate symptoms. Patients with evidence of pulmonary
ongestion can benefit from cautious treatment with digi-
alis, diuretics, and angiotensin converting enzyme (ACE)
nhibitors. Indeed, a cautious reduction in central blood
olume and LV preload can be efficacious in some patients
ith heart failure symptoms. It should be recognized,
owever, that excessive preload reduction can depress car-
iac output and reduce systemic arterial pressure; patients
ith severe AS are especially subject to this untoward effect
ue to a small hypertrophied ventricle. In patients with
cute pulmonary edema due to AS, nitroprusside infusion
ay be used to reduce congestion and improve LV perfor-
ance. Such therapy should be performed in an intensive
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onitoring (213). Digitalis should be reserved for patients
ith depressed systolic function or atrial fibrillation. Atrial
brillation and other atrial arrhythmias have an adverse
ffect on atrial pump function and ventricular rate; if prompt
ardioversion is unsuccessful, pharmacological control of the
entricular rate is essential. If angina is the predominant
ymptom, cautious use of nitrates and beta blockers can
rovide relief. There is no specific medical therapy for
yncope unless it is caused by a bradyarrhythmia or tachy-
rrhythmia.
.1.10. Evaluation After Aortic Valve Replacement
onsidering the known complications of prosthetic aortic
alves (168,170–178,214), patients require periodic clinical
nd selected laboratory examinations after AVR. A com-
lete history and physical examination should be performed
t least once a year. Indications for echocardiography are
iscussed in Section 9.3.
.1.11. Special Considerations in the Elderly
ecause there is no effective medical therapy and balloon
alvotomy is not an acceptable alternative to surgery, AVR
ust be considered in all elderly patients who have symp-
oms caused by AS. Valve replacement is technically possi-
le at any age (215), but the decision to proceed with such
urgery depends on many factors, including the patient’s
ishes and expectations. Older patients with symptoms due
o severe AS, normal coronary arteries, and preserved LV
unction can expect a better outcome than those with CAD
r LV dysfunction (110). Certainly advanced cancer and
ermanent neurological defects as a result of stroke or
ementia make cardiac surgery inappropriate. Decondi-
ioned and debilitated patients often do not return to an
ctive existence, and the presence of the other comorbid
isorders could have a major impact on outcome.
In addition to the confounding effects of CAD and the
otential for stroke, other considerations are peculiar to
lder patients. For example, a narrow LV outflow tract and
small aortic annulus sometimes present in elderly women
ould require enlargement of the annulus. Heavy calcifica-
ion of the valve, annulus, and aortic root may require
ebridement. Occasionally, a composite valve-aortic graft is
eeded. Likewise, excessive or inappropriate hypertrophy
ssociated with valvular stenosis can be a marker for peri-
perative morbidity and mortality (81,83). Preoperative
ecognition of elderly patients with marked LV hypertrophy
ollowed by appropriate perioperative management can
educe this morbidity and mortality substantially. There is
o perfect method for weighing all of the relevant factors
nd identifying specifically high- and low-risk elderly pa-
ients, but this risk can be estimated well in individual
atients (159–162,216). The decision to proceed with AVR
epends on an imprecise analysis that considers the balance
etween the potential for improved symptoms and survival
nd the morbidity and mortality of surgery (217–219). i.2. Aortic Regurgitation
.2.1. Etiology
here are a number of common causes of AR. These
nclude idiopathic dilatation of the aorta, congenital abnor-
alities of the aortic valve (most notably bicuspid valves),
alcific degeneration, rheumatic disease, infective endocar-
itis, systemic hypertension, myxomatous degeneration, dis-
ection of the ascending aorta, and Marfan syndrome. Less
ommon causes include traumatic injuries to the aortic
alve, ankylosing spondylitis, syphilitic aortitis, rheumatoid
rthritis, osteogenesis imperfecta, giant cell aortitis, Ehlers-
anlos syndrome, Reiter’s syndrome, discrete subaortic
tenosis, and ventricular septal defects with prolapse of an
ortic cusp. Recently, anorectic drugs have also been re-
orted to cause AR (see Section 3.9.). The majority of these
esions produce chronic AR with slow, insidious LV dilation
nd a prolonged asymptomatic phase (Table 4) (27). Other
esions, in particular infective endocarditis, aortic dissection,
nd trauma, more often produce acute severe AR, which can
esult in sudden catastrophic elevation of LV filling pres-
ures and reduction in cardiac output.
.2.2. Acute Aortic Regurgitation
.2.2.1. PATHOPHYSIOLOGY
n acute severe AR, the sudden large regurgitant volume is
mposed on a left ventricle of normal size that has not had
ime to accommodate the volume overload. With an abrupt
ncrease in end-diastolic volume, the ventricle operates on
he steep portion of a normal diastolic pressure-volume
elationship, and LV end-diastolic and left atrial pressures
ay increase rapidly and dramatically. The Frank-Starling
echanism is used, but the inability of the ventricle to
evelop compensatory chamber dilatation acutely results in
decrease in forward stroke volume. Although tachycardia
evelops as a compensatory mechanism to maintain cardiac
utput, this is often insufficient. Hence, patients frequently
resent with pulmonary edema or cardiogenic shock. Acute
R creates especially marked hemodynamic changes in
atients with pre-existing pressure overload hypertrophy, in
hom the small, noncompliant LV cavity is set on an even
teeper diastolic pressure-volume relationship and has re-
uced preload reserve. Examples of this latter situation
nclude aortic dissection in patients with systemic hyperten-
ion, infective endocarditis in patients with pre-existing AS,
nd acute regurgitation after balloon valvotomy or surgical
ommissurotomy for congenital AS. Patients may also
resent with signs and symptoms of myocardial ischemia.
s the LV end-diastolic pressure approaches the diastolic
ortic and coronary artery pressures, myocardial perfusion
ressure in the subendocardium is diminished. LV dilation
nd thinning of the LV wall result in increased afterload,
nd this combines with tachycardia to increase myocardial
xygen demand. Therefore, ischemia and its consequences,
ncluding sudden death, occur commonly in acute severe AR.
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any of the characteristic physical findings of chronic AR
re modified or absent when valvular regurgitation is acute,
hich can lead to underestimation of its severity. LV size
ay be normal on physical examination, and cardiomegaly
ay be absent on chest X-ray. Pulse pressure may not be
ncreased because systolic pressure is reduced and the aortic
iastolic pressure equilibrates with the elevated LV diastolic
ressure. Because this diastolic pressure equilibration be-
ween aorta and ventricle can occur before the end of
iastole, the diastolic murmur may be short and/or soft and
herefore poorly heard. The elevated LV diastolic pressure
an close the MV prematurely, reducing the intensity of the
rst heart sound. An apical diastolic rumble can be present,
ut it is usually brief and without presystolic accentuation.
achycardia is invariably present.
Echocardiography is indispensable in confirming the
resence and severity of the valvular regurgitation, deter-
ining its cause, estimating the degree of pulmonary
ypertension (if TR is present), and determining whether
here is rapid equilibration of aortic and LV diastolic
ressure. Evidence for rapid pressure equilibration includes
short AR diastolic half-time (less than 300 ms), a short
itral deceleration time (less than 150 ms), or premature
losure of the MV.
Acute AR caused by aortic root dissection is a surgical
mergency that requires particularly prompt identification
nd management. Transesophageal echocardiography is in-
icated when aortic dissection is suspected (220–222). In
ome settings, computed tomographic imaging or magnetic
esonance imaging should be performed if this will lead to a
ore rapid diagnosis than can be achieved by transesopha-
eal echocardiography (220,221,223). Cardiac catheteriza-
ion, aortography, and coronary angiography are rarely
equired, are associated with increased risk, and might delay
rgent surgery unnecessarily (221,224–227). Angiography
hould be considered only when the diagnosis cannot be
etermined by noninvasive imaging and when patients have
nown CAD, especially those with previous CABG (see
ection 10.2).
.2.2.3. TREATMENT
eath due to pulmonary edema, ventricular arrhythmias,
lectromechanical dissociation, or circulatory collapse is
ommon in acute severe AR, even with intensive medical
anagement. Urgent surgical intervention is recommended.
itroprusside, and possibly inotropic agents such as dopa-
ine or dobutamine to augment forward flow and reduce
V end-diastolic pressure, may be helpful to manage the
atient temporarily before surgery. Intra-aortic balloon
ounterpulsation is contraindicated. Although beta blockers
re often used in treating aortic dissection, these agents
hould be used very cautiously, if at all, in the setting of
cute AR because they will block the compensatory tachy-
ardia. In patients with acute severe AR resulting from
nfective endocarditis, surgery should not be delayed, espe- tially if there is hypotension, pulmonary edema, or evidence
f low output. In patients with mild acute AR, antibiotic
reatment may be all that is necessary if the patient is
emodynamically stable. Exceptions to this latter recom-
endation are discussed in Section 4.6.1.
.2.3. Chronic Aortic Regurgitation
.2.3.1. PATHOPHYSIOLOGY
he left ventricle responds to the volume load of chronic
R with a series of compensatory mechanisms, including an
ncrease in end-diastolic volume, an increase in chamber
ompliance that accommodates the increased volume with-
ut an increase in filling pressures, and a combination of
ccentric and concentric hypertrophy. The greater diastolic
olume permits the ventricle to eject a large total stroke
olume to maintain forward stroke volume in the normal
ange. This is accomplished through rearrangement of
yocardial fibers with the addition of new sarcomeres and
evelopment of eccentric LV hypertrophy (228). As a result,
reload at the sarcomere level remains normal or near
ormal, and the ventricle retains its preload reserve. The
nhanced total stroke volume is achieved through normal
erformance of each contractile unit along the enlarged
ircumference (229). Thus, LV ejection performance is
ormal, and ejection phase indexes such as ejection fraction
nd fractional shortening remain in the normal range.
owever, the enlarged chamber size, with the associated
ncrease in systolic wall stress, also results in an increase in
V afterload and is a stimulus for further hypertrophy
228,230). Thus, AR represents a condition of combined
olume overload and pressure overload (231). As the disease
rogresses, recruitment of preload reserve and compensatory
ypertrophy permit the ventricle to maintain normal ejec-
ion performance despite the elevated afterload (232,233).
he majority of patients remain asymptomatic throughout
his compensated phase, which may last for decades. Vaso-
ilator therapy has the potential to reduce the hemodynamic
urden in such patients.
For purposes of the subsequent discussion, patients with
ormal LV systolic function will be defined as those with
ormal LV ejection fraction at rest. It is recognized that
ther indices of LV function may not be “normal” in chronic
evere AR and that the hemodynamic abnormalities noted
bove may be considerable. It is also recognized that the
ransition to LV systolic dysfunction represents a contin-
um and that there is no single hemodynamic measurement
hat represents the absolute boundary between normal LV
ystolic function and LV systolic dysfunction.
In a large subset of patients, the balance between after-
oad excess, preload reserve, and hypertrophy cannot be
aintained indefinitely. Preload reserve may be exhausted
233), and/or the hypertrophic response may be inadequate
63), so that further increases in afterload result in a
eduction in ejection fraction, first into the low normal
ange and then below normal. Impaired myocardial contrac-
ility may also contribute to this process. Patients often
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ddition, diminished coronary flow reserve in the hypertro-
hied myocardium may result in exertional angina (234).
owever, this transition may be much more insidious, and
t is possible for patients to remain asymptomatic until
evere LV dysfunction has developed.
LV systolic dysfunction (defined as an ejection fraction
elow normal at rest) is initially a reversible phenomenon
elated predominantly to afterload excess, and full recovery
f LV size and function is possible with AVR (235–246).
ith time, during which the ventricle develops progressive
hamber enlargement and a more spherical geometry, de-
able 13. Preoperative Predictors of Surgical Outcome in Aorti
Study, Year Study Design
No. of
Patients Outcome Asse
orman et al., 1980 (251) Retrospective 90 Survival
enry et al., 1980 (257) Prospective 50 Survival 
unha et al., 1980 (250) Retrospective 86 Survival
reves et al., 1981 (252) Retrospective 45 Survival
umpuris et al., 1982 (258) Prospective 43 Survival, heart fa
LV function
aasch et al., 1983 (253) Prospective 32 Symptoms, LV
function
ioretti et al., 1983 (259) Retrospective 47 LV function
tone et al., 1984 (260) Prospective 113 LV function
onow et al., 1985, 1988
(254, 245)
Prospective 80 Survival, LV func
aniel et al., 1985 (261) Retrospective 84 Survival, sympto
LV function
ormier et al., 1986 (262) Prospective 73 Survival
heiban et al., 1986 (263) Retrospective 84 Survival
arabello et al., 1987 (243) Retrospective 14 LV function
aniguchi et al., 1987 (244) Retrospective 62 Survival
ichel et al., 1995 (256) Retrospective 286 LV function
lodas et al., 1996, 1997
(264, 265)
Retrospective 289 Survival
urina et al., 1998 (266) Retrospective 192 Survival
VR indicates aortic valve replacement; CI, cardiac index; EDD, end-diastolic dimension; EF, ejec
hortening; LV, left ventricular; NYHA, New York Heart Association.ressed myocardial contractility predominates over excessive (oading as the cause of progressive systolic dysfunction. This
an progress to the extent that the full benefit of surgical
orrection of the regurgitant lesion, in terms of recovery of
V function and improved survival, can no longer be
chieved (244,247–256).
A large number of studies have identified LV systolic
unction and end-systolic size as the most important determi-
ants of survival and postoperative LV function in patients
ndergoing AVR for chronic AR (235,237–267). Studies of
redictors of surgical outcome are listed in Table 13.
Among patients undergoing valve replacement for
hronic AR with preoperative LV systolic dysfunction
gurgitation
Findings
High-risk group identified by preoperative angiographic LV EF less than 0.50
High-risk group identified by preoperative echocardiographic LV FS less than
0.25 and/or ESD greater than 55 mm
High-risk group identified by preoperative echocardiographic LV FS less than
0.30. Mortality also significantly associated with preoperative ESD.
Among patients with FS less than 0.30, mortality higher in NYHA FC III-IV
than in FC I-II.
High-risk group identified by preoperative angiographic LV EF less than 0.45
and/or CI less than 2.5 L/mm. Among patients with EF less than 0.45,
mortality higher in NYHA FC III-IV than in FC I–II.
Persistent LV dilatation after AVR predicted by preoperative
echocardiographic LV ESD, radius/thickness mean and end-systolic wall
stress. All deaths occurred in patients with persistent LV dilatation.
Persistent LV dilatation after AVR predicted by echocardiographic LV ESD
greater than 2.6 cm/m2 and radius/thickness ratio greater than 3.8.
Trend toward worse survival in patients with persistent LV dilatation.
Persistent LV dysfunction predicted by preoperative EDD 75 mm or greater
and/or ESD 55 mm or greater
Normal LV function after AVR predicted by preoperative LV FS greater than
0.26, ESD less than 55 mm, and EDD less than 80 mm. No preoperative
variable predicted postoperative LV function.
Postoperative survival and LV function predicted by preoperative LV EF, FS,
and ESD. High-risk group identified by subnormal EF at rest. Among
patients with subnormal EF, poor exercise tolerance and prolonged
duration of LV dysfunction identified the highest-risk group.
Outcome after AVR predicted by preoperative LV FS and ESD. Survival at
2.5 years was 90.5% with FS greater than 0.25 and ESD 55 mm or less
but only 70% with ESD greater than 55 mm and FS 25% or less.
High-risk group identified by preoperative LV EF less than 0.40 and ESD 55
mm or greater
High-risk group identified by preoperative LV EF less than 0.50 and ESD
greater than 55 mm
Postoperative LV EF predicted by preoperative ESD, FS, EDD, and radius/
thickness ratio
High-risk group identified by preoperative ESV greater than 200 ml/m2
and/or EF less than 0.40
Postoperative LV dysfunction predicted by preoperative LV EF, FS, ESD, and
EDD
High-risk group identified by symptom severity and preoperative EF less
than 0.50
High-risk group identified by symptom severity, low EF, and elevated end-
diastolic volume
tion; ESD, end-systolic dimension; ESV, end-systolic volume; FC, functional class; FS, fractionalc Re
ssed
ilure,
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ms,defined as an ejection fraction below normal at rest), several
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esults after operation. These are listed in Table 14.
.2.3.2. NATURAL HISTORY
.2.3.2.1. ASYMPTOMATIC PATIENTS WITH NORMAL LEFT VEN-
RICULAR FUNCTION. There are no truly large-scale studies
able 14. Factors Predictive of Reduced Postoperative
urvival and Recovery of Left Ventricular Function in Patients
ith Aortic Regurgitation and Preoperative Left Ventricular
ystolic Dysfunction
everity of preoperative symptoms or reduced exercise tolerance
everity of depression of left ventricular ejection fraction
uration of preoperative left ventricular systolic dysfunction
able 15. Studies of the Natural History of Asymptomatic Patie
Study, Year
No. of
Patients
Mean
Follow-Up, y
Progression
Symptoms
Death, or L
Dysfunctio
Rate per y (
onow et al., 1983, 1991
(268, 271)
104 8.0 3.8
cognamiglio et al., 1986*
(269)
30 4.7 2.1
iemienczuk et al., 1989 (270) 50 3.7 4.0
cognamiglio et al., 1994*
(272)
74 6.0 5.7
ornos et al., 1995 (273) 101 4.6 3.0
shii et al., 1996 (274) 27 14.2 3.6
orer et al., 1998 (275) 104 7.3 6.2
arasoutchi et al., 2003 (276) 72 10 4.7
vangelista et al., 2005 (277) 31 7 3.6
verage 593 6.6 4.3
dash indicates that data were not available. *Two studies by the same authors involved sepa
BP indicates blood pressure; EDD, end-diastolic dimension; EDV, end-diastolic volume; EF, ejection fra
hortening; LV, left ventricular; NYHA, New York Heart Association; and PAP, pulmonary artery pressurevaluating the natural history of asymptomatic patients in
hom LV systolic function was known to be normal (as
etermined by invasive or noninvasive testing). The current
ecommendations are derived from 9 published series (268–
77) involving a total of 593 such patients (range, 27 to 104
atients/series) with a mean follow-up period of 6.6 years
Table 15). This analysis is subject to the usual limitations
f comparisons of different clinical series with different
atient selection factors and different end points. For
xample, 1 series (270) represents patients receiving placebo
n a randomized drug trial (278) that included some patients
ith “early” New York Heart Association (NYHA) func-
ional class II symptoms (although none had “limiting”
ymptoms), and another (272) represents patients receiving
With Aortic Regurgitation
Progression to
Asymptomatic LV
Dysfunction
Mortality,
No. of
Patients Commentsn
Rate per y
(%)
4 0.5 2 Outcome predicted by LV ESD, EDD,
change in EF with exercise, and
rate of change in ESD and EF at
rest with time.
3 2.1 0 3 Patients who developed
asymptomatic LV dysfunction
initially had lower PAP/ESV ratios
and trended toward higher LV
ESD and EDD and lower FS
1 0.5 0 Patients included those receiving
placebo and medical dropouts in
a randomized drug trial; included
some patients with NYHA FC II
symptoms; outcome predicted by
LV ESV, EDV, change in EF with
exercise, and end-systolic wall
stress
15 3.4 0 All patients received digoxin as part
of a randomized trial
6 1.3 0 Outcome predicted by pulse
pressure, LV ESD, EDD, and EF at
rest
— — 0 Development of symptoms
predicted by systolic BP, LV ESD,
EDD, mass index, and wall
thickness. LV function not
reported in all patients
7 0.9 4 20% Of patients in NYHA FC II;
outcome predicted by initial FC II
symptoms, change in LV EF with
exercise, LV ESD, and LV FS
1 0.1 0 Development of symptoms
predicted by LV ESD and EDD. LV
function not reported in all
patients
— — 1 Placebo control group in 7-year
vasodilator clinical trial
37 1.2 0.18% per y
tient groups.nts
to
,
V
n,
%)
rate pa
ction; ESD, end-systolic dimension; ESV, end-systolic volume; FC, functional class; FS, fractional
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ifedipine with digoxin. In 2 studies (274,276), LV function
as not reported in all patients, and it is unclear whether all
ad normal LV systolic function at baseline. In another
tudy (275), 20% of patients were not asymptomatic but
ad “early” NYHA functional class II symptoms, and the
resence of these symptoms was a significant predictor of
eath, LV dysfunction, or development of more severe
ymptoms. Some patients in this latter series had evi-
ence of LV systolic dysfunction (fractional shortening as
ow as 18%).
The results of these 9 studies are summarized in Tables
5 and 16. The rate of progression to symptoms and/or LV
ystolic dysfunction averaged 4.3% per year. Sudden death
ccurred in 7 of the 593 patients, for an average mortality
ate of less than 0.2% per year. Seven of the 9 studies
eported the rate of development of asymptomatic LV
ysfunction, defined as an ejection fraction at rest below
ormal (269–273,275,276); 37 of a total of 535 patients
eveloped depressed systolic function at rest without symp-
oms during a mean 5.9-year follow-up period, a rate of
.2% per year.
Despite the low likelihood of patients developing asymp-
omatic LV dysfunction, it should also be emphasized that
ore than one fourth of patients who die or develop systolic
ysfunction do so before the onset of warning symptoms
269–271,275). Thus, thorough questioning of patients
egarding symptomatic status is not sufficient in the serial
valuation of asymptomatic patients; quantitative evaluation
f LV function is also indispensable. Moreover, patients at
isk of future symptoms, death, or LV dysfunction can also
e identified on the basis of noninvasive testing. Five of the
atural history studies provide concordant information on
he variables associated with higher risk (270–272,275,276).
hese variables are age, LV end-systolic dimension (or
olume), LV end-diastolic dimension (or volume), and the
V ejection fraction during exercise. In 1 study (275), the
V ejection fraction during exercise was an independent risk
actor. However, the direction and magnitude of change in
jection fraction from rest to exercise is related not only to
yocardial contractility (279) but also to severity of volume
able 16. Natural History of Aortic Regurgitation
symptomatic patients with normal LV systolic
function (268–277)
Progression to symptoms and/or LV
dysfunction
Less than 6% per y
Progression to asymptomatic LV dysfunction Less than 3.5% per y
Sudden death Less than 0.2% per y
symptomatic patients with LV dysfunction
(281–283)
Progression to cardiac symptoms Greater than 25% per y
ymptomatic patients (284–288)
Mortality rate Greater than 10% per y
V indicates left ventricular.verload (271,278–280) and exercise-induced changes inreload and peripheral resistance (280). In 2 multivariate
nalyses (271,276), only age and end-systolic dimension on
nitial study were independent predictors of outcome, as were
he rate of increase in end-systolic dimension and decrease in
esting ejection fraction during serial longitudinal studies (271).
uring a mean follow-up period of 8 years, patients with initial
nd-systolic dimensions greater than 50 mm had a likelihood
f death, symptoms, and/or LV dysfunction of 19% per year.
n those with end-systolic dimensions of 40 to 50 mm, the
ikelihood was 6% per year, and when the dimension was less
han 40 mm, it was zero (271).
.2.3.2.2. ASYMPTOMATIC PATIENTS WITH DEPRESSED SYSTOLIC
UNCTION. The limited data in asymptomatic patients with
epressed LV ejection fraction indicate that the majority
evelop symptoms that warrant AVR within 2 to 3 years
281–283). The average rate of symptom onset in such
atients is greater than 25% per year (Table 16)
268–277,281–288).
.2.3.2.3. SYMPTOMATIC PATIENTS. There are no contempo-
ary large-scale studies of the natural history of symptomatic
atients with chronic AR, because the onset of angina or
ignificant dyspnea is usually an indication for valve replace-
ent. The data developed in the presurgical era indicate
hat patients with dyspnea, angina, or overt heart failure
ave a poor outcome with medical therapy, analogous to
hat of patients with symptomatic AS. Mortality rates of
reater than 10% per year have been reported in patients
ith angina pectoris and greater than 20% per year in those
ith heart failure (284–286). LV function was not mea-
ured in these patients, so it is unclear whether symptomatic
atients with normal ejection fractions have the same
dverse outcome as symptomatic patients with LV dysfunc-
ion; however, subsequent data indicate a poor outcome for
ymptomatic patients with medical therapy, even among
hose with preserved LV systolic function (274,287,288).
.2.3.3. DIAGNOSIS AND INITIAL EVALUATION
LASS I
. Echocardiography is indicated to confirm the presence and severity
of acute or chronic AR. (Level of Evidence: B)
. Echocardiography is indicated for diagnosis and assessment of the
cause of chronic AR (including valve morphology and aortic root size
and morphology) and for assessment of LV hypertrophy, dimension
(or volume), and systolic function. (Level of Evidence: B)
. Echocardiography is indicated in patients with an enlarged aortic
root to assess regurgitation and the severity of aortic dilatation.
(Level of Evidence: B)
. Echocardiography is indicated for the periodic re-evaluation of LV
size and function in asymptomatic patients with severe AR. (Level of
Evidence: B)
. Radionuclide angiography or magnetic resonance imaging is indi-
cated for the initial and serial assessment of LV volume and
function at rest in patients with AR and suboptimal echocardio-
grams. (Level of Evidence: B)
. Echocardiography is indicated to re-evaluate mild, moderate, or
severe AR in patients with new or changing symptoms. (Level of
Evidence: B)
C1
2
3
C
1
o
w
t
h
n
r
m
e
l
m
i
s
r
c
s
o
•
•
•
•
•
t
i
c
s
e
v
b
I
r
o
v
o
v
v
r
t
a
s
o
f
p
m
a
i
a
d
t
s
c
o
q
c
p
L
e
a
g
a
f
a
h
d
s
a
f
d
t
s
a
d
t
p
s
3
C
1
C
1
e31JACC Vol. 52, No. 13, 2008 Bonow et al.
September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedLASS IIa
. Exercise stress testing for chronic AR is reasonable for assessment
of functional capacity and symptomatic response in patients with a
history of equivocal symptoms. (Level of Evidence: B)
. Exercise stress testing for patients with chronic AR is reasonable for
the evaluation of symptoms and functional capacity before partici-
pation in athletic activities. (Level of Evidence: C)
. Magnetic resonance imaging is reasonable for the estimation of AR
severity in patients with unsatisfactory echocardiograms. (Level of
Evidence: B)
LASS IIb
. Exercise stress testing in patients with radionuclide angiography
may be considered for assessment of LV function in asymptomatic
or symptomatic patients with chronic AR. (Level of Evidence: B)
The diagnosis of chronic severe AR can usually be made
n the basis of the diastolic murmur, displaced LV impulse,
ide pulse pressure, and characteristic peripheral findings
hat reflect wide pulse pressure. A third heart sound is often
eard as a manifestation of the volume load and is not
ecessarily an indication of heart failure. An Austin-Flint
umble is a specific finding for severe AR (289,290). In
any patients with more mild to moderate AR, the physical
xamination will identify the regurgitant lesion but will be
ess accurate in determining its severity. When the diastolic
urmur of AR is louder in the third and fourth right
ntercostal spaces than in the third and fourth left intercostal
paces, the AR likely results from aortic root dilatation
ather than from a deformity of the leaflets alone (291). The
hest X-ray and ECG are helpful in evaluating overall heart
ize and rhythm, evidence of LV hypertrophy, and evidence
f conduction disorders.
Echocardiography is indicated:
to confirm the diagnosis of AR if there is an equivocal
diagnosis based on physical examination
to assess the cause of AR and to assess valve morphology
to provide a semiquantitative estimate of the severity of
AR
to assess LV dimension, mass, and systolic function
to assess aortic root size.
In asymptomatic patients with preserved systolic func-
ion, these initial measurements represent the baseline
nformation with which future serial measurements can be
ompared. In addition to semiquantitative assessment of the
everity of AR by color flow jet area and width by Doppler
chocardiography, quantitative measurement of regurgitant
olume, regurgitant fraction, and regurgitant orifice area can
e performed in experienced laboratories (Table 4) (27).
ndirect measures of severity of AR are helpful, using the
ate of decline in regurgitant gradient measured by the slope
f diastolic flow velocity, the degree of reversal in pulse wave
elocity in the descending aorta, and the magnitude of LV
utflow tract velocity (2,292,293). Comparison of stroke
olumes at the aortic valve compared with another unin-
olved valve may provide a quantitative measurement ofegurgitant fraction (294), but this measurement is more
echnically demanding.
LV wall stress may also be estimated from blood pressure
nd echocardiographic measurements. However, such wall
tress measurements are difficult to reproduce, have meth-
dological and conceptual problems, and should not be used
or diagnosis or management decision making in clinical
ractice.
For purposes of the subsequent discussion of manage-
ent of patients with AR, severe AR is defined as clinical
nd Doppler evidence of severe regurgitation (Table 4) (27)
n addition to LV cavity dilatation. If the patient is
symptomatic and leads an active lifestyle and the echocar-
iogram is of good quality, no other testing is necessary. If
he patient has severe AR and is sedentary or has equivocal
ymptoms, exercise testing is helpful to assess functional
apacity, symptomatic responses, and hemodynamic effects
f exercise (Fig. 4). If the echocardiogram is of insufficient
uality to assess LV function, radionuclide angiography or
ardiac magnetic resonance should be used in asymptomatic
atients to measure LV ejection fraction at rest and estimate
V volumes. In patients who are symptomatic on initial
valuation, it is reasonable to proceed directly to transesoph-
geal echocardiography or cardiac catheterization and an-
iography if the echocardiogram is of insufficient quality to
ssess LV function or severity of AR.
The exercise ejection fraction and the change in ejection
raction from rest to exercise are often abnormal, even in
symptomatic patients (268,270 –272,275,283,295–303);
owever, these have not been proved to have independent
iagnostic or prognostic value when LV function at rest and
everity of LV volume overload by echocardiography are
lready known. One study that did identify the LV ejection
raction response to exercise as a predictor of symptomatic
eterioration or LV dysfunction (275) included many pa-
ients with NYHA functional class II symptoms, LV
ystolic dysfunction (fractional shortening as low as 18%),
nd severe LV dilatation (end-diastolic and end-systolic
imensions as high as 87 and 65 mm, respectively). Hence,
he predictive nature of this response in asymptomatic
atients with normal LV systolic function and without
evere LV dilatation has not been fully demonstrated.
.2.3.4. MEDICAL THERAPY
LASS I
. Vasodilator therapy is indicated for chronic therapy in patients with
severe AR who have symptoms or LV dysfunction when surgery is
not recommended because of additional cardiac or noncardiac
factors. (Level of Evidence: B)
LASS IIa
. Vasodilator therapy is reasonable for short-term therapy to improve
the hemodynamic profile of patients with severe heart failure
symptoms and severe LV dysfunction before proceeding with AVR.(Level of Evidence: C)
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. Vasodilator therapy may be considered for long-term therapy in
asymptomatic patients with severe AR who have LV dilatation but
normal systolic function. (Level of Evidence: B)
LASS III
. Vasodilator therapy is not indicated for long-term therapy in asymp-
tomatic patients with mild to moderate AR and normal LV systolic
function. (Level of Evidence: B)
. Vasodilator therapy is not indicated for long-term therapy in asymp-
tomatic patients with LV systolic dysfunction who are otherwise
candidates for AVR. (Level of Evidence: C)
. Vasodilator therapy is not indicated for long-term therapy in symp-
tomatic patients with either normal LV function or mild to moderate
LV systolic dysfunction who are otherwise candidates for AVR. (Level
of Evidence: C)
herapy with vasodilating agents is designed to improve
orward stroke volume and reduce regurgitant volume.
hese effects should translate into reductions in LV end-
iastolic volume, wall stress, and afterload, resulting in
reservation of LV systolic function and reduction in LV
igure 4. Management Strategy for Patients With Chronic Severe
reoperative coronary angiography should be performed routinely as determined
ay also be helpful when there is discordance between clinical findings and ech
enters, serial follow-up may be performed with radionuclide ventriculography (RV
ssess left ventricular (LV) volume and systolic function. AVR indicates aortic va
nd SD, end-systolic dimension.ass. The acute administration of sodium nitroprusside, fydralazine, nifedipine, or felodipine reduces peripheral
ascular resistance and results in an immediate augmenta-
ion in forward cardiac output and a decrease in regurgitant
olume (304–313). With nitroprusside and hydralazine,
hese acute hemodynamic changes lead to a consistent
eduction in end-diastolic volume and an increase in ejec-
ion fraction (304–306,312). This is an inconsistent finding
ith a single oral dose of nifedipine (308–311). Reduced
nd-diastolic volume and increased ejection fraction have
lso been observed in small numbers of patients receiving
ong-term oral therapy with hydralazine and nifedipine for
eriods of 1 to 2 years (278,314); with nifedipine, these
ffects are associated with a reduction in LV mass
272,314). Less consistent results have been reported
ith ACE inhibitors, depending on the degree of reduc-
ion in arterial pressure and end-diastolic volume (315–
17). Reduced blood pressure with enalapril and
uinapril has been associated with decreases in end-
iastolic volume and mass but no change in ejection
c Regurgitation
, symptoms, and coronary risk factors. Cardiac catheterization and angiography
ography. “Stable” refers to stable echocardiographic measurements. In some
magnetic resonance imaging (MRI) rather than echocardiography (Echo) to
lacement; DD, end-diastolic dimension; EF, ejection fraction; eval, evaluation;Aorti
by age
ocardi
G) or
lve repraction (316,317).
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedThere are 3 potential uses of vasodilating agents in
hronic AR. It should be emphasized that these criteria
pply only to patients with severe AR. The first is long-term
reatment of patients with severe AR who have symptoms
nd/or LV dysfunction who are considered poor candidates
or surgery because of additional cardiac or noncardiac
actors. The second is improvement in the hemodynamic
rofile of patients with severe heart failure symptoms and
evere LV dysfunction with short-term vasodilator therapy
efore proceeding with AVR. In such patients, vasodilating
gents with negative inotropic effects should be avoided.
he third is prolongation of the compensated phase of
symptomatic patients who have volume-loaded left ventri-
les but normal systolic function.
Whether this latter effect can be achieved has been
nvestigated in only 2 studies. The first study compared
ong-acting nifedipine versus digoxin in a prospective ran-
omized trial (272). Over a 6-year period, fewer patients
andomized to nifedipine required AVR because of symp-
oms or development of LV dysfunction (ejection fraction
ess than 0.50). This study enrolled a relatively small
umber of patients (143 patients); there were relatively few
nd points (20 patients in the digoxin group and 6 in the
ifedipine group underwent AVR); and there was no
lacebo control group. A more recent study compared
lacebo, long-acting nifedipine, and enalapril in 95 consec-
tive patients, who were followed for 7 years (277). Neither
ifedipine nor enalapril reduced the development of symp-
oms or LV dysfunction warranting AVR compared with
lacebo. Moreover, neither drug significantly altered LV
imension, ejection fraction, or mass over the course of time
ompared with placebo. Thus, definitive recommendations
egarding the indications for long-acting nifedipine or ACE
nhibitors cannot be made at this time.
If vasodilator therapy is used, the goal is to reduce systolic
lood pressure, and drug dosage should be increased until
here is a measurable decrease in systolic blood pressure or
he patient develops side effects. It is rarely possible to decrease
ystolic blood pressure to normal because of the increased LV
troke volume, and drug dosage should not be increased
xcessively in an attempt to achieve this goal. Vasodilator
herapy is of unknown benefit and is not indicated in patients
ith normal blood pressure or normal LV cavity size.
Vasodilator therapy is not recommended for asymptom-
tic patients with mild or moderate AR and normal LV
unction in the absence of systemic hypertension, because
hese patients have an excellent outcome with no therapy. In
atients with severe AR, vasodilator therapy is not an
lternative to surgery in asymptomatic or symptomatic
atients with LV systolic dysfunction; such patients should
e considered surgical candidates rather than candidates for
ong-term medical therapy unless AVR is not recommended
ecause of additional cardiac or noncardiac factors. Whether
ymptomatic patients who have preserved systolic function
an be treated safely with aggressive medical management
nd whether aggressive medical management is as good or setter than AVR have not been determined. It is recom-
ended that symptomatic patients undergo surgery rather
han long-term medical therapy.
There is scant information about long-term therapy with
rugs other than vasodilators in asymptomatic patients with
evere AR and normal LV function. Thus, there are no data
o support the long-term use of digoxin, diuretics, nitrates,
r positive inotropic agents in asymptomatic patients and no
ata with regard to any drug in patients with mild or
oderate AR.
.2.3.5. PHYSICAL ACTIVITY AND EXERCISE
here are no data suggesting that exercise, particularly
trenuous periodic exercise, will contribute to or accelerate
he progression of LV dysfunction in AR. Asymptomatic
atients with normal LV systolic function may participate in
ll forms of normal daily physical activity, including mild
orms of exercise and in some cases competitive athletics.
sometric exercise should be avoided. Recommendations
egarding participation in competitive athletics were pub-
ished by the Task Force on Acquired Valvular Heart
isease of the 36th Bethesda Conference (138). Before
articipation in athletics, exercise testing to at least the level
f exercise required by the proposed activity is recom-
ended so that the patient’s tolerance for this degree of
xercise can be evaluated. This does not necessarily evaluate
he long-term effects of strenuous exercise, which are
nknown.
.2.3.6. SERIAL TESTING
he aim of serial evaluation of asymptomatic patients with
hronic AR is to detect the onset of symptoms and
bjectively assess changes in LV size and function that can
ccur in the absence of symptoms. In general, the stability
nd chronicity of the regurgitant lesion and the LV response
o volume load need to be established when the patient first
resents to the physician, especially if AR is moderate to
evere. If the chronic nature of the lesion is uncertain and
he patient does not present initially with one of the
ndications for surgery, repeat physical examination and
chocardiography should be performed within 2 to 3
onths after the initial evaluation to ensure that a subacute
rocess with rapid progression is not under way. Once the
hronicity and stability of the process has been established,
he frequency of clinical re-evaluation and repeat noninva-
ive testing depends on the severity of the valvular regurgi-
ation, the degree of LV dilatation, the level of systolic
unction, and whether previous serial studies have revealed
rogressive changes in LV size or function (Fig. 4). In most
atients, serial testing during the long-term follow-up
eriod should include a detailed history, physical examina-
ion, and echocardiography. Serial chest X-rays and ECGs
ave less value but are helpful in selected patients.
Asymptomatic patients with mild AR, little or no LV
ilatation, and normal LV systolic function can be seen on
yearly basis, with instructions to alert the physician ifymptoms develop in the interim. Yearly echocardiography
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itation has worsened. Routine echocardiography can be
erformed every 2 to 3 years in such patients.
Asymptomatic patients with normal systolic function but
evere AR and significant LV dilatation (end-diastolic
imension greater than 60 mm) require more frequent and
areful re-evaluation, with a history and physical examina-
ion every 6 months and echocardiography every 6 to 12
onths, depending on the severity of dilatation and stability
f measurements. If patients are stable, echocardiographic
easurements are not required more frequently than every
2 months. In patients with more advanced LV dilatation
end-diastolic dimension greater than 70 mm or end-
ystolic dimension greater than 50 mm), for whom the risk
f developing symptoms or LV dysfunction ranges between
0% and 20% per year (271,272), it is reasonable to perform
erial echocardiograms as frequently as every 4 to 6 months.
erial chest X-rays and ECGs have less value but are helpful
n selected patients.
Chronic AR may develop from disease processes that
nvolve the proximal ascending aorta. In patients with aortic
oot dilatation, serial echocardiograms are indicated to
valuate aortic root size, as well as LV size and function.
his is discussed in Section 3.2.4.
Repeat echocardiograms are also recommended when the
atient has onset of symptoms, there is an equivocal history
f changing symptoms or changing exercise tolerance, or
here are clinical findings that suggest worsening regurgita-
ion or progressive LV dilatation. Patients with echocardio-
raphic evidence of progressive ventricular dilatation or
eclining systolic function have a greater likelihood of
eveloping symptoms or LV dysfunction (271) and should
ave more frequent follow-up examinations (every 6
onths) than those with stable LV function.
In some centers with expertise in nuclear cardiology,
erial radionuclide ventriculograms to assess LV volume and
unction at rest may be an accurate and cost-effective
lternative to serial echocardiograms. However, there is no
ustification for routine serial testing with both an echocar-
iogram and a radionuclide ventriculogram. Serial radionu-
lide ventriculograms are also recommended in patients
ith suboptimal echocardiograms, patients with suggestive
ut not definite echocardiographic evidence of LV systolic
ysfunction, and patients for whom there is discordance
etween clinical assessment and echocardiographic data. In
enters with specific expertise in cardiac magnetic resonance
maging, serial magnetic resonance imaging may be per-
ormed in place of radionuclide angiography for the indica-
ions listed above. In addition to accurate assessment of LV
olume, mass, wall thickness, and systolic function (318–
22), cardiac magnetic resonance imaging may be used to
uantify the severity of valvular regurgitation (323–327).
Serial exercise testing is also not recommended routinely
n asymptomatic patients with preserved systolic function;
owever, exercise testing may be invaluable to assess func-
ional capacity and symptomatic responses in patients with hquivocal changes in symptomatic status. Serial exercise
maging studies to assess LV functional reserve are not
ndicated in asymptomatic patients or those in whom
ymptoms develop.
.2.3.7. INDICATIONS FOR CARDIAC CATHETERIZATION
LASS I
. Cardiac catheterization with aortic root angiography and measure-
ment of LV pressure is indicated for assessment of severity of
regurgitation, LV function, or aortic root size when noninvasive tests
are inconclusive or discordant with clinical findings in patients with
AR. (Level of Evidence: B)
. Coronary angiography is indicated before AVR in patients at risk for
CAD. (Level of Evidence: C)
LASS III
. Cardiac catheterization with aortic root angiography and measure-
ment of LV pressure is not indicated for assessment of LV function,
aortic root size, or severity of regurgitation before AVR when nonin-
vasive tests are adequate and concordant with clinical findings and
coronary angiography is not needed. (Level of Evidence: C)
. Cardiac catheterization with aortic root angiography and measure-
ment of LV pressure is not indicated for assessment of LV function
and severity of regurgitation in asymptomatic patients when nonin-
vasive tests are adequate. (Level of Evidence: C)
ardiac catheterization is not required in patients with
hronic AR unless there are questions about the severity of
R, hemodynamic abnormalities, or LV systolic dysfunc-
ion that persist despite physical examination and noninva-
ive testing, or unless AVR is contemplated and there is a
eed to assess coronary anatomy. The indications for
oronary arteriography are discussed in Section 10.2. In
ome patients undergoing left-heart catheterization for cor-
nary angiography, additional aortic root angiography and
emodynamic measurements may provide useful supple-
entary data.
Hemodynamic and angiographic assessment of the sever-
ty of AR and LV function may be necessary in some
atients being considered for surgery when there are con-
icting data between clinical assessment and noninvasive
ests. Less commonly, asymptomatic patients who are not
eing considered for surgery may also require invasive
easurement of hemodynamics and/or determination of
everity of AR when this information cannot be obtained
ccurately from noninvasive tests.
Hemodynamic measurements during exercise are occa-
ionally helpful for determining the effect of AR on LV
unction or making decisions regarding medical or surgical
herapy. In selected patients with severe AR, borderline or
ormal LV systolic function, and LV chamber enlargement
hat is approaching the threshold for surgery (defined
elow), measurement of cardiac output and LV filling
ressures at rest and during exercise with a right-heart
atheter may be valuable for identifying patients with severe
emodynamic abnormalities in whom surgery is warranted.
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ORTIC VALVE REPAIR
he majority of patients with severe AR requiring surgery
ndergo valve replacement (see Section 7.2.). However, in
everal surgical centers, there is increasing experience in
erforming aortic valve replacement in selected patients (see
ection 7.2.6.). In the discussion that follows, the term
AVR” applies to both aortic valve replacement and aortic
alve repair, with the understanding that aortic valve repair
hould be considered only in those surgical centers that have
eveloped the appropriate technical expertise, gained expe-
ience in patient selection, and demonstrated outcomes
quivalent to those of valve replacement. The indications for
alve replacement and repair do not differ.
In patients with pure, chronic AR, AVR should be
onsidered only if AR is severe (Table 4) (27). Patients with
nly mild AR are not candidates for AVR, and if such
atients have symptoms or LV dysfunction, other causes
hould be considered, such as CAD, hypertension, or
ardiomyopathic processes. If the severity of AR is uncertain
fter a review of clinical and echocardiographic data, addi-
ional information may be needed, such as invasive hemo-
ynamic and angiographic data. The following discussion
pplies only to those patients with pure, severe AR.
LASS I
. AVR is indicated for symptomatic patients with severe AR irrespec-
tive of LV systolic function. (Level of Evidence: B)
. AVR is indicated for asymptomatic patients with chronic severe AR
and LV systolic dysfunction (ejection fraction 0.50 or less) at rest.
(Level of Evidence: B)
. AVR is indicated for patients with chronic severe AR while undergo-
ing CABG or surgery on the aorta or other heart valves. (Level of
Evidence: C)
LASS IIa
. AVR is reasonable for asymptomatic patients with severe AR with
normal LV systolic function (ejection fraction greater than 0.50) but
with severe LV dilatation (end-diastolic dimension greater than 75
mm or end-systolic dimension greater than 55 mm).* (Level of
Evidence: B)
LASS IIb
. AVR may be considered in patients with moderate AR while under-
going surgery on the ascending aorta. (Level of Evidence: C)
. AVR may be considered in patients with moderate AR while under-
going CABG. (Level of Evidence: C)
. AVR may be considered for asymptomatic patients with severe AR
and normal LV systolic function at rest (ejection fraction greater
than 0.50) when the degree of LV dilatation exceeds an end-
diastolic dimension of 70 mm or end-systolic dimension of 50 mm,
when there is evidence of progressive LV dilatation, declining exer-
cise tolerance, or abnormal hemodynamic responses to exercise.*
(Level of Evidence: C)
LASS III
. AVR is not indicated for asymptomatic patients with mild, moder-
ate, or severe AR and normal LV systolic function at rest (ejectionConsider lower threshold values for patients of small stature of either gender.fraction greater than 0.50) when degree of dilatation is not moder-
ate or severe (end-diastolic dimension less than 70 mm, end-
systolic dimension less than 50 mm).* (Level of Evidence: B)
.2.3.8.1. SYMPTOMATIC PATIENTS WITH NORMAL LEFT VEN-
RICULAR SYSTOLIC FUNCTION. AVR is indicated in patients
ith normal LV systolic function (defined as ejection
raction greater than 0.50 at rest) who have NYHA func-
ional class III or IV symptoms. Patients with Canadian
eart Association functional class II to IV angina pectoris
hould also be considered for surgery. In many patients with
YHA functional class II dyspnea, the cause of symptoms
s often unclear, and clinical judgment is required. Patients
ith well-compensated AR often have chronic mild dys-
nea or fatigue, and it may be difficult to differentiate the
ffects of deconditioning or aging from true cardiac symp-
oms. In such patients, exercise testing may be valuable. If
he cause of these mild symptoms is uncertain and they are
ot severe enough to interfere with the patient’s lifestyle, a
eriod of observation may be reasonable. However, new
nset of mild dyspnea has different implications in severe
R, especially in patients with increasing LV chamber size
r evidence of declining LV systolic function into the low
ormal range. Thus, even if patients have not achieved the
hreshold values of LV size and function recommended for
urgery in asymptomatic patients, development of mild
ymptoms is an indication for AVR in a patient who is
earing these values.
.2.3.8.2. SYMPTOMATIC PATIENTS WITH LEFT VENTRICULAR
YSFUNCTION. Patients with NYHA functional class II, III,
r IV symptoms and with mild to moderate LV systolic
ysfunction (ejection fraction 0.25 to 0.50) should undergo
VR. Patients with NYHA functional class IV symptoms
ave worse postoperative survival rates and lower likelihood
f recovery of systolic function than patients with less severe
ymptoms (245,250,252,254), but AVR will improve ven-
ricular loading conditions and expedite subsequent man-
gement of LV dysfunction (238).
Severely symptomatic patients (NYHA functional class
V) with advanced LV dysfunction (ejection fraction less
han 0.25 and/or end-systolic dimension greater than 60
m) present difficult management issues. Some patients
ill manifest meaningful recovery of LV function after
VR, but many will have developed irreversible myocardial
hanges. The mortality associated with valve replacement
pproaches 10%, and postoperative mortality over the sub-
equent few years is high. Valve replacement should be
onsidered more strongly in patients with NYHA func-
ional class II and III symptoms, especially if
symptoms and evidence of LV dysfunction are of recent
onset;
intensive short-term therapy with vasodilators and di-
uretics results in symptomatic improvement;
intravenous positive inotropic agents result in substantial
improvement in hemodynamics or systolic function.
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142However, even in patients with NYHA functional class
V symptoms and ejection fraction less than 0.25, the high
isks associated with AVR and subsequent medical manage-
ent of LV dysfunction are usually a better alternative than
he higher risks of long-term medical management alone
328).
.2.3.8.3. ASYMPTOMATIC PATIENTS. AVR in asymptomatic
atients remains a controversial topic, but it is generally
greed (233,329–335) that AVR is indicated in patients
ith LV systolic dysfunction. As noted previously, for the
urposes of these guidelines, LV systolic dysfunction is
efined as an ejection fraction below normal at rest. The
ower limit of normal will be assumed to be 0.50, with the
ealization that this lower limit is technique dependent and
ay vary among institutions. The committee also realizes
hat there may be variability in any given measurement of
V dimension or ejection fraction. Therefore, the commit-
ee recommends that 2 consecutive measurements be ob-
ained before one proceeds with a decision to recommend
urgery in the asymptomatic patient. These consecutive
easurements could be obtained with the same test re-
eated in a short time period (such as a second echocardio-
ram after an initial echocardiogram) or with a separate,
ndependent test (e.g., radionuclide ventriculography, mag-
etic resonance imaging, or contrast left ventriculography
fter an initial echocardiogram).
AVR is also recommended in patients with severe LV
ilatation (end-diastolic dimension greater than 75 mm or
nd-systolic dimension greater than 55 mm), even if ejec-
ion fraction is normal. The majority of patients with this
egree of dilatation will have already developed systolic
ysfunction because of afterload mismatch and will thus be
andidates for valve replacement on the basis of the de-
ressed ejection fraction. The elevated end-systolic dimen-
ion in this regard is often a surrogate for systolic dysfunc-
ion. The relatively small number of asymptomatic patients
ith preserved ejection fraction despite severe increases in
nd-systolic and end-diastolic chamber size should be con-
idered for surgery, because they appear to represent a
igh-risk group with an increased incidence of sudden death
271,336), and the results of valve replacement in such
atients have thus far been excellent (264). In contrast,
ostoperative mortality is considerable once patients with
evere LV dilatation develop symptoms or LV systolic
ysfunction (264). The recommendations regarding the risk
f sudden death and postoperative outcome with severe LV
ilatation were based on reports of sudden death in 2 of 3
atients with an LV end-diastolic dimension greater than
0 mm (271) and 2 patients with an LV end-diastolic
olume index greater than 200 ml/m2 (336). It should be
ecognized, however, that LV end-diastolic dimension,
hether examined as a continuous or as a dichotomous
ariable (less than 80 vs. greater than 80 mm), has not been
ound to be predictive of postoperative survival or LV
unction, whereas ejection fraction is predictive. Conserva-
ively managed patients with an end-diastolic dimension txceeding 70 mm likewise exhibit a favorable clinical out-
ome (276). These data do not strongly support the use of
xtreme LV enlargement as an indication for AVR, unless
ardiac symptoms or systolic dysfunction is present (337).
owever, the committee recommends surgery before the
eft ventricle achieves an extreme degree of dilatation and
ecommends AVR for patients with LV end-diastolic di-
ension greater than 75 mm.
Anthropometric normalization of LV end-diastolic di-
ension (or volume) should be considered, but unfortu-
ately, there is lack of agreement as to whether or not
ormalization based on body surface area or body mass
ndex is predictive of outcome (288,338). Normalization of
nd-diastolic dimension for body surface area tends to mask
he diagnosis of LV enlargement, especially in patients who
re overweight (339). The use of height and a consideration
f gender are likely to be more appropriate than body
urface area (340).
Patients with severe AR in whom the degree of LV
ilatation has not reached but is approaching these thresh-
ld values (e.g., LV end-diastolic dimension of 70 to 75 mm
r end-systolic dimension of 50 to 55 mm) should be
ollowed with frequent echocardiograms every 4 to 6
onths, as noted previously (Fig. 4). In addition, AVR may
e considered in such patients if there is evidence of
eclining exercise tolerance or abnormal hemodynamic
esponses to exercise, for example, an increase in pulmonary
rtery wedge pressure greater than 25 mm Hg with exercise.
Several patient subgroups develop LV systolic dysfunc-
ion with less marked LV dilatation than observed in the
ajority of patients with uncomplicated AR. These include
atients with long-standing hypertension in whom the
ressure-overloaded ventricle has reduced compliance and a
imited potential to increase its chamber size; patients with
oncomitant CAD, in whom myocardial ischemia may
evelop with increasing myocardial wall stress, resulting in
V dysfunction; and patients with concomitant MS, in
hom the left ventricle will not dilate to the same extent as
n patients with pure AR (341). In such patients, it is
articularly important that LV ejection fraction and not
erely systolic dimension be monitored. Women also tend
o develop symptoms and LV dysfunction with less LV
ilatation than men (338); this appears to be related to body
ize, because these differences are not apparent when LV
imensions are corrected for body surface area. Hence, LV
imensions alone may be misleading in small patients of
ither gender, and the threshold values of end-diastolic and
nd-systolic dimension recommended above for AVR in
symptomatic patients (75 and 55 mm, respectively) may
eed to be reduced in such patients. There are no data with
hich to derive guidelines for LV dimensions corrected for
ody size, and clinical judgment is required.
A decrease in ejection fraction during exercise should not
e used as the only indication for AVR in asymptomatic
atients with normal LV systolic function at rest, because
he exercise ejection fraction response is multifactorial, and
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedhe strength of evidence is limited. The ejection fraction
esponse to exercise has not proved to have independent
rognostic value in patients undergoing surgery (254). The
hange in ejection fraction with exercise is a relatively
onspecific response related to both severity of volume load
271,296,300,301) and exercise-induced changes in preload
nd peripheral resistance (280) that develop early in the
atural history of AR. AVR should also not be recom-
ended in asymptomatic patients with normal systolic
unction merely because of evidence of LV dilatation as long
s the dilatation is not severe (end-diastolic dimension less
han 75 mm or end-systolic dimension less than 55 mm).
Patients who demonstrate progression of LV dilatation or
rogressive decline in ejection fraction on serial studies
epresent a higher-risk group who require careful monitor-
ng (271), but such patients often reach a new steady state
nd may do well for extended periods of time. Hence, AVR
s not recommended until the threshold values noted above
re reached or symptoms or LV systolic dysfunction de-
elop. However, prompt referral to AVR once patients
evelop symptoms, subnormal ejection fraction, or progres-
ive LV dilatation results in significantly better postopera-
ive survival than if AVR is delayed until symptoms or LV
ystolic function becomes more severe (254,265,267).
The surgical options for treating AR are expanding, with
rowing experience in aortic homografts, pulmonary au-
ografts, unstented tissue valves, and aortic valve repair. If
hese techniques are ultimately shown to improve long-term
urvival or reduce postoperative valve complications, it is
onceivable that the thresholds for recommending AVR
ay be reduced. Until such data are available, the indica-
ions for surgery for AR should not vary with the operative
echnique to be used.
.2.4. Concomitant Aortic Root Disease
n addition to causing acute AR, diseases of the proximal
orta may also contribute to chronic AR. Dilatation of the
scending aorta is among the most common causes of
solated AR (342). In such patients, the valvular regurgita-
ion may be less important in decision making than the
rimary disease of the aorta, such as Marfan syndrome,
issection, or chronic dilatation of the aortic root related to
ypertension or a bicuspid aortic valve (see Section 3.3). In
uch patients, if the AR is mild or the left ventricle is only
ildly dilated, management should focus on treating the
nderlying aortic root disease. In many patients, however,
R may be severe and associated with severe LV dilatation
r systolic dysfunction, in which case decisions regarding
edical therapy and timing of the operation must consider
oth conditions. In general, AVR and aortic root recon-
truction are indicated in patients with disease of the aortic
oot or proximal aorta and AR of any severity when the
egree of dilatation of the aorta or aortic root reaches or
xceeds 5.0 cm by echocardiography (343). However, some
ave recommended surgery at a lower level of dilatation (4.5
m) or based on a rate of increase of 0.5 cm per year or dreater in surgical centers with established expertise in
epair of the aortic root and ascending aorta (344). Aortic
oot and ascending aorta dilation in patients with bicuspid
ortic valves is discussed in greater detail in Section 3.3.
.2.5. Evaluation of Patients After
ortic Valve Replacement
fter AVR, close follow-up is necessary during the early
nd long-term postoperative course to evaluate prosthetic
alve function and assess LV function, as discussed in
ections 9.3. to 9.3.3. An echocardiogram should be per-
ormed soon after surgery to assess the results of surgery on
V size and function and to serve as a baseline against
hich subsequent echocardiograms may be compared. This
ould be performed either before hospital discharge or
referably at the first outpatient re-evaluation. Within the
rst few weeks of surgery, there is little change in LV
ystolic function, and ejection fraction may even deteriorate
ompared with preoperative values because of the reduced
reload (345), even though ejection fraction may increase
ver the subsequent several months. Thus, persistent or
ore severe systolic dysfunction early after AVR is a poor
redictor of subsequent improvement in LV function in
atients with preoperative LV dysfunction. A better predic-
or of subsequent LV systolic function is the reduction in
V end-diastolic dimension, which declines significantly
ithin the first week or 2 after AVR (240,245,346). This is
n excellent marker of the functional success of valve
eplacement, because 80% of the overall reduction in end-
iastolic dimension observed during the long-term postop-
rative course occurs within the first 10 to 14 days after
VR (240,245,346), and the magnitude of reduction in
nd-diastolic dimension after surgery correlates with the
agnitude of increase in ejection fraction (245).
After the initial postoperative re-evaluation, the patient
hould be seen and examined again at 6 and 12 months and
hen on a yearly basis if the clinical course is uncomplicated.
f the patient is asymptomatic, the early postoperative
chocardiogram demonstrates substantial reduction in LV
nd-diastolic dimension, and LV systolic function is nor-
al, serial postoperative echocardiograms after the initial
arly postoperative study are usually not indicated. How-
ver, repeat echocardiography is warranted at any point at
hich there is evidence of a new murmur, questions of
rosthetic valve integrity, or concerns about LV function.
atients with persistent LV dilatation on the initial post-
perative echocardiogram should be treated as would any
ther patient with symptomatic or asymptomatic LV dys-
unction, including treatment with ACE inhibitors and
eta-adrenergic blocking agents. In such patients, repeat
chocardiography to assess LV size and systolic function is
arranted at the 6- and 12-month re-evaluations. If LV
ysfunction persists beyond this time frame, repeat echo-
ardiograms should be performed as clinically indicated.
anagement of patients after AVR is discussed in greater
etail in Section 9.3.
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he vast majority of elderly patients with aortic valve disease
ave AS or combined AS and AR, and pure AR is
ncommon (347). Elderly patients with AR generally fare
ess well than patients who are young or middle-aged.
atients older than 75 years are more likely to develop
ymptoms or LV dysfunction at earlier stages of LV
ilatation, have more persistent ventricular dysfunction and
eart failure symptoms after surgery, and have worse post-
perative survival rates than their younger counterparts.
any such patients have concomitant CAD, which must be
onsidered in the evaluation of symptoms, LV dysfunction,
nd indications for surgery. Because the goal of therapy is to
mprove the quality of life rather than longevity, symptoms
re the most important guide to determining whether or not
VR should be performed. Nonetheless, asymptomatic or
ildly symptomatic patients who develop LV dysfunction
as defined previously) should be considered for AVR if the
isks of surgery are balanced in otherwise healthy patients
gainst the expected improvement in long-term outcome.
.3. Bicuspid Aortic Valve With Dilated
scending Aorta
LASS I
. Patients with known bicuspid aortic valves should undergo an initial
transthoracic echocardiogram to assess the diameters of the aortic
root and ascending aorta. (Level of Evidence: B)
. Cardiac magnetic resonance imaging or cardiac computed tomog-
raphy is indicated in patients with bicuspid aortic valves when
morphology of the aortic root or ascending aorta cannot be as-
sessed accurately by echocardiography. (Level of Evidence: C)
. Patients with bicuspid aortic valves and dilatation of the aortic root
or ascending aorta (diameter greater than 4.0 cm* should undergo
serial evaluation of aortic root/ascending aorta size and morphol-
ogy by echocardiography, cardiac magnetic resonance, or com-
puted tomography on a yearly basis. (Level of Evidence: C)
. Surgery to repair the aortic root or replace the ascending aorta is
indicated in patients with bicuspid aortic valves if the diameter of
the aortic root or ascending aorta is greater than 5.0 cm* or if the
rate of increase in diameter is 0.5 cm per year or more. (Level of
Evidence: C)
. In patients with bicuspid valves undergoing AVR because of severe
AS or AR (see Sections 3.1.7 and 3.2.3.8), repair of the aortic root or
replacement of the ascending aorta is indicated if the diameter of
the aortic root or ascending aorta is greater than 4.5 cm.* (Level of
Evidence: C)
LASS IIa
. It is reasonable to give beta-adrenergic blocking agents to patients
with bicuspid valves and dilated aortic roots (diameter greater than
4.0 cm*) who are not candidates for surgical correction and who do
not have moderate to severe AR. (Level of Evidence: C)
. Cardiac magnetic resonance imaging or cardiac computed tomog-
raphy is reasonable in patients with bicuspid aortic valves when
aortic root dilatation is detected by echocardiography to further
quantify severity of dilatation and involvement of the ascending
aorta. (Level of Evidence: B)tConsider lower threshold values for patients of small stature of either gender.here is growing awareness that many patients with bicus-
id aortic valves have disorders of vascular connective tissue,
nvolving loss of elastic tissue (348,349), which may result in
ilatation of the aortic root or ascending aorta even in the
bsence of hemodynamically significant AS or AR (350–
53). Aortic root or ascending aortic dilatation can progress
ith time in this condition (354). These patients have a risk
f aortic dissection that is related to the severity of dilatation
349,355–357). Recommendations for athletic participation
n patients with bicuspid valve disease and associated dila-
ation of the aortic root or ascending aorta from the 36th
ethesda Conference (138) are based on limited data but
ith the understanding that aortic dissection can occur in
ome patients with aortic root or ascending aorta diameters
ess than 50 mm (344,356,358). Therapy with beta-
drenergic blocking agents might be effective in slowing the
rogression of aortic dilatation, but the available data have
een developed in patients with Marfan syndrome (359)
nd not in patients with bicuspid aortic valves.
Echocardiography remains the primary imaging tech-
ique for identifying those patients in whom the aortic root
r ascending aorta is enlarged. In many cases, echocardiog-
aphy, including transesophageal imaging, provides all of
he necessary information required to make management
ecisions. More accurate quantification of the diameter of
he aortic root and ascending aorta, as well as full assessment
f the degree of enlargement, can be obtained with cardiac
agnetic resonance imaging or computed tomography.
hese techniques also allow for an accurate depiction of the
ize and contour of the aorta in its arch, descending
horacic, and abdominal segments. When the findings on
ransthoracic echocardiography relative to the aortic root
nd ascending aorta are concordant with those of either
ardiac magnetic resonance or computed tomographic im-
ging, then transthoracic echocardiography can be used for
nnual surveillance. The dimensions of the aortic root and
scending aorta show considerable variability in normal
opulations. Regression formulas and nomograms have
een developed for adolescents and adults that account for
ge and body surface area (360). An upper limit of 2.1 cm
er m2 has been established at the level of the aortic sinuses.
ilatation is considered an increase in diameter above the
orm for age and body surface area, and an aneurysm has
een defined as a 50% increase over the normal diameter (361).
Surgery to repair the aortic root or replace the ascending
orta has been recommended for those patients with greatly
nlarged aortic roots or ascending aortas (344,349,357,358).
n recommending elective surgery for this condition, a
umber of factors must be considered, including the pa-
ient’s age, the relative size of the aorta and aortic root, the
tructure and function of the aortic valve, and the experience
f the surgical team. Aortic valve-sparing operations are
easible in most patients with dilatation of the aortic root or
scending aorta who do not have significant AR or aortic
alve calcification (362–364). It is recommended that pa-
ients with bicuspid valves should undergo elective repair of
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iameter of these structures exceeds 5.0 cm. Such surgery
hould be performed by a surgical team with established
xpertise in these procedures. Others have recommended a
alue of 2.5 cm per m2 or greater as the indication for
urgery (365). If patients with bicuspid valves and associated
ortic root enlargement undergo AVR because of severe AS
r AR (Sections 3.1.7. and 3.2.3.8.), it is recommended that
epair of the aortic root or replacement of the ascending
orta be performed if the diameter of these structures is
reater than 4.5 cm (366).
.4. Mitral Stenosis
.4.1. Pathophysiology and Natural History
S is an obstruction to LV inflow at the level of the MV as
result of a structural abnormality of the MV apparatus,
hich prevents proper opening during diastolic filling of the
eft ventricle. The predominant cause of MS is rheumatic
arditis. Isolated MS occurs in 40% of all patients present-
ng with rheumatic heart disease, and a history of rheumatic
ever can be elicited from approximately 60% of patients
resenting with pure MS (367,368). The ratio of women to
en presenting with isolated MS is 2:1 (367–369). Con-
enital malformation of the MV occurs rarely and is
bserved mainly in infants and children (370). Acquired
auses of MV obstruction, other than rheumatic heart disease,
re rare. These include left atrial myxoma, ball valve thrombus,
ucopolysaccharidosis, and severe annular calcification.
In patients with MS due to rheumatic fever, the patho-
ogical process causes leaflet thickening and calcification,
ommissural fusion, chordal fusion, or a combination of
hese processes (370,371). The result is a funnel-shaped
itral apparatus in which the orifice of the mitral opening
s decreased in size. Interchordal fusion obliterates the
econdary orifices, and commissural fusion narrows the
rincipal orifice (370,371).
The normal MV area is 4.0 to 5.0 cm2. Narrowing of the
alve area to less than 2.5 cm2 typically occurs before the
evelopment of symptoms (139). With a reduction in valve
rea by the rheumatic process, blood can flow from the left
trium to the left ventricle only if propelled by a pressure
radient. This diastolic transmitral gradient is the funda-
ental expression of MS (372) and results in elevation of
eft atrial pressure, which is reflected back into the pulmo-
ary venous circulation. Decreased pulmonary venous com-
liance that results in part from an increased pulmonary
ndothelin-1 spillover rate may also contribute to increased
ulmonary venous pressure (373). Increased pressure and
istension of the pulmonary veins and capillaries can lead to
ulmonary edema as pulmonary venous pressure exceeds
hat of plasma oncotic pressure. In patients with chronic
V obstruction, however, even when it is severe and
ulmonary venous pressure is very high, pulmonary edema
ay not occur owing to a marked decrease in pulmonary
icrovascular permeability. The pulmonary arterioles may heact with vasoconstriction, intimal hyperplasia, and medial
ypertrophy, which lead to pulmonary arterial hypertension.
An MV area greater than 1.5 cm2 usually does not
roduce symptoms at rest (374). However, if there is an
ncrease in transmitral flow or a decrease in the diastolic
lling period, there will be a rise in left atrial pressure and
evelopment of symptoms. From hydraulic considerations,
t any given orifice size, the transmitral gradient is a
unction of the square of the transvalvular flow rate and is
ependent on the diastolic filling period (139). Thus, the
rst symptoms of dyspnea in patients with mild MS are
sually precipitated by exercise, emotional stress, infection,
regnancy, or atrial fibrillation with a rapid ventricular
esponse (374). As the obstruction across the MV increases,
ecreasing effort tolerance occurs.
As the severity of stenosis increases, cardiac output
ecomes subnormal at rest (374) and fails to increase during
xercise (375). The degree of pulmonary vascular disease is
lso an important determinant of symptoms in patients with
S (373,374,376). A second obstruction to flow develops
rom increased pulmonary arteriolar resistance (376,377),
hich may protect the lungs from pulmonary edema
376,377). In some patients, an additional reversible ob-
truction develops at the level of the pulmonary veins
378,379). The low cardiac output and increased pulmonary
rteriolar resistance, which results from functional and
tructural changes (alveolar basement membrane thicken-
ng, adaptation of neuroreceptors, increased lymphatic
rainage, and increased transpulmonary endothelin spillover
ate), contribute to the ability of a patient with severe MS to
emain minimally symptomatic for prolonged periods of
ime (374,376,377).
The natural history of patients with untreated MS has
een defined from studies in the 1950s and 1960s (367–
69). Mitral stenosis is a continuous, progressive, lifelong
isease, usually consisting of a slow, stable course in the
arly years followed by a progressive acceleration later in life
367–369,380). In developed countries, there is a long latent
eriod of 20 to 40 years from the occurrence of rheumatic
ever to the onset of symptoms. Once symptoms develop,
here is another period of almost a decade before symptoms
ecome disabling (367). Overall, the 10-year survival of
ntreated patients presenting with MS is 50% to 60%,
epending on symptoms at presentation (368,369). In the
symptomatic or minimally symptomatic patient, survival is
reater than 80% at 10 years, with 60% of patients having no
rogression of symptoms (368,369,380). However, once
ignificant limiting symptoms occur, there is a dismal 0% to
5% 10-year survival rate (367–369,380,381). Once there is
evere pulmonary hypertension, mean survival drops to less
han 3 years (382). The mortality of untreated patients with
S is due to progressive pulmonary and systemic conges-
ion in 60% to 70%, systemic embolism in 20% to 30%,
ulmonary embolism in 10%, and infection in 1% to 5%
369,370). In North America and Europe, this classic
istory of MS has been replaced by an even milder delayed
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380,383). The mean age of presentation is now in the fifth
o sixth decade (380,383); more than one third of patients
ndergoing valvotomy are older than 65 years (384). In
ome geographic areas, MS progresses more rapidly, pre-
umably due to either a more severe rheumatic insult or
epeated episodes of rheumatic carditis due to new strepto-
occal infections, resulting in severe symptomatic MS in the
ate teens and early 20s (380). Serial hemodynamic and
oppler-echocardiographic studies have reported annual
oss of MV area ranging from 0.09 to 0.32 cm2 (385,386).
Although MS is best described as a disease continuum,
nd there is no single value that defines severity, for these
uidelines, MS severity is based on a variety of hemody-
amic and natural history data (Table 4) (27) using mean
radient, pulmonary artery systolic pressure, and valve area
s follows: mild (area greater than 1.5 cm2, mean gradient
ess than 5 mm Hg, or pulmonary artery systolic pressure
ess than 30 mm Hg), moderate (area 1.0 to 1.5 cm2, mean
radient 5 to 10 mm Hg, or pulmonary artery systolic
ressure 30 to 50 mm Hg), and severe (area less than 1.0
m2, mean gradient greater than 10 mm Hg, or pulmonary
rtery systolic pressure greater than 50 mm Hg).
.4.2. Indications for Echocardiography in Mitral Stenosis
LASS I
. Echocardiography should be performed in patients for the diagnosis of
MS, assessment of hemodynamic severity (mean gradient, MV area,
and pulmonary artery pressure), assessment of concomitant valvular
lesions, and assessment of valve morphology (to determine suitability
for percutaneous mitral balloon valvotomy). (Level of Evidence: B)
. Echocardiography should be performed for re-evaluation in patients
with known MS and changing symptoms or signs. (Level of Evi-
dence: B)
. Echocardiography should be performed for assessment of the he-
modynamic response of the mean gradient and pulmonary artery
pressure by exercise Doppler echocardiography in patients with MS
when there is a discrepancy between resting Doppler echocardio-
graphic findings, clinical findings, symptoms, and signs. (Level of
Evidence: C)
. Transesophageal echocardiography in MS should be performed to
assess the presence or absence of left atrial thrombus and to
further evaluate the severity of MR in patients considered for
percutaneous mitral balloon valvotomy. (Level of Evidence: C)
. Transesophageal echocardiography in MS should be performed to
evaluate MV morphology and hemodynamics in patients when trans-
thoracic echocardiography provides suboptimal data. (Level of Evi-
dence: C)
LASS IIa
. Echocardiography is reasonable in the re-evaluation of asymptom-
atic patients with MS and stable clinical findings to assess pulmo-
nary artery pressure (for those with severe MS, every year; moderate
MS, every 1 to 2 years; and mild MS, every 3 to 5 years). (Level of
Evidence: C)
LASS III
. Transesophageal echocardiography in the patient with MS is not
indicated for routine evaluation of MV morphology and hemody- Tnamics when complete transthoracic echocardiographic data are
satisfactory. (Level of Evidence: C)
The diagnosis of MS should be made on the basis of the
istory, physical examination, chest X-ray, and ECG (Fig.
). Patients may present with no symptoms but have an
bnormal physical examination (380,383). Although some
atients may present with fatigue, dyspnea, or frank pulmo-
ary edema, in others, the initial manifestation of MS is the
nset of atrial fibrillation or an embolic event (367). Rarely,
atients may present with hemoptysis, hoarseness, or dys-
hagia. The characteristic auscultatory findings of rheu-
atic MS are accentuated first heart sound (S1), opening
nap (OS), low-pitched middiastolic rumble, and a presys-
olic murmur. These findings, however, may also be present
n patients with nonrheumatic MV obstruction (e.g., left
trial myxoma) and may be absent with severe pulmonary
ypertension, low cardiac output, and a heavily calcified
mmobile MV. A shorter A2-OS interval and longer dura-
ion of diastolic rumble indicates more severe MS. An
2-OS interval of less than 0.08 seconds implies severe MS
387). Physical findings of pulmonary hypertension, such as
loud P2 or right ventricular (RV) heave, also suggest se-
ere MS.
The diagnostic tool of choice in the evaluation of a
atient with MS is 2D and Doppler echocardiography
388–393). Echocardiography is able to identify restricted
iastolic opening of the MV leaflets due to “doming” of the
nterior leaflet and immobility of the posterior leaflet
388,390,392,393). Other entities that can simulate the
linical features of rheumatic MS, such as left atrial myx-
ma, mucopolysaccharidosis, nonrheumatic calcific MS, cor
riatriatum, and a parachute MV, can be readily identified
y 2D echocardiography. Planimetry of the orifice area may
e possible from the short-axis view. Two-dimensional
chocardiography can be used to assess the morphological
ppearance of the MV apparatus, including leaflet mobility
nd flexibility, leaflet thickness, leaflet calcification, subval-
ular fusion, and the appearance of commissures (391,394–
98). These features may be important when one considers
he timing and type of intervention to be performed
394–400). Patients with mobile noncalcified leaflets, no
ommissural calcification, and little subvalvular fusion may
e candidates for either balloon catheter or surgical com-
issurotomy/valvotomy (394 –399). There are several
ethods used to assess suitability for valvotomy, including a
ilkins score (Table 17) (400), an echocardiographic
rouping (based on valve flexibility, subvalvular fusion, and
eaflet calcification) (397), and the absence or presence of
ommissural calcium (398). Chamber size and function and
ther structural valvular, myocardial, or pericardial abnor-
alities can be assessed with the 2D echocardiographic
tudy.
Doppler echocardiography can be used to assess the
emodynamic severity of the obstruction (389,391,401).
he mean transmitral gradient can be accurately and repro-
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The writing committee recognizes that there may be variability in the measurement of mitral valve area (MVA) and that the mean transmitral gradients, pulmonary artery
edge pressure (PAWP), and pulmonary artery systolic pressure (PP) should also be taken into consideration. †There is controversy as to whether patients with severe mitral
tenosis (MVA less than 1.0 cm2) and severe pulmonary hypertension (pulmonary artery pressure greater than 60 mm Hg) should undergo percutaneous mitral balloon val-
otomy (PMBV) or mitral valve replacement to prevent right ventricular failure. ‡Assuming no other cause for pulmonary hypertension is present. AF indicates atrial fibrillation;
XR, chest X-ray; ECG, electrocardiogram; echo, echocardiography; LA, left atrial; MR, mitral regurgitation; and 2D, 2-dimensional.able 17. Determinants of the Echocardiographic Mitral Valve Score
Grade Mobility Subvalvular Thickening Thickening Calcification
1 Highly mobile valve with only leaflet
tips restricted
Minimal thickening just below the
mitral leaflets
Leaflets near normal in thickness
(4 to 5 mm)
A single area of increased echo
brightness
2 Leaflet mid and base portions have
normal mobility
Thickening of chordal structures
extending up to one third of the
chordal length
Midleaflets normal, considerable
thickening of margins (5 to 8
mm)
Scattered areas of brightness
confined to leaflet margins
3 Valve continues to move forward in
diastole, mainly from the base
Thickening extending to the distal
third of the chords
Thickening extending through the
entire leaflet (5 to 8 mm)
Brightness extending into the
midportion of the leaflets
4 No or minimal forward movement
of the leaflets in diastole
Extensive thickening and
shortening of all chordal
structures extending down to
the papillary muscles
Considerable thickening of all
leaflet tissue (greater than 8 to
10 mm)
Extensive brightness
throughout much of the
leaflet tissueeprinted with permission from Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to
utcome and the mechanism of dilatation. Br Heart J 1988;60:299–308 (400).
d
a
(
D
h
(
w
w
o
t
v
M
d
t
p
t
s
T
s
w
e
2
f
c
w
v
t
s
t
c
m
n
t
M
t
i
f
d
i
p
f
t
w
s
o
s
s
a
p
w
v
M
i
w
a
M
v
a
D
l
g
a
i
o
w
p
g
e
f
s
m
p
s
b
3
3
I
o
t
L
t
t
B
p
c
a
fi
a
t
r
p
t
g
r
(
r
(
d
c
s
p
p
a
p
i
e42 Bonow et al. JACC Vol. 52, No. 13, 2008
ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142ucibly measured from the continuous-wave Doppler signal
cross the MV with the modified Bernoulli equation
391,401). The MV area can be noninvasively derived from
oppler echocardiography with either the diastolic pressure
alf-time method (401–404) or the continuity equation
402). The half-time method may be inaccurate in patients
ith abnormalities of left atrial or LV compliance, those
ith associated AR, and those who have had mitral valvot-
my (403,404). Doppler echocardiography may also be used
o estimate pulmonary artery systolic pressure from the TR
elocity signal (405) and to assess severity of concomitant
R or AR. Formal hemodynamic exercise testing can be
one noninvasively with either a supine bicycle or upright
readmill with Doppler recordings of transmitral and tricus-
id velocities (406–409). This allows measurement of both
he transmitral gradient (407–409) and pulmonary artery
ystolic pressure (406,408) at rest and with exercise (410).
he criteria for the assessment of the severity of MS are
ummarized in Table 4 (27). These criteria are applicable
hen the heart rate is between 60 and 90 bpm.
In all patients with MS, an initial clinical history, physical
xamination, ECG, and chest X-ray should be performed.
D and Doppler echocardiography should also be per-
ormed to confirm the diagnosis of MS and rule out other
auses of MV obstruction and concomitant problems that
ould require further therapy, that is, myocardial or other
alvular heart disease. The morphology of the MV appara-
us and suitability for valvotomy should be assessed. The
everity of MS should be determined using both the mean
ransmitral gradient and valve area from the Doppler echo-
ardiogram, and pulmonary artery pressure should be esti-
ated when possible. A transesophageal echocardiogram is
ot required unless a question about diagnosis remains after
ransthoracic echocardiography.
In the asymptomatic patient who has documented mild
S (valve area greater than 1.5 cm2 and mean gradient less
han 5 mm Hg), no further investigations are needed on the
nitial workup (Fig. 5). These patients usually remain stable
or years (368,369,380). If there is more significant MS, a
ecision to proceed further should be based on the suitabil-
ty of the patient for mitral valvotomy. In patients with
liable, noncalcified valves with no or little subvalvular
usion, no calcification in the commissures, and no left atrial
hrombus, percutaneous mitral valvotomy can be performed
ith a low complication rate and may be indicated if
ymptoms develop. Because of the slowly progressive course
f MS, patients may remain “asymptomatic” with severe
tenosis merely by readjusting their lifestyles to a more
edentary level. Elevated pulmonary vascular resistance
nd/or low cardiac output may also play an adaptive role in
reventing congestive symptoms from occurring in patients
ith severe MS (374,376,377). Elevation of pulmonary
ascular resistance is an important physiological event in
S (377), and the level of pulmonary pressure is an
ndicator of the overall hemodynamic consequence. Patients
ith moderate pulmonary hypertension at rest (pulmonary srtery systolic pressure greater than 50 mm Hg) and pliable
V leaflets may be considered for percutaneous mitral
alvotomy even if they deny symptoms. In patients who lead
sedentary lifestyle, a hemodynamic exercise test with
oppler echocardiography is useful (406–409). Objective
imitation of exercise tolerance with a rise in transmitral
radient greater than 15 mm Hg and a rise in pulmonary
rtery systolic pressure greater than 60 mm Hg may be an
ndication for percutaneous valvotomy if the MV morphol-
gy is suitable. There is a subset of asymptomatic patients
ith severe MS (valve area less than 1.0 cm2) and severe
ulmonary hypertension (pulmonary artery systolic pressure
reater than 75% of systemic pressure either at rest or with
xercise). If these patients do not have a valve morphology
avorable for percutaneous mitral balloon valvotomy or
urgical valve repair, it is controversial whether MV replace-
ent should be performed in the absence of symptoms to
revent RV failure, but surgery is generally recommended in
uch patients. However, the patient (and the family) should
e involved in the decision regarding intervention.
.4.3. Medical Therapy
.4.3.1. MEDICAL THERAPY: GENERAL (UPDATED)
n the patient with MS, the major problem is mechanical
bstruction to inflow at the level of the MV, and no medical
herapy will specifically relieve the fixed obstruction. The
V is protected from a volume or pressure overload, and
hus, no specific medical therapy is required in the asymp-
omatic patient in normal sinus rhythm who has mild MS.
ecause rheumatic fever is the primary cause of MS,
rophylaxis against rheumatic fever is recommended.
In the patient who has more than a mild degree of MS,
ounseling on avoidance of unusual physical stresses is
dvised. Increased flow and a shortening of the diastolic
lling period by tachycardia increase left atrial pressure
gainst an obstructed MV. Agents with negative chrono-
ropic properties, such as beta blockers or heart rate–
egulating calcium channel blockers, may be of benefit in
atients in sinus rhythm who have exertional symptoms if
hese symptoms occur with high heart rates (411,412). The
reater efficacy of a beta blocker compared with a heart
ate–regulating calcium channel blocker has been reported
413). Some patients with MS have increased bronchial
eactivity that may improve with inhaled corticosteroids
414). Salt restriction and intermittent administration of a
iuretic are useful if there is evidence of pulmonary vascular
ongestion. Digitalis does not benefit patients with MS in
inus rhythm unless there is LV or RV dysfunction (415).
Although MS is a slowly progressive condition, acute
ulmonary edema can occur suddenly in asymptomatic
atients with severe MS, especially with the onset of rapid
trial fibrillation, and this can be rapidly fatal. Thus,
atients should be counseled to seek medical attention
mmediately if they experience a sudden marked increase in
hortness of breath.
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atients with MS are prone to developing atrial arrhyth-
ias, particularly atrial fibrillation and atrial flutter. Thirty
o forty percent of patients with symptomatic MS develop
trial fibrillation (367,368). Structural changes from the
ressure and volume overload alter the electrophysiological
roperties of the left atrium (380), and the rheumatic
rocess itself may lead to fibrosis of the internodal and
nteratrial tracts and damage to the sinoatrial node. There
ay be significant hemodynamic consequences resulting
rom the acute development of atrial fibrillation, primarily
rom the rapid ventricular rate, which shortens the diastolic
lling period and causes elevation of left atrial pressure.
trial fibrillation occurs more commonly in older patients
367) and is associated with a poorer prognosis, with a
0-year survival rate of 25% compared with 46% in patients
ho remain in sinus rhythm (369). The risk of arterial
mbolization, especially stroke, is significantly increased in
atients with atrial fibrillation (367,368,416–418).
Treatment of an acute episode of rapid atrial fibrillation
onsists of anticoagulation with heparin and control of the
eart rate response. Intravenous digoxin, heart rate–
egulating calcium channel blockers, or beta blockers should
e used to control ventricular response by slowing conduc-
ion through the atrioventricular node. Intravenous or oral
miodarone can also be used when beta blockers or heart
ate-regulating calcium channel blockers cannot be used. If
here is hemodynamic instability, electrical cardioversion
hould be undertaken urgently, with intravenous heparin
efore, during, and after the procedure. In selected patients,
hemical cardioversion may also be attempted. Patients who
ave been in atrial fibrillation longer than 24 to 48 h
ithout anticoagulation are at an increased risk for embolic
vents after cardioversion, but embolization may occur with
ess than 24 h of atrial fibrillation. The decision to proceed
ith elective cardioversion is dependent on multiple factors,
ncluding duration of atrial fibrillation, hemodynamic re-
ponse to the onset of atrial fibrillation, a documented
istory of prior episodes of atrial fibrillation, and a history of
rior embolic events. If the decision has been made to
roceed with elective cardioversion in a patient who has had
ocumented atrial fibrillation for longer than 24 to 48 h and
ho has not been on long-term anticoagulation, 1 of 2
pproaches is recommended based on data from patients
ith nonrheumatic atrial fibrillation. The first is anticoag-
lation with warfarin for more than 3 weeks, followed by
lective cardioversion (419). The second is anticoagulation
ith heparin and transesophageal echocardiography to look
or left atrial thrombus. In the absence of left atrial throm-
us, cardioversion is performed with intravenous heparin
efore, during, and after the procedure (420). It is important
o continue long-term anticoagulation after cardioversion.
Recurrent paroxysmal atrial fibrillation may be treated for
aintenance of sinus rhythm in selected patients with Class
C antiarrhythmic drugs (in conjunction with negative
romotropic agent) or Class III antiarrhythmic drugs;
C
Towever, eventually, the atrial fibrillation becomes resistant
o prevention or cardioversion (376), and control of ventric-
lar response becomes the mainstay of therapy. Digoxin
lows the heart rate response in patients with atrial fibrilla-
ion and MS (415). However, heart rate–regulating calcium
hannel blockers or beta blockers are more effective for
reventing exercise-induced increases in heart rate. Patients
ith either paroxysmal or sustained atrial fibrillation should
e treated with long-term anticoagulation with warfarin to
revent embolic events if they do not have a strong
ontraindication to anticoagulation (417,421). It is contro-
ersial whether percutaneous mitral valvotomy should be
erformed in patients with new-onset atrial fibrillation and
oderate to severe MS who are otherwise asymptomatic.
Successful percutaneous balloon mitral commissurotomy
ay not prevent the development of atrial fibrillation.
dvanced age and left atrial dimension appear to be the
mportant predictors of development of atrial fibrillation (422).
.4.3.3. MEDICAL THERAPY: PREVENTION OF SYSTEMIC EMBOLIZATION
LASS I
. Anticoagulation is indicated in patients with MS and atrial fibrilla-
tion (paroxysmal, persistent, or permanent). (Level of Evidence: B)
. Anticoagulation is indicated in patients with MS and a prior embolic
event, even in sinus rhythm. (Level of Evidence: B)
. Anticoagulation is indicated in patients with MS with left atrial
thrombus. (Level of Evidence: B)
LASS IIb
. Anticoagulation may be considered for asymptomatic patients with
severe MS and left atrial dimension greater than or equal to 55 mm
by echocardiography.* (Level of Evidence: B)
. Anticoagulation may be considered for patients with severe MS, an
enlarged left atrium, and spontaneous contrast on echocardiogra-
phy. (Level of Evidence: C)
ystemic embolization may occur in 10% to 20% of patients
ith MS (367,368,416). The risk of embolization is related
o age and the presence of atrial fibrillation (367,368,416–
18). One third of embolic events occur within 1 month of
he onset of atrial fibrillation, and two thirds occur within 1
ear. The frequency of embolic events does not seem to be
elated to the severity of MS, cardiac output, size of the left
trium, or even the presence or absence of heart failure
ymptoms (368,417,424). An embolic event may thus be the
nitial manifestation of MS (367). In patients who have
xperienced an embolic event, the frequency of recurrence is
s high as 15 to 40 events per 100 patient-months
417–421).
There are no randomized trials examining the efficacy of
nticoagulation in preventing embolic events specifically in
atients with MS. Retrospective studies have shown a 4- to
5-fold decrease in the incidence of embolic events with
nticoagulation in these patients (417,421). This benefit
pplies to both systemic and pulmonary embolism. Most
This recommendation is based on a grade C level of evidence given by the American
ollege of Chest Physicians Fourth Consensus Conference on Antithrombotic
herapy (423).
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142rials involved patients who had 1 embolus before the onset
f anticoagulation therapy (421). However, large random-
zed trials have demonstrated a significant reduction in
mbolic events by treatment with anticoagulation in subsets
f patients with atrial fibrillation not associated with MS
425,426). In these randomized trials, the subset of patients
ho benefited most from anticoagulation were those with
he highest risk of embolic events (353,354). Patients with
S at the highest risk for future embolic events are those
ith prior embolic events and those with paroxysmal or
ersistent atrial fibrillation (367,368,416–418,421). Parox-
smal atrial fibrillation may be difficult to detect; ambulatory
CG monitoring is valuable in patients with palpitations.
here are no data to support the concept that oral antico-
gulation is beneficial in patients with MS who have not
ad atrial fibrillation or an embolic event. It is controversial
hether patients without atrial fibrillation or an embolic
vent who might be at higher risk for future embolic events
i.e., those with severe MS or an enlarged left atrium)
hould be considered for long-term warfarin therapy
423,427).
Although embolic events are thought to originate from
eft atrial thrombi (417,418), the presence or absence of a
eft atrial thrombus does not appear to correlate with
mbolic events (367,418). Left atrial thrombi are found
uring surgery in 15% to 20% of patients with prior embolic
vents and a similar number of patients without embolic
vents (367,416). However, in clinical practice, anticoagu-
ation is frequently used if obvious left atrial thrombi are
etected.
It has been suggested that surgical commissurotomy
educes the incidence of future embolic events (381). There
re no randomized trial data to support this hypothesis, and
he retrospective studies that have been reported were
erformed before the availability of standardized anticoag-
lation regimens. Other retrospective studies have con-
luded that surgery does not decrease the incidence of
ystemic emboli (380,428,429). One prospective study has
eported decreased risk for arterial embolism after mitral
ommissurotomy (430).
.4.4. Recommendations Regarding Physical Activity
nd Exercise
any patients with mild MS will remain asymptomatic
ven with strenuous exercise. In more severe MS, exercise
an cause sudden marked increases in pulmonary venous
ressure from the increase in heart rate and cardiac output,
t times resulting in pulmonary edema (375,376). The
ong-term effects of repeated exertion-related increases in
ulmonary venous and pulmonary artery pressures on the
ung or right ventricle remain unknown. MS rarely causes
udden death (367–369). These factors must be considered
hen recommending physical activity and exercise for the
atient with MS.
In the majority of patients with MS, recommendationsor exercise are symptom limited. Patients should be en- uouraged to pursue a low-level aerobic exercise program for
aintenance of cardiovascular fitness. Exertional symptoms
f dyspnea are the limiting factors in terms of exercise
olerance. However, there is a subset of asymptomatic
atients who wish to participate in competitive athletics
ho may deny symptoms. The 36th Bethesda Conference
n Recommendations for Determining Eligibility for Com-
etition in Athletes with Cardiovascular Abnormalities
ublished guidelines for patients with MS who wish to
ngage in competitive athletics (138).
.4.5. Serial Testing
erial follow-up testing of a patient with MS should be
ased on whether the results of a test will dictate either a
hange in therapy or a recommendation for a procedure.
atients with MS usually have years without symptoms
efore the onset of deterioration (367,380). All patients
hould be informed that any change in symptoms warrants
e-evaluation. In the asymptomatic patient, yearly re-
valuation is recommended (Fig. 5). At the time of the
early evaluation, a history, physical examination, chest
-ray, and ECG should be obtained. Physical examination
s useful to assess the progression of the severity of MS. A
hortening of the A2-OS interval, longer duration of the
iddiastolic murmur, and the presence of findings of
ulmonary hypertension indicates more severe MS. An
chocardiogram is not recommended yearly unless there is a
hange in clinical status or the patient has severe MS.
mbulatory ECG monitoring (Holter or event recorder) to
etect paroxysmal atrial fibrillation is indicated in patients
ith palpitations.
.4.6. Evaluation of the Symptomatic Patient
atients who develop symptoms should undergo evaluation
ith a history, physical examination, ECG, chest X-ray, and
chocardiogram (Figs. 6 and 7). Two-dimensional and
oppler echocardiography are indicated to evaluate MV
orphology, MV hemodynamics, and pulmonary artery
ressure. Patients with NYHA functional class II symptoms
nd moderate or severe MS (MV area less than or equal to
.5 cm2 or mean gradient greater than 5 mm Hg) may be
onsidered for mitral balloon valvotomy if they have suitable
V morphology and no left atrial thrombi. Patients who
ave NYHA functional class III or IV symptoms and
vidence of severe MS have a poor prognosis if left un-
reated (367–369) and should be considered for intervention
ith either balloon valvotomy or surgery.
A subset of patients have significant limiting symptoms,
et clinical and Doppler echocardiographic evaluation do
ot indicate moderate or severe MS. In such patients,
ormal exercise testing or dobutamine stress may be useful to
ifferentiate symptoms due to MS from other causes of
ymptoms. Exercise tolerance, heart rate and blood pressure
esponse, transmitral gradient, and pulmonary artery pres-
ure can be obtained at rest and during exercise. This can
sually be accomplished with either supine bicycle or up-
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ransmitral velocities (406–409). Right- and left-heart
atheterization with exercise may be helpful and occasion-
lly necessary (431). Patients who are symptomatic with a
ignificant elevation of pulmonary artery pressure (greater
han 60 mm Hg), mean transmitral gradient (greater than
5 mm Hg), or pulmonary artery wedge pressure (greater
han 25 mm Hg) during exercise (375,407–409,432,433)
ave hemodynamically significant MS and should be con-
idered for further intervention. Alternatively, patients who
o not manifest elevation in either pulmonary artery, pul-
onary artery wedge, or transmitral pressures coincident
ith development of exertional symptoms most likely would
ot benefit from intervention on the MV.
.4.7. Indications for Invasive Hemodynamic Evaluation
LASS I
. Cardiac catheterization for hemodynamic evaluation should be
performed for assessment of severity of MS when noninvasive tests
igure 6. Management Strategy for Patients With Mitral Stenosis
The committee recognizes that there may be variability in the measurement of mitr
ure (PAWP), and pulmonary artery systolic pressure (PP) should also be taken into
MVA less than 1.0 cm2) and severe pulmonary hypertension (PH; PP greater than 6
alve replacement to prevent right ventricular failure. CXR indicates chest X-ray; ECG
VG, mean mitral valve pressure gradient; NYHA, New York Heart Association; PAP,are inconclusive or when there is discrepancy between noninvasivetests and clinical findings regarding severity of MS. (Level of Evi-
dence: C)
. Catheterization for hemodynamic evaluation including left ventricu-
lography (to evaluate severity of MR) for patients with MS is
indicated when there is a discrepancy between the Doppler-derived
mean gradient and valve area. (Level of Evidence: C)
LASS IIa
. Cardiac catheterization is reasonable to assess the hemodynamic
response of pulmonary artery and left atrial pressures to exercise
when clinical symptoms and resting hemodynamics are discordant.
(Level of Evidence: C)
. Cardiac catheterization is reasonable in patients with MS to assess
the cause of severe pulmonary arterial hypertension when out of
proportion to severity of MS as determined by noninvasive testing.
(Level of Evidence: C)
LASS III
. Diagnostic cardiac catheterization is not recommended to assess
the MV hemodynamics when 2D and Doppler echocardiographic
Mild Symptoms
e area (MVA) and that the mean transmitral gradient, pulmonary artery wedge pres-
eration. †There is controversy as to whether patients with severe mitral stenosis
0 mm Hg) should undergo percutaneous mitral balloon valvotomy (PMBV) or mitral
rocardiogram; echo, echocardiography; LA, left atrial; MR, mitral regurgitation;
nary artery pressure; and 2D, 2-dimensional.and
al valv
consid
0 to 8
, electdata are concordant with clinical findings. (Level of Evidence: C)
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an be used to determine the severity of MS. Direct
easurements of left atrial and LV pressure determine the
ransmitral gradient, which is the fundamental expression of
everity of MS (372). Because the severity of obstruction is
ependent on both flow and gradient (376), the hydraulic
orlin equation has been used in the catheterization labo-
atory to derive a calculated valve area (139). Pulmonary
rtery pressure and pulmonary vascular resistance can be
easured to determine the effect of MS on the pulmonary
irculation.
With the advent of Doppler echocardiography, cardiac
atheterization is no longer required for assessment of
emodynamics in the majority of patients with isolated MS.
eliable measurements of the transmitral gradient may be
igure 7. Management Strategy for Patients With Mitral Stenosis
The writing committee recognizes that there may be variability in the measurement
edge pressure (PAWP), and pulmonary artery systolic pressure (PP) should also be
alve morphology should undergo percutaneous mitral balloon valvotomy (PMBV) rath
chocardiography; LA, left atrial; MR, mitral regurgitation; MVG, mean mitral valve pr
D, 2-dimensional.btained with the modified Bernoulli equation (389,391). che potential problems of angle dependence, pressure
ecovery, proximal acceleration, and inadequate velocity
ignals that occur in the evaluation of other valve lesions are
ot present with MS. There is often overestimation of the
ransmitral gradient when catheterization is performed with
ulmonary artery wedge pressure as a substitute for left atrial
ressure, even after correction for phase delay. Thus, the
ransmitral gradient derived by Doppler echocardiography
ay be more accurate than that obtained by cardiac cathe-
erization with pulmonary artery wedge pressure (434).
MV area is derived from either the half-time method or
he continuity equation by Doppler echocardiography.
hese measurements correlate well in most instances with
alve areas from cardiac catheterization (401,402). The
oppler half-time method may be inaccurate if there are
Moderate to Severe Symptoms
ral valve area (MVA) and that the mean transmitral gradient, pulmonary artery
into consideration. †It is controversial as to which patients with less favorable
n mitral valve surgery (see text). CXR, chest X-ray; ECG, electrocardiography; echo,
gradient; MVR, mitral valve replacement; NYHA, New York Heart Association; andand
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated402,403), especially after mitral balloon valvotomy, or if
here is concomitant AR. There are limitations to MV area
alculations derived from catheter hemodynamic measure-
ents, because the Gorlin equation may not be valid under
arying hemodynamic conditions, and the empirical coeffi-
ient of discharge may be inaccurate with different orifice
hapes (379,404). Calculation of valve area by catheteriza-
ion is also dependent on measurement of transmitral
radient and cardiac output. Gradients may be inaccurate
hen pulmonary artery wedge pressure is used, as may
ardiac output derived by the thermodilution method.
hen there is concomitant MR, measures of forward flow
y thermodilution or the Fick method will result in under-
stimation of the MV area, as discussed in Section 3.7.2.2.2.
hus, there may be inaccuracies with both Doppler and
atheter-derived valve areas, and a single valve area should
ot be the sole measure of MS severity. Estimates of the
everity of MS should be based on all data, including
ransmitral gradient, MV area, pulmonary artery wedge
ressure, and pulmonary artery pressure.
In most instances, Doppler measurements of transmitral
radient, valve area, and pulmonary pressure will correlate
ell with each other. Catheterization is indicated to assess
emodynamics when there is a discrepancy between
oppler-derived hemodynamics and the clinical status of a
ymptomatic patient. Absolute left- and right-side pressure
easurements should be obtained by catheterization when
here is elevation of pulmonary artery pressure out of
roportion to mean gradient and valve area. Invasive hemo-
ynamic evaluation is also necessary to assess the severity
nd the hemodynamic cause of increased pulmonary vascu-
ar resistance, because pulmonary vasodilator therapy may be
f benefit in such patients. Catheterization including left
entriculography (to evaluate the severity of MR) is indi-
ated when there is a discrepancy between the Doppler-
erived mean gradient and valve area. Aortic root angiog-
aphy may be necessary to evaluate severity of AR. If
ymptoms appear to be out of proportion to noninvasive
ssessment of resting hemodynamics, right- and left-heart
atheterization with exercise may be useful. Transseptal
atheterization may rarely be required for direct measure-
ent of left atrial pressure if there is doubt about the
ccuracy of pulmonary artery wedge pressure. Coronary
ngiography may be required in selected patients who may
eed intervention (see Section 10.2.).
.4.8. Indications for Percutaneous Mitral Balloon
alvotomy
LASS I
. Percutaneous mitral balloon valvotomy is effective for symptomatic
patients (NYHA functional class II, III, or IV), with moderate or severe
MS* and valve morphology favorable for percutaneous mitral bal-
loon valvotomy in the absence of left atrial thrombus or moderate to
severe MR. (Level of Evidence: A)tSee Table 4 (27).. Percutaneous mitral balloon valvotomy is effective for asymptom-
atic patients with moderate or severe MS* and valve morphology
that is favorable for percutaneous mitral balloon valvotomy who
have pulmonary hypertension (pulmonary artery systolic pressure
greater than 50 mm Hg at rest or greater than 60 mm Hg with
exercise) in the absence of left atrial thrombus or moderate to
severe MR. (Level of Evidence: C)
LASS IIa
. Percutaneous mitral balloon valvotomy is reasonable for patients
with moderate or severe MS* who have a nonpliable calcified valve,
are in NYHA functional class III–IV, and are either not candidates for
surgery or are at high risk for surgery. (Level of Evidence: C)
LASS IIb
. Percutaneous mitral balloon valvotomy may be considered for
asymptomatic patients with moderate or severe MS* and valve
morphology favorable for percutaneous mitral balloon valvotomy
who have new onset of atrial fibrillation in the absence of left atrial
thrombus or moderate to severe MR. (Level of Evidence: C)
. Percutaneous mitral balloon valvotomy may be considered for
symptomatic patients (NYHA functional class II, III, or IV) with MV
area greater than 1.5 cm2 if there is evidence of hemodynamically
significant MS based on pulmonary artery systolic pressure greater
than 60 mm Hg, pulmonary artery wedge pressure of 25 mm Hg or
more, or mean MV gradient greater than 15mmHg during exercise.
(Level of Evidence: C)
. Percutaneous mitral balloon valvotomy may be considered as an
alternative to surgery for patients with moderate or severe MS who
have a nonpliable calcified valve and are in NYHA functional class
III–IV. (Level of Evidence: C)
LASS III
. Percutaneous mitral balloon valvotomy is not indicated for patients
with mild MS. (Level of Evidence: C)
. Percutaneous mitral balloon valvotomy should not be performed in
patients with moderate to severe MR or left atrial thrombus. (Level
of Evidence: C)
he concept of mitral commissurotomy was first proposed
y Brunton in 1902, and the first successful surgical mitral
ommissurotomy was performed in the 1920s. By the late
940s and 1950s, both transatrial and transventricular
losed surgical commissurotomy were accepted clinical pro-
edures. With the development of cardiopulmonary bypass,
pen mitral commissurotomy and replacement of the MV
ecame the surgical procedures of choice for the treatment
f MS. Percutaneous mitral balloon valvotomy emerged in
he mid 1980s. This procedure, in which 1 or more large
alloons is inflated across the MV by a catheter-based
pproach, has become the preferred procedure in selected
atients compared with surgical approaches.
The mechanism of improvement from surgical commis-
urotomy or percutaneous valvotomy is related to the
uccessful opening of commissures that were fused by the
heumatic process. This results in a decrease in gradient and
n increase in the calculated MV area, with resulting
mprovement in clinical symptomatology. The extent of
emodynamic and clinical improvement is dependent on
he magnitude of decrease of transmitral gradient and
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alves and minimal fusion of the subvalvular apparatus
chieve the best immediate and long-term results when a
ubstantial increase in the valve area can be achieved.
Closed surgical commissurotomy with either a transatrial
r transventricular approach was popularized in the 1950s
nd 1960s. Early and long-term postoperative follow-up
tudies showed that patients had a significant improvement
n symptoms and survival compared with those treated
edically (435–437). Closed commissurotomy remains the
urgical technique of choice in many developing countries,
ut open commissurotomy is the accepted surgical proce-
ure in most institutions in the United States (438–441),
ecause it allows direct inspection of the MV apparatus and,
nder direct vision, division of the commissures, splitting of
used chordae tendineae and papillary muscles, and debride-
ent of calcium deposits. Amputation of the left atrial
ppendage is recommended to reduce the likelihood of
ostoperative thromboembolic events (442). The results of
he operation are dependent on the morphology of the MV
pparatus and the surgeon’s skill and experience. In patients
ith marked deformity of the MV apparatus, a decision for
V replacement can be made at the time of operation. The
isk of surgery is between 1% and 3%, depending on the
oncomitant medical status of the patient (439–441). Al-
hough there is an inherent bias in the large reported
urgical series, the 5-year reoperation rate is 4% to 7%, and
he 5-year complication-free survival rate ranges from 80%
o 90%.
Percutaneous mitral balloon valvotomy was first per-
ormed in the early 1980s and became a clinically approved
echnique in 1994. In the past decade, there have been
ajor advances in techniques and equipment, as well as
hanges in patient selection. A double-balloon technique
as the initial procedure used by most investigators. Today,
n hourglass-shaped single balloon (Inoue balloon) is used
y most centers performing the technique. Percutaneous
echanical mitral commissurotomy with a metallic valvo-
ome has been introduced, and the results appear to be
imilar. The advantage of this technique is that multiple
ses of the metallic device after sterilization are feasible and
educe the cost of treatment (443); however, it is not widely
vailable, and there is limited experience with this tech-
ique. The balloon valvotomy procedure itself is technically
hallenging and involves a steep learning curve. There is a
igher success rate and lower complication rate in experi-
nced, high-volume centers (444). Thus, the results of the
rocedure are highly dependent on the experience of the
perators involved, which must be considered when making
ecommendations for proceeding with this technique.
The immediate results of percutaneous mitral valvotomy
re similar to those of mitral commissurotomy (444–453).
he mean valve area usually doubles (from 1.0 to 2.0 cm2),
ith a 50% to 60% reduction in transmitral gradient.
verall, 80% to 95% of patients may have a successfulrocedure, which is defined as a MV area greater than 1.5 om2 and a decrease in left atrial pressure to less than 18 mm
g in the absence of complications. The most common
cute complications reported in large series include severe
R, which occurs in 2% to 10%, and a residual atrial septal
efect. A large atrial septal defect (greater than 1.5:1
eft-to-right shunt) occurs in fewer than 12% of patients
ith the double-balloon technique and fewer than 5% with
he Inoue balloon technique. Smaller atrial septal defects
ay be detected by transesophageal echocardiography in
arger numbers of patients. Less frequent complications
nclude perforation of the left ventricle (0.5% to 4.0%),
mbolic events (0.5% to 3%), and myocardial infarction
0.3% to 0.5%). The mortality rate with balloon valvotomy
n larger series has ranged from 1% to 2% (444–447,453);
owever, with increasing experience with the procedure,
ercutaneous mitral valvotomy can be done in selected
atients with a mortality rate of less than 1% (448).
imultaneous echocardiography may be useful in directing
alloon placement and assessing hemodynamics.
Follow-up information after percutaneous balloon valvot-
my is limited. Event-free survival (freedom from death,
epeat valvotomy, or MV replacement) overall is 50% to
5% over 3 to 7 years, with an event-free survival of 80% to
0% in patients with favorable MV morphology (398,446,
48–455). More than 90% of patients free of events remain
n NYHA functional class I or II after percutaneous mitral
alvotomy. Randomized trials have compared percutaneous
alloon valvotomy with both closed and open surgical
ommissurotomy (456–461). These trials, summarized in
able 18, consisted primarily of younger patients (aged 10
o 30 years) with pliable MV leaflets. There was no
ignificant difference in acute hemodynamic results or com-
lication rate between percutaneous mitral valvotomy and
urgery, and early follow-up data indicate no difference in
emodynamics, clinical improvement, or exercise time.
owever, longer-term follow-up studies at 3 to 7 years
459,460) indicate more favorable hemodynamic and symp-
omatic results with percutaneous balloon valvotomy than
ith closed commissurotomy. Of the 2 studies that com-
ared percutaneous balloon valvotomy with open commis-
urotomy, one reported equivalent results (460), and the
ther showed more favorable results with open commissur-
tomy (461). This latter study included older patients with
igher MV scores.
The immediate results, acute complications, and
ollow-up results of percutaneous balloon valvotomy are
ependent on multiple factors. It is of utmost importance
hat this procedure be performed in centers with skilled and
xperienced operators. Other factors include age, NYHA
unctional class, stenosis severity, LV end-diastolic pressure,
ardiac output, and pulmonary artery wedge pressure
446,448,449,453). The underlying MV morphology is the
actor of greatest importance in determining outcome (394–
00,446,449,450,453,454,462), and immediate postvalvo-
omy hemodynamics are predictive of long-term clinical
utcome (448,450,453). Patients with valvular calcification,
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ubvalvular fusion have a higher incidence of acute compli-
ations and a higher rate of recurrent stenosis on follow-up
Table 19). Because the success of the procedure is depen-
ent on the ability to split fused commissures, the presence
f marked fusion and severe calcification of commissures is
ssociated with an increased complication rate and higher
ncidence of recurrent symptoms (396–398). Alternatively,
n patients with noncalcified pliable valves, mild subvalvular
usion, and no calcium in the commissures, the procedure
an be performed with a high success rate (greater than
0%), low complication rate (less than 3%), and sustained
mprovement in 80% to 90% over a 3- to 7-year follow-up
eriod (397,398,400,446,448,450,453,454).
Relative contraindications to percutaneous balloon val-
otomy include the presence of a left atrial thrombus and
ignificant (3 to 4) MR. Transesophageal echocardiog-
aphy is recommended before the procedure to determine
he presence of left atrial thrombus, specifically examining
he left atrial appendage. If a thrombus is found, 3 months
f anticoagulation with warfarin may result in resolution of
he thrombus. A prognostic model for predicting the
esolution of left atrial thrombi in candidates for percuta-
eous mitral commissurotomy has been suggested. Com-
ined clinical functional class and echocardiographic left
trial thrombus are predictive of the outcome of oral
nticoagulation for thrombus resolution (463).
In centers with skilled, experienced operators, percutane-
us balloon valvotomy should be considered the initial
rocedure of choice for symptomatic patients with moderate
o severe MS who have a favorable valve morphology in the
bsence of significant MR or left atrial thrombus. Echocar-
iographic parameters that can predict the risks of develop-
ng severe MR after percutaneous mitral valvotomy by the
noue technique have been reported (464), and the overall
chocardiographic assessment (397,398,400) identifies pa-
ients with less favorable long-term outcome (Tables 17 and
9). In asymptomatic patients with a favorable valve mor-
hology, percutaneous mitral valvotomy may be considered
f there is evidence of a hemodynamic effect on left atrial
ressure or pulmonary circulation (pulmonary artery systolic
ressure greater than 50 mm Hg at rest or greater than 60
m Hg with exercise); the strength of evidence for this
ecommendation is low because there are no data comparing
he results of percutaneous balloon valvotomy and those of
edical therapy in such asymptomatic patients. It is con-
roversial whether severely symptomatic patients with less
avorable valve morphology should undergo this catheter-
ased procedure (465) (Fig. 7; Table 19). Although there is
higher acute complication rate and a lower event-free
urvival rate (approximately 50% at 5 years in these patients
ompared with 80% to 90% in patients with favorable valve
orphology), this must be weighed against the average
n-hospital mortality of surgical MV replacement of 6%
164,165), which is as high as 16% in low-volume centers(166), and the expected long-term outcome. In many cases,Ta Pa
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alvular calcification and deformity.
Patients who are being considered for an intervention
hould undergo evaluation with a history, physical exami-
ation, and 2D and Doppler echocardiographic examina-
ion. The appearance and mobility of the MV apparatus and
ommissures should be evaluated by 2D echocardiography,
nd the transmitral gradient, MV area, and pulmonary
rtery pressure should be obtained from the Doppler exam-
nation. If there is a discrepancy between symptoms and
emodynamics, a formal hemodynamic exercise test may be
erformed. Patients thought to be candidates for percuta-
eous mitral valvotomy should undergo transesophageal
chocardiography to rule out left atrial thrombus and to
xamine the severity of MR. If a left atrial thrombus is
resent, a repeat transesophageal echocardiogram can be
erformed after several months of anticoagulation. Percu-
aneous mitral balloon valvotomy may be safely performed if
here has been resolution of the thrombus. If there is a
uspicion that the severity of MR is 3 or 4 based on the
hysical examination or echocardiogram, a left ventriculo-
ram should be performed. Mitral balloon valvotomy should
ot be performed in patients who have grade 3 or 4
R. Percutaneous mitral balloon valvotomy should be
erformed only by skilled operators at institutions with
xtensive experience in performing the technique (444,447).
hus, the decision to proceed with percutaneous balloon
alvotomy or surgical commissurotomy is dependent on the
able 19. Echocardiographic Prediction of Outcome of Percuta
Author, Year
Mean
Follow-Up,
mo Echo Criteria P
ohen et al., 1992 (446) 36  20 Score less than or equal
to 8
Score greater than 8
alacios et al., 1995 (454) 20  12 Score less than or equal
to 8
Score greater than 8
ean et al., 1996 (449) 38  16 Score less than or equal
to 8
Score 8 to 12
Score greater than 12
ung et al., 1996 (397) 32  18 Group 1
Group 2
Group 3
annan et al., 1997 (398) 22  10 Com Ca
Com Ca
alacios et al., 2002 (453) 50  44 Score greater than 8
Score less than 8
chocardiography score based on scoring system of Wilkins et al. (400); echocardiographic gro
Com Ca indicates commissural calcification; echo, echocardiographic; FC, functional class; MV
alvotomy.xperience of the operator and institution. Because of the *ess invasive nature of percutaneous balloon valvotomy
ompared with surgical intervention, appropriate patients
ithout symptoms or those with NYHA functional class II
ymptoms may be considered for catheter-based therapy
Figs. 5 and 6).
.4.9. Indications for Surgery for Mitral Stenosis
LASS I
. MV surgery (repair if possible) is indicated in patients with symp-
tomatic (NYHA functional class III–IV) moderate or severe MS* when
1) percutaneous mitral balloon valvotomy is unavailable, 2) percu-
taneous mitral balloon valvotomy is contraindicated because of left
atrial thrombus despite anticoagulation or because concomitant
moderate to severe MR is present, or 3) the valve morphology is not
favorable for percutaneous mitral balloon valvotomy in a patient
with acceptable operative risk. (Level of Evidence: B)
. Symptomatic patients with moderate to severe MS* who also have
moderate to severe MR should receive MV replacement, unless
valve repair is possible at the time of surgery. (Level of Evidence: C)
LASS IIa
. MV replacement is reasonable for patients with severe MS* and
severe pulmonary hypertension (pulmonary artery systolic pressure
greater than 60 mm Hg) with NYHA functional class I–II symptoms
who are not considered candidates for percutaneous mitral balloon
valvotomy or surgical MV repair. (Level of Evidence: C)
s Mitral Balloon Valvotomy
s Age, y Survival
Survival
Free of
Events Events
— — 68% at 5 y Death, MVR, repeat
PMBV
— — 28% at 5 y
4814 98% at 4 y 98% at 4 y Death, MVR, NYHA FC
III–IV symptoms
64  11 39% at 4 y 39% at 4 y
49  13 95% at 4 y — Death
58  15 83% at 4 y —
58  15 24% at 4 y —
— 89% at 3 y Death, MVR, repeat
PMBV, FC III–IV
symptoms
46  13 — 78% at 3 y
— 65% at 3 y
— — 86% at 3 y Death, MVR, repeat
PMBV
— — 40% at 3 y
63  14 82% at 12 y 38% at 12 y Death, MVR, repeat
PMBV
51  14 57% at 12 y 22% at 12 y
ed on valve flexibility, chordal fusion, and valve calcification in Iung et al. (397).
l valve replacement; NYHA, New York Heart Association; and PMBV, percutaneous mitral balloonneou
No. of
atient
84
52
211
116
272
306
24
87
311
130
120
29
278
601
up basSee Table 4 (27).
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. MV repair may be considered for asymptomatic patients with mod-
erate or severe MS* who have had recurrent embolic events while
receiving adequate anticoagulation and who have valvemorphology
favorable for repair. (Level of Evidence: C)
LASS III
. MV repair for MS is not indicated for patients with mild MS. (Level of
Evidence: C)
. Closed commissurotomy should not be performed in patients un-
dergoing MV repair; open commissurotomy is the preferred ap-
proach. (Level of Evidence: C)
V replacement is an accepted surgical procedure for
atients with severe MS who are not candidates for surgical
ommissurotomy or percutaneous mitral valvotomy. The
erioperative mortality of MV replacement is dependent on
ultiple factors, including functional status, age, LV func-
ion, cardiac output, concomitant medical problems, and
oncomitant CAD. In the young, healthy person, MV
eplacement can be performed with a risk of less than 5%;
owever, in the older patient with concomitant medical
roblems or pulmonary hypertension at systemic levels, the
erioperative mortality of MV replacement may be as high
s 10% to 20% (166,167). MV replacement with preserva-
ion of subvalvular apparatus aids in maintaining LV func-
ion (466), but this can be particularly difficult in patients
ith rheumatic MS. Alternative approaches to ventricular
reservation exist, such as artificial chordal reconstruction
efore MV replacement (467,468). Complications of MV
eplacement include valve thrombosis, valve dehiscence,
alve infection, valve malfunction, and embolic events.
hese are discussed in Section 7.3. There is also the known
isk of long-term anticoagulation in patients receiving
echanical prostheses.
If there is significant calcification, fibrosis, and subvalvu-
ar fusion of the MV apparatus, commissurotomy or percu-
aneous balloon valvotomy is less likely to be successful, and
V replacement will be necessary. Given the risk of MV
eplacement and the potential long-term complications of a
rosthetic valve, there are stricter indications for MV
peration in these patients with calcified fibrotic valves. In
he patient with NYHA functional class III symptoms due
o severe MS or combined MS/MR, MV replacement
esults in excellent symptomatic improvement. Postpone-
ent of surgery until the patient reaches the functional class
V symptomatic state should be avoided, because operative
ortality is high and the long-term outcome is suboptimal.
owever, if the patient presents in NYHA functional class
V heart failure, surgery should not be denied, because the
utlook without surgical intervention is grave. It is contro-
ersial whether asymptomatic or mildly symptomatic pa-
ients with severe MS (valve area less than 1 cm2) and severe
ulmonary hypertension (pulmonary artery systolic pressure
reater than 60 to 80 mm Hg) should undergo MV
eplacement to prevent RV failure, but surgery is generally
ecommended in such patients. It is recognized that patients rith such severe pulmonary hypertension are rarely asymp-
omatic.
.4.10. Management of Patients After Valvotomy or
ommissurotomy
ymptomatic improvement occurs almost immediately after
uccessful percutaneous balloon valvotomy or surgical com-
issurotomy, although objective measurement of maximum
xygen consumption may continue to improve over several
onths postoperatively owing to slowly progressive im-
rovement in skeletal muscle metabolism (469). Hemody-
amic measurements before and after either percutaneous
alvotomy or surgical commissurotomy have confirmed a
ecrease in left atrial pressure, pulmonary artery pressure,
nd pulmonary arteriolar resistance and an improvement in
ardiac output (470–473). In patients with significant right
eart failure after catheter-based or surgical relief of MV
bstruction, inhaled nitric oxide, intravenous prostacyclin,
r an endothelin antagonist may be useful in reducing
ulmonary vascular resistance and pulmonary hypertension
474). Gradual regression of pulmonary hypertension over
onths has been demonstrated (470–472).
Recurrent symptoms after successful surgical commissur-
tomy have been reported to occur in as many as 60% of
atients after 9 years (405,435,475); however, recurrent
tenosis accounts for symptoms in fewer than 20% of
atients (475). In patients with an adequate initial result,
rogressive MR and development of other valvular or
oronary problems are more frequently responsible for
ecurrent symptoms (475). Thus, in patients presenting
ith symptoms late after commissurotomy, a comprehen-
ive evaluation is required to look for other causes. Patients
ndergoing percutaneous mitral valvotomy with an unfavor-
ble MV morphology have a higher incidence of recurrent
ymptoms at 1- to 2-year follow-up due to either an initial
nadequate result or restenosis (476).
The management of patients after successful percutane-
us balloon valvotomy or surgical commissurotomy is sim-
lar to that of the asymptomatic patient with MS. A baseline
chocardiogram should be performed after the procedure to
btain a baseline measurement of postoperative hemody-
amics and to exclude significant complications such as
R, LV dysfunction, or atrial septal defect (in the case of
ercutaneous valvotomy). This echocardiogram should be
erformed at least 72 h after the procedure, because acute
hanges in atrial and ventricular compliance immediately
fter the procedure affect the reliability of the half-time in
alculation of valve area (402,403). Patients with severe MR
r a large atrial septal defect should be considered for early
urgery; however, the majority of small left-to-right shunts
t the atrial level will close spontaneously over the course of
months. In patients with a history of atrial fibrillation,
arfarin should be restarted 1 to 2 days after the procedure.
A history, physical examination, chest X-ray, and ECG
hould be obtained at yearly intervals in the patient who
emains asymptomatic or minimally symptomatic. Prophy-
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urrence of rheumatic fever (Section 2.3.2.3; Table 11) (45)
hould be followed. If the patient is in atrial fibrillation or
as a history of atrial fibrillation, anticoagulation is recom-
ended, as would be the case for all patients with MS. With
ecurrent symptoms, extensive 2D and Doppler echocardi-
graphy should be performed to evaluate the MV hemody-
amics and pulmonary artery pressure and to rule out
ignificant MR or a left-to-right shunt. As with all patients
ith MS, exercise hemodynamics may be indicated in the
atient with a discrepancy in clinical and hemodynamic
ndings.
Repeat percutaneous balloon valvotomy can be performed
n the patient in whom there is restenosis after either a prior
urgical commissurotomy or a balloon valvotomy (378,477).
he results of these procedures are adequate in many
atients but may be less satisfactory than the overall results
f initial valvotomy, because there is usually more valve
eformity, calcification, and fibrosis than with the initial
rocedure (395,477,478). MV replacement should be con-
idered in those patients with recurrent severe symptoms
nd severe deformity of the mitral apparatus.
.4.11. Special Considerations
.4.11.1. PREGNANT PATIENTS
S often affects young women who are in their childbear-
ng years. The increased intravascular volume, increased
ardiac output, and tachycardia associated with pregnancy
ay raise complex issues in the patient with MS and are
eviewed in Section 5.5.1. Percutaneous mitral valvuloplasty
an be performed with few or no complications to the
other or the fetus and excellent clinical and hemodynamic
esults (479).
.4.11.2. OLDER PATIENTS
n increasing number of older patients now present with
ymptomatic MS, most likely due to a change in the natural
istory of the disease (383,384). Older patients are more
ikely to have heavy calcification and fibrosis of the MV
eaflets, with significant subvalvular fusion. In patients older
han 65 years, the success rate of percutaneous valvotomy is
ower (less than 50%) than in prior reports of younger
atients. Procedural mortality is 3%, and there is an in-
reased risk of complications, including pericardial tampon-
de in 5% and thromboembolism in 3%; however, in
elected patients with favorable valve morphology, the
rocedure may be done safely with good intermediate-term
esults (384). The long-term clinical improvement is con-
iderably less and mortality is higher in older than younger
atients (480).
.5. Mitral Valve Prolapse
.5.1. Pathophysiology and Natural History
VP refers to a systolic billowing of 1 or both mitral leaflets
nto the left atrium with or without MR. Utilizing current
chocardiographic criteria for diagnosing MVP (valve pro- Mapse of 2 mm or more above the mitral annulus in the
ong-axis parasternal view and other views [481]), the
revalence of this entity is 1% to 2.5% of the population
482). MVP occurs as a clinical entity with or without
hickening (5 mm or greater, measured during diastasis) and
ith or without MR.
Primary MVP can be familial or nonfamilial. There is
nterchordal hooding due to leaflet redundancy that includes
oth the rough and clear zones of the involved leaflets (483).
he basic microscopic feature of primary MVP is marked
roliferation of the spongiosa, the delicate myxomatous
onnective tissue between the atrialis (a thick layer of
ollagen and elastic tissue that forms the atrial aspect of the
eaflet) and the fibrosa or ventricularis (dense layer of
ollagen that forms the basic support of the leaflet). Myx-
matous proliferation of the acid mucopolysaccharide–
ontaining spongiosa tissue causes focal interruption of the
brosa. Secondary effects of the primary MVP syndrome
nclude fibrosis of the surface of the MV leaflets, thinning
nd/or elongation of the chordae tendineae, and ventricular
riction lesions. Fibrin deposits often form at the MV–left
trial angle.
Familial MVP is transmitted as an autosomal trait
484,485), and several chromosomal loci have been identi-
ed (486–488). Primary MVP occurs with increased fre-
uency in patients with Marfan syndrome and other con-
ective tissue diseases (483,489 – 491). It has been
peculated that the primary MVP syndrome represents a
eneralized disease of connective tissue. The increased
ncidence of MVP in Von Willebrand’s disease and other
oagulopathies, primary hypomastia, and various connective
issue diseases has been used to support the concept that
ncreased incidence of MVP is a result of defective embry-
genesis of cell lines of mesenchymal origin (492). Thoracic
keletal abnormalities such as straight thoracic spine and
ectus excavatum are commonly associated with MVP.
The auscultatory findings in MVP, when present, may
onsist of a click or multiple clicks that move within systole
ith changes in LV dimensions and/or a late systolic or
olosystolic murmur of MR. There may be left atrial
ilatation and LV enlargement, depending on the presence
nd severity of MR. Involvement of other valves may occur.
ricuspid valve prolapse may occur in 40% of patients with
VP (485). Pulmonic and aortic valve prolapses occur in
% to 10% of patients with MVP (483). There is an
ncreased incidence of associated secundum atrial septal
efect and/or left-sided atrioventricular bypass tracts and
upraventricular arrhythmias.
The natural history of asymptomatic MVP is heteroge-
eous and can vary from benign and normal life expectancy
o adverse with significant morbidity or mortality. The
pectrum of MR ranges from absent to severe. The most
requent predictor of cardiovascular mortality is moderate to
evere MR and, less frequently, an LV ejection fraction less
han 0.50 (493). Echocardiographic evidence of thickenedV leaflets (5 mm or greater) is also a predictor of
c
m
b
f
i
m
v
t
L
n
t
t
p
a
M
s
p
r
s
e
a
s
p
i
d
w
w
f
(
y
t
e
M
q
r
a
3
P
C
1
C
1
2
C
1
2
T
i
c
h
m
a
r
l
m
t
c
T
C
N
M
T
B
Z
R phy.
placem
e53JACC Vol. 52, No. 13, 2008 Bonow et al.
September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedomplications related to MVP (Table 20) (494–499). In
ost patients, the MVP syndrome is associated with a
enign prognosis (500,501). The age-adjusted survival rate
or both men and women with MVP is similar to that of
ndividuals without this entity (485).
The gradual progression of MR in patients with MVP
ay result in the progressive dilatation of the left atrium and
entricle. Left atrial dilatation may result in atrial fibrilla-
ion, and moderate to severe MR may eventually result in
V dysfunction and congestive heart failure (502). Pulmo-
ary hypertension may occur, with associated RV dysfunc-
ion. In some patients, after an initially prolonged asymp-
omatic interval, the entire process may enter an accelerated
hase as a result of left atrial and ventricular dysfunction and
trial fibrillation. In some instances, spontaneous rupture of
V chordae will occur (502). Infective endocarditis is a
erious complication of MVP, which is the leading predis-
osing cardiovascular diagnosis in most series of patients
eported with endocarditis (490,502,503). Because the ab-
olute incidence of endocarditis is extremely low for the
ntire population with MVP, there is much controversy
bout the risk of endocarditis in MVP (504).
Fibrin emboli are responsible in patients with visual
ymptoms consistent with involvement of the ophthalmic or
osterior cerebral circulation (505). Several studies have
ndicated an increased likelihood of cerebrovascular acci-
ents in patients under age 45 years who have MVP beyond
hat would have been expected in a similar population
ithout MVP (506).
Sudden death is a rare complication of MVP, occurring in
ewer than 2% of known cases during long-term follow-up
495,500–511), with annual mortality rates less than 1% per
ear. The likely cause is a ventricular tachyarrhythmia, given
he finding of increased incidence of complex ventricular
ctopy on ambulatory ECG recordings in patients with
VP who had sudden death (512,513). Although infre-
able 20. Use of Echocardiography for Risk Stratification in M
Study, Year
No. of
Patients Features Examined
handraratna et al., 1984 (494) 86 MV leaflets greater than
5.1 mm
ishimura et al., 1985 (495) 237 MV leaflet 5 mm or greate
LVID 60 mm or greater
arks et al., 1989 (496) 456 MV leaflet 5 mm or greate
akamoto et al., 1991 (497) 142 MV leaflet 3 mm or
greater, redundant, low
echo destiny
abuty et al., 1994 (498) 58 Undefined MV thickening
uppiroli et al., 1994 (499) 119 MV leaflet greater than 5
mm
eprinted from the ACC/AHA/ASE 2004 Guidelines for the Clinical Application of Echocardiogra
LVID indicates left ventricular internal diameter; MR, mitral regurgitation; MVR, mitral valve reuent, the highest incidence of sudden death has been heported in the familial form of MVP; some patients have
lso been noted to have QT prolongation (502,514).
.5.2. Evaluation and Management of the Asymptomatic
atient (UPDATED)
LASS I
. Echocardiography is indicated for the diagnosis of MVP and
assessment of MR, leaflet morphology, and ventricular compen-
sation in asymptomatic patients with physical signs of MVP. (Level of
Evidence: B)
LASS IIa
. Echocardiography can effectively exclude MVP in asymptomatic
patients who have been diagnosed without clinical evidence to
support the diagnosis. (Level of Evidence: C)
. Echocardiography can be effective for risk stratification in asymp-
tomatic patients with physical signs of MVP or known MVP. (Level of
Evidence: C)
LASS III
. Echocardiography is not indicated to exclude MVP in asymptomatic
patients with ill-defined symptoms in the absence of a constellation
of clinical symptoms or physical findings suggestive of MVP or a
positive family history. (Level of Evidence: B)
. Routine repetition of echocardiography is not indicated for the
asymptomatic patient who has MVP and noMR or MVP andmild MR
with no changes in clinical signs or symptoms. (Level of Evidence: C)
he primary diagnostic evaluation of the patient with MVP
s the physical examination (502,515). The principal aus-
ultatory feature of this syndrome is the midsystolic click, a
igh-pitched sound of short duration. One or more clicks
ay vary considerably in intensity and timing in systole
ccording to LV loading conditions and contractility. Clicks
esult from sudden tensing of the MV apparatus as the
eaflets prolapse into the left atrium during systole. The
idsystolic click may be followed by a late systolic murmur
hat is usually medium- to high-pitched and loudest at the
ardiac apex. Occasionally the murmur has a musical or
Valve (MV) Prolapse
Outcome p <
1 Cardiovascular abnormalities (60% vs. 6%; Marfan syndrome,
TVP, MR, dilated ascending aorta)
0.001
1 Sum of sudden death, endocarditis, and cerebral embolus 0.02
1 MVR (26% vs. 3.1%) 0.001
1 Endocarditis (3.5% vs. 0%) 0.02
1 Moderate-severe MR (11.9% vs. 0%) 0.001
1 MVR (6.6% vs. 0.7%) 0.02
1 Stroke (7.5% vs. 5.8%) NS
1 Ruptured chordae (48% vs. 5%)
No relation to complex ventricular arrhythmias NS
1 Complex ventricular arrhythmias 0.001
ent; NS, not significant; and TVP, tricuspid valve prolapse. 1 indicates increase.itral
r
ronking quality. The character and intensity of the murmur
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naudible to holosystolic and loud. Dynamic auscultation is
ften useful for establishing the diagnosis of MVP syn-
rome (515). Changes in LV end-diastolic volume result in
hanges in the timing of the midsystolic click(s) and
urmur. When end-diastolic volume is decreased (such as
ith standing), MVP occurs earlier in systole and the
lick–murmur complex occurs shortly after the first heart
ound. In contrast, any maneuver that augments the volume
f blood in the ventricle (such as squatting), reduces
yocardial contractility, or increases LV afterload, length-
ns the time from onset of systole to occurrence of MVP,
nd the click–murmur complex moves toward the second
eart sound. MVP can be present in the absence of these
lassic auscultatory findings, and the clicks may be intermit-
ent and variable.
Although the ECG may provide some information in
atients with MVP, it is often normal. Nonspecific ST-T
ave changes, T-wave inversions, prominent Q waves, and
rolongation of the QT interval also occur. Continuous
mbulatory ECG recordings or event monitors may be
seful for documenting arrhythmias in patients with palpi-
ations. They are not indicated as a routine test for asymp-
omatic patients. Most of the arrhythmias detected are not
ife threatening, and patients often complain of palpitations
hen the ambulatory ECG recording shows no abnormality.
Two-dimensional and Doppler echocardiography is the
ost useful noninvasive test for defining MVP. Valve
rolapse of 2 mm or more above the mitral annulus in the
ong-axis parasternal view and other views, and especially
hen the leaflet coaptation occurs on the atrial side of the
nnular plane, indicates a high likelihood of MVP. There is
isagreement concerning the reliability of echocardio-
raphic appearance of anterior leaflet billowing when ob-
erved only in the apical 4-chamber view (496,516). Leaflet
hickness of 5 mm or more indicates abnormal leaflet
hickness and its added presence makes MVP even more
ertain. Leaflet redundancy is often associated with an
nlarged mitral annulus and elongated chordae tendineae
502). The absence or presence of MR is an important
onsideration and MVP is more likely when MR is detected
s a high velocity eccentric jet in late systole (517).
Reassurance is a major part of the management of
atients with MVP. Patients with mild or no symptoms and
ndings of milder forms of prolapse should be reassured of
he benign prognosis. A normal lifestyle and regular exercise
s encouraged (502, 515).
.5.3. Evaluation and Management of the Symptomatic
atient (UPDATED)
LASS I
. Aspirin therapy (75 to 325 mg per day) is recommended for
symptomatic patients with MVP who experience cerebral transient
ischemic attacks. (Level of Evidence: C)
. In patients with MVP and atrial fibrillation, warfarin therapy is
recommended for patients aged greater than 65 or those with thypertension, MR murmur, or a history of heart failure. (Level of
Evidence: C)
. Aspirin therapy (75 to 325mg per day) is recommended for patients
with MVP and atrial fibrillation who are less than 65 years old and
have no history of MR, hypertension, or heart failure. (Level of
Evidence: C)
. In patients with MVP and a history of stroke, warfarin therapy is
recommended for patients with MR, atrial fibrillation, or left atrial
thrombus. (Level of Evidence: C)
LASS IIa
. In patients with MVP and a history of stroke who do not have MR,
atrial fibrillation, or left atrial thrombus, warfarin therapy is reason-
able for patients with echocardiographic evidence of thickening (5
mm or greater) and/or redundancy of the valve leaflets. (Level of
Evidence: C)
. In patients with MVP and a history of stroke, aspirin therapy is
reasonable for patients who do not have MR, atrial fibrillation, left
atrial thrombus, or echocardiographic evidence of thickening (5mm
or greater) or redundancy of the valve leaflets. (Level of Evidence: C)
. Warfarin therapy is reasonable for patients with MVP with transient
ischemic attacks despite aspirin therapy. (Level of Evidence: C)
. Aspirin therapy (75 to 325mg per day) can be beneficial for patients
with MVP and a history of stroke who have contraindications to
anticoagulants. (Level of Evidence: B)
LASS IIb
. Aspirin therapy (75 to 325 mg per day) may be considered for
patients in sinus rhythm with echocardiographic evidence of high-
risk MVP. (Level of Evidence: C)
Some patients consult their physicians about 1 or more of
he common symptoms that occur with this syndrome:
alpitations, often reported at a time when continuous
mbulatory ECG recordings show no arrhythmias; atypical
hest pain that rarely resembles classic angina pectoris;
yspnea and fatigue, when objective exercise testing often
ails to show any impairment in exercise tolerance; and
europsychiatric complaints, with many patients having
anic attacks and similar syndromes (502). Bankier and
ittman report that a significant number of patients with
goraphobia also have MVP; that 45% of patients with
anic disorder have MVP; and that significant predictors for
alpitations in these patients are depression, poor self-rated
ealth, alcohol intoxication in women, and heavy coffee
rinking and physical inactivity in men (519).
Transient cerebral ischemic episodes occur with increased
ncidence in patients with MVP, and some patients develop
troke syndromes. Reports of amaurosis fugax, homony-
ous field loss, and retinal artery occlusion have been
escribed; occasionally, the visual loss persists (506,520–522).
The roles of cardiac auscultation and echocardiography in
he assessment of symptomatic patients with mitral valve
rolapse are the same as for patients without symptoms.
Patients with MVP and palpitations associated with mild
achyarrhythmias or increased adrenergic symptoms and
hose with chest pain, anxiety, or fatigue often respond to
herapy with beta blockers (523). In many cases, however,
he cessation of stimulants such as caffeine, alcohol, and
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ith recurrent palpitations, continuous or event-activated
mbulatory ECG recordings may reveal the presence or
bsence of arrhythmias at the time of symptoms and
ndicate appropriate treatment of existing arrhythmias. The
ndications for electrophysiological testing are similar to
hose in the general population (e.g., aborted sudden death,
ecurrent syncope of unknown cause, and symptomatic or
ustained ventricular tachycardia) (524).
Orthostatic symptoms due to postural hypotension and
achycardia are best treated with volume expansion, prefer-
bly by liberalizing fluid and salt intake. Mineralocorticoid
herapy or clonidine may be needed in severe cases, and it
ay be beneficial to have the patient wear support stockings.
Daily aspirin therapy (75 to 325 mg per day) is recom-
ended for MVP patients with documented transient focal
eurological events who are in sinus rhythm with no atrial
hrombi. Such patients also should avoid cigarettes and oral
ontraceptives. The American Stroke Association guidelines
524a) recommend aspirin for patients with MVP who have
xperienced an ischemic stroke (Class IIa, Level of Evi-
ence: C), based on the evidence of efficacy of antiplatelet
gents for general stroke patients. No randomized trials
ave addressed the efficacy of selected antithrombotic ther-
pies for the specific subgroup of stroke patients with MVP.
n the current guidelines, the committee recommends aspi-
in for those post-stroke patients with MVP who have no
vidence of MR, atrial fibrillation, left atrial thrombus, or
chocardiographic evidence of thickening (5 mm or greater)
r redundancy of the valve leaflets. However, long-term
nticoagulation therapy with warfarin is recommended
Class I) for post-stroke patients with MVP who have MR,
trial fibrillation, or left atrial thrombus. In the absence of
hese indications, warfarin is also recommended (Class IIa)
n post-stroke patients with MVP who have echocardio-
raphic evidence of thickening (5 mm or greater) or redun-
ancy of the valve leaflets and in MVP patients who
xperience recurrent transient ischemic attacks while taking
spirin. In each of these situations, the international nor-
alized ratio (INR) should be maintained between 2.0 and
.0). In MVP patients with atrial fibrillation, warfarin
herapy is indicated in patients aged greater than 65 years
nd in those with MR, hypertension, or a history of heart
ailure (INR 2.0 to 3.0). Aspirin therapy is satisfactory in
atients with atrial fibrillation who are younger than 65
ears old, have no MR, and have no history of hypertension
r heart failure (525,526). Daily aspirin therapy is often
ecommended for patients with high-risk echocardiographic
haracteristics.
A normal lifestyle and regular exercise are encouraged for
ost patients with MVP, especially those who are asymp-
omatic (511,526). Whether exercise-induced ischemia de-
elops in some patients with MVP remains controversial
527,528). Restriction from competitive sports is recom-
ended when moderate LV enlargement, LV dysfunction,ncontrolled tachyarrhythmias, long-QT interval, unex- dlained syncope, prior resuscitation from cardiac arrest, or
ortic root enlargement is present individually or in combi-
ation (502). A familial occurrence of MVP should be
xplained to the patient and is particularly important in
hose with associated disease who are at greater risk for
omplications. There is no contraindication to pregnancy
ased on the diagnosis of MVP alone.
Asymptomatic patients with MVP and no significant
R can be evaluated clinically every 3 to 5 years. Serial
chocardiography is not necessary in most patients and is
ecommended only in patients who have high-risk charac-
eristics on the initial echocardiogram and in those who
evelop symptoms consistent with cardiovascular disease or
ho have a change in physical findings that suggests
evelopment of significant MR. Patients who have high-
isk characteristics, including those with moderate to severe
R, should be followed up once a year.
Patients with severe MR with symptoms or impaired LV
ystolic function require cardiac catheterization and evalua-
ion for MV surgery (see Section 3.6.4.2). The thickened,
edundant MV can often be repaired rather than replaced
ith a low operative mortality and excellent short- and
ong-term results (529,530). Follow-up studies also suggest
ower thrombotic and endocarditis risk with valve repair
han with prosthetic valves.
.5.4. Surgical Considerations
anagement of MVP may require valve surgery, particu-
arly in those patients who develop a flail mitral leaflet due
o rupture of chordae tendineae or their marked elongation.
ost such valves can be repaired successfully by surgeons
xperienced in MV repair, especially when the posterior
eaflet of the MV is predominantly affected. MV repair for
R due to MVP is associated with excellent long-term
urvival and remains superior to MV replacement beyond 10
ears and up to 20 years after surgery (529,530). Anterior
eaflet MV repair is associated with a higher risk for
eoperation than posterior leaflet repair. As noted in Section
.6.4.2, cardiologists are strongly encouraged to refer pa-
ients who are candidates for complex MV repair to surgical
enters experienced in performing MV repair. Residual MR
s associated with a higher risk for reoperation (530).
ymptoms of heart failure, severity of MR, presence or
bsence of atrial fibrillation, LV systolic function, LV
nd-diastolic and end-systolic volumes, and pulmonary
rtery pressure (rest and exercise) all influence the decision
o recommend MV surgery. Recommendations for surgery
n patients with MVP and MR are the same as for those
ith other forms of nonischemic severe MR. For further
etail, please review Section 7.3. on MV surgery.
.6. Mitral Regurgitation
.6.1. Etiology
he common causes of organic MR include MVP syn-
rome, rheumatic heart disease, CAD, infective endocardi-
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lso occur secondary to a dilated annulus from dilatation of
he left ventricle. In some cases, such as ruptured chordae
endineae, ruptured papillary muscle, or infective endocar-
itis, MR may be acute and severe. Alternatively, MR may
orsen gradually over a prolonged period of time. These 2
nds of the spectrum have quite different clinical presenta-
ions.
.6.2. Acute Severe Mitral Regurgitation
.6.2.1. PATHOPHYSIOLOGY
n acute severe MR, a sudden volume overload is imposed
n the left atrium and left ventricle. Acute volume overload
ncreases LV preload, allowing for a modest increase in total
V stroke volume (531). However, in the absence of
ompensatory eccentric hypertrophy (which has had no time
o develop), forward stroke volume and cardiac output are
educed. At the same time, the unprepared left atrium and
eft ventricle cannot accommodate the regurgitant volume,
hich causes large v waves in the left atrium and results in
ulmonary congestion. In this phase of the disease, the
atient has both reduced forward output (even shock) and
imultaneous pulmonary congestion. In severe MR, the
emodynamic overload often cannot be tolerated, and MV
epair or replacement must often be performed urgently.
.6.2.2. DIAGNOSIS
he patient with acute severe MR is almost always severely
ymptomatic. Physical examination of the precordium may
e misleading, because a normal-sized left ventricle does not
roduce a hyperdynamic apical impulse. The systolic mur-
ur of MR may not be holosystolic and may even be absent.
third heart sound or early diastolic flow rumble may be
he only abnormal physical finding present. Transthoracic
chocardiography may demonstrate the disruption of the
V and help provide semiquantitative information on
esion severity; however, transthoracic echocardiography
ay underestimate lesion severity by inadequate imaging of
he color flow jet. Thus, if there is hyperdynamic systolic
unction of the left ventricle on a transthoracic echocardio-
ram in a patient with acute heart failure, the suspicion of
evere MR should be raised. Because transesophageal echo-
ardiography can more accurately assess the color flow jet
532), transesophageal imaging should be performed if MV
orphology and regurgitant severity are still in question
fter transthoracic echocardiography. Transesophageal
chocardiography is also helpful in demonstrating the ana-
omic cause of acute severe MR and directing successful
urgical repair.
In the hemodynamically stable patient, if CAD is sus-
ected or there are risk factors for CAD (see Section 10.2),
oronary arteriography is necessary before surgery because
yocardial revascularization should be performed during
V surgery in those patients with concomitant CAD533,534). a.6.2.3. MEDICAL THERAPY
n acute severe MR, medical therapy has a limited role and
s aimed primarily to stabilize hemodynamics in preparation
or surgery. The goal of nonsurgical therapy is to diminish
he amount of MR, in turn increasing forward output and
educing pulmonary congestion. In the normotensive pa-
ient, administration of nitroprusside may effectively accom-
lish all 3 goals. Nitroprusside increases forward output not
nly by preferentially increasing aortic flow but also by
artially restoring MV competence as LV size diminishes
535,536). In the patient rendered hypotensive because of a
evere reduction in forward output, nitroprusside should not
e administered alone, but combination therapy with an
notropic agent (such as dobutamine) and nitroprusside is of
enefit in some patients. In such patients, aortic balloon
ounterpulsation increases forward output and mean arterial
ressure while diminishing regurgitant volume and LV
lling pressure and can be used to stabilize the patient while
hey are prepared for surgery. If infective endocarditis is the
ause of acute MR, identification and treatment of the
nfectious organism are essential.
.6.3. Chronic Asymptomatic Mitral Regurgitation
.6.3.1. PATHOPHYSIOLOGY AND NATURAL HISTORY
atients with mild to moderate MR may remain asymp-
omatic with little or no hemodynamic compromise for
any years; however, MR from a primary MV abnormality
ends to progress over time with an increase in volume
verload due to an increase in the effective orifice area.
rogression of the MR is variable and determined by
rogression of lesions or mitral annulus size (537).
Once the MR has become severe, there has been time for
evelopment of eccentric cardiac hypertrophy in which new
arcomeres are laid down in series, which increases the
ength of individual myocardial fibers (228,531). The result-
ng increase in LV end-diastolic volume is compensatory
ecause it permits an increase in total stroke volume, which
llows for restoration of forward cardiac output (538). At
he same time, the increase in LV and left atrial size allows
ccommodation of the regurgitant volume at a lower filling
ressure, and the symptoms of pulmonary congestion abate.
n this phase of compensated MR, the patient may be
ntirely asymptomatic, even during vigorous exercise. It
hould be noted that in the compensatory phase, augmented
reload and reduced or normal afterload (provided by the
nloading of the left ventricle into the left atrium) facilitate
V ejection, which results in a large total stroke volume and
normal forward stroke volume.
The compensated phase of MR is variable but may last
or many years. However, the prolonged burden of
olume overload may eventually result in LV dysfunction.
n this phase, contractile dysfunction impairs ejection,
nd end-systolic volume increases. There may be further
V dilatation and increased LV filling pressure. These
emodynamic events result in reduced forward output
nd pulmonary congestion. However, the still favorable
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedoading conditions often maintain ejection fraction in the
ow normal range (0.50 to 0.60) despite the presence of
ignificant muscle dysfunction (531,539,540). Correction
f MR should be performed before the advanced phases
f LV decompensation.
Numerous studies indicate that patients with chronic
evere MR have a high likelihood of developing symptoms
r LV dysfunction over the course of 6 to 10 years
518,526,541,542). However, the incidence of sudden death
n asymptomatic patients with normal LV function varies
idely among these studies.
The natural history of severe MR due to a flail posterior
eaflet has been documented (518). At 10 years, 90% of
atients are dead or require MV operation. The mortality
ate in patients with severe MR caused by flail leaflets is 6%
o 7% per year. However, patients at risk of death are
redominantly those with LV ejection fractions less than
.60 or with NYHA functional class III–IV symptoms, and
ess so those who are asymptomatic and have normal LV
unction (518,543). Severe symptoms also predict a poor
utcome after MV repair or replacement (543).
.6.3.2. DIAGNOSIS
n evaluating the patient with chronic MR, the history is
nvaluable. A well-established estimation of baseline exer-
ise tolerance is important in gauging the subtle onset of
ymptoms at subsequent evaluations. Physical examination
hould demonstrate displacement of the LV apical impulse,
hich indicates that MR is severe and chronic, producing
ardiac enlargement. A third heart sound or early diastolic
ow rumble is usually present and does not necessarily
ndicate LV dysfunction. Findings consistent with pulmo-
ary hypertension are worrisome because they indicate
dvanced disease with worsened prognosis (544). An ECG
nd chest X-ray are useful in establishing rhythm and for
ssessment of the pulmonary vascularity and pulmonary
ongestion.
.6.3.3. INDICATIONS FOR TRANSTHORACIC ECHOCARDIOGRAPHY
LASS I
. Transthoracic echocardiography is indicated for baseline evaluation
of LV size and function, RV and left atrial size, pulmonary artery
pressure, and severity of MR (Table 4) in any patient suspected of
having MR. (Level of Evidence: C)
. Transthoracic echocardiography is indicated for delineation of the
mechanism of MR. (Level of Evidence: B)
. Transthoracic echocardiography is indicated for annual or semian-
nual surveillance of LV function (estimated by ejection fraction and
end-systolic dimension) in asymptomatic patients with moderate to
severe MR. (Level of Evidence: C)
. Transthoracic echocardiography is indicated in patients with MR to
evaluate the MV apparatus and LV function after a change in signs
or symptoms. (Level of Evidence: C)
. Transthoracic echocardiography is indicated to evaluate LV size and
function and MV hemodynamics in the initial evaluation after MVreplacement or MV repair. (Level of Evidence: C) tLASS IIa
. Exercise Doppler echocardiography is reasonable in asymptomatic
patients with severe MR to assess exercise tolerance and the effects
of exercise on pulmonary artery pressure and MR severity. (Level of
Evidence: C)
LASS III
. Transthoracic echocardiography is not indicated for routine
follow-up evaluation of asymptomatic patients with mild MR and
normal LV size and systolic function. (Level of Evidence: C)
An initial comprehensive 2D, Doppler echocardiogram is
ndispensable in the management of the patient with MR.
he echocardiogram provides a baseline estimation of LV
nd left atrial size, an estimation of LV ejection fraction,
nd approximation of the severity of regurgitation (2).
uantification of the severity of MR (Table 4) (27) is
trongly recommended (27,541,545,546). In the majority of
atients, an estimate of pulmonary artery pressure can be
btained from the TR peak velocity (547). Changes from
hese baseline values are subsequently used to guide the
iming of MV surgery. The blood pressure at the time of
ach study should be documented, because the afterload on
he ventricle will affect the measured severity of the MR.
The initial transthoracic echocardiogram should disclose
he anatomic cause of the MR. A central color flow jet of
R with a structurally normal MV apparatus suggests the
resence of functional MR, which may be due to annular
ilatation from LV dilatation or tethering of the posterior
eaflet because of regional LV dysfunction in patients with
schemic heart disease. An eccentric color flow jet of MR
ith abnormalities of the MV apparatus indicates organic
R. In patients with organic MR, the echocardiogram
hould assess the presence of calcium in the annulus or
eaflets, the redundancy of the valve leaflets, and the MV
eaflet involved (anterior leaflet, posterior leaflet, or bileaf-
et). These factors will help determine the feasibility of valve
epair if surgery is contemplated. The system proposed by
arpentier (548) allows the echocardiographer to focus on
he anatomic and physiologic characteristics of the valve
hat aid the surgeon in planning the repair. The valve
ysfunction is described on the basis of the motion of the
ree edge of the leaflet relative to the plane of the annulus:
ype I, normal; type II, increased, as in MVP; type IIIA,
estricted during systole and diastole, and type IIIB, re-
tricted during systole.
The diagnosis of severe MR should be made by correlat-
ng the findings on physical examination with the findings
rom a comprehensive 2D, Doppler echocardiogram. Mul-
iple parameters from the Doppler examination should be
sed to diagnose severe MR (Table 4) (27), including the
olor flow jet width and area, the intensity of the
ontinuous-wave Doppler signal, the pulmonary venous
ow contour, the peak early mitral inflow velocity, and
uantitative measures of effective orifice area and regurgita-
ion volume (2). In addition, there should be enlargement of
he left ventricle and left atrium in chronic severe MR.
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here is severe MR, but ischemic LV dysfunction may also
esult in severe MR. If a discrepancy is present, or if the
atient has poor windows on transthoracic echocardiogra-
hy, then further evaluation of the severity of MR is
equired, including cardiac catheterization, magnetic reso-
ance imaging, or transesophageal echocardiography.
.6.3.4. INDICATIONS FOR TRANSESOPHAGEAL ECHOCARDIOGRAPHY
SEE ALSO SECTION 8.1.4.)
LASS I
. Preoperative or intraoperative transesophageal echocardiography
is indicated to establish the anatomic basis for severe MR in
patients in whom surgery is recommended to assess feasibility of
repair and to guide repair. (Level of Evidence: B)
. Transesophageal echocardiography is indicated for evaluation of
MR patients in whom transthoracic echocardiography provides non-
diagnostic information regarding severity of MR, mechanism of MR,
and/or status of LV function. (Level of Evidence: B)
LASS IIa
. Preoperative transesophageal echocardiography is reasonable in
asymptomatic patients with severe MR who are considered for
surgery to assess feasibility of repair. (Level of Evidence: C)
LASS III
. Transesophageal echocardiography is not indicated for routine
follow-up or surveillance of asymptomatic patients with native valve
MR. (Level of Evidence: C)
.6.3.5. SERIAL TESTING
he aim of serial follow-up of the patient with MR is to
ubjectively assess changes in symptomatic status and ob-
ectively assess changes in LV function and exercise toler-
nce that can occur in the absence of symptoms. Asymp-
omatic patients with mild MR and no evidence of LV
nlargement, LV dysfunction, or pulmonary hypertension
an be followed on a yearly basis with instructions to alert
he physician if symptoms develop in the interim. Yearly
chocardiography is not necessary unless there is clinical
vidence that MR has worsened. In patients with moderate
R, clinical evaluation including echocardiography should
e performed annually and sooner if symptoms occur.
Asymptomatic patients with severe MR should be fol-
owed up with history, physical examination, and echocar-
iography every 6 to 12 months to assess symptoms or
ransition to asymptomatic LV dysfunction. Exercise stress
esting may be used to add objective evidence regarding
ymptoms and changes in exercise tolerance. Exercise test-
ng is especially important if a good history of the patient’s
xercise capacity cannot be obtained. Measurement of
ulmonary artery pressure and assessment of severity of MR
uring exercise may be helpful.
Interpretation of LV ejection fraction in the patient with
R is made difficult because the loading conditions present
n MR facilitate ejection and increase ejection fraction, the
tandard guide to LV function. Nonetheless, several studies
ave indicated that the preoperative ejection fraction is an smportant predictor of postoperative survival in patients
ith chronic MR (539,544,549–551). Ejection fraction in a
atient with MR with normal LV function is usually greater
han or equal to 0.60. Consistent with this concept, post-
perative ventricular function is lower and survival is re-
uced in patients with a preoperative ejection fraction less
han 0.60 compared with patients with higher ejection
ractions (550,551).
Alternatively or in concert, echocardiographic LV end-
ystolic dimension (or volume) can be used in the timing of
V surgery. End-systolic dimension, which may be less
oad dependent than ejection fraction (552), should be less
han 40 mm preoperatively to ensure normal postoperative
V function (538,551–553). If patients become symptom-
tic, they should undergo MV surgery even if LV function
s normal.
.6.3.6. GUIDELINES FOR PHYSICAL ACTIVITY AND EXERCISE
ecommendations regarding participation in competitive
thletics were published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
138). Asymptomatic patients with MR of any severity who
re in sinus rhythm and who have normal LV and left atrial
imensions and normal pulmonary artery pressure may
xercise without restriction (138). However, those with
efinite LV enlargement (greater than or equal to 60 mm),
ulmonary hypertension, or any degree of LV systolic
ysfunction at rest should not participate in any competitive
ports.
.6.3.7. MEDICAL THERAPY
n the asymptomatic patient with chronic MR, there is no
enerally accepted medical therapy. Although intuitively,
he use of vasodilators may appear to be logical for the same
easons that they are effective in acute MR, there are no
arge, long-term studies to indicate that they are beneficial.
urthermore, because MR with normal ejection fraction is a
isease in which afterload is not increased (230,538,554,
55), drugs that reduce afterload might produce a physio-
ogical state of chronic low afterload with which there is very
ittle experience. There has not been a consistent improve-
ent in LV volumes and severity of MR in the small studies
hat have examined the effect of ACE inhibitors (312,556–
58). The beneficial effect seen in some studies may be more
elated to blockade of tissue angiotensin rather than the
asodilatory effect of the drug (559). Thus, in the absence of
ystemic hypertension, there is no known indication for the
se of vasodilating drugs or ACE inhibitors in asymptom-
tic patients with MR and preserved LV function.
However, in patients with functional or ischemic MR
resulting from dilated or ischemic cardiomyopathy), there
s reason to believe that preload reduction may be beneficial
535). If LV systolic dysfunction is present, primary treat-
ent of the LV systolic dysfunction with drugs such as
CE inhibitors or beta blockers (particularly carvedilol) and
iventricular pacing have all been shown to reduce the
everity of functional MR (560–563).
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedIn patients with MR who develop symptoms but have
reserved LV function, surgery is the most appropriate
herapy. If atrial fibrillation develops, heart rate should be
ontrolled with rate-lowering calcium channel blockers,
eta blockers, digoxin, or, rarely, amiodarone. In patients
ith severe MR and chronic atrial fibrillation, a Maze
rocedure may be added to an MV repair (see Section
.6.4.2.4), because this will reduce the risk of postoperative
troke. Although the risk of embolism with the combination
f MR and atrial fibrillation was formerly considered similar
o that of MS and atrial fibrillation, subsequent studies
uggest that embolic risk may be less in MR (564,565).
onetheless, it is recommended that the INR be main-
ained at 2 to 3 in this population.
.6.3.8. INDICATIONS FOR CARDIAC CATHETERIZATION
LASS I
. Left ventriculography and hemodynamic measurements are indi-
cated when noninvasive tests are inconclusive regarding severity of
MR, LV function, or the need for surgery. (Level of Evidence: C)
. Hemodynamic measurements are indicated when pulmonary artery
pressure is out of proportion to the severity of MR as assessed by
noninvasive testing. (Level of Evidence: C)
. Left ventriculography and hemodynamic measurements are indi-
cated when there is a discrepancy between clinical and noninvasive
findings regarding severity of MR. (Level of Evidence: C)
. Coronary angiography is indicated before MV repair or MV replace-
ment in patients at risk for CAD. (Level of Evidence: C)
LASS III
. Left ventriculography and hemodynamic measurements are not
indicated in patients with MR in whom valve surgery is not contem-
plated. (Level of Evidence: C)
ardiac catheterization, with or without exercise, is neces-
ary when there is a discrepancy between clinical and
oninvasive findings. Catheterization is also performed
hen surgery is contemplated in cases in which there is still
ome doubt about the severity of MR after noninvasive
esting or when there is a need to assess extent and severity
f CAD preoperatively. In patients with MR who have risk
actors for CAD (e.g., advanced age, hypercholesterolemia,
r hypertension) or when there is a suspicion that MR is
schemic in origin (either because of known myocardial
nfarction or suspected ischemia), coronary angiography
hould be performed before surgery.
Patients should usually not undergo valve surgery unless
he degree of MR is severe. If there is a discrepancy
egarding the severity of MR between the physical exami-
ation or elements of the comprehensive 2D, Doppler
xamination, then transesophageal echocardiography, mag-
etic resonance imaging, or left ventriculography should be
erformed. Although the standard semiquantitative ap-
roach to determining the severity of MR from ventricu-
ography has its own limitations (566), ventriculography
oes provide an additional method to assess LV dilatation
nd function and gauge the severity of MR. Exercise aemodynamics may provide additional information that is
elpful in decision making.
During the catheterization procedure, a right-heart cath-
terization should be performed if the severity of MR is
ncertain to obtain right-sided pressures to quantify the
ncrease in left atrial pressure (pulmonary artery wedge
ressure) and pulmonary artery pressure. The presence or
bsence of a large v wave has little diagnostic impact when
ombined with data from the rest of the catheterization
567).
.6.4. Indications for Surgery
.6.4.1. TYPES OF SURGERY
hree different MV operations are currently used for cor-
ection of MR: 1) MV repair; 2) MV replacement with
reservation of part or all of the mitral apparatus; and 3)
V replacement with removal of the mitral apparatus. Each
rocedure has its advantages and disadvantages, and there-
ore, the indications for each procedure are somewhat
ifferent.
In most cases, MV repair is the operation of choice when
he valve is suitable for repair and appropriate surgical skill
nd expertise are available. This procedure preserves the
atient’s native valve without a prosthesis and therefore
voids the risk of chronic anticoagulation (except in patients
n atrial fibrillation) or prosthetic valve failure late after
urgery. Additionally, preservation of the mitral apparatus
eads to better postoperative LV function and survival than
n cases in which the apparatus is disrupted (545,568–573).
mproved postoperative function occurs with repair because
he mitral apparatus is an integral part of the left ventricle
hat is essential for maintenance of normal shape, volume,
nd function of the left ventricle (574). However, MV repair
s technically more demanding than MV replacement, may
equire longer extracorporeal circulation time, and may
ccasionally fail. Valve morphology and surgical expertise
re of critical importance for the success of valve repair (see
elow).
The reoperation rate after MV repair is similar to the
eoperation rate after MV replacement (530). There is a 7%
o 10% reoperation rate at 10 years in patients undergoing
V repair, usually for severe recurrent MR (530,575–578).
pproximately 70% of the recurrent MR is thought to be
ue to the initial procedure and 30% to progressive valve
isease (575). The reoperation rate is lower in those patients
ho had the initial operation for posterior leaflet abnormal-
ties than in those who had bileaflet or anterior leaflet
bnormalities (518,577).
The advantage of MV replacement with preservation of
he chordal apparatus is that this operation ensures postop-
rative MV competence, preserves LV function, and en-
ances postoperative survival compared with MV replace-
ent, in which the apparatus is disrupted (570,579–582).
he disadvantage is the use of a prosthetic valve, with the
isks of deterioration inherent in tissue valves or the need for
nticoagulation inherent in mechanical valves.
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142MV replacement in which the MV apparatus is resected
hould almost never be performed. It should only be
erformed in those circumstances in which the native valve
nd apparatus are so distorted by the preoperative pathology
rheumatic disease, for example) that the mitral apparatus
annot be spared. As noted previously (Section 3.4.9),
rtificial chordal reconstruction does extend the opportuni-
ies for repair in some such patients with rheumatic MR
467,468).
The advantages of MV repair make it applicable across
he full spectrum of MR, including the 2 extremes of the
pectrum. Valve repair might be possible in patients with
ar-advanced symptomatic MR and depressed LV function
ecause it preserves LV function at the preoperative level
572); MV replacement with disruption of the apparatus in
uch patients could lead to worsened or even fatal LV
ysfunction after surgery. At the other extreme, in the
elatively asymptomatic patient with well-preserved LV
unction, repair of a severely regurgitant valve might be
ontemplated to avoid the onset of ventricular dysfunction
rom longstanding volume overload (583). However, failed
V repair would result in the need for a prosthetic valve;
his would represent a clear complication, because it would
mpose the risks of a prosthesis on a patient who did not
reviously require it. Hence, “prophylactic” surgery in an
symptomatic patient with MR and normal LV function
equires a high likelihood of successful repair.
.6.4.2. INDICATIONS FOR MITRAL VALVE OPERATION
LASS I
. MV surgery is recommended for the symptomatic patient with acute
severe MR.* (Level of Evidence: B)
. MV surgery is beneficial for patients with chronic severe MR* and
NYHA functional class II, III, or IV symptoms in the absence of severe
LV dysfunction (severe LV dysfunction is defined as ejection fraction
less than 0.30) and/or end-systolic dimension greater than 55 mm.
(Level of Evidence: B)
. MV surgery is beneficial for asymptomatic patients with chronic
severe MR* and mild to moderate LV dysfunction, ejection fraction
0.30 to 0.60, and/or end-systolic dimension greater than or equal to
40 mm. (Level of Evidence: B)
. MV repair is recommended over MV replacement in the majority of
patients with severe chronic MR* who require surgery, and patients
should be referred to surgical centers experienced in MV repair.
(Level of Evidence: C)
LASS IIa
. MV repair is reasonable in experienced surgical centers for asymp-
tomatic patients with chronic severe MR* with preserved LV func-
tion (ejection fraction greater than 0.60 and end-systolic dimension
less than 40 mm) in whom the likelihood of successful repair
without residual MR is greater than 90%. (Level of Evidence: B)
. MV surgery is reasonable for asymptomatic patients with chronic
severe MR,* preserved LV function, and new onset of atrial fibrilla-
tion. (Level of Evidence: C)
. MV surgery is reasonable for asymptomatic patients with chronic
severe MR,* preserved LV function, and pulmonary hypertensionsSee Table 4 (27).(pulmonary artery systolic pressure greater than 50 mm Hg at rest
or greater than 60 mm Hg with exercise). (Level of Evidence: C)
. MV surgery is reasonable for patients with chronic severe MR* due
to a primary abnormality of the mitral apparatus and NYHA func-
tional class III–IV symptoms and severe LV dysfunction (ejection
fraction less than 0.30 and/or end-systolic dimension greater than
55 mm) in whom MV repair is highly likely. (Level of Evidence: C)
LASS IIb
. MV repair may be considered for patients with chronic severe
secondary MR* due to severe LV dysfunction (ejection fraction less
than 0.30) who have persistent NYHA functional class III–IV symp-
toms despite optimal therapy for heart failure, including biventricu-
lar pacing. (Level of Evidence: C)
LASS III
. MV surgery is not indicated for asymptomatic patients with MR and
preserved LV function (ejection fraction greater than 0.60 and
end-systolic dimension less than 40 mm) in whom significant doubt
about the feasibility of repair exists. (Level of Evidence: C)
. Isolated MV surgery is not indicated for patients with mild or
moderate MR. (Level of Evidence: C)
n many cases, the type of operation, MV repair versus
eplacement, is important in timing surgery. In fact, al-
hough the type of surgery to be performed is never actually
stablished until the operation, many situations lend them-
elves to preoperative prediction of the operation that can be
erformed. This prediction is based on the skill and expe-
ience of the surgeon in performing repair and on the
ocation and type of MV disease that caused the MR.
onrheumatic posterior leaflet prolapse due to degenerative
V disease or a ruptured chordae tendineae can usually be
epaired using a resection of the portion of the valve and an
nnuloplasty (584,585). Involvement of the anterior leaflet
r both anterior and posterior leaflets diminishes the like-
ihood of repair because the operation requires other inter-
entions, such as chordal shortening, chordal transfer, and
nnovative anatomic repairs (586–591). Consequently, the
kill and experience of the surgeon are probably the most
mportant determinants of the eventual operation that will
e performed. In general, rheumatic involvement of the MV
nd calcification of the MV leaflets or annulus diminish the
ikelihood of repair, even in experienced hands (592).
The number of patients undergoing MV repair for MR
as increased steadily over the past decade in the United
tates and Canada in relation to the number undergoing
V replacement. However, among isolated MV procedures
eported in the STS National Cardiac Database from 1999
o 2000 (593), the frequency of repair was only 35.7% (3027
f a total of 8486 procedures), which suggests that MV
epair is underutilized. The STS National Database also
ndicates an operative mortality rate of under 2% in patients
ndergoing isolated MV repair in 2004, which compares
avorably to the greater than 6% operative mortality rate for
atients undergoing isolated MV replacement (165). Con-
idering the beneficial effect of MV repair on survival and
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atients who are candidates for MV repair to surgical
enters experienced in performing MV repair.
.6.4.2.1. SYMPTOMATIC PATIENTS WITH NORMAL LEFT VEN-
RICULAR FUNCTION. Patients with symptoms of congestive
eart failure despite normal LV function on echocardiog-
aphy (ejection fraction greater than 0.60 and end-systolic
imension less than 40 mm) require surgery. Surgery should
e performed in patients with mild symptoms and severe
R (Fig. 8), especially if it appears that MV repair rather
han replacement can be performed. The feasibility of repair
s dependent on several factors, including valve anatomy and
urgical expertise. Successful surgical repair improves symp-
oms, preserves LV function, and avoids the problems of a
rosthetic valve. When repair is not feasible, MV replace-
ent with chordal preservation should relieve symptoms
igure 8. Management Strategy for Patients With Chronic Severe
Mitral valve (MV) repair may be performed in asymptomatic patients with normal le
ood of successful MV repair is greater than 90%. AF indicates atrial fibrillation; Ech
T, hypertension; and MVR, mitral valve replacement.nd maintain LV function. t.6.4.2.2. ASYMPTOMATIC OR SYMPTOMATIC PATIENTS WITH
EFT VENTRICULAR DYSFUNCTION. Preoperative variables
hat are predictive of postoperative survival, symptomatic
mprovement, and postoperative LV function are summa-
ized in Table 21 (538,539,544,549–552). The timing of
urgery for asymptomatic patients is controversial, but most
ould now agree that MV surgery is indicated with the
ppearance of echocardiographic indicators of LV dysfunc-
ion. These include LV ejection fraction less than or equal
o 0.60 and/or LV end-systolic dimension greater than or
qual to 40 mm (Fig. 8). Surgery performed at this time will
ikely prevent further deterioration in LV function and
mprove longevity. This is true whether repair or replace-
ent is performed (551), although repair is clearly pre-
erred. It must be emphasized that, unlike with the timing
f AVR for AR, LV ejection fraction should not be allowed
l Regurgitation
ricular (LV) function if performed by an experienced surgical team and if the likeli-
ocardiography; EF, ejection fraction; ESD, end-systolic dimension; eval, evaluation;Mitra
ft vent
o, echo fall into the lower limit of the normal range in patients
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perative survival are much stronger with LV ejection
raction than with end-systolic dimension (544,549–551),
hereas both ejection fraction and end-systolic dimension
trongly influence postoperative LV function and heart
ailure (538,539,544,551,552). MV surgery should also be
ecommended for symptomatic patients with evidence of
V systolic dysfunction (ejection fraction less than or equal
o 0.60, and/or end-systolic dimension greater than or equal
o 40 mm).
Determining the surgical candidacy of the symptomatic
atient with MR and far-advanced LV dysfunction is a
ommon clinical dilemma. The question that often arises is
hether the patient with MR has such advanced LV
ysfunction that he or she is no longer a candidate for
urgery. Often such cases present difficulty in distinguishing
rimary cardiomyopathy with secondary MR from primary
R with secondary myocardial dysfunction. In the latter
ase, if MV repair appears likely, surgery should still be
ontemplated (Fig. 8). Even though such a patient is likely
o have persistent LV dysfunction, surgery is likely to
mprove symptoms and prevent further deterioration of
V function (328). If MV replacement is necessary in
uch patients, it should be performed only if the chordal
pparatus can be preserved. The modification of MV
eometry by an “undersized” annular ring in patients with
evere LV dysfunction and significant functional MR
ay be beneficial in a subset of patients with primary
yocardial disease (597– 602), although the impact on
utcomes compared with aggressive medical therapy,
able 21. Preoperative Predictors of Surgical Outcome in Mitra
Study, Year
Study
Design
Type of
Surgery
No. of
Patient
chuler et al., 1979 (539) Retrospective MVR 20
hillips et al., 1981 (549) Retrospective MVR 105
ile et al., 1984 (538) Prospective MVR 16
rawford et al., 1990 (544) Prospective MVR 48
isenbaugh et al., 1994 (552) Registry MVR 26
MVR-CP 35
nriquez-Sarano et al., 1994 (550) Retrospective MVR 214
MV repair 195
nriquez-Sarano et al., 1994 (551) Retrospective MVR 104
MV repair 162
P indicates chordal sparing procedure; echo, echocardiographic; EDD, end-diastolic dimension;
A, left atrial; LV, left ventricular; MV, mitral valve; MVR, mitral valve replacement; PAWP, pulmncluding beta blockers and cardiac resynchronization cherapy (560 –563), has not been studied in a prospective
andomized trial.
.6.4.2.3. ASYMPTOMATIC PATIENTS WITH NORMAL LEFT VEN-
RICULAR FUNCTION. As noted previously, repair of a se-
erely regurgitant valve may be contemplated in an asymp-
omatic patient with severe MR and normal LV function to
reserve LV size and function and prevent the sequelae of
hronic severe MR (541). Although there are no random-
zed data with which to recommend this approach to all
atients, the committee recognizes that some experienced
enters are moving in this direction for patients for whom
he likelihood of successful repair is high. Natural history
tudies indicate uniformly that asymptomatic patients with
evere MR and normal LV function have a high likelihood
f developing symptoms and/or LV dysfunction warranting
peration over the course of 6 to 10 years (518,526,541,
42). Two recent studies have also addressed the risk of
udden death (541,542) in asymptomatic patients with
evere MR and normal LV function. In a long-term
etrospective study in which severity of MR was quantified
y Doppler echocardiography (541), 198 patients with an
ffective orifice area greater than 40 mm2 had a 4% per year
isk of cardiac death during a mean follow-up period of 2.7
ears. However, in the second study of 132 patients fol-
owed up prospectively for 5 years, during which the
ndications for surgery were symptoms, development of LV
ysfunction (ejection fraction less than 0.60), LV dilatation
LV end-systolic dimension greater than 45 mm), atrial
brillation, or pulmonary hypertension, there was only 1
gurgitation
Outcome Assessed Findings
V function 12 Patients with average LV EF 0.70 had normal
postoperative EF; 4 patients with average EF 0.58
had postoperative EF 0.25
urvival EF less than 0.50 predicted poor survival
eart failure, LV
function
LV ESD index greater than 2.6 cm per m2 (45 mm)
and LV FS less than 0.32 predicted poor outcome
urvival, LV function LV EF less than 0.50 predicted reduced survival; ESV
less than 50 ml per m2 predicted persistent LV
dilatation
urvival, LV function ESD, EDD, and FS predicted poor survival and LV
function; only ESD significant in multivariate
analysis
urvival LV EF 0.60 or less predicted poor survival whether
MVR or CP was performed; EF estimated by echo
FS or visual analysis
V function EF, ESD, LV diameter/thickness ratio, and end-systolic
wall stress predicted outcome; EF estimated by
echo FS or visual analysis
ction fraction; ESD, end-systolic dimension; ESV, end-systolic volume; FS, fractional shortening;
rtery wedge pressure.l Re
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V dilation (542).
MV repair is often recommended in hemodynamically
table patients with newly acquired severe MR, such as
ight occur with ruptured chordae. Surgery is also recom-
ended in an asymptomatic patient with chronic MR with
ecent onset of atrial fibrillation in whom there is a high
ikelihood of successful valve repair (see below).
Surgery for asymptomatic patients with severe MR and
ormal LV function should only be considered if there is a
reater than 90% likelihood of successful valve repair in a
enter experienced in this procedure. As noted above,
ardiologists are strongly encouraged to refer patients who
re candidates for MV repair to surgical centers experienced
n performing MV repair.
.6.4.2.4. ATRIAL FIBRILLATION. Atrial fibrillation is a com-
on, potentially morbid arrhythmia associated with MR. In
atients with MR due to MVP, there is a high risk of
evelopment of atrial fibrillation. The development of atrial
brillation is independently associated with a high risk of
ardiac death or heart failure (603). Preoperative atrial
brillation is an independent predictor of reduced long-
erm survival after MV surgery for chronic MR (551,603–
05). The persistence of atrial fibrillation after MV surgery
an lead to thromboembolism and partially nullifies an
dvantage of mitral repair by requiring anticoagulation
605). Predictors of the persistence of atrial fibrillation after
uccessful valve surgery are the presence of atrial fibrillation
or greater than 1 year and left atrial size greater than 50 mm
606). In 1 study, an even shorter duration of preoperative
trial fibrillation (3 months) was a predictor of persistent
trial fibrillation after MV repair (607); persistent atrial
brillation after surgery occurred in 80% of patients with
reoperative atrial fibrillation greater than or equal to 3
onths but in no patient with preoperative atrial fibrillation
ess than 3 months. Although patients who develop atrial
brillation also usually manifest other symptomatic or
unctional changes that would warrant MV operation, many
linicians would consider the recent onset of atrial fibrilla-
ion to be an indication in and of itself for surgery, if there
s a high likelihood of valve repair (Fig. 8) (582,607). In
atients presenting for MV operation with chronic atrial
brillation, a concomitant Maze procedure may prevent
uture thromboembolic events by restoring normal sinus
hythm (608–614). The decision to proceed with a Maze
rocedure should be based on the age and health of the
atient, as well as the surgical expertise, because this
rocedure may add to the morbidity of the operation.
.6.5. Ischemic Mitral Regurgitation
he outlook for the patient with ischemic MR is substan-
ially worse than that for regurgitation from other causes
533,615). A worse prognosis accrues from the fact that
schemic MR is usually caused by LV dysfunction resulting
rom myocardial infarction. Furthermore, the MV itself is fsually anatomically normal, and MR is secondary to
apillary muscle displacement and tethering of the mitral
eaflet(s). The mechanism of MR in chronic ischemic
isease is local LV remodeling (apical and posterior dis-
lacement of papillary muscles), which leads to excess
alvular tenting and loss of systolic annular contraction
616–623). The indication for MV operation in the patient
ho undergoes CABG with mild to moderate MR is still
nclear, but there are data to indicate benefit of MV repair
n such patients (624–627). Patients with ischemic heart
isease who have MR have a worse prognosis than those
ho do not have MR (628–631). CABG alone may
mprove LV function and reduce ischemic MR in selected
atients (629,632), especially those with transient severe
R due to ischemia, in whom myocardial revascularization
an eliminate episodes of severe MR. However, CABG
lone is usually insufficient and leaves many patients with
ignificant residual MR, and these patients would benefit
rom concomitant MV repair at the time of the CABG
623–627,633–642). Mitral annuloplasty alone with a
ownsized annuloplasty ring is often effective at relieving
R (637,638,641).
In severe MR secondary to acute myocardial infarction,
ypotension and pulmonary edema often occur. Severe MR
ccurs in 6% to 7% of patients with cardiogenic shock (643).
he cause of the MR should be established, because the
R may be due to a ruptured papillary muscle, papillary
uscle displacement with leaflet tethering, or annular dila-
ation from severe LV dilatation. Those patients with an
cute rupture of the papillary muscle should undergo surgery
n an emergency basis, with either valve repair or MV
eplacement (644). In those patients with papillary muscle
ysfunction, treatment should initially consist of hemody-
amic stabilization, usually with insertion of an intra-aortic
alloon pump. Surgery should be considered for those
atients who do not improve with aggressive medical
herapy. Correction of acute severe ischemic MR usually
equires valve surgery in addition to revascularization. The
est operation for ischemic MR is controversial (645,646),
ut MV repair with an annuloplasty ring is the best
pproach in most instances (624,627,633–642).
.6.6. Evaluation of Patients After Mitral Valve
eplacement or Repair
fter MV surgery, follow-up is necessary to detect late
urgical failure and assess LV function, as discussed in
ection 9.3. For patients in whom a bioprosthesis has been
nserted, the specter of eventual deterioration is always
resent and must be anticipated. If a mechanical valve has
een inserted, anticoagulation is required, and chronic
urveillance of prothrombin time and INR is necessary.
fter valve repair, follow-up to assess the effectiveness of the
epair is indicated early, especially because most repair
ailures are detected soon after surgery.
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lderly patients with MR fare more poorly with valve
urgery than do their counterparts with AS. In general,
perative mortality increases and survival is reduced in
atients older than 75 years of age, especially if MV
eplacement must be performed or if the patient has
oncomitant CAD or other valve lesions (164,167,545,647–
50). Operative mortality in the elderly is low in experi-
nced centers (651), but the overall operative mortality for
V replacement in this age group in the United States
xceeds 14% (167,649,650) and is particularly high (greater
han 20%) in low-volume centers (167). Although the risks
re reduced if MV repair is performed rather than MV
eplacement, the majority of patients in this age group
equire concomitant CABG (650). The average operative
isk for combined MV repair plus CABG in the United
tates is 8% (165), which will undoubtedly be higher in the
lder population. These risks are worth taking in patients
ith significant symptoms. However, under most circum-
tances, asymptomatic patients or patients with mild symp-
oms should be treated medically.
.7. Multiple Valve Disease
.7.1. Introduction
emarkably few data exist to objectively guide the manage-
ent of mixed valve disease. The large number of combined
emodynamic disturbances (and their varied severity) yields
large number of potential combinations to consider, and
ew data exist for any specific category. Hence, each case
ust be considered individually, and management must be
ased on understanding the potential derangements in
emodynamics and LV function and the probable benefit of
edical versus surgical therapy. Other than recommending
valuation with physical examination, echocardiography,
nd cardiac catheterization as clinically indicated for patient
valuation and management, the committee has developed
o specific recommendations in this section.
.7.2. Mixed Single Valve Disease
.7.2.1. PATHOPHYSIOLOGY
n mixed mitral or aortic valve disease, 1 lesion usually
redominates over the other, and the pathophysiology
esembles that of the pure dominant lesion. Thus, for the
atient with mixed AS and AR in whom stenosis predom-
nates, the pathophysiology and management resemble that
f pure AS. The left ventricle develops concentric hyper-
rophy rather than dilatation. The timing of AVR is based
n symptomatic status. However, if the attendant regurgi-
ation is more than mild, it complicates the pathophysiology
y placing the concentrically hypertrophied and noncom-
liant left ventricle on a steeper portion of its diastolic
ressure-volume curve, in turn causing pulmonary conges-
ion. The effect is that neither lesion by itself might be
onsidered severe enough to warrant surgery, but both dogether produce substantial hemodynamic compromise
hat necessitates intervention.
In patients with severe AR and mild AS, the high total
troke volume due to extensive regurgitation may produce a
ubstantial transvalvular gradient. Because the transvalvular
radient varies with the square of the transvalvular flow
139), a high gradient in predominant AR may be predi-
ated primarily on excess transvalvular flow rather than on a
everely compromised orifice area.
In mixed mitral disease, predominant MS produces a left
entricle of normal volume, whereas in predominant MR,
hamber dilatation occurs. A substantial transvalvular gra-
ient may exist in regurgitation-predominant disease be-
ause of high transvalvular flow, but, as in mixed aortic valve
isease with predominant regurgitation, the gradient does
ot represent severe orifice stenosis.
.7.2.2. DIAGNOSIS
.7.2.2.1. TWO-DIMENSIONAL AND DOPPLER ECHOCARDIO-
RAPHIC STUDIES. As noted above, chamber geometry is
mportant in assessing the dominant lesion (stenotic versus
egurgitant), which in turn is important in management.
or instance, a small left ventricle is inconsistent with
hronic severe regurgitation. Doppler interrogation of the
ortic valve and MVs with mixed disease should provide a
eliable estimate of the transvalvular mean gradient; how-
ver, there may be a significant discrepancy between the
oppler-derived maximum instantaneous gradient and
atheter peak gradient with mixed aortic valve disease.
xercise hemodynamics derived by Doppler echocardiogra-
hy have been helpful in managing mixed valve disease. MV
rea can be measured accurately by the half-time method in
ixed MS/MR. Aortic valve area would be measured
naccurately at the time of cardiac catheterization in mixed
S/AR if cardiac output were measured by either thermodi-
ution or the Fick method. The valve area can be measured
ore accurately by the continuity equation from Doppler
chocardiography in mixed AS/AR; however, the continuity
quation calculation of valve area may not be completely
ndependent of flow (652). Although these valve area
easurements by Doppler echocardiography are more ac-
urate than those obtained at cardiac catheterization, in
eneral, the confusing nature of mixed valve disease makes
ardiac catheterization necessary to obtain additional hemo-
ynamic information in most patients.
.7.2.2.2. CARDIAC CATHETERIZATION. Catheterization is of-
en necessary to fully assess hemodynamics. The diagnosis
f “moderate” mixed disease is frequently made on the basis
f noninvasive tests alone. This term suggests that the valve
isease is not severe enough to mandate surgery. However,
s noted previously, the nondominant lesion may exacerbate
he pathophysiology of the dominant lesion and produce
ymptoms. In this context, a complete hemodynamic eval-
ation that includes exercise hemodynamics may be impor-
ant. For example, resting hemodynamics in mixed mitral
isease might show a transmitral gradient of 5 mm Hg, a
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rtery wedge pressure of 15 mm Hg. However, with
xercise, the wedge pressure can increase dramatically,
dentifying a hemodynamic cause for the patient’s symptoms
nd suggesting that mechanical correction will be of benefit.
any cases of mixed valve disease require hemodynamic
xercise testing to delineate proper assessment (653).
Hemodynamic estimation of valve area requires determi-
ation of total valve flow and transvalvular gradient. The
resence of valvular regurgitation in a primarily stenotic
alve causes forward cardiac output to underestimate total
alve flow, which is the sum of forward plus regurgitant
ow. Thus, if standard measures of forward cardiac output
e.g., thermodilution or Fick method) are used to calculate
alve area, the area will be underestimated. One approach to
his problem is to use total stroke volume (angiographic
nd-diastolic volume minus end-systolic volume) in place of
orward stroke volume (Fick or thermodilution cardiac
utput/heart rate) in the Gorlin formula. Although this
pproach is logically valid, it has not been clinically tested or
etted against a “gold standard.” Furthermore, angiographic
troke volume is dependent on accurate calculation of
ardiac volumes, which can be difficult in the very large
nd/or spherical left ventricles encountered in valvular
egurgitation (654). In general, the utility of this approach is
imited. Doppler pressure half-time may be very useful in
his situation.
.7.2.3. MANAGEMENT
nlike the management of a severe pure valve lesion, solid
uidelines for mixed disease are difficult to establish. The
ost logical approach is to surgically correct disease that
roduces more than mild symptoms or, in the case of
dominant aortic valve disease, to operate in the presence of
ven mild symptoms. In regurgitant dominant lesions,
urgery can be delayed until symptoms develop or asymp-
omatic LV dysfunction (as gauged by markers used in pure
egurgitant disease) becomes apparent. The use of vasodi-
ators to forestall surgery in patients with asymptomatic
ixed disease is untested. Anticoagulants should be used in
ixed mitral disease if atrial fibrillation is present. In mixed
itral disease with moderate or severe (3 to 4) regur-
itation, percutaneous mitral balloon valvotomy is contra-
ndicated because regurgitation may worsen.
.7.3. Combined Mitral Stenosis and
ortic Regurgitation
.7.3.1. PATHOPHYSIOLOGY
hen both AR and MS coexist, severe MS usually coexists
ith mild AR with pathophysiology similar to that of
solated MS. However, the coexistent AR is occasionally
evere. The combination of coexistent severe MS and severe
R may present confusing pathophysiology and often leads
o misdiagnosis. MS restricts LV filling, blunting the
mpact of AR on LV volume (341). Thus, even severe ARay fail to cause a hyperdynamic circulation, so that typical pigns of AR are absent during physical examination. Like-
ise, echocardiographic LV cavitary dimensions may be
nly mildly enlarged. Doppler half-time measurements of
V area may be inaccurate in the presence of significant
R. The picture presented by this complex combination of
esions usually requires all diagnostic modalities, including
ardiac catheterization, for resolution.
.7.3.2. MANAGEMENT
echanical correction of both lesions is eventually necessary
n most patients. Development of symptoms or pulmonary
ypertension is the usual indication for intervention. Com-
ined aortic valve and MV replacement is a reasonable
pproach, but when correction is anticipated in patients
ith predominant MS, balloon mitral valvotomy followed
y AVR may be performed. This obviates the need for
ouble-valve replacement, which has a higher risk of peri-
perative mortality and postoperative complications than
ingle-valve replacement (165). In most cases, it is advisable
o perform mitral valvotomy first and then monitor the
atient for symptomatic improvement. If symptoms disap-
ear, correction of AR can be delayed.
.7.4. Combined Mitral Stenosis and
ricuspid Regurgitation
.7.4.1. PATHOPHYSIOLOGY
hen TR coexists with MS, some elements of pulmonary
ypertension are also usually present. Thus, the issue arises
hether TR will or will not improve when MS is corrected
nd pulmonary artery pressure decreases (655). Unfortu-
ately, the status of the tricuspid valve after correction of
S is difficult to predict. In general, if pulmonary hyper-
ension is severe and the tricuspid valve anatomy is not
rossly distorted, improvement in TR can be expected after
orrection of MS (656). On the other hand, if there is severe
heumatic deformity of the tricuspid valve, dilatation of the
ricuspid annulus, or severe TR, competence is likely to be
estored only by surgery.
.7.4.2. DIAGNOSIS
nce TR is suspected by physical examination to coexist
ith MS, both can be further evaluated by Doppler echo-
ardiographic studies. The presence of TR almost guaran-
ees that an estimation of pulmonary artery pressure can be
ade by Doppler interrogation of the tricuspid valve. An
valuation of the anatomy of both the mitral and tricuspid
alves can be made.
.7.4.3. MANAGEMENT
f the MV anatomy is favorable for percutaneous balloon
alvotomy and there is concomitant pulmonary hyperten-
ion, valvotomy should be performed regardless of symptom
tatus. After successful mitral valvotomy, pulmonary hyper-
ension and TR almost always diminish (656).
If MV surgery is performed, concomitant tricuspid an-
uloplasty should be considered, especially if there are
reoperative signs or symptoms of right-sided heart failure,
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itate a second operation (657). If intraoperative assessment
uggests that TR is functional without significant dilatation
f the tricuspid annulus, it may not be necessary to perform
n annuloplasty. However, there is growing evidence that
R associated with dilatation of the tricuspid annulus
hould be repaired (658,659). Tricuspid dilatation is an
ngoing process that may progress to severe TR if un-
reated. Annuloplasty of the tricuspid valve based on tricus-
id dilatation improves functional status independent of the
egree of TR (658). Residual TR after tricuspid annulo-
lasty is determined principally by the degree of preopera-
ive tricuspid leaflet tethering (660).
.7.5. Combined Mitral Regurgitation and
ortic Regurgitation
.7.5.1. PATHOPHYSIOLOGY
s noted in the previous discussions of isolated MR and
R, these are 2 very different diseases with different
athophysiological effects and different guidelines for the
iming of surgery. Thus, in the patient with double-valve
egurgitation, proper management becomes problematic.
he most straightforward approach is the same as for mixed
ingle-valve disease, that is, to determine which lesion is
ominant and to treat primarily according to that lesion.
lthough both lesions produce LV dilatation, AR will
roduce modest systemic systolic hypertension and a mild
ncrease in LV wall thickness.
.7.5.2. DIAGNOSIS AND THERAPY
oppler echocardiographic interrogation shows bivalve re-
urgitation and an enlarged left ventricle. 2D echocardiog-
aphy is usually performed to assess the severity of AR and
R, LV size and function, left atrial size, pulmonary artery
ressure, and feasibility of MV repair. When surgery is
equired, AVR plus MV repair is the preferred strategy
hen MV repair is possible (661).
.7.6. Combined Mitral Stenosis and Aortic Stenosis
.7.6.1. PATHOPHYSIOLOGY
ombined stenotic disease is almost always secondary to
heumatic heart disease. Obstruction of flow at the MV
iminishes aortic valve flow as well. Thus, the problem of
valuating aortic valve severity in a low-flow/low-gradient
ituation often exists.
.7.6.2. DIAGNOSIS AND THERAPY
n patients with significant AS and MS, the physical
ndings of AS generally dominate, and those of MS may be
verlooked, whereas the symptoms are usually those of MS.
oninvasive evaluation should be performed with 2D and
oppler echocardiographic studies to evaluate the severity
f AS and MS, paying special attention to suitability for
itral balloon valvotomy in symptomatic patients, and to
ssess ventricular size and function. If the degree of AS
ppears to be mild and the MV is acceptable for balloon aalvotomy, this should be attempted first. If mitral balloon
alvotomy is successful, the aortic valve should then be
e-evaluated.
.7.7. Combined Aortic Stenosis andMitral Regurgitation
.7.7.1. PATHOPHYSIOLOGY
ombined AS and MR often develop secondary to rheu-
atic heart disease. However, congenital AS and MVP may
ccur in combination in younger patients, as may degener-
tive AS and MR in the elderly. If severe, AS will worsen
he degree of MR. In addition, MR may cause difficulty in
ssessing the severity of AS because of reduced forward
ow. MR will also enhance LV ejection performance,
hereby masking the early development of LV systolic
ysfunction caused by AS. Development of atrial fibrillation
nd loss of atrial systole may further reduce forward output
ecause of impaired filling of the hypertrophied left
entricle.
.7.7.2. DIAGNOSIS AND THERAPY
oninvasive evaluation should be performed with 2D and
oppler echocardiography to evaluate the severity of both
S and MR. Attention should be paid to LV size, wall
hickness, and function; left atrial size; right-heart function;
nd pulmonary artery pressure. Particular attention should
e paid to MV morphology in patients with these combined
esions. Patients with severe AS and severe MR (with
bnormal MV morphology) with symptoms, LV dysfunc-
ion, or pulmonary hypertension should undergo combined
VR and MV replacement or MV repair. AVR plus MV
epair is the preferred strategy when MV repair is possible
661). However, in patients with severe AS and lesser
egrees of MR, the severity of MR may improve greatly
fter isolated AVR, particularly when there is normal MV
orphology. Intraoperative transesophageal echocardiogra-
hy and, if necessary, visual inspection of the MV should be
erformed at the time of AVR to determine whether
dditional MV surgery is warranted in these patients.
In patients with mild to moderate AS and severe MR in
hom surgery on the MV is indicated because of symptoms,
V dysfunction, or pulmonary hypertension, preoperative
ssessment of the severity of AS may be difficult because of
educed forward stroke volume. If the mean aortic valve
radient is greater than 30 mm Hg, AVR should be
erformed. In patients with less severe aortic valve gradi-
nts, inspection of the aortic valve and its degree of opening
n 2D or transesophageal echocardiography and visual
nspection by the surgeon may be important in determining
he need for concomitant AVR.
.8. Tricuspid Valve Disease
.8.1. Pathophysiology
ricuspid valve dysfunction can occur with normal or
bnormal valves. When normal tricuspid valves develop
ysfunction, the resulting hemodynamic abnormality is
lmost always pure regurgitation. This occurs with elevation
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ent, and tricuspid annular dilatation (662,663); RV sys-
olic hypertension occurs in MS, pulmonic valve stenosis,
nd the various causes of pulmonary hypertension. RV
iastolic hypertension occurs in dilated cardiomyopathy, RV
nfarction, and RV failure of any cause (662,663).
acemaker-induced severe TR is rare but may require
ntervention.
Abnormalities of the tricuspid valve leading to TR can
ccur with rheumatic valvulitis, infective endocarditis, car-
inoid, rheumatoid arthritis, radiation therapy, trauma (such
s repeated endomyocardial biopsies), Marfan syndrome,
ricuspid valve prolapse, tricuspid annular dilatation, or
ongenital disorders such as Ebstein’s anomaly (663) or a
left tricuspid valve as part of atrioventricular canal malfor-
ations. Anorectic drugs may also cause TR (see Section 3.9).
Tricuspid stenosis is most commonly rheumatic in origin.
n very rare occasions, infective endocarditis (with large
ulky vegetations), congenital abnormalities, carcinoid,
abry’s disease, Whipple’s disease, or previous methysergide
herapy may be implicated (664). Right atrial mass lesions
epresent a nonvalvular cause of obstruction to the tricuspid
rifice and may also over time destroy the leaflets and cause
egurgitation. Rheumatic tricuspid involvement usually re-
ults in both stenosis and regurgitation.
.8.2. Diagnosis
he clinical features of tricuspid stenosis include a giant a
ave and diminished rate of y descent in the jugular venous
ulse, a tricuspid opening snap, and a murmur that is
resystolic as well as middiastolic and that increases on
nspiration (665). Because chronic rheumatic valve disease is
he most common cause of tricuspid stenosis, there is
sually associated mitral and/or aortic disease, and the
linical findings include those associated with the other 2
alves, especially the MV.
The clinical features of TR include abnormal systolic c
nd v waves in the jugular venous pulse, a lower left
arasternal systolic murmur (holosystolic or less than holo-
ystolic, depending on the severity of hemodynamic de-
angement) that may increase on inspiration (Carvallo’s
ign), a middiastolic murmur in severe regurgitation, and
ystolic hepatic pulsation. In rare instances, severe TR may
roduce systolic propulsion of the eyeballs (666), pulsatile
aricose veins (667), or a venous systolic thrill and murmur
n the neck (668). Other associated clinical features are
elated to the cause of TR. Moderate or severe TR may be
resent without the classic clinical features.
Echocardiography is valuable in assessing tricuspid valve
tructure and motion, measuring annular size, and identi-
ying other cardiac abnormalities that might influence tri-
uspid valve function. Doppler echocardiography permits
stimation of the severity of TR (669), RV systolic pressure,
nd the tricuspid valve diastolic gradient. Although echo-
ardiography is a valuable diagnostic tool, it should be
ointed out that clinically insignificant TR is detected by Tolor Doppler imaging in many normal persons (16,19–22).
his is not an indication for either routine follow-up or
rophylaxis against bacterial endocarditis. Clinical correla-
ion and judgment must accompany the echocardiographic
esults. Systolic pulmonary artery pressures greater than 55
m Hg are likely to cause TR with anatomically normal
ricuspid valves, whereas TR occurring with systolic pulmo-
ary artery pressures less than 40 mm Hg is likely to reflect
structural abnormality of the valve apparatus. Systolic
ulmonary artery pressure estimation combined with infor-
ation about annular circumference will further improve
he accuracy of clinical assessment (662).
.8.3. Management
LASS I
. Tricuspid valve repair is beneficial for severe TR in patients with MV
disease requiring MV surgery. (Level of Evidence: B)
LASS IIa
. Tricuspid valve replacement or annuloplasty is reasonable for se-
vere primary TR when symptomatic. (Level of Evidence: C)
. Tricuspid valve replacement is reasonable for severe TR secondary
to diseased/abnormal tricuspid valve leaflets not amenable to
annuloplasty or repair. (Level of Evidence: C)
LASS IIb
ricuspid annuloplasty may be considered for less than severe TR in
atients undergoing MV surgery when there is pulmonary hypertension
r tricuspid annular dilatation. (Level of Evidence: C)
LASS III
. Tricuspid valve replacement or annuloplasty is not indicated in
asymptomatic patients with TR whose pulmonary artery systolic
pressure is less than 60 mm Hg in the presence of a normal MV.
(Level of Evidence: C)
. Tricuspid valve replacement or annuloplasty is not indicated in
patients with mild primary TR. (Level of Evidence: C)
he patient’s clinical status and the cause of the tricuspid
alve abnormality usually determine the appropriate thera-
eutic strategy. Medical and/or surgical management may
e required. For example, in the patient with severe MS and
ulmonary hypertension with resulting RV dilatation and
R, relief of MS and the resulting decrease in pulmonary
rtery pressure may result in substantial diminution of the
egree of TR. The timing of surgical intervention for TR
emains controversial, as do the surgical techniques. To
ome extent, this controversy has diminished since the
dvent of 2D and Doppler echocardiography for preopera-
ive diagnosis and assessment. Intraoperative transesopha-
eal Doppler echocardiography allows refinement of annu-
oplasty techniques to optimize outcome (670–672). At
resent, surgery on the tricuspid valve for TR occurs
ommonly at the time of MV surgery. As noted in Section
.7.4.3, TR associated with dilatation of the tricuspid
nnulus should be repaired (658,659), because tricuspid
ilatation is an ongoing process that may progress to severe
R if left untreated.
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ricuspid stenosis of various causes (673–675). However,
evere TR is a common consequence of this procedure, and
esults are poor when severe TR develops.
Patients with severe TR of any cause have a poor
ong-term outcome because of RV dysfunction and/or
ystemic venous congestion (676). Tricuspid valve and
hordal reconstruction can be attempted in some cases of
R resulting from endocarditis and trauma (677–679). In
ecent years, annuloplasty has become an established surgi-
al approach to significant TR (657–660,680–684).
When the valve leaflets themselves are diseased, abnor-
al, or destroyed, valve replacement with a low-profile
echanical valve or bioprosthesis is often necessary (685). A
iological prosthesis is preferred because of the high rate of
hromboembolic complications with mechanical prostheses
n the tricuspid position. In patients with associated con-
uction defects, insertion of a permanent epicardial pacing
lectrode at the time of valve replacement can avoid the later
eed to pass a transvenous lead across the prosthetic valve.
.9. Drug-Related Valvular Heart Disease
n addition to the common causes of the valvular lesions
escribed in the preceding sections, there are a number of
ncommon causes related to systemic diseases (e.g., rheu-
atoid arthritis, systemic lupus erythematosus, anti-
hospholipid antibody syndrome, and ankylosing spondyli-
is), drugs (e.g., ergotamine, methysergide, anorexiant
edications, and pergolide), and toxins. It is beyond the
cope of these guidelines to discuss the specific pathology
nd natural history of valve disease stemming from each of
hese many causes. In general, the evaluation and manage-
ent strategies for patients with valve disease related to
hese disorders are directed both toward the underlying
ystemic process when appropriate and to the diagnosis and
reatment of the associated valvular disease according to the
uidelines developed for each of the valve lesions as de-
cribed in Section 3.
The sympathomimetic appetite-suppressant drug fenflu-
amine and its pure d-enantiomer, dexfenfluramine, were
emoved from the market in September 1997 after several
eports of unusual left-sided valvular heart disease (AR and
R) linked to these agents (686–690). These medications,
hen used alone or in combination with the noradrenergic
gent phentermine, had been previously implicated as a
ause of pulmonary hypertension, even when used for less
han 1 month (691–693). The echocardiographic and his-
opathological findings reported were similar to those de-
cribed in patients with carcinoid or ergotamine-induced
alvular heart disease (694–699). The fibroproliferative
esponse appears to be mediated via the 5-HT2B receptor
700). Subsequent reports have estimated a lower prevalence
f anorexiant drug–related valvulopathy meeting Food and
rug Administration (FDA) criteria and have identified
ge, dose, and duration of exposure as risk factors for its
evelopment (701–706). In the meta-analysis by Sachdev pnd colleagues, the pooled prevalence of qualifying valvular
egurgitation among patients treated for more than 90 days
as 12.0% compared with 5.9% for the unexposed group
odds ratio 2.2, 95% confidence interval 1.7–2.7) (707).
his increase was primarily the result of mild or greater AR
exposed 9.6% and unexposed 4.5%, odds ratio 2.5, 95%
onfidence interval 1.9–3.3). The prevalence among pa-
ients exposed for less than 90 days was 6.8% compared with
.8% for unexposed patients (odds ratio 1.4, 95% confidence
nterval 0.8–2.4) (707). Isolated reports have implied that
he valvular disease associated with combination- or single-
rug therapy does not progress and may improve after
essation of treatment (708,709). Concomitant therapy with
selective serotonin reuptake inhibitor for depression or
anic disorder does not appear to confer incremental risk
703). Fewer patients are now presenting for initial evalua-
ion since the drugs were removed from the market in 1997.
o date, an excess prevalence of valvular heart disease has
ot been reported for sibutramine, a serotonin and norepi-
ephrine reuptake inhibitor, or for phentermine when used
s monotherapy for obesity (710,711). The lipase inhibitor
rlistat is not known to produce valvular disease. There are
ow several reports of a carcinoid-like valvulopathy in
arkinson’s disease patients treated with pergolide, a
opamine-receptor agonist (712–714). A history of expo-
ure to any of the ergotamine-like agents briefly reviewed
ere should prompt a careful cardiovascular examination,
chocardiography when indicated, and treatment as would
e dictated by the nature and severity of the heart valve
esion(s).
.10. Radiation Heart Disease
ediastinal radiation may produce cardiac valve abnormal-
ties that usually become evident at least 5 years after the
adiation injury. The assessment and treatment of these
atients can be difficult in part because these valve lesions
ccur within a context of multiple cardiac and noncardiac
bnormalities produced by radiation. Radiation-induced
alvular lesions are based on calcification of valve leaflets and
he fibrous skeleton of the heart. Mixed aortic valve disease
hat combines stenosis and insufficiency is the most com-
on lesion, but MR and TR may also occur. Nonvalvular
spects of radiation-induced heart disease include a restric-
ive cardiomyopathy, aortic and great vessel calcification,
oronary artery stenoses including ostial lesions and diffuse
esions, pericardial constriction, and conduction abnormal-
ties. Noncardiac abnormalities such as skin and sternal
ecrosis, recurrent pleural effusions, and radiation-induced
ulmonary dysfunction can also play a role in the overall
icture.
Valve dysfunction is often part of a presenting picture of
ongestive heart failure and dyspnea, but the relative con-
ributions of valve dysfunction and restrictive cardiomyop-
thy may be difficult to separate. In addition, recurrent
leural effusions are often prominent, and radiation-induced
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yspnea is a multifactorial problem.
For patients with radiation heart disease, surgery for any
ardiac lesion should be approached with caution (715).
irst, symptom relief secondary to valve surgery may be
ncomplete because the restrictive cardiomyopathy may
imit improvement of congestive heart failure symptoms,
nd pulmonary dysfunction may contribute to ongoing
ymptoms of dyspnea. Second, surgical risks are increased
or patients with radiation heart disease both from cardiac
isease and noncardiac conditions, such as aortic calcifica-
ion and skin necrosis. Thus, logic dictates that patients be
ignificantly symptomatic before undergoing surgery or have
ubstantial jeopardy from severe coronary artery lesions.
hird, reoperation for a patient with mediastinal radiation is
n extremely difficult issue, because the radiation injury
ppears to be ongoing after a primary operation, creating
evere mediastinal adhesions and an increased risk of reop-
ration (715). The most common indication for surgery for
atients with radiation heart disease is CAD, a common
ause of late mortality after mediastinal radiation. During
oronary artery surgery, even moderately dysfunctional aor-
ic valves should be replaced to avoid the dangers of early
eoperation in the future (716). Aortic and aortic root
alcification can make even primary surgery for AVR
ifficult, and the lack of aortic root enlargement may limit
he size of a prosthesis that can be implanted. Overall,
adiation heart disease constitutes one of the most difficult
anagement problems in acquired heart disease, and pa-
ients with this condition should be evaluated in centers
ith experience in its management (717).
. EVALUATION AND MANAGEMENT OF
NFECTIVE ENDOCARDITIS
LASS I
. Patients at risk for infective endocarditis who have unexplained
fever for more than 48 h should have at least 2 sets of blood
cultures obtained from different sites. (Level of Evidence: B)
LASS III
. Patients with known valve disease or a valve prosthesis should not
receive antibiotics before blood cultures are obtained for unex-
plained fever. (Level of Evidence: C)
Infective endocarditis may be suspected in a patient with
cardiac murmur suggestive of organic valvular or congen-
tal heart disease or in a patient with a prosthetic heart valve
y the presence of fever, anemia, hematuria, and physical
ndings such as petechiae, Osler’s nodes, Janeway lesions,
oth spots, splenomegaly, and splinter hemorrhages. A
efinitive diagnosis may be made with positive blood
ultures and/or characteristic echocardiographic findings.
he diagnosis of infective endocarditis is often imprecise,
ecause bacteremia can occur without endocardial infection,
nd endocarditis can occur with negative blood cultures, (specially if a patient has received antibiotics for minor
ndiagnosed febrile illness (30). The role of echocardiogra-
hy has emerged with visualization of vegetation by trans-
horacic echocardiography in approximately 60% to 75% of
atients and by transesophageal echocardiography in more
han 95% of patients (718).
Criteria for the diagnosis of infective endocarditis were
roposed by Van Reyn et al. (719) based on the combina-
ion of blood cultures, clinical signs, and symptoms. Durack
t al proposed a new set of diagnostic criteria that placed
chocardiographic findings of endocardial lesions on an
qual footing as positive blood cultures (720). The Duke
riteria designated a patient as “definite,” “rejected,” or
possible” with regard to the likelihood of infective endo-
arditis. Because the designation of “possible” infective
ndocarditis seemed overly broad based on 1 minor criterion
f the patient did not meet requirements for “rejected” (721),
more recent modification of the Duke criteria has been
eveloped with the intent to improve diagnostic specificity
ithout sacrificing sensitivity (722). These modified Duke
riteria are shown in Table 22, which defines major and
inor criteria, and in Table 23, which uses the diagnostic
lassifications of definite, possible, or rejected.
The diagnosis of infective endocarditis in a patient with a
athological murmur or a valvular prosthesis and unex-
lained fever lasting more than 72 h should include an
ssessment for vascular and immunologic phenomena, 3 to
sets of blood cultures, and a transthoracic echocardiogram.
hen the echocardiogram is technically inadequate, is
ondiagnostic, or is negative for infective endocarditis,
ransesophageal echocardiography should be obtained.
.1. Antimicrobial Therapy
ntimicrobial therapy in endocarditis is guided by identifi-
ation of the causative organism. The majority (80%) of
ases of endocarditis are due to streptococcal and staphylo-
occal organisms. The latter species is also the most fre-
uent organism in endocarditis resulting from intravenous
rug abuse. Eighty percent of tricuspid valve infection is by
taphylococcus aureus. This organism is also a frequent
ause of infective endocarditis in patients with insulin-
ependent diabetes mellitus. With prosthetic valve endo-
arditis, a wide spectrum of organisms can be responsible
ithin the first year of operation. However, in “early”
rosthetic valve endocarditis, usually defined as endocarditis
uring the first 2 months after surgery, Staphylococcus
pidermidis is the predominant offending organism. Late-
nset prosthetic valve endocarditis follows the profile of
ative valve endocarditis, that is, streptococci (viridans) and
taphylococci. Enterococcus faecalis and E. faecium account
or 90% of enterococcal endocarditis, which is usually
ssociated with malignancy or manipulation of the genito-
rinary or gastrointestinal tract. Gram-positive and Gram-
egative bacilli are relatively uncommon causes of endocar-
itis. In recent years, the HACEK group of organisms
Haemophilus, Actinobacillus, Cardiobacterium, Eikenella,
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ndocarditis. These organisms cause large vegetations
greater than 1 cm), large-vessel embolism, and congestive
eart failure. They should be considered along with fungal
ndocarditis when large vegetations are noted. Fungi, espe-
ially Candida, are important causes of endocarditis in
atients with prosthetic valves, compromised immune sys-
able 22. Definition of Terms Used in the Proposed Modified D
ajor criteria
Blood culture positive for IE
Typical microorganisms consistent with IE from 2 separate blood cultures:
Viridans streptococci, Streptococcus bovis, HACEK group, Staphylococcus
Community-acquired enterococci in the absence of a primary focus; or
Microorganisms consistent with IE from persistently positive blood cultures,
At least 2 positive cultures of blood samples drawn more than 12 h apar
All of 3 or a majority of greater than 4 separate cultures of blood (with fir
Single positive blood culture for Coxiella burnetti or anti-phase 1 IgG an
Evidence of endocardial involvement
Echocardiogram positive for IE (TEE recommended in patients with prosthetic
abscess]; TTE as first test in other patients), defined as follows:
Oscillating intracardiac mass on valve or supporting structures, in the path
anatomic explanation; or
Abscess; or
New partial dehiscence of prosthetic valve
New valvular regurgitation (worsening or changing of pre-existing murmur not
inor criteria
Predisposition, predisposing heart condition or injection drug use
Fever, temperature greater than 38°C
Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycot
lesions
Immunologic phenomena; glomerulonephritis, Osler’s nodes. Roth’s spots, an
Microbiological evidence: positive blood culture but does not meet a major cri
Echocardiographic minor criteria eliminated
Modifications are shown in bold type. †Excludes single positive cultures for coagulase-negativ
exton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infect
IE indicates infective endocarditis; TEE, transesophageal echocardiography; and TTE, transtho
able 23. Definition of Infective Endocarditis According to the
efinite infective endocarditis
Pathological criteria
(1) Microorganisms demonstrated by culture or histological examination of a v
(2) Pathological lesions; vegetation, or intracardiac abscess confirmed by h
Clinical criteria
(1) 2 major criteria, or
(2) 1 major criterion and 3 minor criteria; or
(3) 5 minor criteria
Possible infective endocarditis
(1) 1 major criterion and 1 minor criterion; or
(2) 3 minor criteria
Rejected
(1) Firm alternate diagnosis explaining evidence of infective endocarditis; o
(2) Resolution of infective endocarditis syndrome with antibiotic therapy for
(3) No pathological evidence of infective endocarditis at surgery or autopsy,
(4) Does not meet criteria for possible infective endocarditis, as noted abovModifications are shown in bold type. Reprinted with permission from Li JS, Sexton DJ, Mick N, et al. P
is 2000;30:633–8 (722).ems, and intravenous drug abuse. Several of the AHA
ecommendations for antimicrobial regimens, updated in
005, are given in Tables 24 through 29 (723). Complete
reatment regimens for resistant organisms are provided in
hat statement from the AHA which can be found at
ttp://www.americanheart.org/presenter.jhtml?identifier
158 (723).
Criteria for the Diagnosis of Infective Endocarditis*
s; or
ed as follows:
last sample drawn at least 1 h apart)
titer greater than 1:800
, rated at least “possible IE” by clinical criteria, or complicated IE [paravalvular
urgitant jets, or on implanted material in the absence of an alternative
ient)
urysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway’s
matoid factor
,† or serological evidence of active infection with organism consistent with IE
ylococci and organisms that do not cause endocarditis. Reprinted with permission from Li JS,
ocarditis. Clin Infect Dis 2000;30:633–8 (722).
chocardiography.
osed Modified Duke Criteria*
ion, a vegetation that has embolized, or an intracardiac abscess specimen; or
ical examination showing active endocarditis
han 4 days; or
antibiotic therapy for less than 4 days; oruke
aureu
defin
t; or
st and
tibody
valves
of reg
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ic ane
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ulture-negative endocarditis most frequently (62%) results
rom prior antibiotic treatment before blood cultures are
rawn (724,725). Other reasons for negative blood cultures
nclude infections due to Candida; Aspergillus; other fas-
idious, slow-growing organisms (726) such as Q-fever and
artonella organisms; and noninfective endocarditis such as
ibman-Sacks endocarditis in patients with systemic lupus
rythematosus. A proposed regimen for culture-negative,
resumed bacterial endocarditis (723) is shown in Table 30.
.3. Endocarditis in HIV-Seropositive Patients
ndocarditis in patients who are HIV (human immunode-
ciency virus) seropositive usually occurs as a complication
f injection drug use or long-term indwelling central cath-
ters. S. aureus is the most frequent pathogen. When
ndocarditis is not related to intravenous drug use, right-
able 24. Therapy of Native Valve Endocarditis Caused by High
treptococcus bovis
Regimen Dosage and Route*
queous crystalline
penicillin G
sodium
12–18 million U per 24 h IV either continuously or in
6 equally divided doses
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose
Pediatric dose†: penicillin 200 000 U per kg per 24 h
4–6 equally divided doses; ceftriaxone 100 mg per
per 24 h IV/IM in 1 dose
queous crystalline
penicillin G
sodium
12–18 million U per 24 h IV either continuously or in
equally divided doses
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose
lus
entamicin sulfate‡ 3 mg per kg per 24 h IV/IM in 1 dose
Pediatric dose: penicillin 200 000 U per kg per 24 h I
4–6 equally divided doses; ceftriaxone 100 mg per
per 24 h IV/IM in 1 dose; gentamicin 3 mg per kg p
24 h
IV/IM in 1 dose or 3 equally divided doses§
ancomycin
hydrochloride
30 mg per kg per 24 h IV in 2 equally divided doses n
exceed 2 g per 24 h unless concentrations in serum
inappropriately low
Pediatric dose: 40 mg per kg per 24 h IV in 2–3 equa
divided doses
inimum inhibitory concentration less than or equal to 0.12 g per ml. *Dosages recommended
Other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used
or children exist, but no data for treatment of infective endocarditis exist. Vancomycin dosages s
odified from Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimi
ommittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular
nesthesia, American Heart Association. Circulation 2005;111:e394–434 (723).
IM indicates intramuscular; and IV, intravenous.nd left-sided valves are equally involved. Intravenous drug Ese is the most common cause of tricuspid valve endocar-
itis. Endocarditis-related mortality in patients with ac-
uired immune deficiency syndrome (AIDS) exceeds that of
IV-positive patients without AIDS. Thus, it is recom-
ended that endocarditis in patients with AIDS be treated
ith maximum-duration antibiotic regimens (723).
.4. Indications for Echocardiography in Suspected
r Known Endocarditis
chocardiography is useful for the detection and character-
zation of the hemodynamic and pathological consequences
f infection. These consequences include valvular vegeta-
ions; valvular regurgitation; ventricular dysfunction; and
ssociated lesions such as abscesses, shunts, and ruptured
hordae (727). The indications for transthoracic and trans-
sophageal echocardiography are discussed in the “ACC/
HA/ASE 2004 Guidelines for the Clinical Application of
nicillin-Susceptible Viridans Group Streptococci and
Duration, wk Comments
4 Preferred in most patients greater than 65 y of age or
patients with impairment of 8th cranial nerve
function or renal function
4
2 Two-week regimen not intended for patients with
known cardiac or extracardiac abscess or for those
with creatinine clearance of less than 20 ml per
min, impaired 8th cranial nerve function, or
Abiotrophia, Granulicatella, or Gemella spp
infection. Gentamicin dosage should be adjusted to
achieve peak serum concentration of 3–4 mcg per
ml and trough serum concentration of less than 1
g per ml when 3 divided doses are used;
nomogram used for single daily dosing.
2
2
2
4 Vancomycin therapy recommended only for patients
unable to tolerate penicillin or ceftriaxone;
vancomycin dosage should be adjusted to obtain
peak (1 h after infusion completed) serum
concentration of 30–45 g per ml and a trough
concentration range of 10–15 g per ml
r patients with normal renal function. †Pediatric dose should not exceed that of a normal adult.
ution in patients receiving gentamicin therapy. §Data for once-daily dosing of aminoglycosides
e infused during course of at least 1 h to reduce risk of histamine-release “red man” syndrome.
therapy, and management of complications: a statement for healthcare professionals from the
e in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery andly Pe
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ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142uidelines (723). Transesophageal imaging is more sensitive
n detecting vegetations than transthoracic imaging (718,
23,728), particularly in patients with prosthetic valves, and
n determining the presence and severity of important
able 25. Therapy of Native Valve Endocarditis Caused by Stra
elatively Resistant to Penicillin
Regimen Dosage* and Route
queous crystalline
penicillin G
sodium
24 million U per 24 h IV either continuously or in 4 to
equally divided doses
r
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose
lus
entamicin sulfate† 3 mg per kg per 24 h IV/IM in 1 dose
Pediatric dose‡: penicillin 300 000 U per 24 h IV in 4
equally divided doses; ceftriaxone 100 mg per kg pe
24 h IV/IM in 1 dose; gentamicin 3 mg per kg per 2
IV/IM in 1 dose or 3 equally divided doses
ancomycin
hydrochloride‡
30 mg per kg per 24 h IV in 2 equally divided doses n
exceed 2 g per 24 h, unless serum concentrations a
inappropriately low
Pediatric dose: 40 mg per kg per 24 h in 2 or 3 equal
divided doses
inimum inhibitory concentration (MIC) greater than 0.12 g per ml to less than or equal to 0.
ppropriate dosage of gentamicin. ‡Pediatric dose should not exceed that of a normal adult. §S
t al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications
awasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical
005;111:e394–434 (723).
IM indicates intramuscular; IV, intravenous; and MIC, minimum inhibitory concentration.
able 26. Therapy for Native Valve or Prosthetic Valve Enteroc
entamicin, and Vancomycin
Regimen Dosage* and Route
mpicillin sodium 12 g per 24 h IV in 6 equally divided doses
r
queous crystalline
penicillin G sodium
18–30 million U per 24 h IV either continuously or in 6
divided doses
lus
entamicin sulfate† 3 mg per kg per 24 h IV/IM in 3 equally divided doses
Pediatric dose‡: ampicillin 300 mg per kg per 24 h IV
6 equally divided doses; penicillin 300 000 U per kg
24 h IV in 4 to 6 equally divided doses; gentamicin
per kg per 24 h IV/IM in 3 equally divided doses
ancomycin
hydrochloride§
30 mg per kg per 24 IV in 2 equally divided doses
lus
entamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses
Pediatric dose: vancomycin 40 mg per kg per 24 h
IV in 2 or 3 equally divided doses; gentamicin 3 mg pe
24 h IV/IM in 3 equally divided doses
Dosages recommended are for patients with normal renal function. †Dosage of gentamicin sh
f less than 1 g per ml. Patients with a creatinine clearance of less than 50 ml per min shoul
hat of a normal adult. §See Table 24 for appropriate dosing of vancomycin. Modified from B
anagement of complications: a statement for healthcare professionals from the Committee on R
nd the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, A
egimens of resistant organisms.
IM indicates intramuscular; IV, intravenous.omplications such as abscesses and perforations. In patients
ith prosthetic valves, it is reasonable to proceed directly to
ransesophageal imaging as the first-line diagnostic test
hen endocarditis is suspected. Echocardiography can be
f Viridans Group Streptococci and Streptococcus bovis
Duration, wk Comments
4 Patients with endocarditis caused by penicillin-resistant
(MIC greater than 0.5 g per ml) strains should be
treated with regimen recommended for enterococcal
endocarditis
4 Recommended for enterococcal endocarditis (see
Table 26) (723)
2
4 Vancomycin§ therapy is recommended only for
patients unable to tolerate penicillin or ceftriaxone
therapy
er ml. *Dosages recommended are for patients with normal renal function. †See Table 24 for
le 24 for appropriate dosage of vancomycin. Modified from Baddour LM, Wilson WR, Bayer AS,
ement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and
gy, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation
l Endocarditis Caused by Strains Susceptible to Penicillin,
Duration, wk Comments
4 to 6 Native valve: 4-wk therapy recommended for patients
with symptoms of illness less than or equal to 3
mo; 6-wk therapy recommended for patients with
symptoms greater than 3 mo
lly 4 to 6 Prosthetic valve or other prosthetic cardiac material:
minimum of 6-wk therapy recommended
4 to 6
o
6 Vancomycin therapy is recommended only for
patients unable to tolerate penicillin or ampicillin
er
6 6 wk of vancomycin therapy recommended because
of decreased activity against enterococci
adjusted to achieve peak serum concentration of 3 to 4 g per ml and a trough concentration
ated in consultation with an infectious diseases specialist. ‡Pediatric dose should not exceed
LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and
tic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young,
Heart Association. Circulation 2005;111:e394–434 (723). See full document for treatmentins o
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedseful in the case of culture-negative endocarditis (729) or
he diagnosis of a persistent bacteremia the source of which
emains unidentified after appropriate evaluation (2).
.4.1. Transthoracic Echocardiography in Endocarditis
LASS I
. Transthoracic echocardiography to detect valvular vegetations with
or without positive blood cultures is recommended for the diagnosis
of infective endocarditis. (Level of Evidence: B)
. Transthoracic echocardiography is recommended to characterize
the hemodynamic severity of valvular lesions in known infective
endocarditis. (Level of Evidence: B)
. Transthoracic echocardiography is recommended for assessment of
complications of infective endocarditis (e.g., abscesses, perforation,
and shunts). (Level of Evidence: B)
. Transthoracic echocardiography is recommended for reassessment
of high-risk patients (e.g., those with a virulent organism, clinical
deterioration, persistent or recurrent fever, new murmur, or persis-
tent bacteremia). (Level of Evidence: C)
LASS IIa
. Transthoracic echocardiography is reasonable to diagnose infective
endocarditis of a prosthetic valve in the presence of persistent fever
able 27. Therapy for Endocarditis Caused by Staphylococci in
Regimen Dosage* and Route
xacillin-susceptible strains
Nafcillin or oxacillin† 12 g per 24 h IV in 4–6 equally divided do
with
Optional addition of
gentamicin sulfate‡
3 mg per kg per 24 h IV/IM in 2 or 3 equa
divided doses
Pediatric dose§: Nafcillin or oxacillin 200 m
per kg per 24 h IV in 4–6 equally divided
doses; gentamicin 3 mg per kg per 24 h
in 3 equally divided doses
or penicillin-allergic
(nonanaphylactoid type)
patients:
Cefazolin 6g per 24 h IV in 3 equally divided doses
with
Optional addition of
gentamicin sulfate
3 mg per kg per 24 h IV/IM in 2 or 3 equa
divided doses
Pediatric dose: cefazolin 100 mg per kg p
24 h IV in 3 equally divided doses; genta
3 mg per kg per 24 h IV/IM in 3 equally
divided doses
xacillin-resilient strains
Vancomycin 30 mg per kg per 24 h IV in 2 equally divid
doses
Dosages recommended are for patients with normal renal function. †Penicillin G 24 million U pe
usceptible (minimum inhibitory concentration less than or equal to 0.1 g per ml) and dose d
ancomycin, nafcillin, or oxacillin dosing. §Pediatric dose should not exceed that of a normal adul
rom Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial the
n Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in
merican Heart Association. Circulation 2005;111:e394–434 (723).
IE indicates infective endocarditis; IM, intramuscular; and IV, intravenous.without bacteremia or a new murmur. (Level of Evidence: C)LASS IIb
. Transthoracic echocardiography may be considered for the re-
evaluation of prosthetic valve endocarditis during antibiotic therapy
in the absence of clinical deterioration. (Level of Evidence: C)
LASS III
. Transthoracic echocardiography is not indicated to re-evaluate uncompli-
cated (includingno regurgitationonbaselineechocardiogram)native valve
endocarditis during antibiotic treatment in the absence of clinical deterio-
ration, new physical findings or persistent fever. (Level of Evidence: C)
.4.2. Transesophageal Echocardiography in Endocarditis
LASS I
. Transesophageal echocardiography is recommended to assess the
severity of valvular lesions in symptomatic patients with infective
endocarditis, if transthoracic echocardiography is nondiagnostic.
(Level of Evidence: C)
. Transesophageal echocardiography is recommended to diagnose
infective endocarditis in patients with valvular heart disease and
positive blood cultures, if transthoracic echocardiography is nondi-
agnostic. (Level of Evidence: C)
. Transesophageal echocardiography is recommended to diagnose
complications of infective endocarditis with potential impact on
prognosis and management (e.g., abscesses, perforation, and
Absence of Prosthetic Materials
Duration Comments
6 wk For complicated right-sided IE and for left-sided IE; for
uncomplicated right-sided IE, 2 wk (see full text)
3–5 d Clinical benefit of aminoglycosides has not been
established
Consider skin testing for oxacillin-susceptible
staphylococci and questionable history of
immediate-type hypersensitivity to penicillin
6 wk Cephalosporins should be avoided in patients with
anaphylactoid-type hypersensitivity to beta lactams;
vancomycin should be used in these cases§
3–5 d Clinical benefit of aminoglycosides has not been
established
6 wk Adjust vancomycin dosage to achieve 1-h serum
concentration of 30–45 g per ml and trough
concentration of 10–15 g per ml
V in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin
t produce beta lactamase. ‡Gentamicin should be administered in close temporal proximity to
pecific dosing adjustment and issues concerning vancomycin, see Table 24 footnotes. Modified
nd management of complications: a statement for healthcare professionals from the Committee
ng, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia,the
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diagnostic study to diagnose prosthetic valve endocarditis and
assess for complications. (Level of Evidence: C)
. Transesophageal echocardiography is recommended for preopera-
tive evaluation in patients with known infective endocarditis, unless
the need for surgery is evident on transthoracic imaging and unless
preoperative imaging will delay surgery in urgent cases. (Level of
Evidence: C)
. Intraoperative transesophageal echocardiography is recommended
for patients undergoing valve surgery for infective endocarditis.
(Level of Evidence: C)
LASS IIa
. Transesophageal echocardiography is reasonable to diagnose pos-
sible infective endocarditis in patients with persistent staphylococ-
able 28. Therapy for Prosthetic Valve Endocarditis Caused by
Regimen Dosage* and Route
xacillin-susceptible strains
Nafcillin or oxacillin 12 g per 24 h IV in 6 equally divided doses
plus
Rifampin 900 mg per 24 h IV/PO in 3 equally divided dos
plus
Gentamicin† 3 mg per kg per 24 h IV/IM in 2 or 3 equally di
doses
Pediatric dose‡: nafcillin or oxacillin 200 mg pe
24 h IV in 4 to 6 equally divided doses; rifam
mg per kg per 24 h IV/PO in 3 equally divide
gentamicin 3 mg per kg per 24 h IV/IM in 2 e
divided doses
xacillin-resistant strains
Vancomycin 30 mg per kg per 24 h in 2 equally divided dos
plus
Rifampin 900 mg per 24 h IV/PO in 3 equally divided dos
plus
Gentamicin 3 mg per kg per 24 h IV/IM in 2 or 3 equally di
doses
Pediatric dose: vancomycin 40 mg per kg per 2
2 or 3 equally divided doses; rifampin 20 mg
per 24 h IV/PO in 3 equally divided doses (up
adult dose); gentamicin 3 mg per kg per 24 h
IM in 3 equally divided doses
Dosages recommended are for patients with normal renal function. †Gentamicin should be ad
xceed that of a normal adult. Modified from Baddour LM, Wilson WR, Bayer AS, et al. Infectiv
ealthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Di
nd Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation 2005;111
IM indicates intramuscular; IV, intravenous; and PO, by mouth.cal bacteremia without a known source. (Level of Evidence: C) tLASS IIb
. Transesophageal echocardiography might be considered to detect
infective endocarditis in patients with nosocomial staphylococcal
bacteremia. (Level of Evidence: C)
.5. Outpatient Treatment
atients with penicillin-susceptible S. viridans endocarditis
ho are hemodynamically stable, compliant, and capable of
anaging the technical aspects of outpatient therapy may be
andidates for a single daily-dose regimen of ceftriaxone
723). Clinical reports suggest that right-sided endocarditis
aused by S. aureus in intravenous drug users may be
menable to a short 2-week course of therapy (730,731).
onotherapy with ceftriaxone or combination therapy with
n aminoglycoside has been tried as an outpatient therapeu-
hylococci
Duration,
wk Comments
At least 6 Penicillin G 24 million U per 24 h IV in 4 to 6 equally
divided doses may be used in place of nafcillin or
oxacillin if strain is penicillin susceptible
(minimum inhibitory concentration less than or
equal to 0.1 mcg per ml) and does not produce
-lactamase; vancomycin should be used in
patients with immediate-type hypersensitivity
reactions to -lactam antibiotics (see Table 24 for
dosing guidelines); cefazolin may be substituted
for nafcillin or oxacillin in patients with non-
immediate-type hypersensitivity reactions to
penicillins
At least 6
er
s;
y
At least 6 Adjust vancomycin to achieve 1-h serum
concentration of 30 to 45 g per ml and trough
concentration of 10 to 15 g per ml
At least 6
in
g
ered in close proximity to vancomycin, nafcillin, or oxacillin dosing. ‡Pediatric dose should not
carditis: diagnosis, antimicrobial therapy, and management of complications: a statement for
Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke,
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ave therapeutic effectiveness equivalent to the established
- to 6-week regimens.
.6. Indications for Surgery in Patients With
cute Infective Endocarditis
urgery is indicated in patients with life-threatening con-
estive heart failure or cardiogenic shock due to surgically
reatable valvular heart disease with or without proven
nfective endocarditis if the patient has reasonable prospects
f recovery with satisfactory quality of life after the opera-
ion (615,723,733–757). Surgery should not be delayed in
he setting of acute infective endocarditis when congestive
eart failure intervenes. Surgery is not indicated if compli-
ations (severe embolic cerebral damage) or comorbid con-
itions make the prospect of recovery remote.
The indications for surgery for infective endocarditis in
atients with stable hemodynamics are less clear. Consulta-
ion with a cardiovascular surgeon is recommended in a
atient with complicated endocarditis so that the surgical
eam is aware of the patient who may suddenly need surgery.
urgery is recommended in patients with annular or aortic
bscesses, heart block, recurrent emboli on appropriate
ntibiotic therapy, infections resistant to antibiotic therapy,
nd fungal endocarditis. It is recognized that the presence of
alvular vegetations poses a threat of embolic events. Pros-
hetic valve endocarditis and native valve endocarditis
aused by S. aureus are almost always surgical diseases. Early
urgery in MV endocarditis caused by virulent organisms
such as S. aureus or fungi) may make repair possible.
chocardiography, especially with transesophageal imaging,
dentifies vegetations and provides size estimation in many
nstances. Patients with a vegetation diameter greater than
0 mm have a significantly higher incidence of embolization
able 29. Therapy for Both Native and Prosthetic Valve Endoca
Regimen Dosage and Route
eftriaxone sodium 2 g per 24 h IV/IM in 1 dose†
r
mpicillin-sulbactam‡ 12 g per 24 IV in 4 equally divided doses
r
iprofloxacin‡§ 1000 mg per 24 h PO or 800 mg per 24 h IV
in 2 equally divided doses
Pediatric dose: Ceftriaxone 100 mg per kg per
24 h IV/IM once daily; ampicillin-sulbactam
300 mg per kg per 24 h IV divided into 4 or
6 equally divided doses; ciprofloxacin 20 to
30 mg per kg per 24 h IV/PO in 2 equally
divided doses
Haemophilus parainfluenzae, Haphrophilus, Actinobacillus actinomycetemcomitans, Cardiob
ntramuscular injection of ceftriaxone is painful. ‡Dosage recommended for patients with norma
ata on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal. Pediatri
l. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications:
awasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical C
005;111:e394–434 (723).
IM indicates intramuscular; IV, intravenous; and PO, by mouth.han those with a vegetation diameter less than or equal to0 mm (718), and this risk appears to be higher in patients
ith MV endocarditis than in those with aortic valve
ndocarditis. However, surgery on the basis of vegetation
ize alone is controversial.
Patients with prosthetic valves who receive warfarin
nticoagulation and develop endocarditis should have their
arfarin discontinued and replaced with heparin. This
ecommendation is less related to the possibility of hemor-
hagic complications of endocarditis (758) than the possi-
ility of urgent surgery. If surgery is required, the effects of
arfarin will have dissipated, and heparin can easily be
eversed. Likewise, aspirin, if part of the medical regimen,
hould also be discontinued. If neurological symptoms
evelop, anticoagulation should be discontinued until an
ntracranial hemorrhagic event is excluded by magnetic
esonance imaging or computed tomographic scanning.
.6.1. Surgery for Native Valve Endocarditis
LASS I
. Surgery of the native valve is indicated in patients with acute
infective endocarditis who present with valve stenosis or regurgita-
tion resulting in heart failure. (Level of Evidence: B)
. Surgery of the native valve is indicated in patients with acute
infective endocarditis who present with AR or MR with hemody-
namic evidence of elevated LV end-diastolic or left atrial pressures
(e.g., premature closure of MV with AR, rapid decelerating MR signal
by continuous-wave Doppler (v-wave cutoff sign), or moderate or
severe pulmonary hypertension). (Level of Evidence: B)
. Surgery of the native valve is indicated in patients with infective
endocarditis caused by fungal or other highly resistant organisms.
(Level of Evidence: B)
. Surgery of the native valve is indicated in patients with infective
endocarditis complicated by heart block, annular or aortic abscess,
or destructive penetrating lesions (e.g., sinus of Valsalva to right
s Caused by HACEK* Microorganisms
tion, wk Comments
4 Cefotaxime or another third- or fourth-generation cephalosporin
may be substituted
4
4 Fluoroquinolone therapy recommended only for patients unable
to tolerate cephalosporin and ampicillin therapy; levofloxacin,
gatifloxacin, or moxifloxacin may be substituted;
fluoroquinolones generally not recommended for patients
less than 18 y old
Prosthetic valve: patients with endocarditis involving prosthetic
cardiac valve or other prosthetic cardiac material should be
treated for 6 wk
m hominis, Eikenella corrodens, and Kingella kingae. †Patients should be informed that
function. §Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published
should not exceed that of a normal adult. Modified from Baddour LM, Wilson WR, Bayer AS, et
ment for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and
gy, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulationrditi
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Regimen Dosage* and Route
Duration,
wk Comments
ative valve
Ampicillin-sulbactam 12 g per 24 h IV in 4 equally divided doses 4–6 Patients with culture-negative endocarditis
should be treated with consultation with
an infectious diseases specialist
plus
Gentamicin sulfate† 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6
Vancomycin‡ 30 mg per kg per 24 h IV in 2 equally divided doses 4–6 Vancomycin recommended only for patients
unable to tolerate penicillins
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 4–6
plus
Ciprofloxacin 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally
divided doses
4–6
Pediatric dose§: ampicillin-sulbactam 300 mg per kg per 24 h
IV in 4–6 equally divided doses; gentamicin 3 mg per kg per
24 h IV/IM in 3 equally divided doses; vancomycin 40 mg
per kg per 24 h in 2 or 3 equally divided doses;
ciprofloxacin 20–30 mg per kg per 24 h IV/PO in 2 equally
divided doses
rosthetic valve (early—less
than or equal to 1 y)
Vancomycin 30 mg per kg per 24 h IV in 2 equally divided doses 6
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
plus
Cefepime 6 g per 24 h IV in 3 equally divided doses 6
plus
Rifampin 900 mg per 24 h PO/IV in 3 equally divided doses 6
Pediatric dose: vancomycin 40 mg per kg per 24 h IV in 2 or 3
equally divided doses; gentamicin 3 mg per kg per 24 h
IV/IM in 3 equally divided doses; cefepime 150 mg per kg
per 24 h IV in 3 equally divided doses; rifampin 20 mg per
kg per 24 h PO/IV in 3 equally divided doses
rosthetic valve
(late—greater than 1 y)
6 Same regimens as listed above for native
valve endocarditis
uspected Bartonella,
culture negative
Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose 6 Patients with Bartonella endocarditis should
be treated in consultation with an
infectious diseases specialist
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
with/without
Doxycycline 200 mg per kg per 24 h IV/PO in 2 equally divided doses 6
ocumented Bartonella,
culture positive
Doxycycline 200 mg per 24 h IV or PO in 2 equally divided doses 6 If gentamicin cannot be given, then replace
with rifampin, 600 mg per 24 h PO/IV in
2 equally divided doses
plus
Gentamicin sulfate 3 mg per kg per 24 h IV/IM in 3 equally divided doses 2
Pediatric dose: ceftriaxone 100 mg per kg per 24 h IV/IM
once daily; gentamicin 3 mg per kg per 24 h IV/IM in 3
equally divided doses; doxycycline 2–4 mg per kg per 24 h
IV/PO in 2 equally divided doses; rifampin 20 mg per kg per
24 h PO/IV in 2 equally divided doses
Dosages recommended are for patients with normal renal function. †See Table 24 for appropriate dosing of gentamicin. ‡See Table 24 for appropriate dosing of vancomycin. §Pediatric dose should
ot exceed that of a normal adult. Modified from Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for
ealthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke,
nd Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation 2005;111:e394–434 (723).
IM indicates intramuscular; IV, intravenous; and PO, by mouth.
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of Evidence: B)
LASS IIa
. Surgery of the native valve is reasonable in patients with infective
endocarditis who present with recurrent emboli and persistent
vegetations despite appropriate antibiotic therapy. (Level of Evi-
dence: C)
LASS IIb
. Surgery of the native valve may be considered in patients with
infective endocarditis who present with mobile vegetations in ex-
cess of 10 mm with or without emboli. (Level of Evidence: C)
Patients with left-sided native valve endocarditis compli-
ated by congestive heart failure, systemic embolization to
ital organs, or presence of a large vegetation on echocar-
iography have poor outcomes on medical treatment alone.
large cohort study using a multivariate model reported
hat valve surgery was associated with improved 6-month
urvival (759). An additional benefit of early surgery is likely
o include successful valve repair as an outcome, especially
or the MV. When at all possible, MV repair should be
erformed instead of MV replacement in the setting of
ctive infection because of the risk of infection of prosthetic
aterials (760–762). Aortic valves may often be repaired as
ell if there are leaflet perforations, and this is preferable to
VR for the same reasons.
.6.2. Surgery for Prosthetic Valve Endocarditis
LASS I
. Consultation with a cardiac surgeon is indicated for patients with
infective endocarditis of a prosthetic valve. (Level of Evidence: C)
. Surgery is indicated for patients with infective endocarditis of a
prosthetic valve who present with heart failure. (Level of Evidence: B)
. Surgery is indicated for patients with infective endocarditis of a
prosthetic valve who present with dehiscence evidenced by cine
fluoroscopy or echocardiography. (Level of Evidence: B)
. Surgery is indicated for patients with infective endocarditis of a
prosthetic valve who present with evidence of increasing obstruc-
tion or worsening regurgitation. (Level of Evidence: C)
. Surgery is indicated for patients with infective endocarditis of a
prosthetic valve who present with complications (e.g., abscess
formation). (Level of Evidence: C)
LASS IIa
. Surgery is reasonable for patients with infective endocarditis of a
prosthetic valve who present with evidence of persistent bacteremia
or recurrent emboli despite appropriate antibiotic treatment. (Level
of Evidence: C)
. Surgery is reasonable for patients with infective endocarditis of a
prosthetic valve who present with relapsing infection. (Level of
Evidence: C)
LASS III
. Routine surgery is not indicated for patients with uncomplicated
infective endocarditis of a prosthetic valve caused by first infectionwith a sensitive organism. (Level of Evidence: C) l. MANAGEMENT OF VALVULAR DISEASE
N PREGNANCY
.1. Physiological Changes of Pregnancy
he evaluation and management of valvular heart disease in
he pregnant patient requires an understanding of the
ormal physiological changes associated with gestation,
abor, delivery, and the early postpartum period. On aver-
ge, there is a 50% increase in circulating blood volume
uring pregnancy that is accompanied by a commensurate
ncrease in cardiac output that usually peaks between the
idportion of the second and third trimesters. The aug-
ented cardiac output derives from an increase in the stroke
olume, although there is also a smaller increase in heart
ate, averaging 10 to 20 beats per minute. Because of the
ffects of uterine circulation and endogenous hormones,
ystemic vascular resistance falls with a disproportionately
reater lowering of diastolic blood pressure and a wide pulse
ressure. Inferior vena caval obstruction from a gravid uterus
n the supine position can result in an abrupt decrease in
ardiac preload, which leads to hypotension with weakness
nd lightheadedness. These symptoms resolve quickly with
change in position (763).
There is a further abrupt increase in cardiac output during
abor and delivery related in part to the associated anxiety
nd pain. Uterine contractions can lead to marked increases
n both systolic and diastolic blood pressure. After delivery,
here is an initial surge in preload related to the autotrans-
usion of uterine blood into the systemic circulation and to
aval decompression (763).
Pregnancy is also associated with a hypercoagulable state
ue to relative decreases in protein S activity, stasis, and
enous hypertension (764). Estrogens can interfere with
ollagen deposition within the media of the medium and
arge muscular arteries. Circulating elastase can break up the
lastic lamellae and weaken the aortic media during preg-
ancy. Weakening of the vascular wall may in turn predis-
ose to dissection with or without an underlying connective
issue disorder (765). Relaxin, an insulin-like growth factor
ormone, is detectable in serum during pregnancy and
auses a decrease in collagen synthesis and may predispose
o aortic dissection during pregnancy (766).
.2. Physical Examination
he physical examination of the normal parturient is nota-
le for a slightly fast resting heart rate, bounding pulses, a
idened pulse pressure with a low normal peak systolic
ressure, and warm extremities. Venous pressure is usually
t or near the upper limits for nonpregnant women but
arely in a clearly abnormal range. The thyroid gland may be
nlarged in the absence of clinical hyperthyroidism. De-
ending on the stage of pregnancy, the lung volumes may be
ow because of the raised diaphragms. The precordial
mpulse is hyperkinetic, and the first heart sound may be
ouder than normal, with prominent splitting. The second
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iden and appear fixed during the later stages of pregnancy.
hird heart sounds are present in most patients. A soft
rade 1 to 2 midsystolic murmur that is best heard along the
id to upper left sternal edge is a frequent finding (26). A
ontinuous murmur, which reflects either a venous hum or
mammary souffle, may sometimes be heard during auscul-
ation. The cervical venous hum is best appreciated in the
ight supraclavicular fossa and can be obliterated by move-
ent of the chin toward the stethoscope or digital pressure
ver the ipsilateral jugular vein. The mammary souffle is a
ystolic or continuous sound over the engorged breast that
an usually be obliterated with firm pressure applied to the
iaphragm of the stethoscope. It is heard in the supine
osition and attenuates or disappears when standing. It is
ppreciated in the late stages of pregnancy or early in the
uerperium. Diastolic heart murmurs are unusual. The
ncreased blood volume and enhanced cardiac output asso-
iated with normal pregnancy can accentuate the murmurs
ssociated with stenotic heart valve lesions (e.g., MS and
S). On the other hand, murmurs of AR, MR, and
entricular septal defect can actually attenuate or become
naudible as systemic vascular resistance is lowered (767).
.3. Echocardiography
ormal pregnancy is accompanied by echocardiographic
vidence of mild ventricular chamber enlargement. Pul-
onic and tricuspid valvular regurgitation, as assessed by
oppler interrogation, is the rule rather than the exception
768). Most women will demonstrate Doppler evidence of
physiological” MR in the absence of structural valve dis-
ase. Atrioventricular valve regurgitation may result from
he annular dilatation that accompanies ventricular enlarge-
ent. Appreciation of these echocardiographic and Doppler
ndings in normal individuals is an important foundation
or the noninvasive evaluation of subjects with suspected
alvular disease. The use of ultrasound during pregnancy
oses no risk to the mother or fetus.
.4. General Management Guidelines
linical experience has shown that there are several cardiac
onditions in which the physiological changes of pregnancy
able 31. Valvular Heart Lesions Associated With High
aternal and/or Fetal Risk During Pregnancy
. Severe AS with or without symptoms
. AR with NYHA functional class III–IV symptoms
. MS with NYHA functional class II–IV symptoms
. MR with NYHA functional class III–IV symptoms
. Aortic and/or mitral valve disease resulting in severe pulmonary
hypertension (pulmonary pressure greater than 75% of systemic pressures)
. Aortic and/or mitral valve disease with severe LV dysfunction (EF less than
0.40)
. Mechanical prosthetic valve requiring anticoagulation
. Marfan syndrome with or without AR
R indicates aortic regurgitation; AS, aortic stenosis; EF, ejection fraction; LV, left ventricular;
R, mitral regurgitation; MS, mitral stenosis; and NYHA, New York Heart Association.re poorly tolerated. For some conditions, such as cyanotic
M
aeart disease, Eisenmenger syndrome, or severe pulmonary
ypertension, pregnancy should be discouraged. Valvular
eart lesions associated with high maternal and fetal risk
uring pregnancy are listed in Table 31. Lesions associated
ith low risk during pregnancy are listed in Table 32.
Reimold and Rutherford (769) and Elkayam and Bitar
770,771) have published excellent reviews for the clinical
ractitioner involved in managing pregnant patients who
ave either valvular or prosthetic heart disease. They delin-
ate the increased risk of adverse maternal, fetal, and
eonatal outcomes on the basis of valvular abnormality and
he NYHA functional class. Additionally, Siu et al. have
dentified predictors of adverse maternal and fetal outcomes
n a heterogeneous group of Canadian women with con-
enital or acquired heart disease (772,773). Abnormal
unctional capacity (NYHA functional class II or higher)
nd left-sided heart obstruction were predictors of neonatal
omplications that included premature birth, intrauterine
rowth retardation, respiratory distress syndrome, intraven-
ricular hemorrhage, and death. However, outcomes data
re limited for pregnant patients with valvular heart disease,
xcept for those with MS (769,770).
Individual counseling usually requires a multidisciplinary
pproach and should include information regarding contra-
eption, maternal and fetal risks of pregnancy, and expected
ong-term outcomes. However, many patients with valvular
eart disease can be successfully managed throughout preg-
ancy and during labor and delivery with conservative
edical measures designed to optimize intravascular volume
nd systemic loading conditions.
Simple interventions such as bed rest and avoidance of
he supine position should not be overlooked. Whenever
ossible, symptomatic or severe valvular lesions should be
ddressed and rectified before conception and pregnancy.
ontemporaneous management with a dedicated obstetric
eam accustomed to working with high-risk patients is
ncouraged. Drugs should generally be avoided whenever
ossible (Table 33) (763).
able 32. Valvular Heart Lesions Associated With Low
aternal and Fetal Risk During Pregnancy
. Asymptomatic AS with low mean gradient (less than 25 mm Hg and aortic
valve area greater than 1.5 cm2) in presence of normal LV systolic function
(EF greater than 0.50)
. NYHA functional class I or II AR with normal LV systolic function
. NYHA functional class I or II MR with normal LV systolic function
. MVP with no MR or with mild to moderate MR with normal LV systolic
function
. Mild MS (MVA greater than 1.5 cm2, gradient less than 5 mm Hg) without
severe pulmonary hypertension
. Mild to moderate pulmonary valve stenosis
R indicates aortic regurgitation; AS, aortic stenosis; EF, ejection fraction; LV, left ventricular;
R, mitral regurgitation; MS, mitral stenosis; MVA, mitral valve area; MVP, mitral valve prolapse;
nd NYHA, New York Heart Association.
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Drug Use in Pregnancy Potential Side Effects Breast Feeding Risk Factors
denosine Maternal and fetal arrhythmias No side effects reported; data on use during first
trimester are limited
Data NA C
miodarone Maternal arrhythmias IUGR, prematurity, congenital goiter, hypothyroidism
and hyperthyroidism, transient bradycardia, and
prolonged QT in the newborn
Not recommended C
ngiotensin-converting
enzyme inhibitors
Hypertension Oligohydramnios, IUGR, prematurity, neonatal
hypotension, renal failure, anemia, death, skull
ossification defect, limb contractures, patent
ductus arteriosus
Compatible C
eta blockers Hypertension, maternal arrhythmias,
myocardial ischemia, mitral
stenosis, hypertrophic
cardiomyopathy, hyperthyroidism,
Marfan syndrome
Fetal bradycardia, low placental weight, possible
IUGR, hypoglycemia, no information on carvedilol
Compatible, monitoring
of infant’s heart rate
recommended
Acebutolol: B
Labetalol: C
Metoprolol: C
Propranolol: C
Atenolol: D
igoxin Maternal and fetal arrhythmias,
heart failure
No evidence for unfavorable effects on the fetus Compatible C
iltiazem Myocardial ischemia, tocolysis Limited data; increased incidence of major birth
defects
Compatible C
isopyramide Maternal arrhythmias Limited data; may induce uterine contraction and
premature delivery
Compatible C
iuretics Hypertension, congestive heart
failure
Hypovolemia leads to reduced uteroplacental
perfusion, fetal hypoglycemia, thrombocytopenia,
hyponatremia, hypokalemia; thiazide diuretics
can inhibit labor and suppress lactation
Compatible C
lecainide Maternal and fetal arrhythmias Limited data; 2 cases of fetal death after successful
treatment of fetal SVT reported, but relation to
flecainide uncertain
Compatible C
eparin Anticoagulation None reported Compatible C
ydralazine Hypertension None reported Compatible C
idocaine Local anesthesia, maternal
arrhythmias
No evidence for unfavorable fetal effects; high
serum levels may cause central nervous
depression at birth
Compatible C
ifedipine Hypertension, tocolysis Fetal distress related to maternal hypotension
reported
Compatible C
itrates Myocardial infarction and ischemia,
hypertension, pulmonary edema,
tocolysis
Limited data; use is generally safe, few cases of
fetal heart rate deceleration and bradycardia
have been reported
Data NA C
rocainamide Maternal and fetal arrhythmias Limited data; no fetal side effects reported Compatible C
ropafenone Fetal arrhythmias Limited data; fetal death reported after direct
intrauterine administration in fetuses with fetal
hydrops
Data NA C
uinidine Maternal and fetal arrhythmias Minimal oxytoxic effect, high doses may cause
premature labor or abortion; transient neonatal
thrombocytopenia and damage to eighth nerve
reported
Compatible C
odium nitroprusside Hypertension, aortic dissection Limited data; potential thiocyanate fetal toxicity,
fetal mortality reported in animals
Data NA C
otalol Maternal arrhythmias, hypertension,
fetal tachycardia
Limited data; 2 cases of fetal death and 2 cases of
significant neurological morbidity in newborns
reported, as well as bradycardia in newborns
Compatible, monitoring
of infant’s heart rate
recommended
B
erapamil Maternal and fetal arrhythmias,
hypertension, tocolysis
Limited data; other than a single case of fetal death
of uncertain cause, no adverse fetal or newborn
effects have been reported
Compatible C
arfarin Anticoagulation Crosses placental barrier; fetal hemorrhage in utero,
embryopathy, central nervous system
abnormalities
Compatible X
DA classification: Category B: Either animal reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women, or animal reproduction studies have shown
n adverse effect that was not confirmed in controlled studies in women. Category C: Either studies in animals have revealed adverse effects on the fetus and there are no controlled studies in women,
r studies in women and animals are not available. Drugs should be given only if potential benefits justify the potential risk to the fetus. Category D: There is positive evidence of human fetal risk, but
he benefits from use in pregnant woman may be acceptable despite the risk. Category X: Studies in animals or human beings have demonstrated fetal abnormalities. The risk of the use of the drug
n pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. Source: Drug Information for the Health Care Professional (USDPI
ol 1); Micromedex; 23rd ed (January 1, 2003). Adapted and modified with permission from Elkayam U. Pregnancy and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors.
raunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA: Elsevier, 2005:1965 (763). The guidelines committee added warfarin, heparin, and hydralazine to this list.
IUGR indicates intrauterine growth retardation; NA, not available; and SVT, supraventricular tachycardia.
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.5.1. Mitral Stenosis
oung pregnant women with a previous history of acute
heumatic fever and carditis should continue to receive
enicillin prophylaxis as indicated in the nonpregnant state.
atients with mild to moderate MS can almost always be
anaged with judicious use of diuretics and beta blockade.
iuretics are given to relieve pulmonary and excess systemic
enous congestion, but care must be taken to avoid vigorous
olume depletion to protect against uteroplacental hypoper-
usion. Beta blockers are chiefly indicated to treat or prevent
achycardia to optimize diastolic filling. Although the non-
elective beta blocker propranolol has been in use for
ecades, some authorities recommend a cardioselective beta
locker such as metoprolol or atenolol to prevent the
otential deleterious effects of epinephrine blockade on
yometrial activity.
Patients with severe MS who are symptomatic before
onception will not predictably tolerate the hemodynamic
urden of pregnancy and should be considered for percuta-
eous balloon mitral valvotomy before conception, provided
he valve is anatomically suitable. Patients with severe MS
ho develop NYHA functional class III–IV symptoms
uring pregnancy should undergo percutaneous balloon
alvotomy (774).
For the rare patients with MS who fail medical manage-
ent during pregnancy with repetitive or persistent heart
ailure, there is now a nearly 10-year experience with
alloon mitral valvotomy, either with very limited fluoros-
opy (less than 1 to 2 minutes’ exposure with both pelvic and
bdominal shielding) or echocardiographic guidance. The
eported results with mitral balloon valvotomy have been
xcellent, with few maternal or fetal complications, al-
hough caution is advised in interpreting outcomes from
ndividual centers reporting relatively few patients (775–
84). Percutaneous mitral balloon valvotomy should only be
erformed in experienced centers and only after aggressive
edical measures have been exhausted. In developing coun-
ries, there is a long history of successful surgical closed
ommissurotomy for pregnant women (785).
.5.2. Mitral Regurgitation
VP is the most common cause of MR in pregnant
omen. The physical findings pertinent to MVP may be
bscured or varied by the physiological changes of preg-
ancy, especially the increased blood volume and reduced
ystemic vascular resistance. Associated MR can usually be
anaged medically, although on rare occasions, MV surgery
s required because of ruptured chordae and acute, severe
orsening of the regurgitant lesion. Medical management
ncludes diuretics for the rare patient with pulmonary
ongestion. Vasodilator therapy is indicated only in the
resence of concomitant systemic hypertension and should
ot be advised in the setting of normal or low systemic
lood pressure. Angiotensin-converting enzyme inhibitors gre considered unsafe and are contraindicated because of
heir multiple adverse effects on fetal development. There is
ide experience with hydralazine, an agent generally con-
idered safe. When MV surgery is required, repair is always
referred, as would be the case for any young patient but
specially in relation to the desirability of avoiding the
otential need for anticoagulation.
.5.3. Aortic Stenosis
he most common cause of AS in pregnant women is
ongenital aortic valve disease. Patients with mild obstruc-
ion and normal LV systolic function can be managed
onservatively throughout the pregnancy. Patients with
oderate to severe obstruction (Table 4) (27) or symptoms
hould be advised to delay conception until relief of AS can
e obtained. Women with severe AS who become pregnant
ut who remain asymptomatic or have mild symptoms may
ften be managed conservatively during pregnancy with bed
est, oxygen, and beta blockers. In women with severe AS
ho develop symptoms, consideration may have to be given
o either percutaneous aortic balloon valvotomy (786,787)
r surgery (depending on the anatomic findings) before
abor and delivery. These procedures are fraught with
anger to both the mother and fetus, although successful
utcomes have been reported. Neither is to be undertaken
ithout caution and forewarning. There is an association
etween the presence of a bicuspid aortic valve and aortic
oot dilatation, which may predispose to spontaneous aortic
issection, usually in the third trimester, especially if there is
n associated aortic coarctation.
.5.4. Aortic Regurgitation
solated AR, like MR, can usually be managed medically
ith a combination of diuretics and, if necessary, vasodilator
herapy (788). Angiotensin-converting enzyme inhibitors
re considered unsafe and are contraindicated because of
heir multiple adverse effects on fetal development. Women
ith symptoms or signs of LV failure should be monitored
hroughout labor and delivery with strict attention to
olume status and blood pressure. As is true for MR, surgery
uring pregnancy should be contemplated only for control
f refractory NYHA functional class III or IV symptoms.
onsideration regarding LV size or systolic function in less
ymptomatic patients should not apply. The recommenda-
ions for AVR based on LV size that apply to nonpregnant
atients should not be used for pregnant patients.
.5.5. Pulmonic Stenosis
ulmonic valve stenosis can exist in isolation but frequently
ccompanies other congenital heart lesions. In general,
atients with cyanotic congenital heart disease tolerate the
tresses of pregnancy far less well than those with acyanotic
esions. Isolated pulmonic stenosis is rarely a significant
mpediment to a successful pregnancy. This lesion can be
pproached with percutaneous valvotomy under echocardio-
raphic guidance when necessary.
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ricuspid valve disease may be congenital (Ebstein’s anom-
ly, tricuspid atresia) or acquired (endocarditis, myxomatous
eplacement/proliferation, carcinoid). The approach to the
atient with tricuspid valve involvement as part of a more
omplex congenital heart disease syndrome is predicated on
he features of the associated lesions. Isolated TR should
ot pose a significant problem during pregnancy, although
reater care may be necessary to protect against diuretic-
nduced hypoperfusion.
.5.7. Marfan Syndrome
he Marfan syndrome is an inheritable disorder of connec-
ive tissue that often stems from abnormalities in the
brillin gene on chromosome 15. It is transmitted in an
utosomal dominant fashion and is recognized clinically by
ts ocular, skeletal, and cardiovascular expressions. Sponta-
eous aortic dissection or rupture is the most feared cardio-
ascular complications associated with pregnancy (765,789,
90). Dissection can occur at any point along the aorta but
ost commonly originates in the ascending portion. En-
argement of the aortic root to greater than 4.0 cm identifies
particularly high-risk group, although a normal dimension
s by no means a guarantee against this catastrophic com-
lication. Aortic root enlargement may or may not be
ccompanied by regurgitation and an audible heart murmur.
VP with regurgitation is also frequently detected.
Any woman with Marfan syndrome should be counseled
gainst pregnancy, because aortic rupture or dissection can
ccur in any root size. All patients with Marfan syndrome
hould have a screening transthoracic echocardiogram with
areful assessment of aortic root dimensions. Enlargement
reater than 4.5 cm is generally considered an indication for
lective repair before conception, usually with a composite
alve-graft conduit and reimplantation of the coronary
rteries. If any degree of aortic root enlargement (greater
han 4.0 cm) is first detected during pregnancy, some
uthorities recommend termination of the pregnancy with
rompt aortic repair, although this is controversial. Less
ontroversial is prompt repair if serial imaging studies
emonstrate progressive dilatation over time. Dissection
nd rupture are most likely to occur during the third
rimester or near the time of delivery. Special care must be
aken to provide adequate analgesia to prevent wide surges
n blood pressure and its rate of rise (dP/dt) during labor
nd delivery. Obstetric techniques to shorten the second
tage of labor are appropriate. General anesthesia and
aesarean section may allow more optimal hemodynamic
ontrol. The use of prophylactic beta blockade throughout
he pregnancy is strongly recommended. Such treatment has
een shown to slow the rate of aortic dilatation and reduce
he cumulative incidence of cardiovascular complications in
onpregnant adolescents and adults (359). Successful sur-
ical correction does not confer a normal risk during
ubsequent pregnancy, because such patients remain at tncreased for aortic dissection, albeit reduced compared with
atients with Marfan syndrome who have not undergone
urgical intervention.
.6. Endocarditis Prophylaxis (UPDATED)
he Committee on Rheumatic Fever, Endocarditis, and
awasaki Disease of the AHA does not recommend routine
ntibiotic prophylaxis in patients with valvular heart disease
ndergoing uncomplicated vaginal delivery or caesarean
ection unless infection is suspected. Antibiotics are op-
ional for high-risk patients with prosthetic heart valves, a
revious history of endocarditis, complex congenital heart
isease, or a surgically constructed systemic-pulmonary
onduit (1070,1072).
.7. Cardiac Valve Surgery
he performance of cardiac valve surgery is a difficult and
omplex undertaking in the pregnant patient. Even under
deal conditions, including the use of cardiopulmonary
ypass techniques that promote high flow rates and warm
erfusion temperatures, there is a high incidence of fetal
istress, growth retardation, or wastage (791–795). If pos-
ible, it is always preferable to delay surgery until the time
he fetus is viable and a caesarean section can be performed
s part of a concomitant procedure (796,797). Surgery
hould be pursued only in the setting of medically refractory
ardiac symptoms (pulmonary congestion), especially if a
ow-output syndrome intervenes.
For suitable valve lesions, repair is always preferred over
eplacement. If valve replacement is necessary, the choice of
heart valve substitute can be problematic. Bioprosthetic
alves degenerate more quickly in younger patients, a
rocess that can be further accelerated during pregnancy
798). Although such valves may not require longer-term
nticoagulation, they do expose the young patient to an
arlier risk of failure and need for reoperation. Mechanical
alve substitutes are more durable, but the obligate need for
nticoagulation may complicate current and future pregnan-
ies. For aortic valve disease, homograft valves or pulmonary
utografts should be considered (799).
.8. Anticoagulation During Pregnancy
iven the paucity of data regarding the efficacy of antico-
gulants during pregnancy, recommendations concerning
heir use during pregnancy are based largely on extrapola-
ions from data from nonpregnant patients, from case reports,
nd from case series of pregnant patients (771,799–802).
.8.1. Warfarin
arfarin (vitamin K antagonist therapy) crosses the pla-
enta and has been associated with an increased incidence of
pontaneous abortion, prematurity, and stillbirth. Warfarin
an also cause bleeding in the fetus, and fetal cerebral
emorrhage can complicate labor and delivery, especially if
orceps evacuation is necessary. The manufacturer considers
he use of warfarin during pregnancy to be strictly contra-
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onsisting of nasal hypoplasia and/or stippled epiphyses
fter in utero exposure during the first trimester of preg-
ancy, and central nervous system abnormalities after expo-
ure during any trimester. The true incidence of warfarin
mbryopathy has been difficult to ascertain. This has ranged
rom less than 5% to as high as 67% (801–804), and an
stimate of 4% to 10% seems reasonable (805,806). However,
he risk of clinically important embryopathy may be lower if
he dose of warfarin is less than or equal to 5 mg per day.
Warfarin is probably safe during the first 6 weeks of
estation, but there is a risk of embryopathy if warfarin is
aken between 6 and 12 weeks of gestation. For women
equiring long-term warfarin therapy who are attempting
regnancy, it seems wise to perform frequent pregnancy
ests with the substitution of unfractionated heparin (UFH)
r low-molecular-weight heparin (LMWH) for warfarin
hen pregnancy is achieved. Warfarin is also relatively safe
uring the second and third trimesters of pregnancy but
ust be discontinued and switched to a heparin compound
everal weeks before delivery.
.8.2. Unfractionated Heparin
everal studies suggest that UFH or LMWH therapy is safe
or the fetus (800–804). Heparin does not cross the
lacenta and does not have the potential to cause fetal
leeding or teratogenicity. Thus, heparin is generally con-
idered safer than warfarin during pregnancy in terms of the
evelopment of embryopathy (805,807). However, bleeding
t the uteroplacental junction is possible, and numerous case
eries and patient registries attest to a high incidence of
hromboembolic complications (12% to 24%), including
atal valve thrombosis, in high-risk pregnant women man-
ged with subcutaneous UFH or LMWH (805,808–810).
hen heparin is used during the first trimester, the risks of
aternal thromboembolism and maternal death are more
han doubled. These studies have been criticized because of
he inclusion of a predominant population of women with
lder-generation and more thrombogenic prostheses, inad-
quate heparin dosing, and/or the lack of meticulous mon-
toring strategies. Unfortunately, the efficacy of adjusted-
ose subcutaneous heparin has not been definitively
stablished.
During pregnancy, the activated partial thromboplastin
ime (aPTT) response to heparin is often attenuated because
f increased levels of factor VIII and fibrinogen. Adjusted-
ose subcutaneous UFH can cause a persistent anticoagu-
ant effect at the time of delivery, which can complicate its
se before labor. Bleeding complications appear to be very
ncommon with LMWH (811).
.8.3. Low-Molecular-Weight Heparins
MWHs have potential advantages over UFH during
regnancy because they 1) cause less heparin-induced
hrombocytopenia; 2) have a longer plasma half-life and aore predictable dose response than UFH; 3) have greater
ase of administration, with lack of need for laboratory
onitoring and the potential for once-daily dosing admin-
stration; 4) are likely associated with a lower risk of
eparin-induced osteoporosis; and 5) appear to have a low
isk of bleeding complications. They do not cross the
lacenta and are likely safe for the fetus (811). Allergic skin
eactions to both LMWH and UFH can occur.
As the pregnancy progresses (and most women gain
eight), the potential volume of distribution for LMWH
hanges. It is thus necessary to measure plasma anti-Xa
evels 4 to 6 h after the morning dose and adjust the dose of
MWH to achieve an anti-Xa level of approximately 0.7 to
.2 units per ml.
Although LMWHs have been used successfully to treat
eep venous thrombosis in pregnant patients, there are no
ata to guide their use in the management of patients with
echanical heart valves (810). Reports of LMWH use in
regnant women with prosthetic heart valves are becoming
ore frequent, and many physicians now prescribe these
gents during pregnancy in women with mechanical valves,
ut treatment failures have been reported. The use of
MWH during pregnancy remains controversial because of
n early warning by the manufacturer and FDA in July 2001
egarding safety concerns in this situation. In 2004, labeling
pproved by the FDA indicated specifically that use of
MWH for thromboprophylaxis in pregnant women with
echanical prosthetic heart valves has not been studied
dequately.
In a clinical study of pregnant women with prosthetic
eart valves given subcutaneous enoxaparin (1 mg per kg
wice daily), 2 of 8 women developed prosthetic valve
hromboses that led to maternal and fetal death. Although
causal relationship has not been established, these deaths
ay have been due to therapeutic failure or inadequate
nticoagulation (811).
.8.4. Selection of Anticoagulation Regimen in
regnant Patients with Mechanical Prosthetic Valves
LASS I
. All pregnant patients with mechanical prosthetic valves must re-
ceive continuous therapeutic anticoagulation with frequentmonitor-
ing (see Section 9.2.). (Level of Evidence: B)
. For women requiring long-term warfarin therapy who are attempt-
ing pregnancy, pregnancy tests should be monitored with discus-
sions about subsequent anticoagulation therapy, so that anticoag-
ulation can be continued uninterrupted when pregnancy is
achieved. (Level of Evidence: C)
. Pregnant patients with mechanical prosthetic valves who elect to
stop warfarin between weeks 6 and 12 of gestation should receive
continuous intravenous UFH, dose-adjusted UFH, or dose-adjusted
subcutaneous LMWH. (Level of Evidence: C)
. For pregnant patients with mechanical prosthetic valves, up to 36
weeks of gestation, the therapeutic choice of continuous intrave-
nous or dose-adjusted subcutaneous UFH, dose-adjusted LMWH, or
warfarin should be discussed fully. If continuous intravenous UFH is
used, the fetal risk is lower, but the maternal risks of prosthetic
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and heparin-induced thrombocytopenia are relatively higher. (Level
of Evidence: C)
. In pregnant patients with mechanical prosthetic valves who receive
dose-adjusted LMWH, the LMWH should be administered twice daily
subcutaneously to maintain the anti-Xa level between 0.7 and 1.2 U
per ml 4 h after administration. (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic valves who receive
dose-adjusted UFH, the aPTT should be at least twice control. (Level
of Evidence: C)
. In pregnant patients with mechanical prosthetic valves who receive
warfarin, the INR goal should be 3.0 (range 2.5 to 3.5). (Level of
Evidence: C)
. In pregnant patients with mechanical prosthetic valves, warfarin
should be discontinued and continuous intravenous UFH given
starting 2 to 3 weeks before planned delivery. (Level of Evidence: C)
LASS IIa
. In patients with mechanical prosthetic valves, it is reasonable to
avoid warfarin between weeks 6 and 12 of gestation owing to the
high risk of fetal defects. (Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is reasonable to
resume UFH 4 to 6 h after delivery and begin oral warfarin in the
absence of significant bleeding. (Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is reasonable to
give low-dose aspirin (75 to 100mg per day) in the second and third
trimesters of pregnancy in addition to anticoagulation with warfarin
or heparin. (Level of Evidence: C)
LASS III
. LMWH should not be administered to pregnant patients with me-
chanical prosthetic valves unless anti-Xa levels are monitored 4 to
6 h after administration. (Level of Evidence: C)
. Dipyridamole should not be used instead of aspirin as an alternative
antiplatelet agent in pregnant patients with mechanical prosthetic
valves because of its harmful effects on the fetus. (Level of Evi-
dence: B)
n April 2004, labeling approved by the FDA stated that
regnancy alone conferred an increased risk for thrombo-
mbolism and an even higher risk with thrombotic disease
nd certain high-risk pregnancy conditions. Although not
dequately studied, women with mechanical prosthetic
eart valves may be at higher risk for thromboembolism
uring pregnancy regardless of the anticoagulant used, and
hen pregnant, they have a higher rate of fetal loss from
tillbirth, spontaneous abortion, and premature delivery.
With both warfarin and UFH, monitoring is required to
ssess whether the antithrombotic effects of these drugs
hange during pregnancy because of alterations in intravas-
ular volume. Both European and North American guide-
ines emphasize that the use of oral coumarin derivatives
hroughout pregnancy targeted to an INR of 2.0 to 3.0
onfers the greatest maternal protection (5.7% risk of death
r thromboembolism) and that heparin used during the first
rimester confers a lesser degree of protection. Unfortu-
ately, these drugs are also associated with a great risk of
etal loss (up to 30%) (812).
To examine the validity of these conclusions and explore
ptimum antithrombotic regimens, Chan and colleagues t813) performed a systematic review of the literature exam-
ning fetal and maternal outcomes of pregnant women with
rosthetic heart valves. Because no randomized trials were
dentified, the overview consisted of prospective and retro-
pective cohort studies. This analysis suggests that warfarin
s more efficacious than UFH for thromboembolic prophy-
axis of women with mechanical heart valves in pregnancy,
ut with an increased risk of embryopathy (813). The use of
ow-dose UFH is inadequate; the use of adjusted-dose UFH
arrants aggressive monitoring and appropriate dose adjust-
ent. Contemporary aPTT reagents are more sensitive to
he anticoagulant effect of heparin. Therefore, a minimum
arget aPTT ratio of 1.5 times the control is likely to be
nadequate. A target aPTT ratio of at least twice the control
hould be attained.
Thus, there are still insufficient grounds to make defini-
ive recommendations about optimal antithrombotic ther-
py in pregnant patients with mechanical heart valves,
ecause properly designed studies have not been performed.
ubstantial concern remains about the fetal safety of war-
arin, the efficacy of subcutaneous UFH and of LMWH in
reventing thromboembolic complications, and the risks of
aternal bleeding with various regimens. European experts
ave recommended warfarin therapy throughout pregnancy
n view of the reports of poor maternal outcomes with
eparin and their impression that the risk of embryopathy
ith coumarin derivatives has been overstated, especially if
he dosage of warfarin is less than or equal to 5 mg per day.
The American College of Chest Physicians Conference
n Antithrombotic and Thrombolytic Therapy (814,815)
oncluded that it is reasonable to use 1 of the following 3
egimens: 1) either LMWH or UFH between 6 and 12
eeks and close to term only, with warfarin used at other
imes; 2) aggressive dose-adjusted UFH throughout preg-
ancy; or 3) aggressive adjusted-dose LMWH throughout
regnancy. Before any of these approaches is used, it is
rucial to explain the risks in detail to the patient. If warfarin
s used, the dose should be adjusted to attain a target INR
f 3.0 (range 2.5 to 3.5). If subcutaneous UFH is used, it
hould be initiated in high doses (17 500 to 20 000 U every
2 h) and adjusted to prolong a 6-h postinjection aPTT of
t least twice the control. Adjusted-dose LMWH appears to
e a reasonable substitute for UFH, but further information
s required about dosing during pregnancy. If LMWH is
sed during pregnancy, it has been recommended that it be
dministered twice daily and dosed to achieve anti-Xa levels
f 0.7 to 1.2 U per ml 4 to 6 h after injection (771,814). The
ddition of aspirin 75 to 100 mg can be considered in an
ttempt to reduce the risk of thrombosis, with the recogni-
ion that it can increase the risk of bleeding (808).
Dipyridamole should not be considered as an alternative
ntiplatelet agent because of its harmful effects on the fetus.
either warfarin nor heparin is contraindicated in postpar-um mothers who breast-feed (807).
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oung Women
major area of ongoing controversy concerns the use of
rosthetic heart valves in women likely to become pregnant
769,771). Bioprostheses are not as durable as mechanical
rostheses, although they may eliminate the need for
nticoagulation therapy associated with mechanical prosthe-
es. Also, MV repair is preferable to MV replacement
henever possible in women contemplating pregnancy,
ecause it does not require anticoagulation. Furthermore,
V balloon commissurotomy is an alternative to surgery in
any patients with MS. The Ross procedure in patients
equiring AVR is an attractive option for women who wish
o become pregnant, but this should be performed only in
nstitutions with established expertise in this procedure (799).
. MANAGEMENT OF CONGENITAL
ALVULAR HEART DISEASE IN ADOLESCENTS
ND YOUNG ADULTS (UPDATED)
lthough the majority of valvular heart disease in older
dults is acquired, the predominant cause is congenital in
dolescents and young adults. It has been estimated that the
revalence of moderate or complex congenital heart disease
n adults is approximately 419 000 in the United States
816). Many patients with congenital heart disease have
ome valvular involvement; frequently, it is part of a more
omplex congenital cardiac anomaly, that is, tricuspid ste-
osis in children with pulmonary atresia and an intact
entricular septum or AS as part of a series of left-sided
eart obstruction lesions (Shone’s syndrome). The manage-
ent of these complex diseases with multiple valve involve-
ent is beyond the scope of these guidelines. Rather, this
ection concerns isolated valve involvement when it is the
rimary anatomic abnormality.
In evaluating valvular stenosis in children, the severity of
alvular obstruction is usually reported as the peak ventricu-
ar–to–peak great artery systolic gradient at cardiac cathe-
erization or maximum instantaneous or mean gradient by
oppler echocardiography rather than valve area. In the
atheterization laboratory, the variation in body size from
he neonate to the adult, difficulties in measuring cardiac
utput (especially in young children), and the relatively rare
atient with low cardiac output have made peak ventricular–
o–peak great artery pressure gradients for semilunar valves
nd atrial a-wave–to–RV or LV end-diastolic or mean
ressure gradients for atrioventricular valves the reference
tandards rather than valve area. With the development of
oppler echocardiographic assessment of valvular obstruc-
ion, many pediatric cardiologists have continued to rely on
radients calculated from peak velocity for the semilunar
alves rather than on mean gradient or valve area. The peak
radient measured by Doppler velocity (based on maximum
nstantaneous velocity) is almost always higher than the
eak ventricular–to–peak great vessel gradient measured at tatheterization. The difference between Doppler peak in-
tantaneous and catheterization peak-to-peak gradients is
reater with AS than with pulmonic stenosis and has
esulted in most cardiologists using mean gradients, espe-
ially in patients with AS. Significant valvular regurgitation
ay exacerbate the differences. In contrast to children and
dolescents, valve area is used by many centers in evaluation
f the young adult.
Ventricular end-systolic or end-diastolic diameter or vol-
mes used in evaluating patients with valvular regurgitation are
requently corrected for the large variations in body size among
dolescents and young adults. Chamber size is corrected for
ody surface area (m2) or commonly by the number of standard
eviations (z score) above or below the mean with standard
omograms that correct for body size (817).
The management of the neonate, infant, and young child
iffers significantly from that of the adolescent and young
dult. This section will deal exclusively with adolescents and
oung adults.
.1. Aortic Stenosis
.1.1. Pathophysiology
lthough most adults with valvular AS have a degenerative-
alcific process that produces immobilization of the valve
usps, adolescents and young adults with isolated AS almost
lways have congenital fusion of 1 or more commissures that
esults in a bicuspid or unicuspid valve. Although the
revalence of bicuspid and unicuspid valves may be as high
s 1% to 2%, only 1 of 50 children born with these
bnormalities will actually have significant obstruction or
egurgitation by adolescence.
For purposes of these guidelines, adolescents and young
dults are defined as patients with minimally calcified valves
ho are less than 30 years old. Some adults with minimally
alcified valves who are more than 30 years old may also
enefit under these guidelines.
Much of what has been written in these guidelines for
dults with acquired AS may be transferred to the adoles-
ent or young adult (see Section 3.1.); however, certain
mportant differences must be emphasized. Throughout
hildhood, the aortic annulus and aortic valve must grow in
arallel with somatic growth. If growth of either the annulus
r valve leaflets lags, increased obstruction may occur.
herefore, the rate of progression during childhood and
dolescent growth can be different from that in the adult
ith acquired heart disease. The report from the joint study
n the Natural History of Congenital Heart Defects (818)
ollowed 473 patients (before the advent of echocardiogra-
hy), 60% of whom were initially evaluated between 2 and
1 years of age and 34% between 11 and 21 years of age.
ne third of the children had an increase in the transaortic
radient measured by cardiac catheterization during the 4-
o 8-year follow-up period. However, the 54 patients greater
han 12 years of age showed very small increases. Those
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emonstrating an increase in the gradient.
Long-term results of the original cohort have been
eported (819), with a mean follow-up period of 20 years.
nly 20% of those with initial peak LV–to–peak aortic
ressure gradients less than 25 mm Hg at initial catheter-
zation had any intervention. However, in those with an
nitial catheter-derived LV–to–peak aortic gradient greater
han 50 mm Hg, arrhythmias, sudden death, or other
orbid events (including endocarditis, congestive heart
ailure, syncope, angina, myocardial infarction, stroke, and
acemaker insertion) occurred at a rate on average of 1.2%
er year. Sudden cardiac death occurred in 25 of the 370
atients followed up over an average of 8000 patient years,
or an average incidence of 0.3% per year. The severity of
bstruction in those who died could not be determined, and
higher-risk subgroup could not be excluded.
.1.2. Evaluation of Asymptomatic Adolescents or
oung Adults With Aortic Stenosis
LASS I
. An ECG is recommended yearly in the asymptomatic adolescent or
young adult with AS who has a Doppler mean gradient greater than
30 mm Hg or a peak velocity greater than 3.5 m per second (peak
gradient greater than 50 mm Hg) and every 2 years if the echocar-
diographic Doppler mean gradient is less than or equal to 30 mm
Hg or the peak velocity is less than or equal to 3.5 m per second
(peak gradient less than or equal to 50 mm Hg). (Level of Evidence C)
. Doppler echocardiography is recommended yearly in the asymp-
tomatic adolescent or young adult with AS who has a Doppler mean
gradient greater than 30 mm Hg or a peak velocity greater than
3.5 m per second (peak gradient greater than 50 mm Hg) and every
2 years if the Doppler gradient is less than or equal to 30 mm Hg or
the peak jet velocity is less than or equal to 3.5 m per second (peak
gradient less than or equal to 50 mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is an effective
diagnostic tool in the asymptomatic adolescent or young adult when
results of Doppler echocardiography are equivocal regarding sever-
ity of AS or when there is a discrepancy between clinical and
noninvasive findings regarding severity of AS. (Level of Evidence: C)
. Cardiac catheterization is indicated in the adolescent or young adult
with AS who has symptoms of angina, syncope, or dyspnea on
exertion if the Doppler mean gradient is greater than 30 mm Hg or
the peak velocity is greater than 3.5 m per second (peak gradient
greater than 50 mm Hg). (Level of Evidence: C)
. Cardiac catheterization is indicated in the asymptomatic adolescent
or young adult with AS who develops T-wave inversion at rest over
the left precordium if the Doppler mean gradient is greater than 30
mm Hg or the peak velocity is greater than 3.5 m per second (peak
gradient greater than 50 mm Hg). (Level of Evidence: C)
LASS IIa
. Graded exercise testing is a reasonable diagnostic evaluation in the
adolescent or young adult with AS who has a Doppler mean gradient
greater than 30 mm Hg or a peak velocity greater than 3.5 m per
second (peak gradient greater than 50 mm Hg) if the patient is
interested in athletic participation, or if the clinical findings andDoppler findings are disparate. (Level of Evidence: C)
*
g. Cardiac catheterization for the evaluation of AS is a reasonable
diagnostic tool in the asymptomatic adolescent or young adult who
has a Doppler mean gradient greater than 40 mm Hg or a peak
velocity greater than 4m per second (peak gradient greater than 64
mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is reasonable in the
adolescent or young adult who has a Doppler mean gradient greater
than 30 mm Hg or a peak velocity greater than 3.5 m per second
(peak gradient greater than 50mmHg) if the patient is interested in
athletic participation or becoming pregnant, or if the clinical find-
ings and the Doppler echocardiographic findings are disparate.
(Level of Evidence C)
he diagnosis of AS can usually be made clinically, with
everity estimated by ECG and Doppler echocardiographic
tudies. Diagnostic cardiac catheterization is occasionally
equired if there is a discrepancy among clinical evaluation,
CG, and/or Doppler echocardiographic findings. Exercise
esting may be useful, especially in those interested in
thletic participation. Diagnostic cardiac catheterization
ay be helpful if the clinical findings and the Doppler
chocardiographic assessment are disparate.
.1.3. Indications for Aortic Balloon Valvotomy in
dolescents and Young Adults
LASS I
. Aortic balloon valvotomy is indicated in the adolescent or young
adult patient with AS who has symptoms of angina, syncope, or
dyspnea on exertion and a catheterization peak LV–to–peak aortic
gradient greater than or equal to 50 mm Hg without a heavily
calcified valve. (Level of Evidence: C)*
. Aortic balloon valvotomy is indicated for the asymptomatic adoles-
cent or young adult patient with AS who has a catheterization peak
LV–to–peak aortic gradient greater than 60 mm Hg. (Level of
Evidence: C)*
. Aortic balloon valvotomy is indicated in the asymptomatic adoles-
cent or young adult patient with AS who develops ST or T-wave
changes over the left precordium on ECG at rest or with exercise and
who has a catheterization peak LV–to–aortic gradient greater than
50 mm Hg. (Level of Evidence: C)*
LASS IIa
. Aortic balloon valvotomy is reasonable in the asymptomatic adoles-
cent or young adult patient with AS when catheterization peak
LV–to–peak aortic gradient is greater than 50 mm Hg and the
patient wants to play competitive sports or desires to become
pregnant. (Level of Evidence: C)*
. In the adolescent or young adult patient with AS, aortic balloon
valvotomy is probably recommended over valve surgery when bal-
loon valvotomy is possible. Patients should be referred to a center
with expertise in balloon valvotomy. (Level of Evidence: C)*
LASS III
. Aortic balloon valvotomy should not be performed when the asymp-
tomatic adolescent or young adult patient with AS has a catheter-
ization peak LV–to–peak aortic gradient less than 40 mm Hg
without symptoms or ECG changes. (Level of Evidence: C)*Gradients are usually obtained with patients sedated. If general anesthesia is used, the
radients may be somewhat lower.
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utes at best very short-term palliation. In contrast, balloon
alvotomy in children and adolescents with obstruction due
o fusion of commissures is considerably more efficacious.
here are insufficient published data to establish an age
utoff. Until more information becomes available, recom-
endations for balloon valvotomy should be limited to
dolescents and young adults. In a large collaborative
egistry involving 606 patients from 23 institutions, the peak
V–to–peak aortic pressure gradients at catheterization
ere reduced by a mean of 60% (820). In a single-institution
tudy of 148 patients dilated at age 1 month to 20 years
821), midterm results showed an 8-year actuarial survival of
5%, with 3 of the 4 deaths occurring in infants who were
ilated at less than 1 year of age. Seventy percent of patients
ere free from operation and 50% were free from interven-
ion 8 years after dilation, which was similar to results
eported with surgical valvuloplasty. Long-term follow-up
nformation is incomplete because balloon valvotomy was
ot introduced until the 1980s.
Although balloon dilation has become standard in chil-
ren and adolescents with AS, it is rarely recommended in
lder adults with calcific valves, because even short-term
alliation is uncommon. Because balloon valvotomy has
esulted in good midterm palliation with little morbidity
nd little or no short- or intermediate-term mortality in
hildren, adolescents, and young adults, the indications for
ntervention are considerably more liberal than those in
lder adults, in whom intervention usually involves valve
eplacement.
Surgical valvotomy is of historic interest but is now rarely
sed except in situations in which interventional cardiolo-
ists are not available. Children and young adults with peak
oppler gradients of 64 mm Hg or more or mean gradients
reater than 40 mm Hg and those with symptoms may be
onsidered for cardiac catheterization and possible balloon
ilation. Patients with lower gradients (50 mm Hg peak or
0 mm Hg mean) are sometimes referred for catheterization
f they are interested in participating in athletics, are
ontemplating pregnancy, or have developed ST–T-wave
hanges over the left precordium at rest or with exercise.
he gradient should be confirmed hemodynamically before
roceeding with dilation. Gradients are usually obtained
ith the patient sedated. If general anesthesia is used, the
radients may be lower. It is reasonable to perform valvot-
my in asymptomatic patients with catheterization gradi-
nts greater than 60 mm Hg and in some patients with a
atheterization peak LV–to–peak aortic pressure gradient of
0 to 60 mm Hg who have symptoms, have associated
schemic changes on rest or exercise ECG, are interested in
articipating in vigorous athletics, or are contemplating
regnancy. In those children who have had a balloon
alvuloplasty when younger, a repeat attempt is usually tried
efore surgical valve replacement using the above criteria if
ignificant AR is not present. *When balloon aortic valvotomy is ineffective or signifi-
ant AR is present, valve repair or replacement may be
ecessary. Long-term follow-up into adulthood is manda-
ory, because the long-term cumulative risks of endocarditis,
hromboembolism, and bleeding from anticoagulation over
0- to 40-year follow-up have been problematic, and
rogressive stenosis has been observed (153,822). Because
egeneration of homograft or bioprosthetic valves is usually
ccelerated in the young (see Sections 7.2 and 7.3), AVR is
sually performed with a mechanical valve. Recently, there
as been a renewed interest in valve repair or the Ross
peration (153,822), that is, moving the native pulmonary
alve to the aortic position using a homograft to replace the
ulmonary valve. Three studies from the Netherlands (343
atients; mean age 26 years) (823), Canada (155 patients;
ean age 35 years) (824), and the United States (328
atients) (825) have shown relatively low operative mortality
2.6%, 0.6%, and 4.6%, respectively) with actuarial survival
f 94% and 98% at 7 years in 2 of the studies and 89.9% at
years in the other. The most common complications were
R, usually secondary to neoaortic root dilation, and RV
utflow tract obstruction, with intervention necessary in
pproximately 10% of patients within 7 to 10 years.
Although the Ross operation, homograft, heterograft,
nd valve repair each appear to offer an attractive alternative
o a mechanical valve for those with a relative contraindi-
ation to warfarin for anticoagulation (e.g., athletes or
oman desiring pregnancy), in the absence of long-term
esults, it is not believed that the indications for surgery with
he Ross operation, heterograft, or homograft differ from
hose for mechanical valve replacement at this time.
.2. Aortic Regurgitation
LASS I
. An adolescent or young adult with chronic severe AR* with onset of
symptoms of angina, syncope, or dyspnea on exertion should re-
ceive aortic valve repair or replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients with chronic
severe AR* with LV systolic dysfunction (ejection fraction less than
0.50) on serial studies 1 to 3 months apart should receive aortic
valve repair or replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients with chronic
severe AR* with progressive LV enlargement (end-diastolic dimen-
sion greater than 4 standard deviations above normal) should
receive aortic valve repair or replacement. (Level of Evidence: C)
. Coronary angiography is recommended before AVR in adolescent or
young adult patients with AR in whom a pulmonary autograft (Ross
operation) is contemplated when the origin of the coronary arteries
has not been identified by noninvasive techniques. (Level of Evi-
dence: C)
LASS IIb
. An asymptomatic adolescent with chronic severe AR* with moder-
ate AS (peak LV–to–peak aortic gradient greater than 40 mm Hg at
cardiac catheterization) may be considered for aortic valve repair or
replacement. (Level of Evidence: C)See Table 4 (27).
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ST depression or T-wave inversion over the left precordium on ECG
at rest may be considered for aortic valve repair or replacement.
(Level of Evidence: C)
R is an uncommon isolated congenital lesion, although it
ay occasionally develop in adolescents and young adults
ith a bicuspid aortic valve, discrete subaortic obstruction,
r prolapse of 1 aortic cusp into a ventricular septal defect.
t is commonly the consequence of attempts to relieve
tenosis of the valve by either balloon dilation or surgical
alvulotomy, as part of a connective tissue disorder, or when
he pulmonary artery is relocated in the aortic position (Ross
rocedure or arterial switch repair of transposition). The
ndications for surgery with severe isolated AR or mixed
ortic valve disease are at present similar to those for adults,
hat is, symptoms, LV dysfunction (ejection fraction less
han 0.50), or very increased LV end-diastolic or end-
ystolic diameter, taking into account variations in body
ize. If the durability of pulmonary autograft and homograft
alves in the RV outflow tract is substantiated in long-term
tudies, the indications for autograft valve replacement are
ikely to become more liberal. Surgery has usually involved
echanical or biological valve replacement (see Sections
.2.3.8 and 7.2), but some have performed the Ross oper-
tion or aortic valve repair. Although not all valves are
menable to repair, some success has been reported for AR
fter balloon dilation (100% freedom from reoperation at 1
ear and 80% from reintervention at 3 years) (826) and with
prolapsing leaflet (freedom from reoperation of 95%, 87%,
nd 84% at 1, 5, and 7 years, respectively) (827). Aortic
alve repair is a viable alternative in some centers and may
e preferred in the future, but in view of the relative youth
f the patients and lack of long-term durability of valve
epair or replacement with biological valves, these alterna-
ives to mechanical valve replacement may be appropriate
nly for those with a contraindication to anticoagulation in
he majority of centers. Indications for surgery in patients
ith AR and dilated aortic roots or ascending aortas are the
ame as in older adult patients (see Sections 3.2.4 and 3.3).
.3. Mitral Regurgitation
LASS I
. MV surgery is indicated in the symptomatic adolescent or young
adult with severe congenital MR* with NYHA functional class III or IV
symptoms. (Level of Evidence: C)
. MV surgery is indicated in the asymptomatic adolescent or young
adult with severe congenital MR* and LV systolic dysfunction (ejec-
tion fraction less than or equal to 0.60). (Level of Evidence: C)
LASS IIa
. MV repair is reasonable in experienced surgical centers in the
asymptomatic adolescent or young adult with severe congenital
MR* with preserved LV systolic function if the likelihood of success-
ful repair without residual MR is greater than 90%. (Level of
Evidence: B)See Table 4 (27).LASS IIb
. The effectiveness of MV surgery is not well established in asymp-
tomatic adolescent or young adult patients with severe congenital
MR* and preserved LV systolic function in whom valve replacement
is highly likely. (Level of Evidence: C)
MR caused by myxomatous MV disease and MVP is a
ommon congenital lesion, but other forms of isolated
ongenital MR are extremely uncommon. MR can be
ssociated with MVP in adolescents or young adults with
onnective tissue, metabolic, or storage diseases. It can be
een with acquired inflammatory diseases such as rheumatic
ever, endocarditis, or Kawasaki disease or with certain
ollagen vascular disorders.
MR also develops commonly in children with primum
trioventricular septal defects. These defects are caused by a
eficiency of the atrioventricular septum in the embryonic
eart. There may be an isolated ostium primum atrial septal
efect; ventricular septal defect in the inlet (posterior)
eptum; abnormalities of the mitral or tricuspid valve,
ncluding clefts; or some combination of the above. In a
omplete atrioventricular septal defect, there is a combina-
ion of a large primum atrial septal defect, a large inlet
posterior) ventricular septal defect, and a common atrio-
entricular valve that failed to develop into separate mitral
nd tricuspid valves. Repair of the defects in early child-
ood, with low mortality and morbidity, is now common-
lace. The most common long-term sequela of surgery is
R, which can be mild, moderate, or severe.
The pathophysiology, diagnosis, and medical therapy of
esidual MR in atrioventricular septal defects, rheumatic
ever, or MVP are similar to those discussed for the adult
ith MR (Section 3.5). When MR is associated with
ymptoms or deteriorating LV systolic function on echocar-
iography or angiography, surgery should be performed. In
hildren with MR associated with atrioventricular septal
efects, the MR can usually be reduced or eliminated with
urgery. In patients with MR after atrioventricular septal
efect repair or MR secondary to MVP, rheumatic fever, or
nflammatory disease, it is usually possible to decrease the
R with MV repair and annular reduction. Rarely, MV
eplacement with a mechanical or biological valve is neces-
ary. When valve repair rather than replacement is likely,
urgery for severe MR is frequently performed in asymp-
omatic patients before the development of heart failure or
V dysfunction. On the other extreme, for symptomatic
atients with MR and severe LV dysfunction, cardiac
ransplantation may be the preferred option to MV replace-
ent or repair.
.4. Mitral Stenosis
LASS I
. MV surgery is indicated in adolescent or young adult patients withcongenital MS who have symptoms (NYHA functional class III or IV)
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cardiography.* (Level of Evidence: C)
LASS IIa
. MV surgery is reasonable in adolescent or young adult patients with
congenital MS who have mild symptoms (NYHA functional class II)
and mean MV gradient greater than 10 mm Hg on Doppler echo-
cardiography.* (Level of Evidence: C)
. MV surgery is reasonable in the asymptomatic adolescent or young
adult with congenital MS with pulmonary artery systolic pressure 50
mm Hg or greater and a mean MV gradient greater than or equal to
10 mm Hg.* (Level of Evidence: C)
LASS IIb
. The effectiveness of MV surgery is not well established in the
asymptomatic adolescent or young adult with congenital MS and
new-onset atrial fibrillation or multiple systemic emboli while receiv-
ing adequate anticoagulation.* (Level of Evidence: C)
In developed countries, MS in adolescents and young
dults is often congenital in origin. In developing areas of
he world, MS is more likely to result from rheumatic fever.
ongenital MS is usually classified by the component of the
itral apparatus that is abnormal, that is, the leaflets,
nnulus, chordae, or papillary muscles. Frequently, multiple
alve components are involved, which results in rolled,
hickened leaflet margins; shortened and thickened chordae
endineae; obliteration of the interchordal spaces with
bnormal chordal insertions; papillary muscle hypoplasia;
nd fusion of the anterolateral and posteromedial papillary
uscles (828). This latter condition causes the mitral
pparatus to appear like a funnel or a parachute. MS results
rom the inability of blood to pass unobstructed from the
eft atrium to the LV through a very abnormal mitral
pparatus.
Congenital MS may be associated with a wide variety of
ther congenital cardiac malformations of the left side of the
eart, including bicuspid aortic valve and AS, supravalvar
itral ring, and/or coarctation of the aorta.
The clinical, electrocardiographic, and radiologic features
f congenital MS are similar to those of acquired MS in
dults. The echocardiogram is essential in evaluating the
V apparatus and papillary muscles and may provide
onsiderable insight into the feasibility of successful valve
epair. The information obtained from transthoracic imag-
ng is usually sufficient, but in adolescents and young adults,
transesophageal echocardiogram is sometimes necessary.
Medical management including beta blockers and diuret-
cs may be of some utility with mild MS. It is important to
revent and treat common complications such as pulmonary
nfections, endocarditis, and atrial fibrillation. Surgical in-
ervention may be necessary in severe cases. The surgical
anagement of congenital MS has improved considerably
ith the improved appreciation of the mechanism of MV
unction and the improved ability to visualize the valve
fforded by transesophageal echocardiography. In those
atients with a parachute MV, creation of fenestrationsqSee Table 4 (27).mong the fused chordae may increase effective orifice area
nd improve symptoms dramatically. MV replacement may
ccasionally be necessary but is especially problematic in
hose with a hypoplastic mitral annulus, in whom an
nnulus-enlarging operation may be necessary. Recently,
alloon dilation of congenital MS has been attempted
829), but its utility is limited in patients with significant
tenosis of the subvalvular apparatus. This is one of the most
ifficult and dangerous therapeutic catheterization proce-
ures and should be undertaken only in centers with
perators who have established experience and skill in this
nterventional procedure. In adolescent and young adult
atients with rheumatic MS, the results of balloon dilation
re similar to those in older adults (see Section 3.4.8).
ulmonary artery hypertension usually resolves with relief of
he MS.
.5. Tricuspid Valve Disease
.5.1. Pathophysiology
cquired disease of the tricuspid valve is very uncommon in
dolescents and young adults. Other than occasional cases of
R secondary to trauma, bacterial endocarditis in intrave-
ous drug abusers, and small ventricular septal defects in
dolescents in whom the jet through the ventricular septum
reates endothelial damage to the tricuspid valve, virtually
ll cases of acquired TR are limited to case reports.
Most cases of tricuspid valve disease are congenital, with
bstein’s anomaly of the tricuspid valve being the most
ommon. In Ebstein’s anomaly, there is inferior displace-
ent of the septal and posterior leaflets of the valve into the
ight ventricle. If there is significant adherence of the leaflets
o the RV wall, the normal or relatively normal anterior
eaflet fails to coapt with the abnormal posterior leaflet,
reating severe TR. If the valve leaflets are not adherent,
here is redundancy of valve tissue with severe prolapse
ssociated with varying degrees of TR.
There is wide variation in the severity of valve leaflet
bnormalities in Ebstein’s disease. Some children may have
evere TR, especially in the perinatal period, when pulmo-
ary vascular resistance and resulting RV pressures are high.
thers have very mild abnormalities that may not be
ecognized until a chest X-ray obtained for other reasons
hows cardiomegaly. An interatrial communication, usually
n the form of a patent foramen ovale, is present in most
ases. If TR elevates right atrial pressure above left atrial
ressure, right-to-left shunting can occur, with resulting
ypoxemia. One or more accessory conduction pathways are
uite common, with a risk of paroxysmal atrial tachycardia
f approximately 25%.
Patients with Ebstein’s anomaly may be asymptomatic
ith no cyanosis and no atrial arrhythmias. They often are
yanotic owing to right-to-left shunting (830), which is
ssociated with exercise intolerance. RV dysfunction may
ventually lead to right-sided congestive heart failure fre-
uently exacerbated by an atrial arrhythmia such as atrial
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esting may be useful in determining symptom status and
egree of exercise-induced arterial desaturation.
The natural history of Ebstein’s anomaly varies. In
atients who present in the perinatal period, the 10-year
ctuarial survival is 61% (831). In a study that included more
hildren who presented after the perinatal period, the
robability of survival was 50% at 47 years of age (832).
redictors of poor outcome include NYHA functional class
II or IV symptoms, cardiothoracic ratio greater than 65%,
trial fibrillation, severity of cyanosis, and magnitude of TR.
owever, patients with Ebstein’s anomaly who reach late
dolescence and adulthood often have an excellent outcome
832).
.5.2. Evaluation of Tricuspid Valve Disease in
dolescents and Young Adults
LASS I
. An ECG is indicated for the initial evaluation of adolescent and
young adult patients with TR, and serially every 1 to 3 years,
depending on severity. (Level of Evidence: C)
. Chest X-ray is indicated for the initial evaluation of adolescent and
young adult patients with TR, and serially every 1 to 3 years,
depending on severity. (Level of Evidence: C)
. Doppler echocardiography is indicated for the initial evaluation of
adolescent and young adult patients with TR, and serially every 1 to
3 years, depending on severity. (Level of Evidence: C)
. Pulse oximetry at rest and/or during exercise is indicated for the
initial evaluation of adolescent and young adult patients with TR if
an atrial communication is present, and serially every 1 to 3 years,
depending on severity. (Level of Evidence: C)
LASS IIa
. If there is a symptomatic atrial arrhythmia, an electrophysiology
study can be useful for the initial evaluation of adolescent and
young adult patients with TR. (Level of Evidence: C)
. Exercise testing is reasonable for the initial evaluation of adolescent
and young adult patients with TR, and serially every 1 to 3 years.
(Level of Evidence: C)
LASS IIb
. Holter monitoring may be considered for the initial evaluation of
asymptomatic adolescent and young adult patients with TR, and
serially every 1 to 3 years. (Level of Evidence: C)
.5.3. Indications for Intervention in Tricuspid
egurgitation
LASS I
. Surgery for severe TR is recommended for adolescent and young
adult patients with deteriorating exercise capacity (NYHA functional
class III or IV). (Level of Evidence: C)
. Surgery for severe TR is recommended for adolescent and young
adult patients with progressive cyanosis and arterial saturation less
than 80% at rest or with exercise. (Level of Evidence: C)
. Interventional catheterization closure of the atrial communication is
recommended for the adolescent or young adult with TR who is
hypoxemic at rest and with exercise intolerance due to increasing
hypoxemia with exercise, when the tricuspid valve appears difficult
to repair surgically. (Level of Evidence: C) pLASS IIa
. Surgery for severe TR is reasonable in adolescent and young adult
patients with NYHA functional class II symptoms if the valve ap-
pears to be repairable. (Level of Evidence: C)
. Surgery for severe TR is reasonable in adolescent and young adult
patients with atrial fibrillation. (Level of Evidence: C)
LASS IIb
. Surgery for severe TR may be considered in asymptomatic adoles-
cent and young adult patients with increasing heart size and a
cardiothoracic ratio of more than 65%. (Level of Evidence: C)
. Surgery for severe TR may be considered in asymptomatic adoles-
cent and young adult patients with stable heart size and an arterial
saturation of less than 85% when the tricuspid valve appears
repairable. (Level of Evidence: C)
. In adolescent and young adult patients with TR who are mildly
cyanotic at rest but who become very hypoxemic with exercise,
closure of the atrial communication by interventional catheteriza-
tion may be considered when the valve does not appear amenable
to repair. (Level of Evidence: C)
. If surgery for Ebstein’s anomaly is planned in adolescents and young
adult patients (tricuspid valve repair or replacement), a preoperative
electrophysiological study may be considered to identify accessory
pathways. If present, these may be considered for mapping and
ablation either preoperatively or at the time of surgery. (Level of
Evidence: C)
urgical management of Ebstein’s anomaly remains chal-
enging (833). A Glenn anastomosis between the superior
ena cava and right pulmonary artery is occasionally per-
ormed to reduce the volume load on the right ventricle. For
dolescents and young adults, tricuspid valve repair has been
ttempted. Reconstruction of the valve is possible, especially
hen there is a mobile anterior leaflet free of tethering to
he ventricular septum. Valvuloplasty may be performed
ith positioning of the displaced leaflet of the tricuspid
alve to the normal level, sometimes with placation of the
trialized portion of the right ventricle to reduce its size. If
R is mild and hypoxemia at rest or exercise is problematic,
losure of the atrial septal defect in the catheterization
aboratory has been successful in eliminating the hypoxemia.
Occasionally, the tricuspid valve is not reparable, and
alve replacement with a bioprosthesis or a mechanical valve
ay be necessary (834). When present, atrial communica-
ions should be closed unless significant postoperative TR or
V dysfunction is anticipated and the presence of an atrial
eptal defect may allow decompression of the right atrium.
f an accessory pathway is present, this should be mapped
nd ablated either preoperatively in the electrophysiology
aboratory or at the time of surgery.
.6. Pulmonic Stenosis
.6.1. Pathophysiology
ecause the pulmonary valve is the least likely valve to be
ffected by acquired heart disease, virtually all cases of
ulmonary valve stenosis are congenital in origin. Most
atients with stenosis have a conical or dome-shaped
ulmonary valve formed by fusion of the valve leaflets.
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ith the stenosis caused by inability of the valve leaflets to
eparate sufficiently during ventricular systole (835).
Symptoms are unusual in children or adolescents with
ulmonary valve stenosis even when severe. Adults with
ong-standing severe obstruction may have dyspnea and
atigue secondary to an inability to increase cardiac output
dequately with exercise. Exertional syncope or light-
eadedness may occur in the presence of severe pulmonic
tenosis with systemic or suprasystemic RV pressures, with
ecreased preload or dehydration, or with a low systemic
ascular resistance state (such as pregnancy). However,
udden death is very unusual. Eventually, with long-
tanding untreated severe obstruction, TR and RV failure
ay occur.
At any age, if the foramen ovale is patent, RV compliance
ay be reduced sufficiently to elevate right atrial pressure,
hich allows right-to-left shunting and cyanosis. This
ncreases the risk of paradoxical emboli.
.6.2. Evaluation of Pulmonic Stenosis in Adolescents
nd Young Adults
LASS I
. An ECG is recommended for the initial evaluation of pulmonic
stenosis in adolescent and young adult patients, and serially every 5
to 10 years for follow-up examinations. (Level of Evidence: C)
. Transthoracic Doppler echocardiography is recommended for the
initial evaluation of pulmonic stenosis in adolescent and young
adult patients, and serially every 5 to 10 years for follow-up exam-
inations. (Level of Evidence: C)
. Cardiac catheterization is recommended in the adolescent or young
adult with pulmonic stenosis for evaluation of the valvular gradient
if the Doppler peak jet velocity is greater than 3 m per second
(estimated peak gradient greater than 36 mm Hg) and balloon
dilation can be performed if indicated. (Level of Evidence: C)
LASS III
. Diagnostic cardiac catheterization is not recommended for the
initial diagnostic evaluation of pulmonic stenosis in adolescent and
young adult patients. (Level of Evidence: C)
The clinical diagnosis of pulmonary valve stenosis is
traightforward, and the severity can usually be determined
ccurately by 2D and Doppler echocardiography. Diagnos-
ic catheterization is rarely required.
.6.3. Indications for Balloon Valvotomy in Pulmonic
tenosis (UPDATED)
LASS I
. Balloon valvotomy is recommended in adolescent and young adult
patients with pulmonic stenosis who have exertional dyspnea,
angina, syncope, or presyncope and an RV–to–pulmonary artery
peak-to-peak gradient greater than 30 mm Hg at catheterization.
(Level of Evidence: C)
. Balloon valvotomy is recommended in asymptomatic adolescent
and young adult patients with pulmonic stenosis and RV–to–pulmo-
nary artery peak-to-peak gradient greater than 40 mm Hg at cath-
eterization. (Level of Evidence: C) 9LASS IIb
. Balloon valvotomy may be reasonable in asymptomatic adolescent
and young adult patients with pulmonic stenosis and an RV–to–
pulmonary artery peak-to-peak gradient 30 to 39 mm Hg at cathe-
terization. (Level of Evidence: C)
LASS III
. Balloon valvotomy is not recommended in asymptomatic adoles-
cent and young adult patients with pulmonic stenosis and RV–to–
pulmonary artery peak-to-peak gradient less than 30 mm Hg at
catheterization. (Level of Evidence: C)
The clinical course of children and young adults with
ulmonary valve stenosis has been well described. The
atural History of Congenital Heart Defects study (836) in
he mid 1960s and early 1970s followed 564 patients with
alvar pulmonary stenosis with cardiac catheterization at 4-
nd 8-year intervals. On admission to the study, an average
f 15% of patients were less than 2 years old; 20% were 12
o 21 years old; and the remainder were 2 to 11 years old. At
nitial cardiac catheterization, they were divided into 4
roups based on severity: less than 25 mm Hg peak-to-peak
radient between the right ventricle and the pulmonary
rtery, trivial; 25 to 49 mm Hg, mild; 50 to 79 mm Hg,
oderate; and greater than 80 mm Hg, severe.
Of the 261 patients (46% of the total) treated medically,
ost had trivial, mild, or moderate obstruction. None of
hese patients had cyanosis or congestive heart failure, and
nly 6% had symptoms. There were no deaths during the
tudy. The pressure gradients were stable in the majority,
ith 14% of patients manifesting a significant increase and
4% a significant decrease. Most of the increases were in
hildren less than 2 years old and/or those with initial
radients greater than 40 mm Hg. Those not in either
ategory had only a 4% chance of an increase in the gradient
reater than 20 mm Hg. There was little or no change in the
verall status of the medically treated patients. During the
eriod of observation, 304 patients, most with moderate or
evere disease, were treated surgically. Only 1 death oc-
urred among the 245 patients in this group who underwent
urgery beyond infancy. At postoperative follow-up, the
radient had been reduced to insignificant levels in more
han 90%, with no recurrence of pulmonary stenosis in those
ollowed up to 14 years.
In 1993, the second Natural History of Congenital Heart
efects study (837) reported on the 16- to 29-year (mean
2 years) follow-up of the same group of patients. The
robability of 25-year survival was 96%, not statistically
ifferent from the normal control group. Fewer than 20% of
atients managed medically during the first Natural History
tudy subsequently required a valvotomy, and only 4% of
he patients who had undergone surgery required a second
peration. Most patients, whether managed medically or
urgically, had mild obstruction by Doppler echocardiogra-
hy. For patients who had an initial transpulmonary gradi-
nt less than 25 mm Hg in the first Natural History Study,
6% were free of cardiac operation over a 25-year period.
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedSurgical relief of severe obstruction by valvotomy with a
ransventricular (838) or transpulmonary artery (839) ap-
roach predates the introduction of cardiopulmonary by-
ass. A nonsurgical approach with balloon valvotomy was
escribed in 1982 (840) and by the late 1980s had become
he procedure of choice in the United States for the typically
omed, thickened valve, both for children (841) and adults
842,843). Surgery is still usually required for the dysplastic
alve often seen in Noonan’s syndrome. Although long-
erm follow-up of pulmonary balloon valvotomy is not yet
vailable, the early and midterm results (up to 10 years)
844) suggest that the long-term results will be similar to
urgical valvotomy, that is, little or no recurrence over a 22-
o 30-year period. Some pulmonary regurgitation almost
nvariably occurs after valvuloplasty, but it is rarely clinically
mportant in this group.
In those with severe or long-standing valvular obstruc-
ion, infundibular hypertrophy may cause secondary ob-
truction when the pulmonary valve is successfully dilated.
his frequently regresses over time without treatment.
ome have advocated transient pharmacological beta block-
de, but there is insufficient information to determine
hether this is effective or necessary.
From the Natural History Study data, it appears that
ongenital mild pulmonary stenosis is a benign disease that
arely progresses, that moderate or severe pulmonary steno-
is can be improved with either surgery or balloon valvotomy
t very low risk, and that patients who undergo surgery or
alloon valvotomy have an excellent prognosis and a low
ate of recurrence. Thus, the goal of the clinician is to
scertain the severity of the disease, treat those in whom it
s moderate or severe, and infrequently follow up on those
ith mild disease (845).
.7. Pulmonary Regurgitation
ulmonary valve regurgitation is an uncommon congenital
esion seen occasionally with what has been described as
diopathic dilation of the pulmonary artery or with connec-
ive tissue disorders. In this condition, the annulus of the
ulmonary valve dilates, which causes failure of the leaflets
o coapt during diastole. Mild pulmonary regurgitation may
e a normal finding on Doppler echocardiography.
Although pulmonary regurgitation is unusual as an iso-
ated congenital defect, it is an almost unavoidable result of
ither surgical or balloon valvuloplasty of valvular pulmonic
tenosis or surgical repair of tetralogy of Fallot. Among
atients with pulmonic stenosis who underwent surgical
alvotomy in the first Natural History Study (836), 87% had
ulmonary regurgitation by Doppler echocardiography in
he second Natural History Study (837), although it was
udible in only 58%. The echocardiogram tended to over-
stimate severity compared with auscultation, with 20%
onsidered moderate to severe by Doppler but only 6% by
uscultation. In those with pulmonary regurgitation, the
ight ventricle tended to be larger, but RV systolic dysfunc-
ion was uncommon, being present in only 9%. vPulmonary regurgitation also commonly occurs after
uccessful repair of tetralogy of Fallot. Several studies have
ocumented that the vast majority of children and young
dults who underwent surgery in the late 1950s and 1960s
ontinued to do well for up to 35 years after surgery (846).
owever, an increasing number of patients with long-
tanding pulmonary regurgitation have developed severe RV
ilatation and diminished RV systolic performance, which
an lead to an inadequate ability to augment cardiac output
ith exercise and, in some cases, congestive heart failure.
his group has also been shown to have a significant
ncidence of ventricular arrhythmias known to be associated
ith late sudden death. Increased pulmonary artery pressure
rom LV dysfunction or residual peripheral pulmonary
rtery stenosis will increase the amount of regurgitation, and
hese conditions should be treated when present. Cardiac
agnetic resonance has proven to be a useful tool for
valuating pulmonary regurgitant fraction, RV end-diastolic
nd end-systolic volumes, and RV ejection fraction. A wide
ariation has been observed, but many adolescents and
oung adults with repaired tetralogy of Fallot have regurgi-
ant fractions exceeding 40% to 50%, with RV end-diastolic
imensions of more than 150 ml per m2 (normal 75 ml per
2) and RV ejection fractions of less than 0.40. Gatzoulis et
l. have noted that QRS prolongation (greater than 180 m
er second) relates to RV size and predicts malignant
entricular arrhythmias and sudden death after tetralogy of
allot repair (847). Pulmonary valve replacement, usually
ith a homograft or xenograft, has been performed with low
isk (833), has been shown to stabilize QRS duration, and,
n conjunction with cryoablation, has decreased the inci-
ence of pre-existing atrial and ventricular tachyarrhythmias
848). Pulmonary valve replacement has also been found to
esult in reduction in regurgitant fraction and RV end-
iastolic volumes but little change in RV ejection fraction
849,850).
Most physicians would perform pulmonary valve replace-
ent in patients with NYHA functional class II or III
ymptoms and severe pulmonary regurgitation, but for
symptomatic patients, the indications based on regurgitant
raction, RV end-diastolic or end-systolic volume, and RV
jection fraction remain unclear. Many would share the
oncern that it may be unwise to wait until RV function
eteriorates, and that with pulmonary regurgitation, as with
R, valve replacement (see Section 3.2.3.8) should be
onsidered before irreversible damage to ventricular perfor-
ance occurs (851). That point has yet to be determined,
owever.
. SURGICAL CONSIDERATIONS
ardiac valve surgery began with off-pump trans-LV and/or
rans-left atrial commissurotomy performed to treat rheu-
atic MS in the early 1950s. Since this limited beginning,alve surgery has flourished on the basis of advances in
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pment of cardiopulmonary bypass, effective prosthetic
alves, and consistent intraoperative myocardial protection.
The availability of cardiopulmonary bypass allowed iso-
ation of the heart from the circulation and the performance
f true open heart operations. Early valve operations were by
ecessity conservative in nature and included open commis-
urotomy of the MV, simple repair of some types of MR
nd AR, and decalcification of aortic valves.
The development of cardiac valve prostheses in the early
960s expanded the spectrum of pathologies in patients
ith valvular heart disease that could be treated surgically.
any different designs for prosthetic heart valves were
tudied experimentally and clinically during the 1970s, but
y 1980, the basic designs of the prostheses used today had
een established. Available heart valve prostheses can be
rouped into 2 major categories: mechanical valves and
ioprostheses. Mechanical valves have the advantage of
tructural stability but the disadvantage of requiring antico-
gulation with warfarin. Bioprostheses have the advantage
f not requiring anticoagulation with warfarin but the
isadvantage of being subject to time-related structural valve
ailure. All heart valve replacement strategies are imperfect.
n excellent review of long-term durability and complica-
ions of valve prostheses has been published by Grunk-
meier et al. (852) based on 265 clinical studies involving
ore than 61 000 prostheses and a cumulative experience of
19 749 valve-years (Table 34).
After the development of cardiopulmonary bypass and
alvular prostheses, the next important technological ad-
ance was development of cardioplegic myocardial protec-
ion, a strategy that allows intraoperative protection of
entricular function, even for patients with diffuse CAD,
nd at the same time provides a favorable surgical field for
omplex valve operations. As a result, abnormal preoperative
yocardial function is no longer the major predictor of risk
or patients undergoing valve surgery, and the overall
n-hospital mortality and morbidity have decreased. In
ddition, effective myocardial protection has made possible
he most recent technological trend in valve surgery, which
s in the direction of complex valve reparative procedures
nd the avoidance of valve replacement.
.1. American Association for Thoracic Surgery/
ociety of Thoracic Surgeons Guidelines for
linical Reporting of Heart Valve Complications
n 1988, standards for defining and reporting complications
fter heart valve operations were proposed by the Ad Hoc
iaison Committee for Standardizing Definitions of Pros-
hetic Heart Valve Morbidity, a joint committee of the
merican Association for Thoracic Surgery and the STS
853). These guidelines were revised in 1996 (854,855). The
omplications determined to be of critical importance in the
996 guidelines are summarized as follows: fStructural valvular deterioration refers to any change in
function of an operated valve that results from an
intrinsic abnormality that causes stenosis or regurgita-
tion.
Nonstructural dysfunction is a composite category that
includes any abnormality that results in stenosis or
regurgitation of the operated valve that is not intrinsic to
the valve itself, exclusive of thrombosis and infection.
This category includes inappropriate sizing, also called
“valve prosthesis-patient mismatch” (856), and tissue
ingrowth around the prosthesis that may cause a fixed
stenosis or inhibit valve motion, causing stenosis and/or
regurgitation.
Valve thrombosis is any thrombus, in the absence of
infection, attached to or near an operated valve that
occludes part of the blood flow path or interferes with
function of the valve.
Embolism is any embolic event that occurs in the absence
of infection after the immediate perioperative period
(when anesthesia-induced unconsciousness is completely
reversed). This includes any new, temporary or perma-
nent, focal or global neurological deficit and peripheral
embolic event; emboli proven to consist of nonthrom-
botic material are excluded.
Bleeding event (formerly anticoagulant hemorrhage) is
any episode of major internal or external bleeding that
causes death, hospitalization, or permanent injury or
requires transfusion. The complication “bleeding event”
applies to all patients, whether or not they are taking
anticoagulants or antiplatelet drugs.
Operated valvular endocarditis is any infection that
involves an operated valve. Morbidity associated with
active infection, such as valve thrombosis, thrombotic
embolus, bleeding event, or paravalvular leak, is included
under this category and not in other categories of
morbidity.
The consequences of the above events include reopera-
ion; valve-related mortality; sudden unexpected, unex-
lained death; cardiac death; total deaths; and permanent
alve-related impairment (854,855) in addition to cardiac-
elated symptoms such as dyspnea, fatigue, and angina. In
ddition, valve prosthesis may produce hemolysis due either
o the valve itself or to associated perivalvular leak.
There is a wide range in the reported incidence of
omplications with the same prosthetic valve and between
ifferent valves (852). This is most likely due to variation
mong series rather than to valve type and model (857). It
as been emphasized (858) that these variations include
actors associated with patients (e.g., ventricular function,
omorbidities), medical center (e.g., surgical variables, def-
nitions of complications, thoroughness of follow-up), and
ata analysis (e.g., influences of patient-related factors)
857). In addition, published data represent only a small
raction of valves implanted (852,858).
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedMany types of bias affect reported results (859), which
ight be overcome with randomized trials; however, ran-
omized trials also have difficulties (860,861). The number
f randomized studies of prosthetic heart valves is small, and
he majority of those that have been reported are of
nsufficient size to add importantly to the knowledge already
btained from careful observational studies.
.2. Aortic Valve Surgery
he types of operations available to treat aortic valve
able 34. Prosthetic Valve Clinical Studies
Type Model Posi
echanical valves
Ball Starr-Edwards Aor
Mit
Disc Björk-Shiley Aor
Mit
Monostrut Aor
Mit
Medtronic Hall Aor
Mit
Omniscience Aor
Mit
Omnicarbon Aor
Mit
Ultracor Aor
Mit
Bileaflet St. Jude Aor
Mit
Carbomedics Aor
Mit
Edwards Tekna Aor
Duromedics Mit
Sorin Bicarbon Aor
Total mechanical
iological valves
Porcine Hancock I Aor
Mit
Hancock II Aor
Mit
Intact Aor
Mit
Carpentier-Edwards Aor
Mit
Freestyle Aor
Bicor Aor
Mit
Pericardial C-E Perimount Aor
Mit
Mitroflow Aor
Mit
Homograft Homograft Aor
Total biological
otal
odified with permission from Grunkemeier GL, Li HH, Naftel DC, et al. Long-term performanceysfunction include AVR with a mechanical or a biopros- Ahetic valve, AVR with an allograft (homograft) valve,
ulmonic valve autotransplantation (Ross operation) (153,
22–825,862), aortic valve repair, and left ventricle–to–
escending aorta shunt. Each has specific advantages and
isadvantages. Cardiopulmonary bypass is used in aortic
alve operations, and these procedures are usually performed
hrough a median sternotomy incision, although partial
ternotomy (minimally invasive incisions) is gaining accep-
ance. See Sections 3.1.7 and 3.2.3.8 for indications for
Series Valves Valve-Years
5 2339 19 069
8 2524 20 928
4 795 5954
6 1330 8895
4 4950 16 776
3 4265 14 747
8 1964 11 918
4 638 3256
2 185 1239
1 103 716
2 232 1280
1 95 463
1 225 751
1 172 660
14 6813 33 379
15 5636 28 456
5 2252 7928
4 1094 3917
4 1039 4586
2 439 1903
1 163 408
95 37 253 187 230
10 4118 30 260
6 2014 16 282
2 858 5010
3 551 3086
3 1265 2779
3 779 2066
9 3069 15 962
7 1977 12 632
1 699 577
1 856 2317
1 137 510
10 4865 23 027
3 481 2179
2 318 1800
1 96 576
8 2119 13 457
70 24 202 132 519
265 61 455 319 749
rt valve prostheses. Curr Probl Cardiol 2000;25:73–154 (852).tion
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
ral
tic
tic
ral
tic
ral
tic
ral
tic
ral
tic
tic
ral
tic
ral
tic
ral
ticVR or repair in patients with AS and AR.
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he voluntary STS database (165) received reports regard-
ng 9108 to 11 665 isolated AVRs per year during the years
999 through 2004 (total of 62 834 operations). This
oluntary registry is not inclusive of national practice, but it
epresents the best approximation currently available. Se-
ected patient-related descriptors were mean age 66 years,
emale gender 42%, and previous cardiac surgery 16.5%.
pproximately 76% of patients had AS, and the mean LV
jection fraction was 0.53. In-hospital mortality by year
anged from 2.9% to 3.6%, and the risk of permanent stroke
as 1.5% to 1.8%. Experienced centers have reported
ortality rates for primary isolated AVR of less than 1% to
%, although the national average in the STS database is 3%
o 4% (165) and is higher in low-volume centers (166).
uring the 1999 to 2002 time frame, the implantation of
echanical valves declined from 41% to 33% of total cases,
ith a corresponding increase in the implantation of bio-
rostheses from 50% to 65%, whereas the use of homografts
as steady at approximately 2%.
The majority of patients undergoing AVR have other
ardiac lesions, most commonly CAD, and more complex
athology has been associated with increased risk. Experi-
nced centers have reported very little incremental risk
ssociated with combined pathology, but the mortality rates
or a combined AVR and CABG is 6% to 7% (165). Even
echnical expertise does not negate the influence of cardiac
nd noncardiac comorbidity associated with diffuse athero-
clerosis or aneurysmal disease.
.2.2. Mechanical Aortic Valve Prostheses
esigns of mechanical aortic valve prostheses currently
vailable in the United States include ball-and-cage valves,
ingle tilting disc prostheses, and bileaflet prostheses. Ball-
nd-cage valves have the disadvantage of noise and hemo-
ynamic inefficiency and today are rarely used, although the
echanical stability of ball-and-cage prostheses has been
xcellent at follow-up intervals of more than 30 years.
ingle-tilting disc valves currently available in the United
tates are the Medtronic-Hall valve and the Omnicarbon
alve. These valves have superior hemodynamic efficiency to
all-and-cage valves and have been structurally stable. The
ost severe disadvantage of the single-disc design is severe
emodynamic compromise if disc thrombosis or immobility
ccurs.
The most common mechanical valve design used in the
ortic position is the bileaflet valve, with versions available
n the United States being manufactured by St. Jude,
arboMedics, ATS Medical, and On-X. The bileaflet
alves are relatively quiet, appear to be mechanically stable,
nd are relatively hemodynamically efficient. The operation
or implantation of mechanical prostheses is standard, as is
he surgery for reoperation when that is needed. The
isadvantages of mechanical valves are the need to take
arfarin for anticoagulation to prevent thromboembolism, vhe risk of bleeding complications, the risk of thromboem-
olism despite warfarin therapy, endocarditis, and hemody-
amic inefficiency in smaller sizes. Also, the structural
tability of mechanical valves does not eliminate the possi-
ility of reoperation for other indications such as valve
hrombosis, tissue ingrowth and valve dysfunction,
eriprosthetic leak, endocarditis, symptomatic patient-
rosthesis mismatch, and multiple bleeding episodes sec-
ndary to warfarin therapy.
.2.2.1. ANTITHROMBOTIC THERAPY FOR PATIENTS WITH AORTIC MECHANICAL
EART VALVES
fter mechanical AVR, the goal of antithrombotic therapy
s usually to achieve an INR of 2.5 to 3.5 for the first 3
onths after surgery and 2.0 to 3.0 beyond that time (see
ection 9.2). Low-dose aspirin (75 to 100 mg per day) is
lso indicated in addition to warfarin (808), as discussed in
ection 9.2.1. At that level of anticoagulation, the risk of
ignificant hemorrhage appears to be 1% to 2% per year.
lthough the goal of mechanical and materials engineering
as been to produce a mechanical valve that does not require
nticoagulation with warfarin, that goal has not yet been
chieved. Trials diminishing or eliminating anticoagulation
ith warfarin or substituting platelet inhibitors for warfarin
ave so far noted a high rate of thromboembolism.
.2.3. Stented and Nonstented Heterografts
.2.3.1. AORTIC VALVE REPLACEMENT WITH STENTED HETEROGRAFTS
he most commonly used aortic valve prostheses in the
nited States today are stented heterografts that are con-
tructed with bovine pericardial tissue or porcine aortic valve
issue arranged on a cloth and metal frame. These valves
ave the advantages of a low thromboembolism rate without
arfarin, a simple and standard implantation technique, a
tandard reoperation risk, a low risk of catastrophic valve
ailure, and widespread availability in many valve sizes. The
isadvantages of stented heterografts are structural valve
eterioration, imperfect hemodynamic efficiency, a standard
isk of prosthetic valve endocarditis, and a low (0.7% per
ear) but present risk of thromboembolism without warfarin
nticoagulation. Stented pericardial heterografts have better
emodynamic performance than porcine heterografts, espe-
ially in smaller sizes (less than 21 mm) (863–866). In a
andomized trial comparing stented porcine xenografts and
tented pericardial valves (866), the reduced pressure gradients
ith the pericardial valve translated into greater reduction in
V mass at a mean 1.2-year follow-up period after AVR.
The first-generation stented heterografts (porcine hetero-
rafts) exhibited a freedom from structural valve deteriora-
ion of approximately 40% by 18 postoperative years. How-
ver, the rate of structural valve deterioration is age-related
168,867–880), being increased for younger patients, and in
atients less than 40 years of age, approximately half of
orcine valves fail by 10 years (Table 35). Bovine pericardial
alves appear to have a lower rate of structural valve
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alves in surviving patients of all ages are functioning
ithout explantation, and among patients undergoing pri-
ary AVR at an age greater than 65 years, fewer than 10%
nderwent valve explantation by 15 postoperative years
168,876). The reported rate of structural valve deteriora-
ion for second-generation porcine valves appears so far to
able 35. Structural Valve Deterioration of Bioprosthetic Valve
Author, Year
Mean
Follow-Up, y
Number of
Valves
Time of SVD
Estimate, y AAVR MVR
amieson et al.,
1988 (867)
5.6 572 509 10 3
Greate
ohn et al.,
1989 (868)
6.0 971 708 15 40
4
70 or
ones et al.,
1990 1990
(869)
8.3 610 528 10 Less
4
5
6
urdon et al.,
1992 (872)
7.3 857 793 15 1
4
5
6
Greate
urr et al.,
1992 (873)
— 574 500 7 Less
6
7
80 or
13–15 Less
6
7
80 or
elletier et al.,
1992 (874)
7.0 451 547 10 Less
4
5
65 or
osgrove et al.,
1995 (875)
7.8 310 — 10 Less
65 or
elletier et al.,
1995 (876)
4.5 416 — 10 Less
6
70 or
ohn et al.,
1998 (877)
6.1 843 — 10 50
5
70 or
15 50
5
70 or
anbury et al.,
2001 (168)
12 267 — 15
amieson et al.,
2001 (879)
6.2 836 332 12 5
6
Greate
VR indicates aortic valve replacement; MVR, mitral valve replacement; SVD, structural valve dee equivalent to that of stented bovine valves. e.2.3.2. AORTIC VALVE REPLACEMENT WITH STENTLESS HETEROGRAFTS
tentless heterografts are valves constructed from porcine
ortic valves that use a smaller amount of cloth for stabili-
ation, sewing, and tissue ingrowth than a full cloth-metal
tent. The major goal of stentless heterografts is to achieve
nhanced hemodynamic efficiency relative to stented valves
881–886). The long-term importance of hemodynamic
Freedom From
SVD, %
CommentsAVR MVR
81 4 78 5 Carpentier-Edwards standard porcine
bioprosthesis
60 91 3 71 9
er
68 9
86 2
94 3
68 10
84 13
84 10
Hancock porcine bioprosthesis (includes
146 combined AVR  MVR procedures)
0 46 7
60
79
92 2
47 8
48 8
61
80 6
Hancock or Carpentier-Edwards porcine
bioprosthesis (includes 88 combined AVR
 MVR procedures)
70
33 7
54 10
57 6
73 6
93 3
37 6
38 12
38 5
61 15
62 6
Hancock I and Hancock modified orifice
porcine bioprosthesis
5
er
94 1
98 1
100
100
88 2
90 4
95 3
100
Carpentier-Edwards standard porcine
bioprosthesis (similar results were
obtained with Carpentier-Edwards supra-
annular porcine bioprosthesis)
5 62 8 37 7
98 3 63 8
95 5 74 19
er 100 —
5
er
70
84
84
93
55
64
69
95
Carpentier-Edwards standard (302 AVR, 324
MVR) improved annulus (97 AVR, 135
MVR), supra-annular (52 AVR, 88 MVR)
porcine bioprostheses (includes 121
combined AVR  MVR and 5 combined
MVR  TVR procedures)
5
er
88.6
95.5
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
0
er
86.3
95.3
100
—
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
er
57
77
96
—
—
—
Hancock modified orifice porcine aortic
valve
16 —
54 —
er 87 —
58
70
82
91
—
—
—
—
Carpentier-Edwards pericardial aortic
bioprosthesis
70
92 3
96 2
98 1
90 3
97 3
Medtronic Intact porcine bioprosthesis
tion; and TVR, tricuspid valve replacement.s
ge, y
0–59
r than
or less
1–69
great
than 4
0–49
0–59
0–69
6–39
0–49
0–59
0–69
r than
than 6
5–69
0–79
great
than 6
5–69
0–79
great
than 4
5–54
5–64
great
than 6
great
than 6
0–69
great
or less
1–69
great
or less
1–69
great
45
55
65
75
1–60
1–70
r thanfficiency of prosthetic heart valves is currently a subject of
i
u
a
e
L
w
s
c
v
m
s
e
L
a
b
t
n
s
a
t
a
H
a
t
s
T
s
b
w
t
s
s
d
t
t
a
v
7
A
A
r
d
t
m
t
r
h
r
n
w
w
r
m
v
i
s
o
d
a
c
(
a
o
T
i
i
t
r
t
r
p
o
w
a
u
7
P
o
b
(
i
s
m
a
o
t
a
T
a
t
i
e
a
c
a
t
b
r
i
o
n
a
o
o
e96 Bonow et al. JACC Vol. 52, No. 13, 2008
ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated September 23, 2008:e1–142nvestigation and disagreement. The argument favoring the
se of stentless valves is that stented valves of any kind are
t least partially stenotic (particularly in small sizes) and that
ven small postoperative gradients may lead to incomplete
V mass regression postoperatively (883,885–887), which
ill, in turn, lead to impaired long-term survival and
ymptom status. Some randomized and nonrandomized but
omparative studies (885–887) have reported lower trans-
alvular gradients and more consistent regression of LV
ass after AVR when stentless valves are used than with
tented prostheses, whereas other studies show no differ-
nces (888,889). In addition, the long-term importance of
V mass regression is not clear.
One nonrandomized study reported improved postoper-
tive survival with stentless than with stented porcine
ioprostheses (890). However, in the several randomized
rials comparing stented and stentless valves, there has been
o difference in patient outcomes at 1 to 3 years after
urgery (886–889). It is clear that the combination of large
nd active patients and small aortic valve prostheses can lead
o high transprosthetic gradients (particularly with exercise)
nd symptoms related to patient-prosthesis mismatch (856).
owever, the importance of small transvalvular gradients is
s yet unclear. Stentless heterografts have the disadvantage
hat their implantation is more complex than that for
tented valves, and their long-term outcomes are unknown.
here is a low incidence (7% to 10%) of early mild AR in
ome series (883,884,886), which may progress with time,
ut it is uncertain whether this differs from the experience
ith some stented bioprostheses (856,883,884). Observa-
ional studies with 8- to 10-year follow-up (891) appear to
how a low risk of structural valve deterioration with
tentless heterografts, and the hope is that improved hemo-
ynamic design will lead to improved longevity. Time will
ell. Stentless valves are implanted with techniques similar
o those used for aortic valve homografts, but they have the
dvantage of increased availability compared with aortic
alve homografts.
.2.4. Aortic Valve Homografts
ortic valve allografts (homografts) have been used for
VR since early in the cardiac surgical era (892), but the
apid failure rate of early homografts (30% structural valve
eterioration by 10 years) and the complex implantation
echniques required limited their use. The use of ho-
ografts has been revived by cryopreservation techniques
hat appear to diminish the rate of structural valve deterio-
ation (169,171). Homografts may be implanted as a “free
and” valve in the subcoronary position; as a “mini-root”
eplacement, during which the valve is implanted within the
ative root cylinder; and as a full root replacement, during
hich the native aortic root is removed and entirely replaced
ith the homograft aortic root, the coronary arteries being
eimplanted into the homograft. All these operations are
ore complex than the implantation of standard mechanical malves or stented heterografts. Total aortic root replacement
s currently the most common homograft implantation
trategy.
It had been hoped that aortic valve homografts would
utlast heterografts, particularly in young patients, but to
ate, long-term data do not support this view. One possible
dvantage of homografts is in the avoidance of early endo-
arditis and in the treatment of aortic valve endocarditis
893–896), particularly complex aortic root endocarditis,
lthough the literature does not demonstrate the superiority
f any single prosthesis in these situations (852,897–900).
he risk of thromboembolism is very low after homograft
mplantation, and hemodynamic efficiency is excellent even
n small sizes. The biggest disadvantage of homografts is
hat reoperation after homograft AVR is more difficult than
eoperation after placement of standard prostheses, because
he entire homograft may become severely calcified. In a
andomized trial comparing homografts and stentless bio-
rosthetic valves, there was no difference in hemodynamics
r patient outcomes at 1 year after operation (901,902). As
ith stentless bioprostheses, AR may develop, and there is
n increased likelihood of need for reoperation in patients
nder the age of 40 years (903).
.2.5. Pulmonic Valve Autotransplantation
ulmonic valve autotransplantation (Ross operation) is an
peration developed in an attempt to provide a permanent
iological aortic valve prosthesis using the pulmonic valve
153,822,823,825,862) In this operation, the pulmonic valve
s excised and used to replace the aortic valve either as a
ubcoronary implantation or as a full aortic root replace-
ent, while the pulmonic valve is then replaced with an
lternative prosthesis, usually a pulmonic homograft. This
peration has been performed in small numbers, and long-
erm follow-up studies have been inconsistent, which makes
nalysis of long-term advantages and disadvantages difficult.
he known advantages of the procedure are that the
utograft may grow in children, warfarin is not required,
here is a low incidence of thromboembolism, the autograft
s a hemodynamically efficient valve, and the incidence of
ndocarditis is low (904). The disadvantage of pulmonic
utotransplantation is that the operation is much more
omplex than standard AVR and in most series has been
ssociated with at least some increase in in-hospital mor-
ality. There is also an incidence of early aortic valve failure
ased on technical considerations or dilatation of the aortic
oot, and the homograft used to replace the pulmonic valve
s also subject to failure, sometimes early, within a few years
f operation (862). Small, short-term randomized and
onrandomized comparisons of pulmonary autografts and
ortic homografts have demonstrated no definite advantage
f either in adults in terms of hemodynamics and patient
utcome (905–907). Deterioration of the pulmonary ho-
ograft also offsets potential advantages of the autograft.
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ultiple strategies for aortic valve repair have been ex-
lored, some successfully. Aortic valve repair by decalcifying
tenotic calcific aortic valves was used in the preprosthesis
ra but abandoned because of recalcification and restenosis.
evival of its use with modern myocardial protection and
ecalcification techniques still is associated with a high rate
f restenosis. Repair of rheumatic aortic valves has, in
eneral, not been successful over time. In contrast, repair of
nsufficient bicuspid aortic valves in the adult has been
ncreasingly successful at limited numbers of centers
827,908,909). Among the advantages of this strategy are
he lack of need for anticoagulation, a low thromboem-
olic risk, a low endocarditis risk, a hemodynamically
fficient valve, and a straightforward reoperation, if
eeded. The disadvantages are lack of uniform applica-
ility, lack of widespread experience with surgical tech-
iques, and the need for reoperation. Long-term data are
imited, but the risk of reoperation appears to be about
5% by 10 postoperative years. Although late calcification
f these repaired valves has to be considered likely given
nough time, calcification may be delayed in some
atients with repaired bicuspid valves, who may avoid
eoperation for decades.
Much progress has been made in the repair of aortic
alves rendered insufficient by aortic root pathology
364,910–915). When an aortic root aneurysm exists, the
peration to restore competence to the aortic valve involves
esecting the aorta and resuspending the valve in association
ith a Dacron graft that is used to replace the aorta.
dvantages of this strategy include avoidance of warfarin, a
ow thromboembolic risk, a very efficient valve, and what
ppears to be a low risk of prosthetic valve endocarditis. The
isadvantages are, again, limited applicability in the setting
f intrinsic leaflet pathology and the high level of surgical
able 36. Probability of Death Due to Any Cause, Any Valve-Re
5 Years After Randomization in the Veterans Affairs Cooperat
Event
Aortic Valve
Mechanical
(n  198)
Porcine
(n  196)
eath due to any cause 66 3 79 3
ny valve-related complications 65 4 66 5
ystemic embolism 18 4 18 4
leeding 51 4 30 4
ndocarditis 7 2 15 5
alve thrombosis 2 1 1 1
erivalvular regurgitation 8 2 2 1
eoperation 10 3 29 5
tructural valve failure 0 0 23 5
alues are actuarial percentages plus/minus standard error. Note: p values are for differences b
l. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: fi
ith permission.xpertise and experience required. p.2.7. Left Ventricle–to–Descending Aorta Shunt
n situations involving pathologies that make standard AVR
perations particularly risky, such as multiple previous
perations, severe aortic calcification, and previous radiation
herapy, a left ventricle–to–descending thoracic aortic shunt
sing a Dacron graft containing a valve can be an effective
lternative treatment (916). This procedure is performed
hrough a left thoracotomy with or without cardiopulmo-
ary bypass. A valved conduit is connected to the LV apex
ia a metal connector and then anastomosed to the descend-
ng intrathoracic aorta. Favorable short-term outcomes have
een reported, but the long-term hemodynamics results and
omplication rate associated with this strategy are currently
nknown.
.2.8. Comparative Trials and Selection of Aortic Valve
rostheses
wo randomized trials have compared outcomes for pa-
ients receiving mechanical and bioprosthetic valves in the
ortic position, the Edinburgh Heart Valve Trial (1975–
979) (917) and the Veterans Affairs Cooperative Study on
alvular Heart Disease (1979–1982) (174,918). Both com-
ared the Bjork-Shiley tilting-disc valve with first-
eneration porcine heterografts. In the Veterans Affairs
rial, 15-year survival rates were superior for patients with
echanical valves (34%) compared with those with biopros-
heses (21%) in the aortic position (p  0.02), but 20-year
urvival rates were no different in the Edinburgh trial. As
xpected, bleeding rates were significantly higher for pa-
ients with mechanical valves, and structural valve deterio-
ation and reoperation rates were higher for patients with
ioprostheses in both trials (174,917,918). The long-term
esults of the Veterans Affairs Cooperative Study (174) are
hown in Table 36.
Despite the randomized design of these trials and the
pparent slight advantage for patients receiving mechanical
Complications, and Individual Valve-Related Complications
tudy on Valvular Heart Disease
Mitral Valve
p
Mechanical
(n  88)
Porcine
(n  93) p
0.02 81 4 79 4 0.30
0.26 73 6 81 5 0.56
0.66 18 5 22 5 0.96
0.001 53 7 31 6 0.01
0.45 11 4 17 5 0.37
0.33 1 1 1 1 0.95
0.09 17 5 7 4 0.05
0.004 25 6 50 8 0.15
0.001 5 4 44 8 0.001
mechanical and porcine valves. Data are from Hammermeister K, Sethi GK, Henderson WG, et
rt of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000;36:1152–8 (174). Reprintedlated
ive S
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or multiple reasons.
Current bioprostheses appear to have lower rates of
structural valve deterioration than those used during the
randomized trials that involved first-generation biopros-
theses. Reoperation rates for patients over 65 years of age
are particularly low with modern stented bioprostheses
(Table 35).
The risks of reoperation have continued to decrease since
these trials were completed, particularly the risk of a first
reoperation.
Patients undergoing AVR today represent an older pop-
ulation than those studied in the randomized trials.
Young patients undergoing aortic valve surgery are often
reluctant to accept warfarin therapy and the activity
constraints associated with anticoagulants.
There are some nonrandomized but relatively large com-
parative trials that have shown apparent survival benefit
for patients receiving bioprostheses, particularly for those
over the age of 65 years (919).
On the basis of these considerations, most patients over
5 years of age receive a bioprosthesis. There are no data
nvolving large patient numbers that clearly show long-term
dvantages for one type of aortic valve operation over
nother or for any individual prosthesis over another.
At many major valve surgery centers, the age threshold
or the use of bioprosthetic valves in the aortic position has
ecreased to well below 65 years in those patients who do
ot wish to take anticoagulation. The decision requires full
iscussion with the patient, with the understanding that
here is a higher chance of the need for reoperation with a
ioprosthesis.
In the previous 1998 ACC/AHA Guidelines for the
anagement of Patients with Valvular Heart Disease,
echanical valves were recommended (Class IIa) in patients
ith end-stage renal failure, especially those undergoing
hronic dialysis, because of the concern of accelerated
alcification of bioprosthetic valves. Subsequent retropsec-
ive studies (919a) have demonstrated no significant differ-
nce in outcome of such patients treated with mechanical
rostheses versus bioprostheses. The current writing com-
ittee has made no specific recommendations for valve
election in dialysis patients, but notes the difficulties in
aintaining anticoagulation in these patients.
Selection among biological valve operations is based on logic
nd opinion rather than consistently defined differences and
utcomes. Surgeon experience is important, because there are
o long-term data justifying the use of operations that increase
erioperative risk. The most common biological valve used is a
tented heterograft because of its easy implantation, the ease of
eoperation, the extensive data defining its late outcomes, and
he lack of data supporting the use of more complex strategies.
lthough it had been hoped that homografts would have an
mproved failure rate relative to stented heterografts, at this
oint, data do not support that view. A stentless allograft or tomografts are a good choice for patients with small aortic root
izes at risk for patient-prosthesis mismatch (856,863–865).
tentless heterografts have been effective in the short term, but
he extent of their advantage is unclear in regard to valve
fficiency, and long-term failure rates are not known
886,889,920). Current data noting a 20% failure rate by 10
ostoperative years do not indicate improved long-term out-
omes compared with stented bioprostheses. Pulmonic valve
utotransplantation is used by some to allow growth of the
utograft in children. Its use in adults has been limited by some
ncrease in operative risk and data indicating a reoperation rate
f approximately 20% by 10 postoperative years.
.2.9. Major Criteria for Aortic Valve Selection
LASS I
. A mechanical prosthesis is recommended for AVR in patients with a
mechanical valve in the mitral or tricuspid position. (Level of Evi-
dence: C)
. A bioprosthesis is recommended for AVR in patients of any age who
will not take warfarin or who have major medical contraindications
to warfarin therapy. (Level of Evidence: C)
LASS IIa
. Patient preference is a reasonable consideration in the selection of
aortic valve operation and valve prosthesis. A mechanical prosthe-
sis is reasonable for AVR in patients under 65 years of age who do
not have a contraindication to anticoagulation. A bioprosthesis is
reasonable for AVR in patients under 65 years of age who elect to
receive this valve for lifestyle considerations after detailed discus-
sions of the risks of anticoagulation versus the likelihood that a
second AVR may be necessary in the future. (Level of Evidence: C)
. A bioprosthesis is reasonable for AVR in patients aged 65 years or
older without risk factors for thromboembolism. (Level of Evidence: C)
. Aortic valve re-replacement with a homograft is reasonable for
patients with active prosthetic valve endocarditis. (Level of Evi-
dence: C)
LASS IIb
. A bioprosthesis might be considered for AVR in a woman of child-
bearing age (see Sections 5.7 and 5.8). (Level of Evidence: C)
.3. Mitral Valve Surgery
V surgery began with valve-conserving operations for
heumatic MS and expanded to treat a variety of pathologies
nce prosthetic valve replacement became available. Today,
alve-conserving operations have become more common
nd are used to treat a variety of pathologies. Analysis of the
utcomes after MV surgery is complex. Those outcomes are
ffected not only by the valve-coronary pathology treated
ut also by LV function, cardiac rhythm, and surgeon
xperience. Operations currently available to treat MV
ysfunction include closed mitral commissurotomy, replace-
ent with a mechanical prosthesis, replacement with a
ioprosthesis, replacement with an MV homograft or Ross-
ype autograft, and a variety of reparative MV procedures.
The surgical approaches to MV surgery are varied. Closed
r “off-pump” mitral commissurotomy can be performed
ither percutaneously with a balloon catheter or surgically
hrough a left thoracotomy (see Sections 3.4.8 and 3.4.9).
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedhe standard approach for MV replacement or complex
epair is use of a median sternotomy with cardiopulmonary
ypass; however, many alternative incisions are now used,
ncluding partial sternotomy and small right thoracotomy
ccess, strategies described as “minimally invasive.” Video-
ssisted and robotic-assisted MV surgery are becoming
ore feasible, and standard outcomes have been described
or small numbers of selected patients undergoing surgery at
enters that specialize in these alternative surgical strategies.
When the MV is replaced, an attempt is made to preserve
t least part of the subvalvular apparatus, that is, the chordae
endineae connecting the papillary muscles with the valve
nnulus. Experimental and clinical data show that long-
erm LV function may benefit by this strategy.
.3.1. Mitral Valve Repair
V surgery began with conservative operations for rheu-
atic MS; within the last 20 years, conservative operations
o treat MR have been developed and popularized to treat
egenerative and functional MV disease, as well as some
atients with MV endocarditis. The outcomes of MV repair
ust be analyzed according to the pathologies treated rather
han the operation alone.
.3.1.1. MYXOMATOUS MITRAL VALVE
LASS I
. MV repair is recommended when anatomically possible for patients
with severe degenerative MR who fulfill clinical indications, and
patients should be referred to surgeons who are expert in repair.
(Level of Evidence: B)
. Patients who have undergone successful MV repair should continue
to receive antibiotics as indicated for endocarditis prophylaxis.
(Level of Evidence: C)
. Patients who have undergone successful MV repair and have
chronic or paroxysmal atrial fibrillation should continue to receive
long-term anticoagulation with warfarin. (Level of Evidence: B)
. Patients who have undergone successful MV repair should undergo
2D and Doppler echocardiography before discharge or at the first
postoperative outpatient visit. (Level of Evidence: C)
. Tricuspid valve repair is beneficial for severe TR in patients with MV
disease that requires MV surgery. (Level of Evidence: B)
LASS IIa
. Oral anticoagulation is reasonable for the first 3 months after MV
repair. (Level of Evidence: C)
. Long-term treatment with low-dose aspirin (75 to 100 mg per day)
is reasonable in patients who have undergone successful MV repair
and remain in sinus rhythm. (Level of Evidence: C)
. Tricuspid annuloplasty is reasonable for mild TR in patients under-
going MV repair when there is pulmonary hypertension or tricuspid
annular dilatation. (Level of Evidence: C)
LASS IIb
. In patients with MR and a history of atrial fibrillation, a Maze procedure
may be considered at the time of MV repair. (Level of Evidence: B)
Myxomatous MV disease produces MR based on rupture
r elongation of chordae tendineae, valve leaflet instability, snnulus dilatation, or multiple causes that result in excessive
V leaflet motion. In the majority of these conditions,
xperienced surgeons can repair the MV using strategies
hat involve removal of unsupported leaflet structures, trans-
er of chordae (467,468), or the use of artificial chordae to
upport unstable areas of the leaflet, the sliding of supported
reas of the leaflet to cover the MV orifice, and stabilization
f the size and shape of the MV annulus with an artificial
ing (529,530,545,568–573). When possible, MV repair is
he treatment of choice for degenerative valve disease,
ecause patients in sinus rhythm do not need warfarin, the
hromboembolism rate is low, valve efficiency and hemody-
amics are good, there is little adverse effect on LV
unction, the risk of endocarditis is low, and the long-term
urvival rate is favorable compared with MV replacement
see Section 3.6.4). Concomitant tricuspid valve repair
hould be performed when there is severe TR or mild-to-
oderate TR and tricuspid annular dilatation (see Section
.7.4.3 and Section 3.8.3). In patients presenting for MV
epair with chronic atrial fibrillation, a concomitant surgical
rocedure to eliminate atrial fibrillation may prevent future
mbolic events by restoring normal sinus rhythm (608–
14). The decision to proceed with a surgical procedure to
liminate atrial fibrillation should be made based on the age
nd health of the patient, as well as the surgical expertise,
ecause this procedure may add to the morbidity of the
peration (see Section 3.6.4.2.4).
The likelihood of a successful MV repair is related to the
xtent of the MV dysfunction (with isolated posterior leaflet
ysfunction being the most favorable condition); the pres-
nce and extent of calcification; the amount of pliable,
oncalcified valve tissue; and surgeon experience. Recurrent
R after repair may occur with time, but in favorable
ituations, more than 90% of valves are still functioning well
fter 10 years (529,530).
.3.1.2. RHEUMATIC HEART DISEASE
LASS I
. Percutaneous or surgical MV commissurotomy is indicated when
anatomically possible for treatment of severe MS, when clinically
indicated. (Level of Evidence: C)
Rheumatic MR is inconsistently reparable, and the long-
erm outcomes after repair are not as good as for valve repair
or degenerative MV disease. Rheumatic pathology often
eads to leaflet and chordal scarring, which restricts the
eaflet motion, and leaflet scarring may be progressive after
epair. Rheumatic MS that is not associated with severe
hordal fusion or shortening or with calcification may be
reated with either percutaneous or open mitral commissur-
tomy with a high degree of long-term success. Clinical
ndications for these procedures are discussed in Section 3.4.8.
.3.1.3. ISCHEMIC MITRAL VALVE DISEASE
y definition, all patients with ischemic MR have signifi-
ant CAD that usually has a significant effect on long-term
urvival. The pathology of ischemic MR has multiple
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ional MR, in which the valve leaflets are structurally
ormal, but LV chamber enlargement and papillary muscle
isplacement tether the MV via the chordal attachments
nd prevent leaflet coaptation (616–623). When functional
R is severe, it may be corrected by placement of an
nnuloplasty ring that decreases the annular circumference,
hortens the intertrigonal distance, reduces the septal-lateral
anterior-posterior) annular diameter, and restores the ge-
metry of the annulus, thereby allowing the MV leaflets to
oapt (624–627,633–642). This strategy acutely decreases
r eliminates MR, but because the fundamental abnormality
s related to LV function, the late survival rate of these
atients is relatively low compared with patients with other
V pathologies, and the recurrence rate of mitral dysfunc-
ion is higher. For patients with moderate functional MR, it
s not yet clear whether MV repair improves outcomes.
Patients with ischemic MV disease who have anatomic
R based on infarction or rupture of the papillary muscles
enefit from either mitral repair or MV replacement.
apillary muscle rupture often produces severe MR and
emodynamic decompensation, which is an indication for
mergency surgery.
.3.1.4. MITRAL VALVE ENDOCARDITIS
ith increased surgical experience in mitral reparative
echniques, MV endocarditis has become more consistently
reatable with repair (760–762). There appears to be a low
isk of recurrent infection, and in experienced hands, it is
ften possible to avoid the need for an MV prosthesis (see
ection 4.6.1). Surgery, however, must not be delayed until
xtensive valve disruption has occurred.
.3.2. Mitral Valve Prostheses (Mechanical
r Bioprostheses)
echanical Prostheses: Ball-and-cage valves, single-tilting
isc valves, and bileaflet prostheses are available MV pros-
heses. Ball-and-cage valves have been effective but can
ause some degree of outflow tract obstruction by projecting
nto the LV outflow tract, a problem not present with
ileaflet or disc valves. Most studies have shown that the
hromboembolism risk is greater for patients with mechan-
cal MV prostheses than for patients with aortic valves, even
hen adjusted for the presence of atrial fibrillation. Thus,
nticoagulation for patients with mechanical MV prostheses
s maintained at an INR of 2.5 to 3.5 indefinitely.
Bioprostheses: Both porcine heterografts and bovine peri-
ardial heterografts are available in the United States for
V replacement. Porcine heterografts have been followed
p for longer intervals, but limited data appear to show a
lower rate of structural valve deterioration for second-
eneration porcine heterografts and bovine pericardial
alves (921,922). The failure rate of mitral heterografts
ppears to be higher than that for aortic heterografts (Table
5). For example, in the VA Cooperative Study, 29% of hortic valve and 50% of mitral porcine heterografts needed
eoperation by 15 postoperative years (Table 36) (174).
.3.2.1. SELECTION OF A MITRAL VALVE PROSTHESIS
LASS I
. A bioprosthesis is indicated for MV replacement in a patient who will
not take warfarin, is incapable of taking warfarin, or has a clear
contraindication to warfarin therapy. (Level of Evidence: C)
LASS IIa
. A mechanical prosthesis is reasonable for MV replacement in
patients under 65 years of age with long-standing atrial fibrillation.
(Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in patients 65
years of age or older. (Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in patients under
65 years of age in sinus rhythm who elect to receive this valve for
lifestyle considerations after detailed discussions of the risks of
anticoagulation versus the likelihood that a second MV replacement
may be necessary in the future. (Level of Evidence: C)
he STS National Cardiac Surgery Database (165) indi-
ates that the numbers of MV reparative procedures are
ncreasing relative to MV replacement. For isolated MV
perations during the years 2000 through 2004, valve repairs
umbered 2335, 2755, 3779, 3978, and 3712, respectively,
ompared with 4215, 4141, 4517, 4145, and 3579 MV
eplacement operations, respectively. Mortality rates were
.5% to 2.0% for repair versus 5.4% to 6.4% for MV
eplacement. Among patients receiving a MV replacement,
ore patients received mechanical valves than bioprosthe-
es. Medicare data indicate that the mortality for isolated
V replacement in patients older than 65 years is 14.1%,
hich increases to 20.5% in low-volume centers (167).
hen MV pathology is combined with CAD, the risks of
urgery increase. For the same 5 years noted above, an
verage of 3637 patients per year underwent MV repair
ombined with CABG (165), with mortality rates ranging
rom 7% to 8.7%, and 2814 patients per year underwent MV
eplacement plus CABG, with mortality rates in excess of
1%. The majority of patients in this group received
ioprostheses. The selection of a valve is a multifactorial
ecision.
.3.2.2. CHOICE OF MITRAL VALVE OPERATION
V repair should be able to be achieved by experienced
urgeons for the majority of patients with degenerative MV
isease and ischemic valve disease, and patients should be
eferred to surgeons expert in repair. For patients with
heumatic MV disease and endocarditis, repair may be more
ifficult.
For patients undergoing MV replacement, preservation
f the chordal apparatus preserves LV function and en-
ances postoperative survival compared with MV replace-
ent in which the apparatus is disrupted (570,579–582), as
iscussed in Section 3.6.4.1. In the randomized trials, there
as no difference in survival rate based on valve type;
owever, the failure rate of bioprostheses has been higher in
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporatedhe mitral than in the aortic position (Table 35), which adds
mpetus to the use of mechanical prostheses in younger
atients.
The availability of surgical ablation procedures for atrial
brillation offers the possibility of converting the patient to
inus rhythm and avoiding anticoagulation after MV repair
r replacement with a bioprosthesis (608–614). If patients
an be maintained in sinus rhythm, the advantage of a
ioprosthesis is enhanced. For patients with a history of
trial fibrillation who are undergoing MV repair, a Maze-
ype procedure results in sinus rhythm in 75% to 90% of
ases by 6 postoperative months, with long-term data
ndicating sustained results up to 8 years and reduced risk of
troke (611,614). The effect of ablation of atrial fibrillation
or patients with multivalve disease or valve disease com-
ined with CAD is not known.
.4. Tricuspid Valve Surgery
LASS I
. Severe TR in the setting of surgery for multivalvular disease should
be corrected. (Level of Evidence: C)
LASS IIa
. Tricuspid annuloplasty is reasonable for mild TR in patients under-
going MV surgery when there is pulmonary hypertension or tricuspid
annular dilatation. (Level of Evidence: C)
The most common cause of TR is dilatation of the
ricuspid valve annulus caused by pulmonary hypertension.
he tricuspid leaflets are usually normal, and tricuspid valve
nnuloplasty usually corrects or improves the situation.
evere TR should be treated with annuloplasty during
perations for multivalvular disease (see Sections 3.7.4.3
nd 3.8.3). Other causes of TR include rheumatic valvular
isease, endocarditis, leaflet scarring due to inflammatory
onditions, and adherence of tricuspid valve structures to
ranstricuspid pacing wires. When leaflet anatomy is se-
erely abnormal, tricuspid valve replacement may be needed,
ut this situation is not common. There are no data clearly
howing the advantage of one type of tricuspid prosthesis
ver another.
.5. Valve Selection for Women of Childbearing Age
here is no ideal valve prosthesis for women of childbearing
ge who might wish to become pregnant (see detailed
iscussion in Section 5.8). Bioprostheses may be subject to
remature heterograft or homograft failure. Because me-
hanical valves require anticoagulation, there is an increased
isk of fetal abnormalities and mortality, and there may be
n increased risk of maternal complications, including
hromboembolism. Discussion with the patient concerning
he risk of the prosthesis is important (see Section 5.8.4).
. INTRAOPERATIVE ASSESSMENT
LASS I
. Intraoperative transesophageal echocardiography is recommended
for valve repair surgery. (Level of Evidence: B) s. Intraoperative transesophageal echocardiography is recommended
for valve replacement surgery with a stentless xenograft, ho-
mograft, or autograft valve. (Level of Evidence: B)
. Intraoperative transesophageal echocardiography is recommended
for valve surgery for infective endocarditis. (Level of Evidence: B)
LASS IIa
. Intraoperative transesophageal echocardiography is reasonable for
all patients undergoing cardiac valve surgery. (Level of Evidence: C)
Detailed and comprehensive evaluation of valve lesions
uring cardiac surgery has become possible and common
ince the development of transesophageal echocardiography.
his includes confirmation of the preoperative diagnosis
nd associated pathology, provision of additional detail and
epth about the severity and mechanism of valve dysfunc-
ion, detection of previously undiagnosed conditions, and
valuation of the surgical result in the operating room,
hich makes possible the immediate correction of detected
roblems. Studies have documented the impact of intraop-
rative transesophageal echocardiography on valve surgery,
ith changes in the operative plan based on transesophageal
chocardiography findings reported in 11% to 14% of cases
nd detection of problems with surgical procedure and
ubsequent need to return to cardiopulmonary bypass re-
orted in 2% to 6% (923–926). Other important aspects of
ransesophageal echocardiography during valve surgery in-
lude assessment of ventricular function and detection of
ntracardiac air and aortic dissection.
Currently, the application of transesophageal echocardi-
graphy during valve surgery varies a great deal from
nstitution to institution. Availability of equipment and
xpertise are important factors in determining this applica-
ion, and the committee recognizes that such resources may
ary. Although controlled, randomized trials substantiating
he benefit of intraoperative transesophageal echocardiogra-
hy during valve surgery have not been performed, there are
any nonrandomized studies, case series, and significant
xpert experience that support its utility in this setting.
Intraoperative transesophageal echocardiography is espe-
ially important during valve repair surgery. Examination
efore cardiopulmonary bypass provides insight into the
echanism of valve dysfunction and therefore facilitates
urgical planning. More importantly, intraoperative trans-
sophageal echocardiography allows immediate assessment
f the repair after cardiopulmonary bypass. Intraoperative
ransesophageal echocardiography during valve replacement
urgery with a stented prosthetic valve is also useful,
lthough there will be a lower rate of problems detected
fter cardiopulmonary bypass. Valve replacement with a
tentless xenograft, homograft, or autograft valve will have a
igher likelihood of technical problems during surgery, and
herefore, transesophageal echocardiography is virtually es-
ential in this setting because it is currently the best way to
ssess valve function intraoperatively. Because of the poten-
ial for multiple valve involvement and associated lesions
uch as abscesses and fistulas, transesophageal echocardiog-
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cute infective endocarditis. Patients undergoing valve sur-
ery may have other indications for intraoperative trans-
sophageal echocardiography, such as severely decreased LV
unction or hemodynamic instability. The committee rec-
mmends that institutions performing valve surgery estab-
ish consistent and credible intraoperative echocardiography
rograms with knowledgeable echocardiographers commit-
ed to and capable of providing accurate anatomic and
unctional information relevant to valve operations. Such
ervices should be available during surgery to facilitate
valuation of unexpected difficulties. Although transesoph-
geal echocardiography is generally a safe procedure when
roperly performed in appropriate patients, there are risks to
ts performance (927). Thus, preoperative screening for risk
actors and the obtainment of informed consent should be a
outine part of every intraoperative transesophageal study.
A physician trained in transesophageal echocardiography,
e it a cardiologist, cardiac anesthesiologist, or cardiac
urgeon, must perform the intraoperative transesophageal
chocardiogram (928). Intraoperative transesophageal echo-
ardiography studies may vary considerably in duration
epending on complexity of the information being sought.
or instance, evaluation of complex MV repair before
ardiopulmonary bypass often requires a detailed, time-
onsuming study, whereas evaluation of severe calcific AS
ends to be more limited and less time consuming. The
hysician must have sufficient time to obtain comprehensive
mages as needed to ensure an accurate diagnosis, facilitate
erioperative decision making, and enhance patient out-
ome. Echocardiography technicians or sonographers
hould not manipulate an intraoperative transesophageal
chocardiography probe, nor should they be put in a
osition to provide patient outcome-related interpretations
r advice.
Several means of evaluating patients during valve surgery
ther than transesophageal echocardiography are available,
ut they are not a substitute for the direct anatomic
nformation provided by transesophageal echocardiography.
easurements of intracardiac pressures and flows may be
ade with central venous and pulmonary artery catheters or
y direct transmyocardial needle insertion after exposure of
he heart. A surface echocardiographic transducer may be
laced in a sterile sheath and passed onto the surgical field
or application directly to the heart or the ascending aorta,
technique called epicardial and epiaortic echocardiogra-
hy, as a useful alternative in patients in whom transesoph-
geal probe insertion cannot be performed or is contraindi-
ated (929). Information gained from all these techniques
ay be complementary and may be combined to obtain a
ore comprehensive characterization of the lesion.
In general, whenever possible, the decision to treat a valve
esion surgically should be made before the patient is in the
perating room. Specifically, in cases of MR, intraoperative
ssessment of the degree of MR can be misleading owing to
he unloading effects of general anesthesia. In a patient taving surgery for another reason (e.g., CABG or another
alve), intraoperative transesophageal echocardiography oc-
asionally might provide the basis for this decision, but it
hould not replace preoperative assessment of the valve
esion with transthoracic echocardiography or catheteriza-
ion. Intraoperative transesophageal echocardiography can
onfirm the preoperative diagnosis, provide additional de-
ails that may guide the surgical procedure, and help to
uide management of hemodynamics. It remains the best
eans of immediately assessing the technical results of the
urgical procedure in the operating room.
.1. Specific Valve Lesions
.1.1. Aortic Stenosis
he surgical treatment for AS is almost always replacement
ith a prosthetic valve. Intraoperative transesophageal
chocardiography (926) can be used to measure the size of
he aortic annulus to facilitate selection of the proper size
rosthesis and also, in patients with bicuspid valves, to
rovide information regarding aortic root dilatation and
eed for repair (see Section 3.3). After implantation of the
rosthesis, transesophageal echocardiography can detect
echnical problems such as paravalvular regurgitation or
bnormal leaflet motion. Stentless prostheses and ho-
ografts are more prone to distortion, with resulting
egurgitation, and should be assessed in the operating room
y transesophageal echocardiography. Excessive cardiac
ent return or arterial pulsatility during cardiopulmonary
ypass may be indications of significant AR after AVR.
ransesophageal echocardiography can be used to confirm
he diagnosis. Transesophageal imaging can also determine
he adequacy of coronary reimplantation by both direct
maging of the coronaries and assessment of LV function.
.1.2. Aortic Regurgitation
lthough the severity and significance of AR is partially
ependent on afterload and may be difficult to quantify with
ransesophageal echocardiography during surgery, trans-
sophageal echocardiography usually provides high-
esolution images of the aortic valve and is quite helpful in
etermining the mechanism and cause of regurgitation. The
mount of cardiac vent return and arterial pulsatility during
ardiopulmonary bypass may provide some indication of
everity as well. The surgical treatment for AR is usually
eplacement with a prosthetic valve, but valve repair is
ometimes attempted. Measurements of the size of the
ortic root may direct the surgeon toward root replacement
ather than simple replacement of the regurgitant valve.
ntraoperative transesophageal echocardiography should be
sed to evaluate the results of an aortic valve repair imme-
iately after cardiopulmonary bypass. Considerations of the
ransesophageal echocardiography evaluation of a prosthetic
ortic valve after cardiopulmonary bypass are similar to
hose for AS.
8M
r
a
s
c
s
t
w
o
t
t
a
a
M
e
m
i
r
(
g
t
c
d
c
i
t
a
p
c
c
8
P
m
O
i
t
g
t
e
a
p
a
m
p
d
m
d
9
b
t
e
c
a
o
m
a
p
t
c
t
c
d
c
c
w
a
v
w
8
T
d
c
c
f
b
p
e
t
w
a
e
t
b
t
t
r
r
8
T
d
o
r
t
l
t
8
I
o
i
o
s
t
n
s
t
e103JACC Vol. 52, No. 13, 2008 Bonow et al.
September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update Incorporated.1.3. Mitral Stenosis
ost adult patients presenting for surgery for MS have
heumatic heart disease, although extremely severe mitral
nnular calcification on occasion may cause significant
tenosis. Intraoperative transesophageal echocardiography
an provide anatomic information, especially about the
ubvalvar structures, that is difficult to directly visualize
hrough the left atriotomy and is critical in deciding
hether to replace or repair a rheumatic valve. The presence
f thrombus in the left atrium may be detected with
ransesophageal echocardiography as well. Intraoperative
ransesophageal echocardiography should be used to evalu-
te the results of a mitral commissurotomy immediately
fter cardiopulmonary bypass, primarily to detect significant
R. Residual stenosis may be difficult to quantify by
chocardiography. For example, the pressure half-time
ethod to measure MV area is probably not accurate
mmediately after a commissurotomy and should not be
elied on solely to assess adequacy of the commissurotomy
403). Although the Doppler-derived transmitral pressure
radient is easily obtained and may help in this situation,
his may underestimate MS severity in the presence of a low
ardiac output. The transmitral gradient can be measured by
irect transduction of LV and left atrial pressures if there is
oncern about residual stenosis. If a prosthetic MV is
mplanted, transesophageal echocardiography can detect
echnical problems such as paravalvular regurgitation or
bnormal leaflet motion. Small, insignificant central and
aravalvular leaks are commonly seen immediately after
ardiopulmonary bypass and should not be a cause for
oncern (930).
.1.4. Mitral Regurgitation
atients undergoing surgery for MR usually have either
yxomatous degeneration (MVP) or ischemic heart disease.
ther less common causes of MR that requires surgery are
nfective endocarditis and rheumatic heart disease. Because
he change in hemodynamic loading conditions caused by
eneral anesthesia during surgery may lead to underestima-
ion of the severity of MR by intraoperative transesophageal
chocardiography (632,633,931,932), the decision to oper-
te is best made before surgery based on the symptoms and
reoperative testing. If intraoperative evaluation is required
s a precursor to MV repair or replacement, the operator
ust attempt to reproduce both preoperative afterload and
reload conditions. Intraoperative transesophageal echocar-
iography may provide additional information about the
echanism of regurgitation and may be helpful to direct the
ecision whether to repair or replace the valve (923,924,
33). Thus, intraoperative transesophageal imaging should
e used whenever a repair is contemplated. Intraoperative
ransesophageal echocardiography should also be used to
valuate the results of an MV repair immediately after
ardiopulmonary bypass to assess for residual MR, systolic
nterior motion of the valve leaflets, and restriction of mitral tpening with stenosis. Representative loading conditions
ay need to be created with volume or vasopressors to fully
ssess the adequacy of the MV repair immediately after the
atient is weaned from cardiopulmonary bypass. If a pros-
hetic MV is implanted, transesophageal echocardiography
an detect technical problems such as paravalvular regurgi-
ation or abnormal leaflet motion. Small, insignificant
entral or paravalvular leaks are commonly observed imme-
iately after cardiopulmonary bypass, and should not be a
ause for concern (930). It is possible to injure the left
ircumflex coronary artery or tether a cusp of the aortic valve
ith a suture placed in the mitral annulus. Therefore,
ssessment of LV function and examination of the aortic
alve and adjacent structures should always be performed
ith transesophageal echocardiography after MV surgery.
.1.5. Tricuspid Regurgitation
R that requires surgery is most often secondary to annular
ilation with right-sided heart enlargement, which is usually
orrected with tricuspid valve repair. Secondary TR can
hange with the hemodynamic loading conditions. There-
ore, the decision to address TR surgically is best made
efore induction of general anesthesia and surgery whenever
ossible (see Sections 3.7.4 and 3.8). Intraoperative trans-
sophageal echocardiography can provide detailed informa-
ion about the mechanism of TR that is useful in deciding
hether to repair or replace a valve and should be used when
repair is contemplated. Intraoperative transesophageal
chocardiography should be used to evaluate the results of a
ricuspid valve repair immediately after cardiopulmonary
ypass to assess for residual regurgitation and restriction of
he tricuspid valve opening with stenosis. If a prosthetic
ricuspid valve is implanted, transesophageal echocardiog-
aphy can detect technical problems such as paravalvular
egurgitation or abnormal leaflet motion.
.1.6. Tricuspid Stenosis
ricuspid stenosis that requires surgery is most commonly
ue to rheumatic heart disease and is treated by replacement
f the valve with a prosthesis. As with other prosthetic valve
eplacements, transesophageal echocardiography can detect
echnical problems such as paravalvular leaks or immobile
eaflets after cardiopulmonary bypass and allow correction of
he problem during the same operation.
.1.7. Pulmonic Valve Lesions
n adults, the pulmonic valve is much less commonly
perated on than the aortic, mitral, and tricuspid valves. It
s often difficult to image with transesophageal echocardi-
graphy, and decisions to operate on the pulmonic valve
hould be made based on preoperative studies such as
ransthoracic echocardiography or cardiac magnetic reso-
ance whenever possible. Pulmonic valve lesions are treated
urgically by prosthetic valve replacement in adults, and
ransesophageal echocardiography may be able to detect
echnical problems such as paravalvular leaks or immobile
l
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hen the issue of pulmonic stenosis is raised during heart
urgery, direct measurement of RV and pulmonary artery
ressures with catheters or needles can be very helpful.
.2. Specific Clinical Scenarios
.2.1. Previously Undetected Aortic Stenosis
uring CABG
AD and AS are commonly present in the same patient.
n occasion, intraoperative transesophageal echocardiogra-
hy detects previously undiagnosed AS in a patient under-
oing CABG surgery. Indications for AVR in this situation
re the same as described in Section 10.4. If the AS is
oderate or severe, AVR is indicated. Controversy persists
s to whether AVR should be performed during CABG
urgery when mild AS is present. There may be difficulty in
ccurately assessing the severity of AS with intraoperative
ransesophageal echocardiography by Doppler techniques in
ome patients. Confirmation of the severity of the gradient
ay be obtained after the heart is exposed by direct transduc-
ion of the LV and aortic pressures. Epicardial echocardiogra-
hy may also provide additional, helpful information.
.2.2. Previously Undetected Mitral Regurgitation
uring CABG
n occasion, intraoperative transesophageal echocardiogra-
hy may detect previously undiagnosed, significant MR in a
atient undergoing CABG surgery (see Sections 3.6.5,
.3.1.3, and 10.5). An examination of the valve with
ransesophageal echocardiography should be performed to
etermine the mechanism of the MR. If there is a structural
bnormality such as prolapse or flail, the valve should be
epaired or replaced. Ischemic MR due to LV remodeling
nd apical tenting of the leaflets can be very dynamic and
ay respond to acute hemodynamic management in the
perating room by increasing or decreasing in severity
ccording to changes in afterload and LV size. Patients with
evere ischemic MR should undergo MV repair or MV
eplacement (see Sections 3.6.5 and 7.3.1.3). Controversy
xists as to whether patients having CABG surgery with
oderate or mild MR should undergo MV repair as well.
owever, the hemodynamic effects of drugs received during
urgery often lessen the severity of the MR, and mild
ntraoperative MR may increase postoperatively. Hence, it is
easonable to perform MV repair when there is moderate
nd, in many cases, mild MR detected on intraoperative
ransesophageal echocardiography.
. MANAGEMENT OF PATIENTS WITH
ROSTHETIC HEART VALVES
he results of valve surgery with regard to survival, func-
ional class, valve function, and complications are dependent
n patient related factors, cardiac function, type of surgery,
ype of prosthesis, and medical comorbidities (857).
*
a.1. Antibiotic Prophylaxis
.1.1. Infective Endocarditis
ll patients with prosthetic valves need appropriate antibi-
tics for prophylaxis against infective endocarditis (see
ection 2.3.1).
.1.2. Recurrence of Rheumatic Carditis
atients with rheumatic heart disease continue to need
ntibiotics as prophylaxis against recurrence of rheumatic
arditis (see Section 2.3.2).
.2. Antithrombotic Therapy (Table 37)
LASS I
. After AVR with bileaflet mechanical or Medtronic Hall prostheses, in
patients with no risk factors,* warfarin is indicated to achieve an
INR of 2.0 to 3.0. If the patient has risk factors, warfarin is indicated
to achieve an INR of 2.5 to 3.5. (Level of Evidence: B)
. After AVR with Starr-Edwards valves or mechanical disc valves
(other than Medtronic Hall prostheses), in patients with no risk
factors,* warfarin is indicated to achieve an INR of 2.5 to 3.5. (Level
of Evidence: B)
. After MV replacement with any mechanical valve, warfarin is indi-
cated to achieve an INR of 2.5 to 3.5. (Level of Evidence: C)
. After AVR or MV replacement with a bioprosthesis and no risk
factors,* aspirin is indicated at 75 to 100 mg per day. (Level of
Evidence: C)
. After AVR with a bioprosthesis and risk factors,* warfarin is indi-
cated to achieve an INR of 2.0 to 3.0. (Level of Evidence: C)
. After MV replacement with a bioprosthesis and risk factors,* warfa-
rin is indicated to achieve an INR of 2.0 to 3.0. (Level of Evidence: C)
. For those patients who are unable to take warfarin after MV
replacement or AVR, aspirin is indicated in a dose of 75 to 325 mg
per day. (Level of Evidence: B)
. The addition of aspirin 75 to 100 mg once daily to therapeutic
warfarin is recommended for all patients with mechanical heart
valves and those patients with biological valves who have risk
factors.* (Level of Evidence: B)
LASS IIa
. During the first 3 months after AVR with a mechanical prosthesis, it
is reasonable to give warfarin to achieve an INR of 2.5 to 3.5. (Level
of Evidence: C)
. During the first 3 months after AVR or MV replacement with a
bioprosthesis, in patients with no risk factors,* it is reasonable to
give warfarin to achieve an INR of 2.0 to 3.0. (Level of Evidence: C)
LASS IIb
. In high-risk patients with prosthetic heart valves in whom aspirin
cannot be used, it may be reasonable to give clopidogrel (75 mg
per day) or warfarin to achieve an INR of 3.5 to 4.5. (Level of
Evidence: C)
All patients with mechanical valves require warfarin
herapy, as indicated in Table 37 (934). Aspirin is recom-
ended for all patients with prosthetic heart valves: aspirin
lone in patients with bioprostheses and no risk factors, and
spirin combined with warfarin in patients with mechanicalRisk factors include atrial fibrillation, previous thromboembolism, LV dysfunction,
nd hypercoagulable condition.
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igh-risk patients who cannot take aspirin, the addition of
lopidogrel to warfarin therapy should be considered. Even
ith the use of warfarin, risk of thromboemboli is 1% to 2%
er year (171,172,174,214,852,935), but the risk is consid-
rably higher without treatment with warfarin (936). The
isk of a clinical thromboembolism is on average 0.7% per
ear in patients with biological valves in sinus rhythm; this
gure is derived from several studies in which the majority
f patients were not undergoing therapy with warfarin
171,172,174,214,937). Almost all studies have shown that
he risk of embolism is greater with a valve in the mitral
osition (mechanical or biological) than with one in the
ortic position (172,178,852,936,938). With either type of
rosthesis or valve location, the risk of emboli is probably
igher in the first few days and months after valve insertion
937), before the valve is fully endothelialized (804).
It is frequently difficult to maintain a patient at a fixed or
elatively fixed level of anticoagulation owing to changes in
bsorption of medication, the effects of various foods and
edications, and changes in liver function. Therefore, in
linical practice, the patient’s anticoagulation level is main-
ained within a certain therapeutic range. This can be
ptimized through a program of patient education and close
urveillance by an experienced healthcare professional.
.2.1. Mechanical Valves
ll patients with mechanical valves require anticoagulation.
or mechanical prostheses in the aortic position, the INR
ith warfarin therapy should be maintained between 2.0
nd 3.0 for bileaflet valves and Medtronic Hall valves and
etween 2.5 and 3.5 for other disc valves and Starr-Edwards
able 37. Recommendations for Antithrombotic Therapy in Pat
Aspirin
(75–100 mg)
echanical prosthetic valves
AVR–low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR–high risk Class I
MVR Class I
iological prosthetic valves
AVR–low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR–high risk Class I
MVR–low risk
Less than 3 months Class I
Greater than 3 months Class I
MVR–high risk Class I
epending on patients’ clinical status, antithrombotic therapy must be individualized (see specia
actors: atrial fibrillation, left ventricular dysfunction, previous thromboembolism, and hypercoagu
isc valves and Starr-Edwards valves. Modified with permission from McAnulty JH, Rahimtoola S
eart. New York, NY: McGraw-Hill, 1998:1867–74 (934).
AVR indicates aortic valve replacement; and MVR, mitral valve replacement.alves; for prostheses in the mitral position, the INR should re maintained between 2.5 and 3.5 for all mechanical valves
172,174,852,938–947). There is a difference of opinion
egarding the Starr-Edwards valve in the aortic position,
ith the minority opinion recommending that INR be
aintained between 2.0 and 3.0. The recommendation for
igher INR values in the mitral position is based on the
reater risk of thromboembolic complications with mechan-
cal valves in the mitral position (171,852,936,938,942,
43,946,947) and the greater risk of bleeding at higher
NRs (946). In patients with aortic mechanical prosthesis
ho are at higher risk of thromboembolic complications,
NR should be maintained at 2.5 to 3.5, and the addition of
spirin should be considered (see below). These include
atients with atrial fibrillation, previous thromboembolism,
nd a hypercoagulable state. Many would also include
atients with severe LV dysfunction in this higher-risk
roup (948). Some prostheses are thought to be more
hrombogenic than others (particularly the tilting-disc
alves), and a case could be made for increasing the INR to
etween 3 and 4.5; however, this level of anticoagulation is
ssociated with a considerably increased risk of bleeding
938,949).
The addition of low-dose aspirin (75 to 100 mg per day)
o warfarin therapy (INR 2.0 to 3.5) not only further
ecreases the risk of thromboembolism (808,946,950–953)
ut also decreases mortality due to other cardiovascular
iseases. A slight increase in the risk of bleeding with this
ombination should be kept in mind (950,954). The risk of
astrointestinal irritation and hemorrhage with aspirin is
ose dependent over the range of 100 to 1000 mg per day,
nd the antiplatelet effects are independent of dose over this
With Prosthetic Heart Valves
Warfarin
R 2.0–3.0)
Warfarin
(INR 2.5–3.5) No Warfarin
Class I Class IIa
Class I
Class I
Class I
Class IIa Class IIb
Class IIa
Class I
Class IIa
Class IIa
Class I
ons in text). In patients receiving warfarin, aspirin is recommended in virtually all situations. Risk
ndition. International normalized ratio (INR) should be maintained between 2.5 and 3.5 for aortic
thrombotic therapy in valvular heart disease. In: Schlant R, Alexander RW, editors. Hurst’s Theients
(IN
l situati
lable co
H. Antiange (955,956). There are no data in patients with pros-
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00 to 325 mg per day. Doses of 500 to 1000 mg per day
learly increase the risk of bleeding (957–959). The addition
f aspirin (75 to 100 mg per day) to warfarin should be
trongly considered unless there is a contraindication to the
se of aspirin (i.e., bleeding or aspirin intolerance). This
ombination is particularly appropriate in patients who have
ad an embolus while undergoing warfarin therapy, those
ith known vascular disease, and those who are known to be
articularly hypercoagulable. As an example, such combina-
ion therapy is recommended by a committee concerning
he use of antithrombotic therapy in women during preg-
ancy (807). The method of anticoagulation in pregnant
atients is controversial and is discussed in Section 5.8.
Thromboembolic risk is increased early after insertion of
he prosthetic heart valve. The use of UFH early after
rosthetic valve replacement, before warfarin achieves ther-
peutic levels, is controversial. Many centers start UFH as
oon as the risk of increased surgical bleeding is reduced
usually within 24 to 48 h), with maintenance of aPTT
etween 55 and 70 s. After an overlap of UFH and warfarin
or 3 to 5 days, UFH is discontinued when an INR of 2.0 to
.0 is achieved. In some patients, achievement of therapeu-
ic INR must be delayed several days after surgery because of
itigating complications.
.2.2. Biological Valves
ecause of an increased risk of thromboemboli during the
rst 3 months after implantation of a biological prosthetic
alve, anticoagulation with warfarin is often used, especially
hen the valve is in the mitral position (937), although most
enters use only aspirin for biological valves in the aortic
osition. The risk is particularly high in the first few days
fter surgery, and many centers start UFH as soon as the
isk of increased surgical bleeding is reduced (usually within
4 to 48 h), with maintenance of aPPT between 55 and 70
econds. After an overlap of UFH and warfarin for 3 to 5
ays, UFH may be discontinued when an INR of 2.0 to 3.0
s achieved. After 3 months, the tissue valve can be treated
ike native valve disease, and warfarin can be discontinued in
ore than two thirds of patients with biological valves
174,937,960). In the remaining patients with associated
isk factors for thromboembolism, such as atrial fibrillation,
revious thromboembolism, or hypercoagulable condition,
ifelong warfarin therapy is indicated to achieve an INR of
.0 to 3.0. Many would also recommend continuing anti-
oagulation in patients with severe LV dysfunction (ejection
raction less than 0.30) (948).
.2.3. Embolic Events During Adequate Antithrombotic
herapy
n the patient who has a definite embolic episode while
ndergoing adequate antithrombotic therapy, the dosage of
ntithrombotic therapy should be increased, when clinically
afe, as follows:
c
vWarfarin, INR 2.0 to 3.0: warfarin dose increased to
achieve INR of 2.5 to 3.5
Warfarin, INR 2.5 to 3.5: warfarin dose may need to be
increased to achieve INR of 3.5 to 4.5
Not taking aspirin: aspirin 75 to 100 mg per day should
be initiated
Warfarin plus aspirin 75 to 100 mg per day: aspirin dose
may also need to be increased to 325 mg per day if the
higher dose of warfarin is not achieving the desired
clinical result
Aspirin alone: aspirin dose may need to be increased to
325 mg per day, clopidogrel 75 mg per day per day
added, and/or warfarin added.
.2.4. Excessive Anticoagulation
n most patients with INR above the therapeutic range,
xcessive anticoagulation can be managed by withholding
arfarin and monitoring the level of anticoagulation with
erial INR determinations (804). Excessive anticoagulation
INR greater than 5) greatly increases the risk of hemor-
hage. However, rapid decreases in INR that lead to INR
alling below the therapeutic level increase the risk of
hromboembolism. Patients with prosthetic heart valves
ith an INR of 5 to 10 who are not bleeding can be treated
y withholding warfarin and administering 1 to 2.5 mg of
ral vitamin K1 (phytonadione) (804,961). The INR should
e determined after 24 h and subsequently as needed.
arfarin therapy is restarted and adjusted dose appropri-
tely to ensure that the INR is in the therapeutic range. In
mergency situations, the use of fresh frozen plasma is
referable to high-dose vitamin K1 (962), especially paren-
eral vitamin K1, because use of the latter increases the risk
f overcorrection to a hypercoagulable state. Low-dose intra-
enous vitamin K (1 mg) appears safe in this situation (963).
.2.5. Bridging Therapy in Patients With Mechanical
alves Who Require Interruption of Warfarin
herapy for Noncardiac Surgery, Invasive Procedures,
r Dental Care
LASS I
. In patients at low risk of thrombosis, defined as those with a
bileaflet mechanical AVR with no risk factors,* it is recommended
that warfarin be stopped 48 to 72 h before the procedure (so the
INR falls to less than 1.5) and restarted within 24 h after the
procedure. Heparin is usually unnecessary. (Level of Evidence: B)
. In patients at high risk of thrombosis, defined as those with any
mechanical MV replacement or a mechanical AVR with any risk
factor, therapeutic doses of intravenous UFH should be started
when the INR falls below 2.0 (typically 48 h before surgery), stopped
4 to 6 h before the procedure, restarted as early after surgery as
bleeding stability allows, and continued until the INR is again
therapeutic with warfarin therapy. (Level of Evidence: B)
Risk factors: atrial fibrillation, previous thromboembolism, LV dysfunction, hyper-
oagulable conditions, older-generation thrombogenic valves, mechanical tricuspid
alves, or more than 1 mechanical valve.
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. It is reasonable to give fresh frozen plasma to patients withmechan-
ical valves who require interruption of warfarin therapy for emer-
gency noncardiac surgery, invasive procedures, or dental care. Fresh
frozen plasma is preferable to high-dose vitamin K1. (Level of
Evidence: B)
LASS IIb
. In patients at high risk of thrombosis, therapeutic doses of subcu-
taneous UFH (15 000 U every 12 h) or LMWH (100 U per kg every
12 h) may be considered during the period of a subtherapeutic INR.
(Level of Evidence: B)
LASS III
. In patients with mechanical valves who require interruption of
warfarin therapy for noncardiac surgery, invasive procedures, or
dental care, high-dose vitamin K1 should not be given routinely,
because this may create a hypercoagulable condition. (Level of
Evidence: B)
The risk of increased bleeding during a procedure per-
ormed with a patient receiving antithrombotic therapy has
o be weighed against the increased risk of a thromboem-
olism caused by stopping the therapy. The risk of stopping
arfarin can be estimated and is relatively slight if the drug
s withheld for only a few days. As an example, in a
orst-case scenario (e.g., a patient with a mechanical
rosthesis with previous thromboemboli), the risk of a
hromboembolism when the patient is not taking warfarin is
0% to 20% per year. Thus, if therapy were stopped for 3
ays, the risk of an embolus would be 0.08% to 0.16%.
here are theoretical concerns that stopping the drug and
hen reinstituting it might result in hypercoagulability or
hat there might be a thrombotic “rebound.” An increase in
arkers for activation of thrombosis with abrupt discontin-
ation of warfarin therapy has been observed (964), but it is
ot clear whether the clinical risk of thromboembolism
ncreases (965). In addition, when warfarin therapy is
einstituted, there are theoretical concerns about a hyperco-
gulable state caused by suppression of protein C and
rotein S before the drug affects the thrombotic factors.
lthough these risks are only hypothetical, individuals at
ery high risk should be treated with heparin until INR
eturns to the desired range.
Management of antithrombotic therapy must be individ-
alized, but some generalizations apply (934). Antithrom-
otic therapy should not be stopped for procedures in which
leeding is unlikely or would be inconsequential if it
ccurred, for example, surgery on the skin, dental cleaning,
r simple treatment for dental caries. Eye surgery, particu-
arly for cataracts or glaucoma, is usually associated with
ery little bleeding and thus is frequently performed without
lterations to antithrombotic treatment. When bleeding is
ikely or its potential consequences are severe, antithrom-
otic treatment should be altered. If a patient is taking
spirin, it should be discontinued 1 week before the proce-
ure and restarted as soon as it is considered safe by the aurgeon or dentist. Clopidogrel should be stopped at least 5
ays before the procedure.
Spyropoulos et al. performed a retrospective analysis of
osts and clinical outcomes associated with LMWH for
erioperative bridging in patients receiving long-term oral
nticoagulant therapy (966). The mean total healthcare
osts in the perioperative period were significantly lower (by
13 114) in patients receiving long-term oral anticoagulant
herapy with LMWH than in those receiving it with UFH
or an elective surgical procedure. The cost savings associ-
ted with LMWH use were accomplished through the
voidance or minimization of inpatient stays and no increase
n the overall rate of clinical adverse events in the postop-
rative period (966).
For patients with a bileaflet mechanical aortic valve and
o risk factors, warfarin should be stopped before the
rocedure so that the INR is less than 1.5 (which is often 48
o 72 h after warfarin is discontinued) (934,967) and
estarted within 24 h after a procedure. Admission to the
ospital or a delay in discharge to give heparin is usually
nnecessary (965,968–970). Patients at high risk of throm-
osis include all patients with mechanical mitral or tricuspid
alve replacements and patients with an AVR and any risk
actors. Such risk factors include atrial fibrillation, previous
hromboembolism, hypercoagulable condition, older-
eneration mechanical valves, LV dysfunction (ejection
raction less than 0.30), or more than 1 mechanical valve
971–973). When UFH is used, it should be started when
NR falls below 2.0 (i.e., 48 h before surgery) and stopped
to 6 h before the procedure. UFH should be restarted as
arly after surgery as bleeding stability allows, and the aPTT
hould be maintained at 55 to 70 s until warfarin is
herapeutic. LMWH is attractive because it is more easily
sed outside the hospital. One study of bridging therapy for
nterruption of warfarin included 215 patients with mechan-
cal valves. In the total group of 650 patients, the risk of
hromboembolism (including possible events) was 0.62%,
ith 95% confidence intervals of 0.17% to 1.57%. Major
leeding occurred in 0.95% (0.34% to 2.00%) (974). How-
ver, concerns about the use of LMWH for mechanical
alves persists, and package inserts continue to list a warning
or this use of these medications (815).
High-dose vitamin K1 should not be given routinely,
ecause this may create a hypercoagulable condition. For
mergency situations, fresh frozen plasma is preferable to
igh-dose vitamin K1 (see Section 9.2.4).
.2.6. Antithrombotic Therapy in Patients Who Need
ardiac Catheterization/Angiography
n an emergency or semiurgent situation, cardiac catheteriza-
ion can be performed in a patient taking warfarin, but
referably, the drug should be stopped, on average, 72 h before
he procedure so that INR is less than 1.5 (see above). The
rug should be restarted as soon as the procedure is completed.
his is true for patients with biological valves who are receivingntithrombotic therapy and for those with mechanical valves. If
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hromboembolism, heparin should be started when INR falls
elow 2.0 and should be continued when warfarin is restarted.
fter an overlap of 3 to 5 days, heparin may be discontinued
hen the desired INR is achieved. If the catheterization
rocedure is to include a transseptal puncture (especially in a
atient who has not had previous opening of the pericardium),
atients should be removed from all antithrombotic therapy,
nd INR should be less than 1.2; the same is true if an LV
uncture is to be performed (975). In patients who are to
ndergo transseptal or LV puncture and are receiving heparin
herapy, heparin should be discontinued 4 to 6 h before the
rocedure(s) and can be restarted without a bolus more than
h after the sheath in the peripheral vessel has been removed.
.2.7. Thrombosis of Prosthetic Heart Valves
LASS I
. Transthoracic and Doppler echocardiography is indicated in patients
with suspected prosthetic valve thrombosis to assess hemodynamic
severity. (Level of Evidence: B)
. Transesophageal echocardiography and/or fluoroscopy is indicated
in patients with suspected valve thrombosis to assess valve motion
and clot burden. (Level of Evidence: B)
LASS IIa
. Emergency operation is reasonable for patients with a thrombosed
left-sided prosthetic valve and NYHA functional class III–IV symp-
toms. (Level of Evidence: C)
. Emergency operation is reasonable for patients with a thrombosed
left-sided prosthetic valve and a large clot burden. (Level of Evi-
dence: C)
. Fibrinolytic therapy is reasonable for thrombosed right-sided pros-
thetic heart valves with NYHA functional class III–IV symptoms or a
large clot burden. (Level of Evidence: C)
LASS IIb
. Fibrinolytic therapy may be considered as a first-line therapy for
patients with a thrombosed left-sided prosthetic valve, NYHA func-
tional class I–II symptoms, and a small clot burden. (Level of
Evidence: B)
. Fibrinolytic therapy may be considered as a first-line therapy for
patients with a thrombosed left-sided prosthetic valve, NYHA func-
tional class III–IV symptoms, and a small clot burden if surgery is
high risk or not available. (Level of Evidence: B)
. Fibrinolytic therapy may be considered for patients with an ob-
structed, thrombosed left-sided prosthetic valve who have NYHA
functional class II–IV symptoms and a large clot burden if emer-
gency surgery is high risk or not available. (Level of Evidence: C)
. Intravenous UFH as an alternative to fibrinolytic therapy may be
considered for patients with a thrombosed valve who are in NYHA
functional class I–II and have a small clot burden. (Level of Evi-
dence: C)
bstruction of prosthetic heart valves may be caused by
hrombus formation, pannus ingrowth, or a combination of
oth. The cause may be difficult to determine and requires
nowledge of the clinical presentation and findings on
chocardiography, including transesophageal echocardiog-
aphy (976–981). If the prosthesis is obstructed by pannus, wbrinolytic therapy will be ineffective, and the valve needs to
e replaced. Fibrinolytic therapy for a left-sided prosthetic
alve obstructed by thrombus is associated with significant
isks (cerebral emboli in 12% to 15% of cases) and is often
neffective. Fibrinolytic therapy in such patients is reserved
or those in whom surgical intervention carries a high risk and
hose with contraindications to surgery (976–980,982–986).
In patients with a “small clot” who are in NYHA
unctional class I or II, treatment with short-term intrave-
ous UFH therapy or continuous infusion of fibrinolytic
herapy may be considered (976–980,982–986). The size
hreshold for this recommendation is difficult to define
ecause of the lack of large cohort studies and differing
hresholds from small studies (ranging from 5 to 10 mm, as
etermined by transesophageal echocardiography), below
hich intravenous UFH or fibrinolytic therapy is safe and
ffective (976–978,984). The risk associated with clot size is
continuous function, with 1 study showing an odds ratio of
.41 per 1-cm2 increment (978). Data support the use of
rokinase, streptokinase, or recombinant tissue plasminogen
ctivator as the fibrinolytic agents in this situation. Factors
hat identify patients at risk for adverse outcomes of
brinolytic therapy include active internal bleeding, history
f hemorrhagic stroke, recent cranial trauma of neoplasm,
iabetic hemorrhagic retinopathy, large thrombi, mobile
hrombi, hypertension (greater than 200 over 120 mm Hg),
ypotension or shock, and NYHA functional class III–IV
ymptoms. If fibrinolytic therapy is successful, it should be
ollowed by intravenous UFH until warfarin achieves an
NR of 3.0 to 4.0 for aortic prosthetic valves and 3.5 to 4.5
or mitral prosthetic valves. If partially successful, fibrino-
ytic therapy may be followed by a combination of subcu-
aneous UFH twice daily (to achieve an aPTT of 55 to 80 s)
lus warfarin (INR 2.5 to 3.5) for a 3-month period (985).
Patients with small thrombi who receive intravenous
FH as first-line therapy and who do not respond success-
ully may receive a trial of continuous-infusion fibrinolytic
herapy. If fibrinolytic therapy is unsuccessful or there is an
ncreased risk associated with fibrinolytic therapy, reopera-
ion should be considered. An alternative in patients who
emain hemodynamically stable is to convert intravenous
FH to combined therapy with subcutaneous UFH (twice
aily to an aPTT of 55 to 80 s) and warfarin (INR 2.5 to
.5) for 1 to 3 months on an outpatient basis to allow for
ndogenous fibrinolysis (985). If intravenous UFH, fibrino-
ytic therapy, combined UFH/fibrinolytic therapy, or com-
ined UFH/warfarin is successful, warfarin doses should be
ncreased so that INR is between 3.0 and 4.0 (approximately
.5) for prosthetic aortic valves and between 3.5 and 4.5
approximately 4.0) for prosthetic MVs. These patients
hould also receive low-dose aspirin.
Thrombosis of mechanical tricuspid valve prostheses may
e treated with fibrinolytic therapy, although experience
ith this is limited (987,988).
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LASS I
. For patients with prosthetic heart valves, a history, physical exami-
nation, and appropriate tests should be performed at the first
postoperative outpatient evaluation, 2 to 4 weeks after hospital
discharge. This should include a transthoracic Doppler echocardio-
gram if a baseline echocardiogram was not obtained before hospi-
tal discharge. (Level of Evidence: C)
. For patients with prosthetic heart valves, routine follow-up visits
should be conducted annually, with earlier re-evaluations (with
echocardiography) if there is a change in clinical status. (Level of
Evidence: C)
LASS IIb
. Patients with bioprosthetic valves may be considered for annual
echocardiograms after the first 5 years in the absence of a change
in clinical status. (Level of Evidence: C)
LASS III
. Routine annual echocardiograms are not indicated in the absence
of a change in clinical status in patients with mechanical heart
valves or during the first 5 years after valve replacement with a
bioprosthetic valve. (Level of Evidence: C)
.3.1. First Outpatient Postoperative Visit
he first outpatient evaluation after valve surgery usually
ccurs 3 to 4 weeks after hospital discharge. By this time,
he patient’s physical capabilities and expected improvement
n functional capacity can be assessed.
The workup on this visit should include an interval or
omplete history and physical examination, ECG, chest
-ray, 2D and Doppler echocardiography, complete blood
ount, blood urea nitrogen/creatinine, electrolytes, lactate
ehydrogenase, and INR, if indicated. The main focus of
he examination is on signs that relate to function of the
rosthesis or that might suggest the presence of infection or
myocardial infarction, conduction, or valvular disorder.
evere perivalvular MR may be inaudible on physical
xamination, a fact to remember when one considers the
ossible causes of functional deterioration in a patient. In
atients who undergo surgery in the setting of acute valvular
nfection, the first postoperative visit may occur at the end of
postoperative course of antibiotics. Surveillance blood
ultures may be indicated at this visit if 1 or more weeks
ave passed since cessation of antibiotics to confirm bacte-
iologic cure.
Echocardiography is the most useful noninvasive test. It
rovides information about prosthesis stenosis/regurgi-
ation, valve area, assessment of other valve disease(s), pul-
onary hypertension, atrial size, LV and RV hypertrophy,
V and RV size and function, and pericardial effusion/
hickening. It is an essential component of the first postop-
rative visit because it allows an assessment of the effects and
esults of surgery, as well as serving as a baseline for
omparison should complications or deterioration occur
ater.
Every prosthetic heart valve has an intrinsic degree of
bstruction (857,989–992); one reason for obtaining a faseline Doppler echocardiogram early after valve replace-
ent is so that this intrinsic gradient can be measured and
ompared with subsequent measurements if necessary. The
radient varies among different types of prosthetic valves.
oppler echocardiography also detects the prosthetic valve
egurgitation that is normal for various types of mechanical
alve.
Multiple other noninvasive tests (e.g., cardiac magnetic
esonance) have emerged for the assessment of valvular and
entricular function, but these should be performed only in
elected patients for specific indications. Fluoroscopy can
eveal abnormal rocking of a dehiscing prosthesis, limitation
f the occluder if the latter is opaque, and strut fracture of
he convexoconcave Björk-Shiley valve. Radionuclide an-
iography or cardiac magnetic resonance is useful to deter-
ine whether functional deterioration is the result of
educed ventricular function and is performed if the same
ata cannot be obtained by echocardiography. Cardiac
agnetic resonance is safe for all commercially available
rosthetic heart valves.
.3.2. Follow-Up Visits in Patients Without Complications
atients who have undergone valve replacement are not
ured but still have serious heart disease. They have ex-
hanged native valve disease for prosthetic valve disease and
ust be followed with the same care as patients with native
alve disease (993). The clinical course of patients with
rosthetic heart valves is influenced by several factors (857),
ncluding LV dysfunction, progression of other valve dis-
ase, pulmonary hypertension, other cardiac diseases, com-
lications of prosthetic heart valves, and clinical heart
ailure. The interval between routine follow-up visits de-
ends on the patient’s needs. Anticoagulant regulation does
ot require visits to the physician’s office but should be
losely supervised by an experienced healthcare professional.
The asymptomatic uncomplicated patient needs to be
een only at 1-year intervals, at which time a complete
istory and thorough physical examination should be per-
ormed. ECG and chest X-ray examinations are not rou-
inely indicated but are valuable in individual patients.
dditional tests that are often performed include hemoglo-
in, hematocrit, and lactate dehydrogenase. No further
chocardiographic testing is required after the initial post-
perative evaluation in patients with mechanical valves who
re stable and who have no symptoms or clinical evidence of
V dysfunction, prosthetic valve dysfunction, or dysfunc-
ion of other heart valves, in keeping with the ACC/AHA/
SE 2003 Guidelines for the Clinical Application of
chocardiography (2). Once regurgitation is detected, close
ollow-up with 2D and Doppler echocardiography every 3
o 6 months is indicated. Echocardiography is indicated in
ny patient with a prosthetic heart valve whenever there is
vidence of a new murmur or change in clinical status, when
here are questions about prosthetic valve integrity and
unction, and when there are concerns about ventricular
unction.
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LASS I
. Patients with LV systolic dysfunction after valve surgery should
receive standard medical therapy for systolic heart failure. This
therapy should be continued even if there is improvement of LV
dysfunction. (Level of Evidence: B)
LV dysfunction and clinical heart failure after valve
eplacement may be the result of
preoperative LV dysfunction that persists or improves
only partially
perioperative myocardial damage
other valve disease that has progressed
complications of prosthetic heart valves
associated heart disease such as CAD and systemic
hypertension.
Any patient with a prosthetic heart valve who does not
mprove after surgery or who later shows deterioration of
unctional capacity should undergo appropriate testing,
ncluding 2D and Doppler echocardiography and, if neces-
ary, transesophageal echocardiography and cardiac cathe-
erization with angiography to determine the cause. Patients
ith postoperative LV systolic dysfunction, even if asymp-
omatic, should receive standard medical therapy for systolic
eart failure, and this therapy should be continued indefi-
itely even if there is improvement in systolic function
nd/or symptoms. All patients should also receive primary
nd secondary prevention measures to reduce the risk of
uture cardiovascular events.
.4. Reoperation to Replace a Prosthetic Valve
eoperation to replace a prosthetic heart valve is a serious
linical event. It is usually required for moderate to severe
rosthetic dysfunction (structural and nonstructural), dehis-
ence, and prosthetic endocarditis. Reoperation may also be
eeded for recurrent thromboembolism, severe intravascular
emolysis, severe recurrent bleeding from anticoagulant
herapy, and thrombosed prosthetic valves In a patient with
small aortic annulus, valve prosthesis-patient mismatch
ay occur after AVR (856,989–992,994,995), especially if a
tented bioprosthesis is used. If a patient with AS does not
mprove clinically after AVR, prosthetic valve function
hould be evaluated. In selected situations, repeat AVR to
eplace a malfunctioning prosthesis may be necessary.
The patient who is in stable condition without prosthetic
alve endocarditis under many circumstances undergoes
eoperation with only slightly greater risk than that accom-
anying the initial surgery. For the patient with catastrophic
rosthetic valvular dysfunction, surgery is clearly indicated
nd urgent. The patient without endocarditis or severe
rosthetic valve dysfunction requires careful hemodynamic
valuation, and the decision about reoperation should then
e based on hemodynamic abnormalities, symptoms, ven-
ricular function, and current knowledge of the natural
istory of the particular prosthesis. b0. EVALUATION AND TREATMENT OF
ORONARY ARTERY DISEASE IN PATIENTS
ITH VALVULAR HEART DISEASE
any patients with valvular heart disease have concomitant
AD, but there are only limited data regarding the optimal
trategies for diagnosis and treatment of CAD in such
atients. Thus, management decisions are usually developed
y blending information from the randomized studies of
reatment of CAD and the smaller published series of
atients undergoing surgical treatment of valvular heart
isease.
0.1. Probability of Coronary Artery Disease in
atients With Valvular Heart Disease
he probability of developing CAD in the general popula-
ion (996) and the prevalence of CAD in patients who come
o medical attention (997) can be estimated on the basis of
ge, sex, and clinical risk factors. The prevalence of CAD in
atients with valvular heart disease is determined by these
ame variables (998). Risk factors for coronary atheroscle-
osis in patients with valvular disease should be approached
ith the prevention and risk reduction strategies that have
een recommended for the general population (999).
Ischemic symptoms are important markers of CAD in
he general population. Thus, the prevalence of CAD
average) has been estimated at 90% in middle-aged men
ith typical angina AS, 50% in those with atypical angina,
6% in those with nonanginal chest pain, and 4% in
symptomatic subjects (997). On the basis of data from the
ramingham Study, the rate of CAD increases with age,
nd in asymptomatic individuals who are low risk, it ranges
rom 1% to 6%. In those aged less than 45 years, the risk is
% to 2% (1000). In contrast, ischemic symptoms in
atients with valvular heart disease may have multiple
auses, such as LV chamber enlargement, increased wall
tress or wall thickening with subendocardial ischemia
1001), and RV hypertrophy (1002). Angina is thus a less
pecific indicator of CAD in patients with valvular heart
isease than in the general population.
Among patients with severe AS, angina is a common
ymptom in young patients with normal coronary arteries
nd congenital or rheumatic AS. On the other hand, CAD
s a common finding in older symptomatic men with AS.
mong patients with AS, the prevalence of CAD is 40% to
0% in those with typical angina, an average 25% in those
ith atypical chest pain, and an average 20% in those
ithout chest pain (1003–1010). Even in patients less than
0 years old with no chest pain and no coronary risk factors,
he prevalence of CAD is 0% to 5% (998,1005,1011). In
lderly patients (greater than 70 years old), angina is a
trong determinant of CAD (sensitivity 78%, specificity
2%) (1012). Calcification of the aortic valve is also associ-
ted with a high presence of CAD (90%) (1013). In general,
ecause angina is a poor marker of CAD in patients with
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September 23, 2008:e1–142 ACC/AHA VHD Guidelines: 2008 Focused Update IncorporatedS, coronary angiography is recommended in symptomatic
atients before AVR in men older than 35 years; premeno-
ausal women older than 35 years with coronary risk factors,
s well as asymptomatic men older than 45 years; women
lder than 55 years; and those with 2 or more coronary risk
actors.
CAD is less prevalent in patients with AR than in those
ith AS (1003–1010,1014–1020), which is related in part
o the younger age of patients with AR. The prevalence of
AD in patients with MS (an average of 20%) is lower than
n patients with aortic valve disease (1015,1017,1018,
021,1022), an observation explained principally on the
asis of differences in age and gender. Nonetheless, because
f the impact of untreated CAD on perioperative and
ong-term postoperative survival, preoperative identification
f CAD is of great importance in patients with AR or MS
nd those with AS. Thus, in symptomatic patients and/or
hose with LV dysfunction, preoperative coronary angiog-
aphy is recommended in men aged greater than 35 years,
remenopausal women aged greater than 35 years with
oronary risk factors, and postmenopausal women.
The relation between MR and CAD is unique in that
AD is frequently the cause of this valve lesion. The
anagement of these patients is discussed in Section 3.6.5.
either angina nor heart failure symptoms are reliable
arkers of CAD in these patients. In patients undergoing
atheterization to evaluate the cause and severity of MR,
AD is present in an average of 33% (1023,1024). In
atients undergoing catheterization for acute ischemic syn-
romes, an average of 20% have associated MR (1025).
hose with chronic CAD and MR usually have lower LV
jection fractions and more extensive CAD than those
ithout MR (1023,1026). However, CAD is infrequent in
atients with degenerative MV disease undergoing surgery.
n a large series, only 1.3% of such patients had CAD, and
hey only had single-vessel disease. Thus, routine coronary
ngiography is not indicated in patients undergoing MV
urgery for MR due to MV degeneration in the absence of
ymptoms and without risk factors when they are less than
5 years of age (1027).
0.2. Diagnosis of Coronary Artery Disease
LASS I
. Coronary angiography is indicated before valve surgery (including
infective endocarditis) or mitral balloon commissurotomy in pa-
tients with chest pain, other objective evidence of ischemia, de-
creased LV systolic function, history of CAD, or coronary risk factors
(including age). Patients undergoing mitral balloon valvotomy need
not undergo coronary angiography solely on the basis of coronary
risk factors. (Level of Evidence: C)
. Coronary angiography is indicated in patients with apparently mild
to moderate valvular heart disease but with progressive angina
(Canadian Heart Association functional CLASS II or greater), objective
evidence of ischemia, decreased LV systolic function, or overt
congestive heart failure. (Level of Evidence: C)
. Coronary angiography should be performed before valve surgery in
men aged 35 years or older, premenopausal women aged 35 years (or older who have coronary risk factors, and postmenopausal
women. (Level of Evidence: C)
LASS IIa
. Surgery without coronary angiography is reasonable for patients
having emergency valve surgery for acute valve regurgitation, aortic
root disease, or infective endocarditis. (Level of Evidence: C)
LASS IIb
. Coronary angiography may be considered for patients undergoing
catheterization to confirm the severity of valve lesions before valve
surgery without pre-existing evidence of CAD, multiple coronary risk
factors, or advanced age. (Level of Evidence: C)
LASS III
. Coronary angiography is not indicated in young patients undergoing
nonemergency valve surgery when no further hemodynamic assess-
ment by catheterization is deemed necessary and there are no
coronary risk factors, no history of CAD, and no evidence of isch-
emia. (Level of Evidence: C)
. Patients should not undergo coronary angiography before valve
surgery if they are severely hemodynamically unstable. (Level of
Evidence: C)
he resting ECG in patients with valvular heart disease
requently shows ST-segment changes due to LV hypertro-
hy, LV dilatation, or bundle-branch block, which reduces
he accuracy of the ECG at rest and during exercise for the
iagnosis of concomitant CAD.
Similarly, resting or exercise-induced regional wall-
otion abnormalities are nonspecific markers for CAD in
atients with underlying valvular heart disease who have LV
ypertrophy and/or chamber dilatation (1028–1030), as are
yocardial perfusion abnormalities induced by exercise or
harmacological stress (1029,1031–1034). Limited data are
vailable on the use of myocardial perfusion imaging with
hallium-201 or technetium-99m perfusion agents in pa-
ients with severe valvular disease. Although some studies of
erfusion imaging in AS have demonstrated a sensitivity of
7% and a specificity of 77%, the presence of CAD is
issed in 13% of patients with CAD (1035). Given the
mportance of determining the presence of CAD, coronary
ngiography remains the most appropriate method for the
efinitive diagnosis of CAD (1004). Noninvasive imaging is
seful when CAD is suspected in patients with mild valve
tenosis or regurgitation and normal LV cavity size and wall
hickness.
In patients undergoing emergency valve surgery for
cute AR, aortic dissection, or endocarditis with hemo-
ynamic instability, cardiac catheterization, aortography,
nd coronary angiography are rarely required, are associ-
ted with increased risk, and might delay urgent surgery
nnecessarily (221,224 –227). Angiography should be
onsidered only when the valve diagnosis cannot be
etermined by noninvasive imaging and when patients
ave known CAD, especially those with previous CABG
see Section 3.2.2.3).
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ime of Aortic Valve Replacement
LASS I
. Patients undergoing AVR with significant stenoses (greater than or
equal to 70% reduction in luminal diameter) inmajor coronary arteries
should be treated with bypass grafting. (Level of Evidence: C)
LASS IIa
. In patients undergoing AVR and coronary bypass grafting, use of the
left internal thoracic artery is reasonable for bypass of stenoses of
the left anterior descending coronary artery greater than or equal to
50% to 70%. (Level of Evidence: C)
. For patients undergoing AVR with moderate stenosis (50% to 70%
reduction in luminal diameter), it is reasonable to perform coronary
bypass grafting in major coronary arteries. (Level of Evidence: C)
s noted previously, more than 33% of patients with AS
ho are undergoing AVR have concomitant CAD. More
han 50% of patients older than 70 years have CAD. Several
tudies have reported the outcomes of patients undergoing
ombined CABG and AVR. Although combined myocar-
ial revascularization and AVR increases cross-clamp time
1036) and has the potential to increase perioperative
yocardial infarction and early postoperative mortality
ompared with patients without CAD undergoing isolated
VR (1037–1040), in several series, combined CABG has
ad little or no adverse effect on operative mortality (1041–
047). Moreover, combined CABG and AVR reduces the
ates of perioperative myocardial infarction, operative mor-
ality, and late mortality and morbidity compared with
atients with significant CAD who do not undergo revas-
ularization at the time of AVR (1045,1046,1048,1049). In
ddition to severity of CAD, the multivariate factors for late
ostoperative mortality include severity of AS, severity of
V dysfunction, age greater than 70 years (especially in
omen), and presence of NYHA functional class IV symp-
oms (1046,1050,1051). Incomplete revascularization is as-
ociated with greater postoperative systolic dysfunction
1052,1053) and reduced survival rates (1054) after surgery
ompared with patients who receive complete revasculariza-
ion. For more than a decade, improved myocardial preser-
ation techniques have been associated with reduced overall
perative mortality (1055), and it has become standard
ractice to bypass all significant coronary artery stenoses
hen possible in patients undergoing AVR. The committee
ecommends this approach.
0.4. Aortic Valve Replacement in Patients
ndergoing Coronary Artery Bypass Surgery
LASS I
. AVR is indicated in patients undergoing CABG who have severe AS
who meet the criteria for valve replacement (see Section 3.1.7).
(Level of Evidence: C)
LASS IIa
. AVR is reasonable in patients undergoing CABG who have moderate
AS (mean gradient 30 to 50 mm Hg or Doppler velocity 3 to 4 m per
second). (Level of Evidence: B) eLASS IIb
. AVRmay be considered in patients undergoing CABG who havemild
AS (mean gradient less than 30mmHg or Doppler velocity less than
3 m per second) when there is evidence, such as moderate-severe
valve calcification, that progression may be rapid. (Level of Evi-
dence: C)
Patients undergoing CABG who have severe AS should
ndergo AVR at the time of revascularization. Decision
aking is less clear in patients who have CAD that requires
ABG when these patients have mild to moderate AS.
ontroversy persists regarding the indications for “prophy-
actic” AVR at the time of CABG in such patients. This
ecision should be made only after the severity of AS is
etermined by Doppler echocardiography and cardiac cath-
terization.
Confirmation by cardiac catheterization is especially im-
ortant in patients with reduced stroke volumes, mixed
alve lesions, or intermediate mean aortic valve gradients
between 30 and 50 mm Hg) by Doppler echocardiography,
ecause many such patients may actually have severe AS (as
iscussed in Section 3.1.6). The more complex and contro-
ersial issue is the decision to replace the aortic valve for
nly mild AS at the time of CABG, because the degree of
S may become more severe within a few years, necessitat-
ng a second, more difficult AVR operation in a patient with
atent bypass grafts.
It is difficult to predict whether a given patient with CAD
nd mild AS is likely to develop significant AS in the years
fter CABG. As noted previously (see Section 3.1.3), the
atural history of mild AS is variable, with some patients
anifesting a relatively rapid progression of AS with a
ecrease in valve area of up to 0.3 cm2 per year and an
ncrease in pressure gradient of up to 15 to 19 mm Hg per
ear; however, the majority may show little or no change
61,86–95,107,1056). The average rate of reduction in valve
rea is 0.12 cm2 per year (61), but the rate of change in an
ndividual patient is difficult to predict.
Retrospective studies of patients who have come to AVR
fter previous CABG have been reported in which the mean
ime to reoperation was 5 to 8 years (1057–1062). The
ortic valve gradient at the primary operation was small, less
han 20 mm Hg, but the mean gradient increased signifi-
antly to greater than 50 mm Hg at the time of the second
peration. These reports represent selected patients in
hom AS progressed to the point that AVR was warranted.
he number of patients in these surgical series who had
imilar gradients at the time of the primary operation but
ho did not have significant progression of AS is unknown.
Although definitive data are not yet available, patients
ith intermediate aortic valve gradients (mean gradient 30
o 50 mm Hg at catheterization or transvalvular velocity of
to 4 m per second by Doppler echocardiography) who are
ndergoing CABG may warrant AVR at the time of
evascularization (181–185), whereas patients with gradi-
nts below 10 mm Hg do not need valve replacement. The
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actors predicting more rapid progression of aortic disease
nd should be taken into consideration, particularly in those
ith gradients between 10 and 25 mm Hg (98,181,185–
87,1063–1066). Because of the lack of data, controversy
xists regarding AVR at the time of CABG, and the
trength of these recommendations is reduced.
0.5. Management of Concomitant Mitral Valve
isease and Coronary Artery Disease
ost patients with both MV disease and CAD have
schemic MR, as discussed in Sections 3.6.5 and 7.3.1.3. In
atients with 1 to 2 MR, ischemic symptoms usually
ictate the need for revascularization. Patients with more
evere ischemic MR usually have significant LV dysfunc-
ion, and the decision to perform revascularization and MV
epair is based on symptoms, severity of CAD, LV dysfunc-
ion, and inducible myocardial ischemia.
In patients with MV disease due to diseases other than
schemia, significantly obstructed coronary arteries identi-
ed at preoperative cardiac catheterization are generally
evascularized at the time of MV surgery. There are no data
o indicate the wisdom of this general policy, but because
evascularization usually adds little morbidity or mortality to
he operation, the additional revascularization surgery is
sually recommended.)
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